<SEC-DOCUMENT>0001558370-23-008132.txt : 20230504
<SEC-HEADER>0001558370-23-008132.hdr.sgml : 20230504
<ACCEPTANCE-DATETIME>20230504163056
ACCESSION NUMBER:		0001558370-23-008132
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		44
CONFORMED PERIOD OF REPORT:	20230331
FILED AS OF DATE:		20230504
DATE AS OF CHANGE:		20230504

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Protalix BioTherapeutics, Inc.
		CENTRAL INDEX KEY:			0001006281
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				650643773
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33357
		FILM NUMBER:		23889286

	BUSINESS ADDRESS:	
		STREET 1:		2 UNIVERSITY PLAZA
		STREET 2:		SUITE 100
		CITY:			HACKENSACK
		STATE:			NJ
		ZIP:			07601
		BUSINESS PHONE:		201-696-9345

	MAIL ADDRESS:	
		STREET 1:		2 UNIVERSITY PLAZA
		STREET 2:		SUITE 100
		CITY:			HACKENSACK
		STATE:			NJ
		ZIP:			07601

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ORTHODONTIX INC
		DATE OF NAME CHANGE:	19980422

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EMBASSY ACQUISITION CORP
		DATE OF NAME CHANGE:	19960124
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>plx-20230331x10q.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 10.2.5.9 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 5/4/2023 7:35:10 PM -->
      <!-- iXBRL Library version: 1.0.8476.13996 -->
      <!-- iXBRL Service Job ID: 737882ac-d10d-4dfb-97d6-4ace7f2e8cb5 -->

  <html xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:plx="http://www.protalix.com/20230331" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" xs:nil="true" contextRef="As_Of_3_31_2023_lQ4VofWCfU-ERA4iKttplQ" name="us-gaap:CommitmentsAndContingencies" id="Hidden_qx9a_LJ0kUyO05_Ul4HyJw"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" xs:nil="true" contextRef="As_Of_12_31_2022_H53zBT4W7kaDDa9Xye-U_Q" name="us-gaap:CommitmentsAndContingencies" id="Hidden_-OnFasH4jEy4yn00zm1FBw"></ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw" name="dei:EntityCentralIndexKey" id="Tc_vf1keXzUA0SZiNbf-gQFtQ_2_1">0001006281</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw" name="dei:CurrentFiscalYearEndDate" id="Tc_iXthAhY0PUuaLwtaKRluRg_3_1">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw" name="dei:DocumentFiscalYearFocus" id="Tc_YagIgBr8CkaB3psguOLOnw_4_1">2023</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw" name="dei:DocumentFiscalPeriodFocus" id="Tc_r5VQF_iGBk2GkV5ztSH9-w_5_1">Q1</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw" name="dei:AmendmentFlag" id="Tc_p4ooJc-Mh0Cy3pka0UDOEw_6_1">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="plx-20230331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_E_QLG5yGnUWYSbAfH9__OQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_IL0F69SjoE2AcVxC9gRdAg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_td4XMHFZWkWCZfhPrs2Yog"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_xvyzPFwz2Ei9WGmzrZtTKA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_sessMVhLlE-60nptH85tHA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_P1TRpg9XL0SipWskVIymPg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember__Fk6t8bO9k-wg-VncCAqpg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_vOwYA9rCf0W5Bz8PPuTQvg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_bMnoYH_kPEuyqw6R4J9L2Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_B-MKROg0kkWsBATWzcCW9g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Ma9XQZkyu0yv3iLSHCbY5g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_J7EBNPBz8ESJc8H_4uZ72w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_fttaWimhoUeG-S7zMyaisw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_hmYTDCpI-ECukL-F-IOjvQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_1ErUchefYE24icEBkPux0A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_0OKK-_bib0C_UleLAi20GA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_3_31_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_WcMRAOlFCE6_UAs2eyxXCA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_3_31_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_ChiesiMember_1_EnASsBOky6dNtE7sYeqA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:ChiesiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_3_31_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_PBB8cE7vikCPoa7ZmvpzOA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_3_31_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_TLlwu1kiM067CBBRXPNrNw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_3_31_2022_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_rv5oVU7cTEWzAOzlbF-VFA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtmEquityOfferingSalesAgreementMember_aO6xvvEThkasCzfWTSPBgQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtmEquityOfferingSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtmEquityOfferingSalesAgreementMember_TYdGwaWNbE6JmroON4hlzg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtmEquityOfferingSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_M5gF58pjUEaKAVvefka9Pw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_P_C-vkYM70mz4hoQ7UVhOg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_a9VnZ-vJPkiHhaBFIDBw-A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember__GmWbcoY7kCTcvgHXmTtag"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_6rulpN2cdUS_aFAtMHgQ0Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_sRkxswHoFESpgC_hhX6rNw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_aCnJ8YZWTEKINZXa-WibNQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_plx_MeasurementInputYieldMember_fyqadwF3d0u2BkkX4IRliA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">plx:MeasurementInputYieldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_9xvbhmNJFkageC4WyZOI_Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_vCJMvVrkpEey12nFHwmq_g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtMarketEquityOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2022_cjzuDz-ZiUubY38dhB0s0A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_x-pm8I0vjUS_ATBiwepawg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_f8-sCIf2RkuxwvCb3yISvA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_O-2jNHV-AUW4fRDBPZldoA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_kovew3nQoUW7X8jAVRvjhw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_3_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_QMhb-FrbfESVBC7w8w5e4A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_3_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_ACjpei32d0mTu26aZxZF-Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_3_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_M9nMRkvbzkONqh4KPar8cg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_lQ4VofWCfU-ERA4iKttplQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_Am7rx-rvZUywApMit-lb-A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUsAgreementAndChiesiExUsAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-07-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_z3hwihuoBkC5xNBh7hXP6A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUsAgreementAndChiesiExUsAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-10-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_4_30_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_tROqvzE5iEKYWMElS1CURw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_o5KTQD_NWEC6IWOAHM7tDQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_H53zBT4W7kaDDa9Xye-U_Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_M0avG7-u206lSf4X6whkbA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_chSQy1P71EiszadyqHEgpA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_pTjg192DOkSYYbGFlFzhqA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_27_2023_To_2_27_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_Q-zSWd_o2UuvPzl41Xf3MA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtMarketEquityOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-27</xbrli:startDate><xbrli:endDate>2023-02-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_0iU3Zlmqr0On_CGrbCti_Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtMarketEquityOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_NlK07qNF70WUx9TiUtAq1A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtMarketEquityOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_6M0Qz8IYh02zFSz41wRItw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_23_2018_To_7_23_2018_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_qGhtjJbQ70ugptcYziO39Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-23</xbrli:startDate><xbrli:endDate>2018-07-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_23_2018_To_7_23_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_VXlGDMYSYka-21A_FiXp3A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-23</xbrli:startDate><xbrli:endDate>2018-07-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_19_2017_To_10_19_2017_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_Sax1Fe0WOEOjE9gRCUPqYQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-19</xbrli:startDate><xbrli:endDate>2017-10-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_19_2017_To_10_19_2017_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_D2oITtj5_U2sjJO37_gN5w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-19</xbrli:startDate><xbrli:endDate>2017-10-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_ZgUoVauLFkSr1Jlp4jtK7Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2015_To_10_31_2015_dei_LegalEntityAxis_plx_ProtalixBioTherapeuticsIncorporationMember_srt_StatementGeographicalAxis_country_BR_us-gaap_TypeOfArrangementAxis_plx_AmendedPfizerAgreementMember_2qZfvaa21UeJuh9OQT_1zQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">plx:ProtalixBioTherapeuticsIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:AmendedPfizerAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-10-01</xbrli:startDate><xbrli:endDate>2015-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_3_31_2022_N1jzYHJ1VECWf3tLdKC1jw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_13_2021_To_5_13_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_18jRabrPoUa3e12IYdZR0w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-13</xbrli:startDate><xbrli:endDate>2021-05-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_13_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_egFQOM62D0mceKOHvMGXcw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_3yJmheSn6UeRYw8iwyMgIg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-07-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_GyY7-odK10eb47EO_FtixA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-10-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_30_2023_HFiWapI7CUuGG9dGexPKfw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_shares_4bVAm6lD50yLNxvQT1GIoA"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_pure_0xGx53TVLESXmSrWd-Jrvw"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_agreement_l_AIB71m8UmKtkYDila2Og"><xbrli:measure>plx:agreement</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_USD_shares_65Ko0I-nrkSGY9fEMAqs6Q"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Unit_Standard_Y_lrd4ffoII0uwy2NmYOCxhg"><xbrli:measure>plx:Y</xbrli:measure></xbrli:unit><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_yTxTuHFDc0CebaIJf12WuA_9_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_mfQTaw5le0imjmuMBx4ODg_14_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_v0W510vMt0WtRFcsOlezUQ_6_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_dgYszTwrTEefeCZ3ZKmo1Q_11_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_exCmImm6ckG9_1mX6eB13g_12_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_EWUveCzkOkWNPC49U8GrGw_18_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_eCxjacwjWUC54yg3cb-XsA_6_6" toRefs="_decff55c_b6f1_4b4f_9c4c_20bfc2a1e99e" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_weldJHKNTU-LFl_B0NjZQw_6_3" toRefs="_decff55c_b6f1_4b4f_9c4c_20bfc2a1e99e" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_o7CMDO5nykicD24BOuYAWg_7_6" toRefs="_8530ca94_6c84_4f48_984f_7cc5a2959400" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_l3K5Bpo4okmUExRcDvJpSA_7_3" toRefs="_8530ca94_6c84_4f48_984f_7cc5a2959400" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_FWjhg_ga90yHw-Q3cLx8eA_8_6" toRefs="_64475d15_2bf5_4e75_bed3_14deb6a39d55" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_fTYVNJWnjESxIeMvtTihVg_8_3" toRefs="_64475d15_2bf5_4e75_bed3_14deb6a39d55" order="1"></ix:relationship></ix:resources></ix:header></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;min-height:9.2pt;"><p style="border-bottom-style:none;font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:0pt;padding-top:1pt;text-align:center;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="border-bottom-style:none;border-top-style:none;font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:0pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="border-top-style:none;font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;text-align:center;border-bottom:1.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_93340c33_7625_4d4c_8f6f_e18378327f0a"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Washington, D.C. 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:8.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:16pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw" name="dei:DocumentType" id="Narr_RTkzTGZXCk2CIM02XYHMUQ"><b style="font-weight:bold;">10-Q</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:8.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(Mark One)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw" name="dei:DocumentQuarterlyReport" id="Narr_hy43Ub5jKkmONkWqhZZCIQ"><b style="font-family:'Segoe UI Symbol';font-weight:bold;">&#9746;</b></ix:nonNumeric><b style="font-weight:bold;">&#160;&#160;&#160;QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><b style="font-size:8pt;font-weight:bold;">For</b><span style="font-size:8pt;"> </span><b style="font-size:8pt;font-weight:bold;">the quarterly period ended </b><ix:nonNumeric format="ixt:datemonthdayyearen" contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw" name="dei:DocumentPeriodEndDate" id="Narr_hdq9h3FQVEy1m0ZRBcylkQ"><b style="font-size:8pt;font-weight:bold;">March&#160;31, 2023</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OR</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw" name="dei:DocumentTransitionReport" id="Narr_l8QwNi_xrE-VUBI9HrQPBg"><b style="font-family:'Segoe UI Symbol';font-weight:bold;">&#9744;</b></ix:nonNumeric><b style="font-weight:bold;">&#160;&#160;&#160;TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 18pt;"><b style="font-weight:bold;">For the transition period from </b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</b><b style="font-weight:bold;">&#160; to</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw" name="dei:EntityFileNumber" id="Narr_WhTmVY89PU-qBL4qmVMDEQ"><b style="font-size:8pt;font-weight:bold;">001-33357</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Commission file number)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:8.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:16pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw" name="dei:EntityRegistrantName" id="Narr_79QOTFIVg0icwM1AhDThbw"><b style="font-weight:bold;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Exact name of registrant as specified in its charter)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:8.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_a1bb36ca_e2bf_4dc9_949a_f711226b91ef"></a><a id="Tc_7PMUj3iavEGTuBuA45pevQ_1_1"></a><a id="Tc_ly-n023C5Uu3CYi6SblM6w_2_0"></a><a id="Tc_0eAUDEOBfke9uz9sQCiWTA_2_1"></a><a id="Tc_fmmOvG8Zt0iQVu_2jk7Q7w_4_0"></a><a id="Tc_v8LBQHvtqkapFCx_G0bUyQ_5_0"></a><a id="Tc_O3WrKA3U_0WRPFkVPUen5g_5_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw" name="dei:EntityIncorporationStateCountryCode" id="Tc_2Ko8D2XjVkCuH7sYV9AnTw_1_0"><b style="font-size:8pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;">&#160;</span><b style="font-size:8pt;font-weight:bold;">__</b><ix:nonNumeric contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw" name="dei:EntityTaxIdentificationNumber" id="Narr_PA6Rn9ejhECmmEjUn1ZDKA"><b style="font-size:8pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">65-0643773</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;">__</b></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(State or other jurisdiction</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">of incorporation or organization)&#160;</b></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(I.R.S. Employer</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Identification No.)&#160;</b></p></td></tr><tr><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw" name="dei:EntityAddressAddressLine1" id="Narr_rhiNRVwzUUKPTehXZil4vg"><b style="font-size:8pt;font-weight:bold;">2 University Plaza</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw" name="dei:EntityAddressAddressLine2" id="Narr_a1hSC4crG0CZtuLsz-aFww"><b style="font-size:8pt;font-weight:bold;">Suite 100</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw" name="dei:EntityAddressCityOrTown" id="Narr_ntzWAf97d0y4ET25dorw9g"><b style="font-size:8pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Hackensack</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">, </b><ix:nonNumeric contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw" name="dei:EntityAddressStateOrProvince" id="Narr_Hy6GUZK_I0KstzRLQNzUKg"><b style="font-size:8pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">NJ</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw" name="dei:EntityAddressPostalZipCode" id="Tc_nLdBbhNsmUWRAv4IDIAcuQ_4_1"><b style="font-size:8pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">07601</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Address of principal executive offices)</b></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Zip Code)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:8pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">(</b><ix:nonNumeric contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw" name="dei:CityAreaCode" id="Narr__Km7AmpleE2wm39zx4Tx_Q"><b style="font-size:8pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">201</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">)-</b><ix:nonNumeric contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw" name="dei:LocalPhoneNumber" id="Narr_1IZYcxARV0G91a82efDotA"><b style="font-size:8pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">696-9345</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Registrant&#8217;s telephone number, including area code)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">N/A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Former name, former address and former fiscal&#160;year, if changed since last report)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_45e8230e_f727_4422_812c_a1e35f80e47e"></a><a id="Tc_i-JnWDQLNEuCMV06ArS2_A_1_0"></a><a id="Tc_RsA7PBCN7kKSTRi5enAU5g_1_2"></a><a id="Tc_qYbYtwQ_00eLA7Vaw_FhzQ_1_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:30.93%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"></td><td style="vertical-align:top;width:3.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.88%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"></td><td style="vertical-align:top;width:3.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30.93%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"></td></tr><tr><td style="vertical-align:bottom;width:30.93%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title of each class</b></p></td><td style="vertical-align:top;width:3.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.88%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Trading Symbol(s)</b></p></td><td style="vertical-align:top;width:3.12%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30.93%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Name of each exchange on which registered</b></p></td></tr><tr><td style="vertical-align:top;width:30.93%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw" name="dei:Security12bTitle" id="Tc_w6tcv4-CtU6Amj5MCu1zVg_2_0"><span style="font-size:8pt;">Common stock, $0.001 par value</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:3.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.88%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw" name="dei:TradingSymbol" id="Tc__8QDTel_HEaJuO8J6f0gnQ_2_2"><span style="font-size:8pt;">PLX</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:3.12%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:30.93%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw" name="dei:SecurityExchangeName" id="Tc_LzEOxhRwXkii79Op4RWSpw_2_4"><span style="font-size:8pt;">NYSE American</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:5pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. </span><ix:nonNumeric contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw" name="dei:EntityCurrentReportingStatus" id="Narr_7RLc_SATfU-nz0iL8Yp6kw"><span style="font-size:8pt;">Yes</span></ix:nonNumeric><span style="font-size:8pt;">&#160;&#160;</span><span style="font-family:'Times New Roman';font-size:8pt;">&#8999;</span><span style="font-size:8pt;">&#160;&#160;No&#160;&#160;</span><span style="font-family:'Times New Roman';font-size:8pt;">&#9723;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167;&#160;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files). </span><ix:nonNumeric contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw" name="dei:EntityInteractiveDataCurrent" id="Narr_CbJu1IEStUGdWhkMLVl0xw"><span style="font-size:8pt;">Yes</span></ix:nonNumeric><span style="font-size:8pt;"> </span><span style="font-family:'Times New Roman';font-size:8pt;">&#8999;</span><span style="font-size:8pt;">&#160; No&#160;&#160;</span><span style="font-family:'Times New Roman';font-size:8pt;">&#9723;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_a975f266_f6c7_407d_aa80_42ce67244ae1"></a><a id="Tc_yy7kt-_3tUW-sZ1fxT0Gwg_1_0"></a><a id="Tc_FrReW2N0hESbRbWpZiXOzA_1_1"></a><a id="Tc_FOVtSGex2kGK2Qeu0xdroQ_1_2"></a><a id="Tc_e8l6G0HmEkSQmKuo6U8l6Q_1_3"></a><a id="Tc_pm5StVtYzUum1waJvdeEGg_2_1"></a><a id="Tc_ybJxQYOM0kWwjBFxpv7BzQ_2_2"></a><a id="Tc_KeHS2r_uO0KT55xwHagYkQ_3_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:90.06%;"><tr style="height:1pt;"><td style="vertical-align:top;width:25.99%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:38.02%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:10.96%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:25.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Large accelerated filer</p></td><td style="vertical-align:top;width:38.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Accelerated filer</p></td><td style="vertical-align:top;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td></tr><tr><td style="vertical-align:top;width:25.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:entityfilercategoryen" contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw" name="dei:EntityFilerCategory" id="Tc_7ONUbNuYZES6Gg_TekzZZg_2_0"><span style="font-size:8pt;">Non-accelerated filer</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:38.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:'Times New Roman';">&#8999;</span></p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Smaller reporting company</p></td><td style="vertical-align:top;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw" name="dei:EntitySmallBusiness" id="Tc_vsal4hQgCUSudb3rLgOeqw_2_3"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:25.99%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:38.02%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Emerging growth company</p></td><td style="vertical-align:top;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw" name="dei:EntityEmergingGrowthCompany" id="Tc_TVDrjNV3L02KNUcED2sXXQ_3_3"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. <span style="font-family:'Times New Roman';">&#9723;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). Yes&#160;&#160;</span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw" name="dei:EntityShellCompany" id="Narr_XKDqWtaNckmsHlGKBd51GA"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric><span style="font-size:8pt;"> &#160;&#160;No&#160;&#160; </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">On April&#160;30, 2023, approximately <ix:nonFraction unitRef="Unit_Standard_shares_4bVAm6lD50yLNxvQT1GIoA" format="ixt:numdotdecimal" scale="0" contextRef="As_Of_4_30_2023_HFiWapI7CUuGG9dGexPKfw" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" id="Narr_rH6KJNkCuE2mhYbOIvyMQw">65,414,917</ix:nonFraction> shares of the Registrant&#8217;s common stock, $0.001 par value, were outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_9944cb5a_dfb1_4dbb_bd8e_22e46e05caf4"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM 10-Q</b></p><a id="TOC"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">TABLE OF CONTENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:7.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:86.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:5.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td></tr><tr><td style="vertical-align:middle;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;text-align:center;border-bottom:1px solid #000000;margin:0pt;"><b style="font-weight:bold;">Page</b></p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><a href="#PARTIFINANCIALINFORMATION_363674"><b style="font-style:normal;font-weight:bold;">PART I &#8211; FINANCIAL INFORMATION</b></a></p></td><td style="vertical-align:top;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1FinancialStatements_969154"><span style="font-style:normal;font-weight:normal;">Item&#160;1.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1FinancialStatements_969154"><span style="font-style:normal;font-weight:normal;">Financial Statements</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CONDENSEDCONSOLIDATEDBALANCESHEETS_49495"><span style="font-style:normal;font-weight:normal;">Condensed Consolidated Balance Sheets (Unaudited) &#8211; As of March&#160;31, 2023 and December&#160;31, 2022</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATI"><span style="font-style:normal;font-weight:normal;">Condensed Consolidated Statements of Operations (Unaudited) &#8211; For the Three Months Ended March&#160;31, 2023 and 2022</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGES"><span style="font-style:normal;font-weight:normal;">Condensed Consolidated Statements of Changes in </span><span style="font-style:normal;font-weight:normal;">Stockholders&#8217; Equity (</span><span style="font-style:normal;font-weight:normal;">Capital Deficiency) (Unaudited) &#8211; For the Three Months Ended March&#160;31, 2023 and 2022</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;background:#ffffff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLO"><span style="font-style:normal;font-weight:normal;">Condensed Consolidated Statements of Cash Flows (Unaudited) &#8211; For the Three Months ended March&#160;31, 2023 and 2022</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;background:#ffffff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">5</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#NOTE1SIGNIFICANTACCOUNTINGPOLICIES_79340"><span style="font-style:normal;font-weight:normal;">Notes to Condensed Consolidated Financial Statements</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">7</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2ManagementsDiscussionandAnalysisofF"><span style="font-style:normal;font-weight:normal;">Item&#160;2.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2ManagementsDiscussionandAnalysisofF"><span style="font-style:normal;font-weight:normal;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">13</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3QuantitativeandQualitativeDisclosur"><span style="font-style:normal;font-weight:normal;">Item&#160;3.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3QuantitativeandQualitativeDisclosur"><span style="font-style:normal;font-weight:normal;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">29</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4ControlsandProcedures_865226"><span style="font-style:normal;font-weight:normal;">Item&#160;4.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4ControlsandProcedures_865226"><span style="font-style:normal;font-weight:normal;">Controls and Procedures</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">30</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><a href="#PARTIIOTHERINFORMATION_770480"><b style="font-style:normal;font-weight:bold;">PART II &#8211; OTHER INFORMATION</b></a></p></td><td style="vertical-align:top;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1LegalProceedings_676392"><span style="font-style:normal;font-weight:normal;">Item&#160;1.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1LegalProceedings_676392"><span style="font-style:normal;font-weight:normal;">Legal Proceedings</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">31</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1ARiskFactors_983377"><span style="font-style:normal;font-weight:normal;">Item&#160;1A.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1ARiskFactors_983377"><span style="font-style:normal;font-weight:normal;">Risk Factors</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">31</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2UnregisteredSalesofEquitySecurities"><span style="font-style:normal;font-weight:normal;">Item&#160;2.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2UnregisteredSalesofEquitySecurities"><span style="font-style:normal;font-weight:normal;">Unregistered Sales of Equity Securities and Use of Proceeds</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">31</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3DefaultsUponSeniorSecurities_505234"><span style="font-style:normal;font-weight:normal;">Item&#160;3.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3DefaultsUponSeniorSecurities_505234"><span style="font-style:normal;font-weight:normal;">Defaults Upon Senior Securities</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">31</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4MineSafetyDisclosure_204781"><span style="font-style:normal;font-weight:normal;">Item&#160;4.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4MineSafetyDisclosure_204781"><span style="font-style:normal;font-weight:normal;">Mine Safety Disclosures</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">31</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item5OtherInformation_679200"><span style="font-style:normal;font-weight:normal;">Item&#160;5.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item5OtherInformation_679200"><span style="font-style:normal;font-weight:normal;">Other Information</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">31</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item6Exhibits_829552"><span style="font-style:normal;font-weight:normal;">Item&#160;6.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item6Exhibits_829552"><span style="font-style:normal;font-weight:normal;">Exhibits</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">31</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:94.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#SIGNATURES_574709"><span style="font-style:normal;font-weight:normal;">Signatures</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">33</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_f275c393_200f_4cab_af06_1e5a9312cf62"></a><a id="PARTIFINANCIALINFORMATION_363674"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PART&#160;I&#160;&#8211; FINANCIAL INFORMATION</p><a id="Item1FinancialStatements_969154"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 6pt 0pt;">Item&#160;1. Financial Statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><a id="CONDENSEDCONSOLIDATEDBALANCESHEETS_49495"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONDENSED CONSOLIDATED BALANCE SHEETS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(U.S. dollars in thousands)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Unaudited)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_26ebb788_9b3d_4dbb_85f8_adaa92a7253b"></a><a id="Tc_Q1r9aW3MDkSxCLTl4yc5Vg_1_2"></a><a id="Tc_jFxqm2kutE-zyzX2EV3p4Q_1_5"></a><a id="Tc_GdEn1vlETU2Lghdd-0HwyA_3_0"></a><a id="Tc_DqhNlIbB9U-pDn8e2ZPjvQ_5_0"></a><a id="Tc_oF8qdGATdUu7P4OAf-xRuQ_6_0"></a><a id="Tc_G4YLeQK7EkSEhLZFaVpwHQ_6_2"></a><a id="Tc_aborSiK5HkaY5Cf1hp9ryw_6_5"></a><a id="Tc_ww8LElNjyEOk9LTvZYS_7A_7_0"></a><a id="Tc_FQgcxb_n_UKpXHuXQiq1TA_7_3"></a><a id="Tc_J4EITzjgdUGy3VLOVjZHcQ_8_0"></a><a id="Tc_GDQBlYMa0k2znisfGjSZHA_9_0"></a><a id="Tc_II3d7MFLAE6v1735OGQx-g_10_0"></a><a id="Tc_akp9JXXFREeUAXMc63oB9g_11_0"></a><a id="Tc_PrcE2VFXUUm5dB5HGCz0tQ_11_2"></a><a id="Tc_fPnrWONC8UGfJ9u2k40YWA_11_5"></a><a id="Tc_mE3WmhM0G0SVWAWQq9Jbew_13_0"></a><a id="Tc_C3lYoLUEiEOewnjeBXnGTQ_14_0"></a><a id="Tc_t1Za8egjLE6MgDejCA4EOA_14_2"></a><a id="Tc_pp2dFYC8VEuWPuHPh_7dvA_14_5"></a><a id="Tc_l86NVe8TG0KTmsqLrvo98Q_15_0"></a><a id="Tc_yxrqw78U_kWWfMWRpQQtyQ_16_0"></a><a id="Tc_I8L-yf9EN0aY9TUHrxuNAQ_17_0"></a><a id="Tc_YUdXnc7TWkeLeazfbxeU-Q_17_2"></a><a id="Tc_7_s2JxRXS0q6ov7MJuHJow_17_5"></a><a id="Tc_uoQFjWCxvki19nUCgIk0yA_19_0"></a><a id="Tc_rZ7NsPFI3EKy1_KFdiG0NA_21_0"></a><a id="Tc_4eynnmGcnU-20wdzdwTH9w_22_0"></a><a id="Tc_kvJUF-VB40GSiXqCydQdTQ_23_0"></a><a id="Tc__WcLNdP35UGihS2-eHr6bw_23_2"></a><a id="Tc_PNuzaQMELE2I9btsGRWgRQ_23_5"></a><a id="Tc_yfXbQORvXkGQpQglVcj8hw_24_0"></a><a id="Tc_O3Wyw_ACMUiJ2TCcxwZopw_25_0"></a><a id="Tc_QM8u3UhW70q8PqxHfS3F1g_26_0"></a><a id="Tc_26c-WP3jUk22H4xJ4rv6aA_27_0"></a><a id="Tc_kjq6KnAIy0-rnmsChRBsgA_27_2"></a><a id="Tc_piYCrh4L_E6HREhENPMhEA_27_5"></a><a id="Tc_HZhmStmdy0aBqTsFa6ijZw_29_0"></a><a id="Tc_QVtSV4-Qek2Uei5dSBm4OQ_30_0"></a><a id="Tc_rrCysu75AEmk_d0Qlj_J8g_30_2"></a><a id="Tc_7wFPNswS6Uq78lL5Vi5zng_30_5"></a><a id="Tc_XrCY8HyaFUaoDm_3KDUIuA_31_0"></a><a id="Tc_06xVodOvNE2CxHc5-l4fIQ_32_0"></a><a id="Tc_bD1rziI410e9_pvU_LALMg_33_0"></a><a id="Tc_AFPkHO6opE-z7O4gLX-fNA_33_2"></a><a id="Tc_HGXE07bob0OC5sERBclCaA_33_5"></a><a id="Tc_BNmaihE2RESzPYkFGDFC9w_34_0"></a><a id="Tc_IAiG1B9AOkCcL8Q-5-ATdw_34_2"></a><a id="Tc_lWeiHOFDGEmKxUhq4xgpEw_34_5"></a><a id="Tc_drxA5BOlMUGX41r0m1BtBg_36_0"></a><a id="Tc_FMd11TBx_ESSd0JzAyFbxg_38_0"></a><a id="Tc_Zd1QaD1h-UCSFP3_tJ3Mew_39_0"></a><a id="Tc_oOYu3563OU6T-Yy51lNIbw_39_2"></a><a id="Tc_Xpb-0bgoREyOykt_KJ-8yA_39_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">ASSETS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">CURRENT ASSETS:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="As_Of_3_31_2023_lQ4VofWCfU-ERA4iKttplQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_zgVS2BbzHkOmJCqJHG28sA_6_3">33,036</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="As_Of_12_31_2022_H53zBT4W7kaDDa9Xye-U_Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_c4qJ2PG9_EGpUPYDC9mMVw_6_6">17,111</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Short-term bank deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="As_Of_12_31_2022_H53zBT4W7kaDDa9Xye-U_Q" decimals="-3" format="ixt:numdotdecimal" name="plx:ShortTermBankDeposits" scale="3" id="Tc_-VJUCHWhi0G8-E0g3gBXdg_7_6">5,069</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Accounts receivable &#8211; Trade</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="As_Of_3_31_2023_lQ4VofWCfU-ERA4iKttplQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="Tc_4_GcIXvl_EqRIYTqSDNHNQ_8_3">1,304</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="As_Of_12_31_2022_H53zBT4W7kaDDa9Xye-U_Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="Tc_NB_q3f-FxUWkImM1QwNv_Q_8_6">4,586</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="As_Of_3_31_2023_lQ4VofWCfU-ERA4iKttplQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="3" id="Tc_NvokxZ8rW0Cy2i4t3yKVBQ_9_3">758</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="As_Of_12_31_2022_H53zBT4W7kaDDa9Xye-U_Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="3" id="Tc_1oFk8UTi5kikgVXIZ2lCPQ_9_6">1,310</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Inventories</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="As_Of_3_31_2023_lQ4VofWCfU-ERA4iKttplQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_xfQxwCkE-UOKSuOUfSvk6g_10_3">20,303</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="As_Of_12_31_2022_H53zBT4W7kaDDa9Xye-U_Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_5AehK0rAd0KmNaF_EE6diQ_10_6">16,804</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="As_Of_3_31_2023_lQ4VofWCfU-ERA4iKttplQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_VwoVAwzZG0qd82RSXBcfyw_11_3">55,401</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="As_Of_12_31_2022_H53zBT4W7kaDDa9Xye-U_Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_20n8B62hmEaOVkUnWYk6Xw_11_6">44,880</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">NON-CURRENT ASSETS:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Funds in respect of employee rights upon retirement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="As_Of_3_31_2023_lQ4VofWCfU-ERA4iKttplQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" scale="3" id="Tc_CeUduVfktUeaLxz0s8miJg_14_3">1,252</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="As_Of_12_31_2022_H53zBT4W7kaDDa9Xye-U_Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" scale="3" id="Tc_qHsAbiFYskCcnqKveuMs5g_14_6">1,267</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="As_Of_3_31_2023_lQ4VofWCfU-ERA4iKttplQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_r1F0qVOD30CKs-wQOD7OBw_15_3">4,704</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="As_Of_12_31_2022_H53zBT4W7kaDDa9Xye-U_Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_0v_fmIgJU0GebtOW6yMKiA_15_6">4,553</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating lease right of use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="As_Of_3_31_2023_lQ4VofWCfU-ERA4iKttplQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_ABPr-sCTr0Ci3dZEuRUaQg_16_3">5,202</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="As_Of_12_31_2022_H53zBT4W7kaDDa9Xye-U_Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_xSJxBlr_lUSX5dFJcLOhaw_16_6">5,087</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="As_Of_3_31_2023_lQ4VofWCfU-ERA4iKttplQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_cePGG0gK5UCD_XfKCXMWCA_17_3">66,559</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="As_Of_12_31_2022_H53zBT4W7kaDDa9Xye-U_Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc__Y2UMgZk7kCloA1GqsWjVg_17_6">55,787</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">LIABILITIES AND STOCKHOLDERS&#39; EQUITY (NET OF CAPITAL DEFICIENCY)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">CURRENT LIABILITIES:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Accounts payable and accruals:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Trade</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="As_Of_3_31_2023_lQ4VofWCfU-ERA4iKttplQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableTradeCurrent" scale="3" id="Tc_RZT76YgVVke4zj7gvQq3NA_23_3">5,105</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="As_Of_12_31_2022_H53zBT4W7kaDDa9Xye-U_Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableTradeCurrent" scale="3" id="Tc_mHp6-_WM2USIsmqCFhozSw_23_6">5,862</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="As_Of_3_31_2023_lQ4VofWCfU-ERA4iKttplQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableOtherCurrent" scale="3" id="Tc_dINMgE6ALUqUOH1JhzaPuA_24_3">13,471</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="As_Of_12_31_2022_H53zBT4W7kaDDa9Xye-U_Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableOtherCurrent" scale="3" id="Tc_-uxkn8L0hkKd_iyUrzpJbA_24_6">12,271</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="As_Of_3_31_2023_lQ4VofWCfU-ERA4iKttplQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_Gv1FYphB4UG-tWyTpUB4Mg_25_3">1,149</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="As_Of_12_31_2022_H53zBT4W7kaDDa9Xye-U_Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_-8f0_b6OZkKI8VHMWcF-tg_25_6">1,118</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Contracts liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="As_Of_3_31_2023_lQ4VofWCfU-ERA4iKttplQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="Tc_dzyhqZQudEaCyk84FFfEmQ_26_3">11,790</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="As_Of_12_31_2022_H53zBT4W7kaDDa9Xye-U_Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="Tc_7HS4088AYUSVuaipdYKvHQ_26_6">13,178</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="As_Of_3_31_2023_lQ4VofWCfU-ERA4iKttplQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_AdOXDAuKykmLnJ4WVG9qxg_27_3">31,515</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="As_Of_12_31_2022_H53zBT4W7kaDDa9Xye-U_Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_dSi_3fxveU6NgEc7-fA5mQ_27_6">32,429</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">LONG TERM LIABILITIES:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Convertible notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="As_Of_3_31_2023_lQ4VofWCfU-ERA4iKttplQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebtNoncurrent" scale="3" id="Tc_i1WFjrs5Z0qTRTDbvj9LNQ_30_3">28,267</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="As_Of_12_31_2022_H53zBT4W7kaDDa9Xye-U_Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebtNoncurrent" scale="3" id="Tc_bSz_p1gUlEuOCsCSkbKTmg_30_6">28,187</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Liability for employee rights upon retirement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="As_Of_3_31_2023_lQ4VofWCfU-ERA4iKttplQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" scale="3" id="Tc_PJUxr0rw8kWZFOYDdBkjeQ_31_3">1,617</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="As_Of_12_31_2022_H53zBT4W7kaDDa9Xye-U_Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" scale="3" id="Tc_e8PwGEUMZEKTBZdw6N_7Kw_31_6">1,642</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="As_Of_3_31_2023_lQ4VofWCfU-ERA4iKttplQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_cm7f5dRCC0K3yUQvdpFe_w_32_3">4,152</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="As_Of_12_31_2022_H53zBT4W7kaDDa9Xye-U_Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_LgrNRFRwu0Kc3u8SqDfsZw_32_6">4,169</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total long term liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="As_Of_3_31_2023_lQ4VofWCfU-ERA4iKttplQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesNoncurrent" scale="3" id="Tc_r91afrmvG0K23EEWd4CTFA_33_3">34,036</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="As_Of_12_31_2022_H53zBT4W7kaDDa9Xye-U_Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesNoncurrent" scale="3" id="Tc_Gnmpa_7jSEuWchLztLrubw_33_6">33,998</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="As_Of_3_31_2023_lQ4VofWCfU-ERA4iKttplQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_o5qBPGY7EkC0RTNNaD9yYw_34_3">65,551</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="As_Of_12_31_2022_H53zBT4W7kaDDa9Xye-U_Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_iHCxgmERk021LcXpDVYbqA_34_6">66,427</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">COMMITMENTS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">STOCKHOLDERS&#39; EQUITY (CAPITAL DEFICIENCY)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="As_Of_3_31_2023_lQ4VofWCfU-ERA4iKttplQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_xfm0M7WY00WBIubq-ZH53g_38_3">1,008</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="As_Of_12_31_2022_H53zBT4W7kaDDa9Xye-U_Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_8n18JUUZ1UGNIjlxGddM4Q_38_6">10,640</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total liabilities and stockholders&#39; equity (net of capital deficiency)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="As_Of_3_31_2023_lQ4VofWCfU-ERA4iKttplQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_c4rDe1x9I0iSaFf9rrsCZg_39_3">66,559</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="As_Of_12_31_2022_H53zBT4W7kaDDa9Xye-U_Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_4W9TSwchDE-snhC7PVobKg_39_6">55,787</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">The accompanying notes are an integral part of the condensed consolidated financial statements.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_a8488e67_cd30_41d6_985c_7b2b2667ccf1"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><a id="CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATI"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(U.S. dollars in thousands, except share and per share data)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Unaudited)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_56f12b7f_6569_4577_8b68_5640a4558c2e"></a><a id="_245770eb_1795_4abb_94f5_de46e607fba1"></a><a id="Tc_BPQU_ebec0GTAeFoUmv4fA_1_2"></a><a id="Tc_Yl-0D4PlKEi1GSaEZ6nuig_2_2"></a><a id="Tc_0E3REI0CZEqmJiFh1Dalhg_2_5"></a><a id="Tc_3FFDHwnFmk2mjoSI2WONrQ_3_0"></a><a id="Tc_eHKysIra7EmE9HEKtGmSlg_3_2"></a><a id="Tc_S5575rT9XU-fbPKZMraUmg_3_5"></a><a id="Tc_bKt8FrAMQ0O16q0HHmyfTw_4_0"></a><a id="Tc_9cATxFG2zkeEpbjptZTCjw_5_0"></a><a id="Tc_DEtmXmKnR0iE1GxwY70ldw_6_0"></a><a id="Tc_oohBozpsC0WKF8ZKKzeXGQ_7_0"></a><a id="Tc_t8_7ETtrq0WD_oOElFxPoQ_8_0"></a><a id="Tc_XrRWK5D-BEKgYEPIDNkRVw_9_0"></a><a id="Tc_2PyVvoP8jUaruaxObktNwg_10_0"></a><a id="Tc_AGcQn48LU0m3LQnbFA4Nsg_11_0"></a><a id="Tc_z8jsU0VTS0eeIe9woH32YQ_12_0"></a><a id="Tc_4GOxEYDf7EW2J-Y5V7iCRA_13_0"></a><a id="Tc_msIPMxMqoU2L3GJGF47ccg_14_0"></a><a id="Tc_aaPW8YnukEOe3rDcS54Hnw_14_6"></a><a id="Tc_DAwyQC0mxEqs-x2JBwPY1Q_15_0"></a><a id="Tc_1tfB7qtZtkSUlcK-Eh-0TA_15_2"></a><a id="Tc_ztXrJD9nIkyRkQcnq7zWMg_15_5"></a><a id="Tc_DDcCfobrw0u5yTcdjJVz3A_16_0"></a><a id="Tc_xHqKYFBUXEW02JGmghdQ8A_16_2"></a><a id="Tc_Z8eqegXgw0yo2hDipZ1GLQ_16_5"></a><a id="Tc_78igIAR37Ui7-uWh5Vqszw_17_0"></a><a id="Tc_7kUOXTyifEu6hZU6ZCNHQw_18_0"></a><a id="Tc_vUVwDnHSMUiWUuZCzoFwbw_19_0"></a><a id="Tc_fZkFULsDskykVlxsPR_tvw_19_2"></a><a id="Tc_PQ00oI18aEaJqn3luuAWdg_19_5"></a><a id="Tc_ULE6ZOQkqUylyRYb5xs2Hw_20_0"></a><a id="Tc_futRS0LW2UKdwrI9EjLWeg_20_2"></a><a id="Tc_Ip8BOlM9CUu8pEfMRnHj7A_20_5"></a><a id="Tc_SHyQcnfK_UmnI5C7oLlQYg_21_0"></a><a id="Tc_tpuJr34Z8k6udSV-lwZ9xQ_21_2"></a><a id="Tc_hFbi_YTP5UKAHxkstJZYnA_21_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-1.7083359%;padding-left:0pt;padding-right:0pt;width:103.41%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:60.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:36.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:60.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;2022</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">REVENUES FROM SELLING GOODS</b></p></td><td style="vertical-align:bottom;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="Duration_1_1_2023_To_3_31_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_1ErUchefYE24icEBkPux0A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_imnrnIymU0S2LFhpCWxtKQ_3_3">5,066</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="Duration_1_1_2022_To_3_31_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_TLlwu1kiM067CBBRXPNrNw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_X1rua7BamkyeuBiU8BaK-Q_3_6">9,028</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:60.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">REVENUES FROM LICENSE AND R&amp;D SERVICES</b></p></td><td style="vertical-align:bottom;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="Duration_1_1_2023_To_3_31_2023_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_0OKK-_bib0C_UleLAi20GA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_6vC62m0OY0O5dJpEk7191A_4_3">4,522</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="Duration_1_1_2022_To_3_31_2022_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_rv5oVU7cTEWzAOzlbF-VFA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_eHEQYr_Ptk-ig6ztv_-7UQ_4_6">7,057</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:60.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">TOTAL REVENUE</b></p></td><td style="vertical-align:bottom;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_wg1iUyeDMU2XOiVNwOn9IA_5_3">9,588</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="Duration_1_1_2022_To_3_31_2022_N1jzYHJ1VECWf3tLdKC1jw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_DPOGyhNJc0mMkELbQ6QmgQ_5_6">16,085</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:60.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">COST OF GOODS SOLD (1)</b></p></td><td style="vertical-align:bottom;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfRevenue" scale="3" id="Tc_weldJHKNTU-LFl_B0NjZQw_6_3">3,085</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="Duration_1_1_2022_To_3_31_2022_N1jzYHJ1VECWf3tLdKC1jw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfRevenue" scale="3" id="Tc_eCxjacwjWUC54yg3cb-XsA_6_6">6,034</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">RESEARCH AND DEVELOPMENT EXPENSES (2)</b></p></td><td style="vertical-align:bottom;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_l3K5Bpo4okmUExRcDvJpSA_7_3">5,847</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="Duration_1_1_2022_To_3_31_2022_N1jzYHJ1VECWf3tLdKC1jw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_o7CMDO5nykicD24BOuYAWg_7_6">8,767</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">SELLING, GENERAL AND ADMINISTRATIVE EXPENSES (3)</b></p></td><td style="vertical-align:bottom;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="Tc_fTYVNJWnjESxIeMvtTihVg_8_3">3,115</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="Duration_1_1_2022_To_3_31_2022_N1jzYHJ1VECWf3tLdKC1jw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="Tc_FWjhg_ga90yHw-Q3cLx8eA_8_6">3,154</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:60.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">OPERATING LOSS</b></p></td><td style="vertical-align:bottom;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_Ja8JiVagPEeZFBynBELdXg_9_3">2,459</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="Duration_1_1_2022_To_3_31_2022_N1jzYHJ1VECWf3tLdKC1jw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_nCKtM2FR3UGRuKgx47JuAA_9_6">1,870</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:60.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">FINANCIAL EXPENSES</b></p></td><td style="vertical-align:bottom;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingExpense" scale="3" id="Tc_swN-AB3tcU2lz8XYcgGj5Q_10_3">649</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="Duration_1_1_2022_To_3_31_2022_N1jzYHJ1VECWf3tLdKC1jw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingExpense" scale="3" id="Tc_BiYx9QAPwEiLz7-1m3VgiA_10_6">618</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:60.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">FINANCIAL INCOME</b></p></td><td style="vertical-align:bottom;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncome" scale="3" id="Tc_vMD5fsUkx0aImZrgpnxjng_11_3">172</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="Duration_1_1_2022_To_3_31_2022_N1jzYHJ1VECWf3tLdKC1jw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncome" scale="3" id="Tc_qEjaLKalhkmwHiLqIg4_dQ_11_6">202</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:60.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">FINANCIAL EXPENSES, NET</b></p></td><td style="vertical-align:bottom;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" sign="-" scale="3" id="Tc_x04bAnZAXUCxAuDg_-YYVg_12_3">477</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="Duration_1_1_2022_To_3_31_2022_N1jzYHJ1VECWf3tLdKC1jw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" sign="-" scale="3" id="Tc_MtvVh_JIAUCpk_xTvrGjgg_12_6">416</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:60.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">LOSS BEFORE TAXES ON INCOME</b></p></td><td style="vertical-align:bottom;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_HU-d2JjfTEO3ViosXeJ0DA_13_3">2,936</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="Duration_1_1_2022_To_3_31_2022_N1jzYHJ1VECWf3tLdKC1jw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_bEArjs423Em_5QW5bPyPfw_13_6">2,286</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:60.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">TAXES ON INCOME</b></p></td><td style="vertical-align:bottom;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_HfZ0hFX-Jk6AcMdkMljIkA_14_3">195</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">NET LOSS FOR THE PERIOD</b></p></td><td style="vertical-align:bottom;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_u3bjcH7Bi06NXHJZcXxttQ_15_3">3,131</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="Duration_1_1_2022_To_3_31_2022_N1jzYHJ1VECWf3tLdKC1jw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_rrDyNmFzhEGpboQOrDqOZg_15_6">2,286</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">LOSS PER SHARE OF COMMON STOCK &#8211; BASIC AND DILUTED</b></p></td><td style="vertical-align:bottom;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.1%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_65Ko0I-nrkSGY9fEMAqs6Q" contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_XbRPM9NTTE2SGBFqeB9mAg_16_3"><ix:nonFraction unitRef="Unit_Divide_USD_shares_65Ko0I-nrkSGY9fEMAqs6Q" contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_XbRPM9NTTE2SGBFqeB9mAg_16_3_2">0.05</ix:nonFraction></ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.12%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_65Ko0I-nrkSGY9fEMAqs6Q" contextRef="Duration_1_1_2022_To_3_31_2022_N1jzYHJ1VECWf3tLdKC1jw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_rWM_b1ygHE-cNyGvSNu5nw_16_6"><ix:nonFraction unitRef="Unit_Divide_USD_shares_65Ko0I-nrkSGY9fEMAqs6Q" contextRef="Duration_1_1_2022_To_3_31_2022_N1jzYHJ1VECWf3tLdKC1jw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_rWM_b1ygHE-cNyGvSNu5nw_16_6_2">0.05</ix:nonFraction></ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK </b></p></td><td style="vertical-align:bottom;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">USED IN COMPUTING LOSS PER SHARE &#8211; BASIC AND DILUTED</b></p></td><td style="vertical-align:bottom;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_4bVAm6lD50yLNxvQT1GIoA" contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_fLmz2eItK0i3gFFi5N-xNg_18_3"><ix:nonFraction unitRef="Unit_Standard_shares_4bVAm6lD50yLNxvQT1GIoA" contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_fLmz2eItK0i3gFFi5N-xNg_18_3_2">57,480,009</ix:nonFraction></ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_4bVAm6lD50yLNxvQT1GIoA" contextRef="Duration_1_1_2022_To_3_31_2022_N1jzYHJ1VECWf3tLdKC1jw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_rM_53rzO9E-2iG51YhlYOg_18_6"><ix:nonFraction unitRef="Unit_Standard_shares_4bVAm6lD50yLNxvQT1GIoA" contextRef="Duration_1_1_2022_To_3_31_2022_N1jzYHJ1VECWf3tLdKC1jw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_rM_53rzO9E-2iG51YhlYOg_18_6_2">45,843,563</ix:nonFraction></ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:60.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;"><ix:footnote xml:lang="en-US" id="_decff55c_b6f1_4b4f_9c4c_20bfc2a1e99e"><b style="font-size:8pt;font-weight:bold;">(1) Includes share-based compensation</b></ix:footnote></p></td><td style="vertical-align:bottom;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;"><span style="font-size:8pt;font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_kovew3nQoUW7X8jAVRvjhw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_EzNc6Yz3eUeEdEtsg1EABg_19_3">58</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_M9nMRkvbzkONqh4KPar8cg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" sign="-" scale="3" id="Tc_yFx6awzeZ0mGoZFMt7_exA_19_6">6</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:60.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;"><ix:footnote xml:lang="en-US" id="_8530ca94_6c84_4f48_984f_7cc5a2959400"><b style="font-size:8pt;font-weight:bold;">(2) Includes share-based compensation</b></ix:footnote></p></td><td style="vertical-align:bottom;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;"><span style="font-size:8pt;font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_O-2jNHV-AUW4fRDBPZldoA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_Sd5VSQRqfEiwi5sNfNoxLA_20_3">180</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_ACjpei32d0mTu26aZxZF-Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_l7sNONWGjUKCLKMbKlGHzw_20_6">76</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:60.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;"><ix:footnote xml:lang="en-US" id="_64475d15_2bf5_4e75_bed3_14deb6a39d55"><b style="font-size:8pt;font-weight:bold;">(3) Includes share-based compensation</b></ix:footnote></p></td><td style="vertical-align:bottom;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;"><span style="font-size:8pt;font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_f8-sCIf2RkuxwvCb3yISvA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_ma9pYR_V1kacfHOinaGwzA_21_3">308</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_QMhb-FrbfESVBC7w8w5e4A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_Q35hpGJO7kqghqualPKGeg_21_6">766</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">The accompanying notes are an integral part of the condensed consolidated financial statements.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_d89eec5e_357a_4111_86ce_812eb43d3102"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><a id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGES"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">STOCKHOLDERS&#8217; EQUITY (CAPITAL DEFICIENCY)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(U.S. dollars in thousands, except share data)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Unaudited)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_51b0fa27_d06a_4470_84d5_013b9f213bd8"></a><a id="Tc_R42OHnv35UaSkACNOAbqmg_1_7"></a><a id="Tc_tHcns7B6aU61RsqzlmOqpg_2_2"></a><a id="Tc_aRb3qV2S60Gmkf47ZEep7Q_2_4"></a><a id="Tc_YzPTowhNMEmSZXsaUqpuWg_2_7"></a><a id="Tc_nuCrBtlcTEmkJoXBqeLAfw_2_10"></a><a id="Tc_HXKJdqAY1kO5G-VGkvj5XA_3_2"></a><a id="Tc_JxL-Ebg250GxIhk1jclZjA_3_4"></a><a id="Tc_FFGMWJNQ2kCyY-dDhVF-tQ_3_7"></a><a id="Tc_Ht2igly1wEK7cVlynKRkfA_3_10"></a><a id="Tc_vW89zUfdB0qcBblqiLBu1g_3_13"></a><a id="Tc_m8x7zdvonku4rvOJ1hAo4g_4_2"></a><a id="Tc_ruuo_WPn2EyiV1ExGOJFDQ_5_2"></a><a id="Tc_OHh9tNpin0mgEZcHmtyEQg_5_4"></a><a id="Tc_jKxJ8gRAVkyPCH8iml40vQ_6_0"></a><a id="Tc_fP2bqM6uzk-jcBcu2hlQTg_6_4"></a><a id="Tc_9Kh91gtATU-JdyJnnr-E1Q_6_7"></a><a id="Tc_jChZRZsZKEq16YwwJID5qQ_6_10"></a><a id="Tc_DjOQ820daEyx6uvu1frRqg_6_13"></a><a id="Tc_C3uIRdpHkUCYldluVIk8EA_7_0"></a><a id="Tc_kmhUrRdqkEe4cZFkgLxFLw_8_0"></a><a id="Tc_Fz9DM3Nd9E2qQ9xQxsP_bQ_9_0"></a><a id="Tc_3t9fJ8k1E0uhUy_TpliLAw_9_5"></a><a id="Tc_hqcWFCc1OUitdUM6kNOi_w_10_0"></a><a id="Tc_44kqXQAcVUGpK_G5AolPFA_11_0"></a><a id="Tc_Zph50ShYwkCfn9pEvkCXSA_11_4"></a><a id="Tc_UUtBl74QT02hM_fH37iIoQ_11_7"></a><a id="Tc_AinkVjH9-EG_hFKN121stA_11_10"></a><a id="Tc_BB8N5MsQ7k6tRzNh7FQdpw_11_13"></a><a id="Tc_wqzt6ZYejkiVSO8Y7TwHxw_12_0"></a><a id="Tc_mTujyZium0CZbqkui8UuYw_12_4"></a><a id="Tc_G8d5zo0PREuidXdwxs7pEA_12_7"></a><a id="Tc_gkJi6jB_iE-f7wrD1uu2lg_12_10"></a><a id="Tc_i05BRR_ZTUCmtOPxjCMYag_12_13"></a><a id="Tc_8O5GcCapYkqS1L6s0iD5IQ_13_0"></a><a id="Tc_kX16EFfSL0CmlbjSu5YIJw_14_0"></a><a id="Tc_AtCzGYb8XUekkkm9BsueKA_15_0"></a><a id="Tc_Qw2Eb-xBHUe6zLYvPqN7FQ_16_0"></a><a id="Tc_0nb78OURuUe0zAT5B45W2Q_17_0"></a><a id="Tc_cWAT2swf4kuyfFUzUj6dYA_18_0"></a><a id="Tc_gCYNgWvIrESwgMC8kh8zhw_18_4"></a><a id="Tc_JWtBTVs_0UGYzIZ-xkuKqw_18_7"></a><a id="Tc_l-EiZXEMpUq3uqORnmtDiA_18_10"></a><a id="Tc_nOYeBfZKhUau1rNHuWfy6w_18_13"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Common</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Common</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Paid-In</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Stock (1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:40.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at January 1, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_4bVAm6lD50yLNxvQT1GIoA" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_J7EBNPBz8ESJc8H_4uZ72w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_v0W510vMt0WtRFcsOlezUQ_6_2">45,556,647</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_J7EBNPBz8ESJc8H_4uZ72w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_GEmucjc6PkWJ_BHsh3d16Q_6_5">46</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_vOwYA9rCf0W5Bz8PPuTQvg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_UbVedHXfxUG6h_aOzpaxOw_6_8">368,852</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember__Fk6t8bO9k-wg-VncCAqpg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_BBuCf6nYk0GPH8uxj3_nEA_6_11">374,934</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="As_Of_12_31_2021_x-pm8I0vjUS_ATBiwepawg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_9uZfNvtTaUWLDKnu87ki0g_6_14">6,036</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Changes during the three-month period ended March&#160;31,&#160;2022:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:46.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation related to stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_pTjg192DOkSYYbGFlFzhqA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_WleW3eJpkE-ue8sCPq4RzA_8_8">149</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="Duration_1_1_2022_To_3_31_2022_N1jzYHJ1VECWf3tLdKC1jw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_wia29lh5n0aIjLSYqa-j3A_8_14">149</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation related to restricted stock awards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_4bVAm6lD50yLNxvQT1GIoA" contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_M0avG7-u206lSf4X6whkbA" decimals="INF" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" scale="0" id="Tc_yTxTuHFDc0CebaIJf12WuA_9_2">759,482</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_pTjg192DOkSYYbGFlFzhqA" decimals="-3" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_Fm6qmMMKekauGaGNgr_hOA_9_8">687</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="Duration_1_1_2022_To_3_31_2022_N1jzYHJ1VECWf3tLdKC1jw" decimals="-3" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc__aOAaa015E2h0fQ3YQYZUA_9_14">687</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Net loss for the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_P_C-vkYM70mz4hoQ7UVhOg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_wBdLT37iKU-G1EXoD2Ga6w_10_11">2,286</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="Duration_1_1_2022_To_3_31_2022_N1jzYHJ1VECWf3tLdKC1jw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_lW4RpCcYTESLhSMWViV8jw_10_14">2,286</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at March&#160;31,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_4bVAm6lD50yLNxvQT1GIoA" contextRef="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Ma9XQZkyu0yv3iLSHCbY5g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_dgYszTwrTEefeCZ3ZKmo1Q_11_2">46,316,129</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Ma9XQZkyu0yv3iLSHCbY5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_-p7bq2dsek2ZfOUkYUBgkQ_11_5">46</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_P1TRpg9XL0SipWskVIymPg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_KSOGZykx_UyTrdaOiIVZ2A_11_8">369,688</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_sessMVhLlE-60nptH85tHA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_BOiYAS6n-0WPIKxzUnC6dQ_11_11">377,220</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="As_Of_3_31_2022_cjzuDz-ZiUubY38dhB0s0A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_r3ASuL4Vd0CiMunRa86oIg_11_14">7,486</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at January 1, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_4bVAm6lD50yLNxvQT1GIoA" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_B-MKROg0kkWsBATWzcCW9g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_exCmImm6ckG9_1mX6eB13g_12_2">53,790,167</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_B-MKROg0kkWsBATWzcCW9g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_Bl3kZf5VE0Cxo1h5VZmyWA_12_5">54</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_xvyzPFwz2Ei9WGmzrZtTKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_P2rAMuazoE203pp2a_-Xjg_12_8">379,167</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_td4XMHFZWkWCZfhPrs2Yog" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc__ACYK-Pd20esDP0CAegAcA_12_11">389,861</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="As_Of_12_31_2022_H53zBT4W7kaDDa9Xye-U_Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_5lyVxFwW1EKG6QG6DLI3Ew_12_14">10,640</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Changes during the three-month period ended March&#160;31,&#160;2023:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:46.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of common stock under the Sales Agreement, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_4bVAm6lD50yLNxvQT1GIoA" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_o5KTQD_NWEC6IWOAHM7tDQ" decimals="INF" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodSharesSalesAgreement" scale="0" id="Tc_mfQTaw5le0imjmuMBx4ODg_14_2">8,212,482</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_o5KTQD_NWEC6IWOAHM7tDQ" decimals="-3" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueSalesAgreement" scale="3" id="Tc_08SrCHxp8kSOuA7gdTovBA_14_5">8</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_chSQy1P71EiszadyqHEgpA" decimals="-3" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueSalesAgreement" scale="3" id="Tc_NqV6jxOwGEq1opWpDrwcQA_14_8">14,225</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw" decimals="-3" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueSalesAgreement" scale="3" id="Tc_uCYYIpTqs0G6cDDgU858Ig_14_14">14,233</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation related to stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_chSQy1P71EiszadyqHEgpA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_VRE1EH6hzkOBEhNwR_BbuA_15_8">453</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_eQIyHVg6mkqN0GliWuwjjA_15_14">453</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation related to restricted stock awards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_chSQy1P71EiszadyqHEgpA" decimals="-3" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_sw0RuQ9mA0W5YdBwzczWfA_16_8">93</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw" decimals="-3" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_3aTISMeIY02cHXcJwyrkeQ_16_14">93</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Net loss for the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_M5gF58pjUEaKAVvefka9Pw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_P8Y3vTkndEKkN85PfpLgwQ_17_11">3,131</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_iq34XAgSX0mndax1chJPeQ_17_14">3,131</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:46.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at March&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_4bVAm6lD50yLNxvQT1GIoA" contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_bMnoYH_kPEuyqw6R4J9L2Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_EWUveCzkOkWNPC49U8GrGw_18_2">62,002,649</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_bMnoYH_kPEuyqw6R4J9L2Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_bcxV9fbgeE6Inish6WBISQ_18_5">62</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_IL0F69SjoE2AcVxC9gRdAg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_bvz4P9KfV02Oer2O2Lt46Q_18_8">393,938</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_E_QLG5yGnUWYSbAfH9__OQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_wMj68Qovokqq15QRkdlpxA_18_11">392,992</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="As_Of_3_31_2023_lQ4VofWCfU-ERA4iKttplQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_MK4tQawPMEGaQZVKn09bvA_18_14">1,008</ix:nonFraction></b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="background:#ffffff;">*Represents an amount equal to less than $1.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_a2e03645_2643_4168_926d_13e04faf108a"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">(1)&#160;<ix:footnote xml:lang="en-US" id="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7">Common stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_65Ko0I-nrkSGY9fEMAqs6Q" contextRef="As_Of_3_31_2022_cjzuDz-ZiUubY38dhB0s0A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_H8bJoskOX0yVvO0s2dy3jw"><ix:nonFraction unitRef="Unit_Divide_USD_shares_65Ko0I-nrkSGY9fEMAqs6Q" contextRef="As_Of_3_31_2023_lQ4VofWCfU-ERA4iKttplQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_pAwFV1t5yUqbnHUopInOFA">0.001</ix:nonFraction></ix:nonFraction> par value; Authorized &#8211; as of March&#160;31, 2023 and 2022 &#8211; <ix:nonFraction unitRef="Unit_Standard_shares_4bVAm6lD50yLNxvQT1GIoA" contextRef="As_Of_3_31_2023_lQ4VofWCfU-ERA4iKttplQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_-ES6nSAE10K6xII9lrm-JQ">144,000,000</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_4bVAm6lD50yLNxvQT1GIoA" contextRef="As_Of_3_31_2022_cjzuDz-ZiUubY38dhB0s0A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_MtsL9p7LdESJbCeMtxR42A">120,000,000</ix:nonFraction> shares, respectively.</ix:footnote></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">The accompanying notes are an integral part of the condensed consolidated financial statements.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_1969ae3b_b04b_4ede_8d7d_86a45b16dd76"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><a id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLO"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(U.S. dollars in thousands)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Unaudited)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_036b0258_18a7_4ba6_9dee_ce3a7dd27b55"></a><a id="Tc_9ZZpBIDWW0C6Qd6P4Oya4Q_1_2"></a><a id="Tc_HRuRtvCCsU-HJ_V-AQkZ_g_2_2"></a><a id="Tc_BiADlhVoekOIpNtQVULl7Q_2_5"></a><a id="Tc_CZvETF_XwEST8edBcReY2A_3_0"></a><a id="Tc_DfZ1shhWbU6Nv5Jk9G5GQA_4_0"></a><a id="Tc_uZBrR0tloUWEzC1pwEYRuQ_4_2"></a><a id="Tc_Vs2Nbo0Jfk2uCofh86Xghg_4_5"></a><a id="Tc_hOm-YT2VekmRscoHFzLIWQ_5_0"></a><a id="Tc_P-OF0WKfFU2KQwWywnTTGw_6_0"></a><a id="Tc_uhWsXymAjEmQnMmqjh3jWQ_7_0"></a><a id="Tc_2ueup3ZLjUq3eds0NhuPKg_8_0"></a><a id="Tc_hZ_1UHFq5E2uba-xFWOaTA_9_0"></a><a id="Tc_C0k7Omql2kO0DJtgayTPuQ_10_0"></a><a id="Tc_XT1A6UxgpkyNsaLwZ9U0SA_11_0"></a><a id="Tc_ZVeQueFTB0aJHr53t_8xVg_12_0"></a><a id="Tc_orKi9W0JXk6XL4eJbaJzhA_13_0"></a><a id="Tc_HvnH4lh5WEW_5IAdIV9PDQ_14_0"></a><a id="Tc_yCuPGJwtXEKVFWqXOiCaQg_15_0"></a><a id="Tc_BNFA9FfHckOUhff0xyzHpA_16_0"></a><a id="Tc_QKg0RfEjVU-SktSUqhW_HQ_17_0"></a><a id="Tc_zdwieEElfU2JoFn8vz6yeg_18_0"></a><a id="Tc_5NMUau4XAEOonmcmMbsFXQ_18_2"></a><a id="Tc_89p9O5mU7USn5BI1ruc5Ow_18_5"></a><a id="Tc_NUpo0fKZuECoqBBcwktamw_20_0"></a><a id="Tc_cBhQKX3yskmnxdph_a49dA_21_0"></a><a id="Tc_rX5STFPsbUiepZud8rMbHA_21_5"></a><a id="Tc_oFSOdEI8kEmJ9ypP6H7rAg_22_0"></a><a id="Tc_DU3krQDG7U-2ia5yEmFfcw_22_2"></a><a id="Tc_j1Gj81LLmUO1Ih53ZnncxQ_23_0"></a><a id="Tc_tU-V6TkcOk-Brhr-TMZbIA_24_0"></a><a id="Tc_y6LVOmjL3UKwe89CxABamw_25_0"></a><a id="Tc_CJxR_HVNq0Cm5zS3rJH6pg_25_2"></a><a id="Tc_dwuHx-7eZEGEk9ZxVVGJdg_25_5"></a><a id="Tc_rb5vNr8oxUu5e_gihjc6DA_27_0"></a><a id="Tc_bL7cJ0nLckecZf5ukVVaVg_28_0"></a><a id="Tc_iEp9ZhLa_EmLRhfcWWTvRw_28_2"></a><a id="Tc_q2hRD1Hrl0yYu2G-dPos6w_29_0"></a><a id="Tc_yt26Cx0xFkioPr2x69ba-A_29_2"></a><a id="Tc_jWnetghw7kOUvIo9igNXbg_29_6"></a><a id="Tc_ZPHw91S0GEaxceRGsC7lJA_30_0"></a><a id="Tc_Gf8GoPFGfUK2ES62agRxzQ_30_2"></a><a id="Tc_UsO50xZbJkK1pL8x0o2S4Q_30_5"></a><a id="Tc_LVoVER_KNkWt0-FCbQBtLg_31_0"></a><a id="Tc_t1Ul9t_k-ky11PBWSLni8w_32_0"></a><a id="Tc_N8fJzWD-qE2GlCoDyMJcSA_33_0"></a><a id="Tc_Z_6GUf-AW0277Ma2uXwJUg_33_2"></a><a id="Tc_K7KTG9Acr0yp_TObjokY9g_33_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">CASH FLOWS FROM OPERATING ACTIVITIES:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_gzcauP7Z5kmh0iwQoP5R9g_4_3">3,131</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="Duration_1_1_2022_To_3_31_2022_N1jzYHJ1VECWf3tLdKC1jw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_HS-NknV5TE2qj63CgMakmA_4_6">2,286</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Adjustments required to reconcile net loss to net cash used in operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Share-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_f0A_2evQPE-JwMIfEJgG5A_6_3">546</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="Duration_1_1_2022_To_3_31_2022_N1jzYHJ1VECWf3tLdKC1jw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_LVlbcfnMOkKhVtgz0rR9gg_6_6">836</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="Tc_qoQ6W3H33UiJguodkl80JA_7_3">280</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="Duration_1_1_2022_To_3_31_2022_N1jzYHJ1VECWf3tLdKC1jw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="Tc_LsRbmJ7dI0WSXAisipJWCw_7_6">270</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Financial income, net (mainly exchange differences)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" scale="3" id="Tc_3wEOp56ZCk2-A_IFdxSKDw_8_3">91</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="Duration_1_1_2022_To_3_31_2022_N1jzYHJ1VECWf3tLdKC1jw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" scale="3" id="Tc_aJUao3I0bUqBYmHbKvpdNA_8_6">198</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Changes in accrued liability for employee rights upon retirement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PensionAndOtherPostretirementBenefitExpense" scale="3" id="Tc_uU_02oSD00OwCv2Q5ytv9A_9_3">19</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="Duration_1_1_2022_To_3_31_2022_N1jzYHJ1VECWf3tLdKC1jw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PensionAndOtherPostretirementBenefitExpense" scale="3" id="Tc_1whmY-Bhx0ubtX34SjxEFw_9_6">75</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Loss on amounts funded in respect of employee rights upon retirement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw" decimals="-3" format="ixt:numdotdecimal" name="plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" sign="-" scale="3" id="Tc_AzVI7lDt60mv9mS1YcM_Wg_10_3">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="Duration_1_1_2022_To_3_31_2022_N1jzYHJ1VECWf3tLdKC1jw" decimals="-3" format="ixt:numdotdecimal" name="plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" sign="-" scale="3" id="Tc_3ygxeR2w00eQFL7WRWqx4A_10_6">10</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Amortization of debt issuance costs and debt discount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="Tc_p_M9xV-3f0Okhy12-yfOMw_11_3">80</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="Duration_1_1_2022_To_3_31_2022_N1jzYHJ1VECWf3tLdKC1jw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="Tc_tEG6KvpY4EONZtsCUiTIJw_11_6">75</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Changes in operating assets and liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Decrease in contracts liability (including non-current portion)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" sign="-" scale="3" id="Tc_d5i3BkNofES-koPEWXHz2A_13_3">1,388</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="Duration_1_1_2022_To_3_31_2022_N1jzYHJ1VECWf3tLdKC1jw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" sign="-" scale="3" id="Tc_mNAipb1tyU-E0q2W_4zgLA_13_6">2,644</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Decrease (increase) in accounts receivable-trade and other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" sign="-" scale="3" id="Tc_MARbc29eqEa3Cxqobijlag_14_3">3,823</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="Duration_1_1_2022_To_3_31_2022_N1jzYHJ1VECWf3tLdKC1jw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="Tc_i49cAhdE40-keWkF5a2lfg_14_6">2,314</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Changes in operating lease right of use assets, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw" decimals="-3" format="ixt:numdotdecimal" name="plx:ChangeInOperatingLeaseRightOfUseAssets" sign="-" scale="3" id="Tc__dKV5pt8oEGoW-PtLGPHqg_15_3">9</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="Duration_1_1_2022_To_3_31_2022_N1jzYHJ1VECWf3tLdKC1jw" decimals="-3" format="ixt:numdotdecimal" name="plx:ChangeInOperatingLeaseRightOfUseAssets" scale="3" id="Tc_tMbbAlo6D0msb6dlBJss7A_15_6">2</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Decrease (increase) in inventories</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="Tc_AEMerhhXCEuLbufUgQuCOg_16_3">3,499</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="Duration_1_1_2022_To_3_31_2022_N1jzYHJ1VECWf3tLdKC1jw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" sign="-" scale="3" id="Tc_xQwi-X0uIk2Wp1_RFthAlg_16_6">1,360</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Increase (decrease) in accounts payable and accruals</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="Tc_tY08W5A1W0ab0IT7s_JcXw_17_3">353</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="Duration_1_1_2022_To_3_31_2022_N1jzYHJ1VECWf3tLdKC1jw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" sign="-" scale="3" id="Tc_MtmDycDpqECzFBo6B1LBfQ_17_6">1,011</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_CyNd8dWwY0uofLESaoSV0Q_18_3">2,998</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="Duration_1_1_2022_To_3_31_2022_N1jzYHJ1VECWf3tLdKC1jw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_vKPDya3bPEmq7XUwYcqxEw_18_6">5,829</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">CASH FLOWS FROM INVESTING ACTIVITIES:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Investment in bank deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="Duration_1_1_2022_To_3_31_2022_N1jzYHJ1VECWf3tLdKC1jw" decimals="-3" format="ixt:numdotdecimal" name="plx:IncreaseDecreaseInBankDeposits" scale="3" id="Tc_uM_XGJF41Eyx4Nu-c11abw_21_6">16,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Proceeds from sale of short-term deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw" decimals="-3" format="ixt:numdotdecimal" name="plx:ProceedsFromSaleOfShortTermDeposits" scale="3" id="Tc_fE9YnMPwRkK0YvySZElVzA_22_3">5,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Purchase of property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_-J0hsjeXkk-UCOV0SwSTlQ_23_3">248</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="Duration_1_1_2022_To_3_31_2022_N1jzYHJ1VECWf3tLdKC1jw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc__AyKT-0I8EWTudXW8kKuzA_23_6">229</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Amounts funded in respect of employee rights upon retirement, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="3" id="Tc_XzxymGrzn0u811t7V1T5_A_24_3">20</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="Duration_1_1_2022_To_3_31_2022_N1jzYHJ1VECWf3tLdKC1jw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="3" id="Tc_hlcOXDXovk2YdS34IktegA_24_6">28</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Net cash provided by (used in) investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="Tc_-BtWtO9GO0eEDHGZxE6qfQ_25_3">4,732</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="Duration_1_1_2022_To_3_31_2022_N1jzYHJ1VECWf3tLdKC1jw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_ZRLUrygayU6VHuQR8pdXqQ_25_6">16,257</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">CASH FLOWS FROM FINANCING ACTIVITIES:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Proceeds from issuance of common stock under the Sales Agreement, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Tc_VF5vca3efkWefetw0GC-4w_28_3">14,233</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net cash provided by financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_wJq6zOC7BUmGJOvWeR75Xw_29_3">14,233</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents" sign="-" scale="3" id="Tc_hxpNsBKGF0KTWwM2OQCkRw_30_3">42</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="Duration_1_1_2022_To_3_31_2022_N1jzYHJ1VECWf3tLdKC1jw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents" sign="-" scale="3" id="Tc_KZXqToDoGkG81ru957RdJw_30_6">11</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="Tc_Z6K_yX-mnUarAOPaxE5Sfg_31_3">15,925</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="Duration_1_1_2022_To_3_31_2022_N1jzYHJ1VECWf3tLdKC1jw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="3" id="Tc_Xf22wY_K6E6Nunx89m_yRg_31_6">22,097</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="As_Of_12_31_2022_H53zBT4W7kaDDa9Xye-U_Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_QlPAnhg5cU6ewJli5juewA_32_3">17,111</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="As_Of_12_31_2021_x-pm8I0vjUS_ATBiwepawg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_GzQv2w122ECZWBA607SVqg_32_6">38,985</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">BALANCE OF CASH AND CASH EQUIVALENTS AT END OF PERIOD</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="As_Of_3_31_2023_lQ4VofWCfU-ERA4iKttplQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_Yf_vVJ2EZ024awGf7nk4gQ_33_3">33,036</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="As_Of_3_31_2022_cjzuDz-ZiUubY38dhB0s0A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_68jg6tKR9UOnEVgVcfM_ZQ_33_6">16,888</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">The accompanying notes are an integral part of the condensed consolidated financial statements.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(U.S. dollars in thousands)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;">(Unaudited)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Continued)&#160;&#8211; 2</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_46a503f9_bdde_4384_ae1e_7932ccc325a6"></a><a id="Tc_ExnAIhH9ZUevYZ2hA8JmCA_1_2"></a><a id="Tc__DTRNSE270idSvoeTStfpA_2_2"></a><a id="Tc_1XlfLTfqW0aRC0J1KkBvXw_2_5"></a><a id="Tc_jXJsdaqGQ0a7vdBak7Bjhw_3_0"></a><a id="Tc_bCnUc6mnVEaTDJWb08gCkw_4_0"></a><a id="Tc_h_gxitUvOkKOWVMddbgYRA_4_2"></a><a id="Tc_Ne0G4M3DS0aaTXetwZCEfw_4_5"></a><a id="Tc_pQNCqz3VdEabWlemaAHyJQ_5_0"></a><a id="Tc_CUeQ5QW-z0u0XQjub-nmXA_5_2"></a><a id="Tc_QtLOiIafuUiWrFa6ND_L-A_5_5"></a><a id="Tc_MxMNyznXVUK-b0dd07KYpA_6_0"></a><a id="Tc_Nu594OrF3UCY0Eva1GuJEQ_7_0"></a><a id="Tc_sAeDkStCdkqxqYe6gGoUIQ_7_2"></a><a id="Tc_xCviHh13N0a7g4XwoLkA8Q_7_5"></a><a id="Tc_sSYs1SlKRk-u7UScF4nSxQ_8_0"></a><a id="Tc_0O_3DzE8NU2Xp2z47JOOWg_8_2"></a><a id="Tc_urBLDb_C00mlRfjkh-uRsg_8_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Purchase of property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="Tc__GF_lzmiO0mg04orJ132-Q_4_3">326</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="Duration_1_1_2022_To_3_31_2022_N1jzYHJ1VECWf3tLdKC1jw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="Tc_qj6GOg5aUkqurIFZikuvzA_4_6">67</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating lease right of use assets obtained in exchange for new operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="Tc_lKvC3wsYqUi35tEl2uGEzg_5_3">312</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="Duration_1_1_2022_To_3_31_2022_N1jzYHJ1VECWf3tLdKC1jw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="Tc_ctciluhnoEqn7cf9K-Z6xQ_5_6">99</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">SUPPLEMENTARY DISCLOSURE ON CASH FLOWS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Interest paid</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="Tc_Nr6iWJtJxkStnAzr1eReDQ_7_3">1,078</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="Duration_1_1_2022_To_3_31_2022_N1jzYHJ1VECWf3tLdKC1jw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="Tc_SmrebSgHyEWmOcLqYOFmlQ_7_6">1,120</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Interest received</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw" decimals="-3" format="ixt:numdotdecimal" name="plx:InterestReceivedNet" scale="3" id="Tc_oT9rkxg-k0mWwLy5sUbwYA_8_3">78</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="Duration_1_1_2022_To_3_31_2022_N1jzYHJ1VECWf3tLdKC1jw" decimals="-3" format="ixt:numdotdecimal" name="plx:InterestReceivedNet" scale="3" id="Tc_-qU7x_JJI0urE_yxYBUvng_8_6">36</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">The accompanying notes are an integral part of the condensed consolidated financial statements.</b></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;max-width:100%;position:relative;"><a id="NOTE1SIGNIFICANTACCOUNTINGPOLICIES_79340"></a><ix:nonNumeric contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="Tb_UINnGcgczk-sYBPTsgtE9A" continuedAt="Tb_UINnGcgczk-sYBPTsgtE9A_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;1&#160;- SIGNIFICANT ACCOUNTING POLICIES</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw" name="plx:NatureOfOperationsPolicyTextBlock" id="Tb_OEW348Bc6EKVcPHgG9dl4Q" continuedAt="Tb_OEW348Bc6EKVcPHgG9dl4Q_cont1" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">a.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">General</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the &#8220;Company&#8221;) and its wholly-owned subsidiaries, Protalix Ltd. and Protalix B.V. (collectively, the &#8220;Subsidiaries&#8221;), are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&#8217;s proprietary ProCellEx<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> protein expression system (&#8220;ProCellEx&#8221;). To date, the Company has successfully developed taliglucerase alfa (marketed under the name BioManguinhos alfataliglicerase in Brazil and certain other Latin American countries and Elelyso<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> in the rest of the territories) for the treatment of Gaucher disease that has been approved for marketing in the United States, Brazil, Israel and other markets. The Company has a number of product candidates in varying stages of the clinical development process. The Company&#8217;s strategy is to develop proprietary recombinant proteins that are therapeutically superior to existing recombinant proteins currently marketed for the same indications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The most advanced investigational drug in the Company&#8217;s product pipeline is pegunigalsidase alfa, or PRX-102, a therapeutic protein candidate for the treatment of Fabry disease, a rare, genetic lysosomal disorder, which was the subject of a phase&#160;III clinical program. The PRX-102 phase&#160;III clinical program included three separate studies, which are referred to as the <i style="font-style:italic;">BALANCE</i> study, the <i style="font-style:italic;">BRIDGE</i> study and the <i style="font-style:italic;">BRIGHT</i> study, each of which has been completed. The studies were designed to evaluate the potential for improved efficacy and better quality of life for adult patients with Fabry disease and to evaluate the safety of the Company&#8217;s drug/therapy. The phase&#160;III clinical program analyzed two potential dosing regimens: 1&#160;mg/kg every two weeks and 2&#160;mg/kg every four weeks. In addition, the phase&#160;III clinical program included two extension studies in which subjects that participated in the Company&#8217;s phase&#160;I/II clinical trials and phase&#160;III clinical trials had the opportunity to enroll and continue to be treated with PRX-102. As of March&#160;1, 2023, sponsorship of the two open-label extension studies was transferred to the Company&#8217;s development and commercialization partner for PRX-102, Chiesi Farmaceutici S.p.A. (&#8220;Chiesi&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The U.S.&#160;Food and Drug Administration (the &#8220;FDA&#8221;) has indicated that the biologics license application (&#8220;BLA&#8221;) for PRX-102 for the potential treatment of adult patients with Fabry disease resubmitted on November&#160;9, 2022 by the Company, together with Chiesi, was considered a complete, class&#160;2 response and set a PDUFA action date of&#160;May&#160;9, 2023. The initial BLA for PRX-102 was submitted to the FDA on May&#160;27, 2020 under the FDA&#8217;s Accelerated Approval pathway, and was subsequently accepted by the FDA and granted Priority Review designation. However, in April 2021, the FDA issued a Complete Response Letter (CRL) in response to the initial BLA. In preparation for the BLA resubmission, the Company and Chiesi participated in a Type&#160;A (End of Review) meeting with the FDA on September&#160;9, 2021. As part of the meeting minutes provided by the FDA, which included the preliminary comments and meeting discussion, the FDA, in principle, agreed that the data package proposed to the FDA for a BLA resubmission has the potential to support a traditional approval of PRX-102 for the treatment of Fabry disease. The data package in the BLA resubmission, given the change in the regulatory landscape in the United States, included the final two-year analyses of the Company&#8217;s phase&#160;III <i style="font-style:italic;">BALANCE</i> clinical trial of PRX-102, which was completed in July 2022, and long-term data from the Company&#8217;s open-label extension study of PRX-102 in adult patients treated with a 2&#160;mg/kg every four&#160;weeks dosage of PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On February&#160;7, 2022, the Company, together with Chiesi, submitted a Marketing Authorization Application (&#8220;MAA&#8221;) for PRX-102 to the European Medicines Agency (&#8220;EMA&#8221;) which was subsequently validated by the EMA. The submission was made after the October&#160;8, 2021 meeting the Company held, together with Chiesi, with the Rapporteur and Co-Rapporteur of the EMA regarding PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">The MAA submission included a comprehensive set of preclinical, clinical and manufacturing data compiled from the Company&#8217;s completed and ongoing clinical studies evaluating PRX-102 as a potential alternative treatment for adult patients with Fabry disease, including data from the Company&#8217;s completed 12&#8211;month switch&#8211;over phase&#160;III <i style="font-style:italic;">BRIGHT</i>&#160;clinical trial in adult patients with Fabry disease treated with a 2&#160;mg/kg every four&#160;weeks dosage to support an additional potential treatment regimen for Fabry patients. As part of the EMA review process, Chiesi and the Company responded to the Day&#160;120 list of questions in September 2022 (following a 3-month clock-stop period) and the list of outstanding issues of Day&#160;180 in December 2022. An essential portion of the Day&#160;120 response included the submission of the final analysis of the two-year <i style="font-style:italic;">BALANCE</i> study (the final Clinical Study Report), and an interim analysis of the </p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_UINnGcgczk-sYBPTsgtE9A_cont1" continuedAt="Tb_UINnGcgczk-sYBPTsgtE9A_cont2"><ix:continuation id="Tb_OEW348Bc6EKVcPHgG9dl4Q_cont1" continuedAt="Tb_OEW348Bc6EKVcPHgG9dl4Q_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Company&#8217;s long-term, open-label extension study of PRX-102 in adult patients with Fabry disease treated with the 2&#160;mg/kg every four&#160;weeks dosage.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On February&#160;24, 2023, the Company, together with Chiesi, announced that the EMA&#8217;s Committee for Medicinal Products for Human Use (the &#8220;CHMP&#8221;) adopted a positive opinion, recommending marketing authorization for PRX-102. The CHMP opinion was referred for final action to the European Commission (the &#8220;EC&#8221;). A final EC decision on the MAA is expected in the beginning of&#160;May 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In addition to PRX-102, the Company&#8217;s product pipeline currently includes, among other candidates:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">PRX-115, the Company&#8217;s plant cell-expressed recombinant PEGylated uricase (urate oxidase) &#8211; a chemically modified enzyme to treat severe gout; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">PRX-119, the Company&#8217;s plant cell-expressed PEGylated recombinant human DNase&#160;I product candidate being designed to elongate half-life in the circulation for NETs-related diseases.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Obtaining marketing approval with respect to any product candidate in any country is dependent on the Company&#8217;s ability to implement the necessary regulatory steps required to obtain such approvals. The Company cannot reasonably predict the outcome of these activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On July&#160;2, 2021, the Company entered into an At The Market Offering Agreement (the &#8220;2021 Sales Agreement&#8221;) with H.C.&#160;Wainwright &amp; Co., LLC, as the Company&#8217;s sales agent (the &#8220;Agent&#8221;) which was amended on May&#160;2, 2022. Pursuant to the terms of the 2021 Sales Agreement, the Company was able to sell, from time to time through the Agent, shares of its common stock, par value $<ix:nonFraction unitRef="Unit_Divide_USD_shares_65Ko0I-nrkSGY9fEMAqs6Q" contextRef="As_Of_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_vCJMvVrkpEey12nFHwmq_g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_mvrK0y0Dc0W5YIVIXo9G4w">0.001</ix:nonFraction> per share (the &#8220;Common Stock&#8221;), having an aggregate offering price of up to $<ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_NlK07qNF70WUx9TiUtAq1A" decimals="-5" format="ixt:numdotdecimal" name="plx:SaleOfStockMaximumOfferingPrice" scale="6" id="Narr_HEB57ZT8UE2ztI6jOYPS4Q">20.0</ix:nonFraction>&#160;million (the &#8220;ATM Shares&#8221;). Upon execution of the 2021 Sales Agreement, the Company terminated the ATM Equity Offering<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">SM</sup> Sales Agreement it had entered into on October&#160;1, 2020 with BofA Securities, Inc. (&#8220;BofA Securities&#8221;). During the term of the sales agreement with BofA Securities, the Company sold a total of <ix:nonFraction unitRef="Unit_Standard_shares_4bVAm6lD50yLNxvQT1GIoA" contextRef="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtmEquityOfferingSalesAgreementMember_TYdGwaWNbE6JmroON4hlzg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_K8txZ77RqEaEAKA3dRzzgg">3,296,123</ix:nonFraction> shares of Common Stock for total gross proceeds of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtmEquityOfferingSalesAgreementMember_TYdGwaWNbE6JmroON4hlzg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_W7VAPu2gvEGamXDbyQ6kEg">13.8</ix:nonFraction>&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">As of March&#160;31, 2023, the Company sold a total of <ix:nonFraction unitRef="Unit_Standard_shares_4bVAm6lD50yLNxvQT1GIoA" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_0iU3Zlmqr0On_CGrbCti_Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_MiHdWXx5qE-TcD0NECwfnA">13,980,060</ix:nonFraction> ATM Shares for total gross proceeds of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_0iU3Zlmqr0On_CGrbCti_Q" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_R_rP9CiOYkaoJr3pBs1LPg">20.0</ix:nonFraction>&#160;million under the 2021 Sales Agreement, thereby completing the ATM program under said agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On February&#160;27, 2023, the Company entered into an At The Market Offering Agreement (the &#8220;2023 Sales Agreement&#8221;) with the Agent. Pursuant to the terms of the 2023 Sales Agreement, the Company may sell, from time to time through the Agent, ATM Shares having an aggregate offering price of up to $<ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="Duration_2_27_2023_To_2_27_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_Q-zSWd_o2UuvPzl41Xf3MA" decimals="-5" format="ixt:numdotdecimal" name="plx:SaleOfStockMaximumOfferingPrice" scale="6" id="Narr_pmPh69CnTkOV0K2V_7cFdw">20.0</ix:nonFraction>&#160;million. As of March&#160;31, 2023, shares of Common Stock for total gross proceeds of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_0iU3Zlmqr0On_CGrbCti_Q" decimals="-5" format="ixt:numdotdecimal" name="plx:SaleOfStockMaximumOfferingPrice" scale="6" id="Narr_g1nPVdHiOUKt328GpwJJvw">16.5</ix:nonFraction>&#160;million remain available to be sold under the 2023 Sales Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On October&#160;19, 2017, Protalix Ltd. and Chiesi entered into an Exclusive License and Supply Agreement (the &#8220;Chiesi Ex-US Agreement&#8221;) pursuant to which Protalix Ltd. granted to Chiesi an exclusive license for all markets outside of the United States to commercialize pegunigalsidase alfa. On July&#160;23, 2018, Protalix Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the &#8220;Chiesi US Agreement&#8221;) with respect to the commercialization of pegunigalsidase alfa in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">Under each of the Chiesi Ex-US Agreement and the Chiesi US Agreement (collectively, the &#8220;Chiesi Agreements&#8221;), Chiesi made an upfront payment to Protalix&#160;Ltd. of $<ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_z3hwihuoBkC5xNBh7hXP6A" decimals="-5" format="ixt:numdotdecimal" name="plx:UpfrontNonrefundableNoncreditablePaymentReceivable" scale="6" id="Narr_hTjdU3JA-kyL72QF05F5rA"><ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_Am7rx-rvZUywApMit-lb-A" decimals="-5" format="ixt:numdotdecimal" name="plx:UpfrontNonrefundableNoncreditablePaymentReceivable" scale="6" id="Narr_yk-zk8kN5Eu5agSQQ7_bxw">25.0</ix:nonFraction></ix:nonFraction>&#160;million in connection with the execution of each agreement. In addition, under the Chiesi Ex-US Agreement, Protalix&#160;Ltd. is entitled to additional payments of up to $<ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_GyY7-odK10eb47EO_FtixA" decimals="-5" format="ixt:numdotdecimal" name="plx:AdditionalAmountsPayableToCoverDevelopmentCosts" scale="6" id="Narr_o88oCtwjAU-7fE_-qMDKYg">25.0</ix:nonFraction>&#160;million in pegunigalsidase alfa development costs and to receive additional payments of up to $<ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_GyY7-odK10eb47EO_FtixA" decimals="-5" format="ixt:numdotdecimal" name="plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" scale="6" id="Narr_encmai31kkOKTJhvtgx8VQ">320.0</ix:nonFraction>&#160;million, in the aggregate, in regulatory and commercial milestone payments. Under the Chiesi US Agreement, Protalix&#160;Ltd. is entitled to payments of up to a maximum of $<ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_3yJmheSn6UeRYw8iwyMgIg" decimals="-5" format="ixt:numdotdecimal" name="plx:AdditionalAmountsPayableToCoverDevelopmentCosts" scale="6" id="Narr_Wx5nOk-AmUykDHtmAdyzfA">20.0</ix:nonFraction>&#160;million to cover development costs for pegunigalsidase alfa and to receive additional payments of up to a maximum of $<ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_3yJmheSn6UeRYw8iwyMgIg" decimals="-5" format="ixt:numdotdecimal" name="plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" scale="6" id="Narr_1toyQ7ROAUqS1-9tny_gbw">760.0</ix:nonFraction>&#160;million, in the aggregate, in regulatory and commercial milestone payments. To date, Protalix Ltd. has received the complete amount of development costs to which it is entitled under the Chiesi Agreements.</p></ix:continuation></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_UINnGcgczk-sYBPTsgtE9A_cont2" continuedAt="Tb_UINnGcgczk-sYBPTsgtE9A_cont3"><ix:continuation id="Tb_OEW348Bc6EKVcPHgG9dl4Q_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">Under the terms of both of the Chiesi Agreements, Protalix Ltd. will manufacture all of the pegunigalsidase alfa needed under the agreements, subject to certain exceptions, and Chiesi will purchase pegunigalsidase alfa from Protalix, subject to certain terms and conditions. Under the Chiesi Ex-US Agreement, Chiesi is required to make tiered payments of <ix:nonFraction unitRef="Unit_Standard_pure_0xGx53TVLESXmSrWd-Jrvw" contextRef="Duration_10_19_2017_To_10_19_2017_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_Sax1Fe0WOEOjE9gRCUPqYQ" decimals="INF" format="ixt:numdotdecimal" name="plx:PaymentOnNetSalesPercentage" scale="-2" id="Narr_LJt5NBe6vkGtXg93qQnekg">15</ix:nonFraction>% to <ix:nonFraction unitRef="Unit_Standard_pure_0xGx53TVLESXmSrWd-Jrvw" contextRef="Duration_10_19_2017_To_10_19_2017_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_D2oITtj5_U2sjJO37_gN5w" decimals="INF" format="ixt:numdotdecimal" name="plx:PaymentOnNetSalesPercentage" scale="-2" id="Narr_3yx1FjAqw0qeNYOS5GsYGw">35</ix:nonFraction>% of its net sales, depending on the amount of annual sales outside of the United States, as consideration for product supply. Under the Chiesi US Agreement, Chiesi is required to make tiered payments of <ix:nonFraction unitRef="Unit_Standard_pure_0xGx53TVLESXmSrWd-Jrvw" contextRef="Duration_7_23_2018_To_7_23_2018_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_qGhtjJbQ70ugptcYziO39Q" decimals="INF" format="ixt:numdotdecimal" name="plx:PaymentOnNetSalesPercentage" scale="-2" id="Narr_zipq38pT1UiOcRS76p_Yew">15</ix:nonFraction>% to <ix:nonFraction unitRef="Unit_Standard_pure_0xGx53TVLESXmSrWd-Jrvw" contextRef="Duration_7_23_2018_To_7_23_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_VXlGDMYSYka-21A_FiXp3A" decimals="INF" format="ixt:numdotdecimal" name="plx:PaymentOnNetSalesPercentage" scale="-2" id="Narr_omOn1kForUWt3D2x1ZK2YA">40</ix:nonFraction>% of its net sales, depending on the amount of annual sales in the United States, as consideration for product supply.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">On May&#160;13, 2021, the Company signed a binding term sheet with Chiesi pursuant to which the Company and Chiesi amended the Chiesi Agreements in order to provide the Company with near-term capital. Chiesi agreed to make a $<ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="As_Of_5_13_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_egFQOM62D0mceKOHvMGXcw" decimals="-5" format="ixt:numdotdecimal" name="plx:AgreementAmendmentPaymentReceivable" scale="6" id="Narr_JEeCCJWYIkCbedPA3i4FnQ">10.0</ix:nonFraction>&#160;million payment to the Company before the end of the second quarter of 2021 in exchange for a $<ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="Duration_5_13_2021_To_5_13_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_18jRabrPoUa3e12IYdZR0w" decimals="-5" format="ixt:numdotdecimal" name="plx:ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" scale="6" id="Narr_Kfk_-Nre-Uedb_JE_ZzELg">25.0</ix:nonFraction>&#160;million reduction in a longer term regulatory milestone payment provided in the Chiesi EX-US Agreement. All other regulatory and commercial milestone payments remain unchanged. The Company received the payment in June&#160;2021. The Company also agreed to negotiate certain manufacturing related matters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">Since its approval by the FDA, taliglucerase alfa has been marketed by Pfizer Inc. (&#8220;Pfizer&#8221;) in accordance with the exclusive license and supply agreement entered into between Protalix Ltd. and Pfizer, which is referred to herein as the Pfizer Agreement. In October 2015, Protalix Ltd. and Pfizer entered into an amended exclusive license and supply agreement, which is referred to herein as the Amended Pfizer Agreement, pursuant to which the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for <ix:nonFraction unitRef="Unit_Standard_pure_0xGx53TVLESXmSrWd-Jrvw" contextRef="Duration_10_1_2015_To_10_31_2015_dei_LegalEntityAxis_plx_ProtalixBioTherapeuticsIncorporationMember_srt_StatementGeographicalAxis_country_BR_us-gaap_TypeOfArrangementAxis_plx_AmendedPfizerAgreementMember_2qZfvaa21UeJuh9OQT_1zQ" decimals="2" format="ixt:numdotdecimal" name="plx:CollaborativeArrangementRevenuesExpensesSharingPercentage" scale="-2" id="Narr_D3-qlLT_rEqLrEPjy9zXVA">100</ix:nonFraction>% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">On June&#160;18, 2013, the Company entered into a Supply and Technology Transfer Agreement (the &#8220;Brazil Agreement&#8221;) with Funda&#231;&#227;o Oswaldo Cruz (&#8220;Fiocruz&#8221;), an arm of the Brazilian Ministry of Health (the &#8220;Brazilian MoH&#8221;), for taliglucerase alfa. Fiocruz&#8217;s purchases of BioManguinhos alfataliglicerase to date have been significantly below certain agreed-upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the termination right, the Company is, at this time, continuing to supply BioManguinhos alfataliglicerase to Fiocruz and patients continue to be treated with BioManguinhos alfataliglicerase in Brazil.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">The novel coronavirus disease (&#8220;COVID-19&#8221;), which was declared by the World Health Organization to be a global pandemic on March&#160;11, 2020, has had numerous adverse effects on the global economy. To date, the Company&#8217;s clinical trials have not been adversely affected by COVID-19, although certain practices the Company adopted during the earlier stages of the pandemic in its offices and facilities in an effort to promote social distancing resulted in minor delays in the performance of administrative activities outside of the clinical programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">The Company expects to continue to incur significant expenditures in the near future due to research and developments efforts with respect to the product candidates. Under the terms of the Company&#8217;s outstanding <ix:nonFraction unitRef="Unit_Standard_pure_0xGx53TVLESXmSrWd-Jrvw" contextRef="As_Of_3_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_ZgUoVauLFkSr1Jlp4jtK7Q" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_RenMmz2meUKs_LbRa-5eNg">7.50</ix:nonFraction>% Senior Secured Convertible Notes due 2024 (the &#8220;2024 Notes&#8221;)<span style="font-family:'28mugxoulnobhnx';">, </span>the Company is required to comply with certain<span style="color:#222222;background:#ffffff;"> </span>financial covenants, including the maintenance of a minimum cash balance of at least $<ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="As_Of_3_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_ZgUoVauLFkSr1Jlp4jtK7Q" decimals="-5" format="ixt:numdotdecimal" name="plx:MaintainOfMinimumCashBalance" scale="6" id="Narr_lQeZma1e2kqrXGFnvq96zg">7.5</ix:nonFraction>&#160;million. As of March&#160;31, 2023, the Company is in<span style="background:#ffffff;"> compliance with all such covenants. </span>The Company believes that its cash and cash equivalents as of March&#160;31, 2023, together with additional funds raised from the sale of ATM Shares under the 2023 Sales Agreement subsequent to March&#160;31, 2023 are sufficient to satisfy the Company&#8217;s capital needs for at least 12&#160;months from the date that these financial statements are issued.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="Tb_3tjqtk-fxEmlfXM_Os346Q" continuedAt="Tb_3tjqtk-fxEmlfXM_Os346Q_cont1" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;">b.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;">Basis of presentation</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States (&#8220;GAAP&#8221;) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_UINnGcgczk-sYBPTsgtE9A_cont3" continuedAt="Tb_UINnGcgczk-sYBPTsgtE9A_cont4"><ix:continuation id="Tb_3tjqtk-fxEmlfXM_Os346Q_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form&#160;10-K for the year ended December&#160;31, 2022, filed by the Company with the U.S.&#160;Securities and Exchange Commission (the &#8220;Commission&#8221;). The comparative balance sheet at December&#160;31, 2022 has been derived from the audited financial statements at that date. There have been no material changes in our significant accounting policies as described in our consolidated financial statements for the year ended December&#160;31, 2022.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw" name="us-gaap:EarningsPerSharePolicyTextBlock" id="Tb_9j_Sp_bU50-Zw_BYNw4JFA" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">c.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Loss per share</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">Basic and diluted loss per share (&#8220;LPS&#8221;) are computed by dividing net loss by the weighted average number of shares of Common Stock attributable to common stockholders outstanding for each period. The calculation of diluted LPS does not include <ix:nonFraction unitRef="Unit_Standard_shares_4bVAm6lD50yLNxvQT1GIoA" contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Narr_iwlsqMoVuESG1PYiGZ9kFw">36,292,208</ix:nonFraction> shares of Common Stock underlying outstanding options and shares of Common Stock issuable upon conversion of the outstanding 2024 Notes and the exercise of outstanding warrants for the three months ended March&#160;31, 2023, and <ix:nonFraction unitRef="Unit_Standard_shares_4bVAm6lD50yLNxvQT1GIoA" contextRef="Duration_1_1_2022_To_3_31_2022_N1jzYHJ1VECWf3tLdKC1jw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Narr_JqexpDW1YU-RMym9YD3spQ">33,004,217</ix:nonFraction> shares of Common Stock underlying outstanding options and shares of Common Stock issuable upon conversion of the Company&#8217;s then outstanding 2024 Notes and the exercise of outstanding warrants for the three months ended March&#160;31, 2022 because their effect would be anti-dilutive.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="Tb_2z1CcaURYk2tdagYT1JkhQ" continuedAt="Tb_2z1CcaURYk2tdagYT1JkhQ_cont1" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">d.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Revenue recognition</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company accounts for revenue pursuant to Accounting Standards Codification, Topic 606, Revenue from Contracts with Customers (&#8220;ASC 606&#8221;). Under ASC 606, a contract with a customer exists only when: the parties to the contract have approved it and are committed to perform their respective obligations, the Company can identify each party&#8217;s rights regarding the distinct goods or services to be transferred (&#8220;performance obligations&#8221;), the Company can determine the transaction price for the goods or services to be transferred, the contract has commercial substance and it is probable that the Company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Revenues are recorded in the amount of consideration to which the Company expects to be entitled in exchange for performance obligations upon transfer of control to the customer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;">1.&#160;&#160;&#160;&#160;Revenues from selling products</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The Company recognizes revenues from selling goods at a point in time when control over the product is transferred to customers (upon delivery).</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Revenues from Chiesi Agreements</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The Company has identified <ix:nonFraction unitRef="Unit_Standard_agreement_l_AIB71m8UmKtkYDila2Og" contextRef="As_Of_3_31_2023_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_6M0Qz8IYh02zFSz41wRItw" decimals="INF" format="ixt-sec:numwordsen" name="plx:RevenuePerformanceObligationNumber" scale="0" id="Narr_A27zUIzSbE-bXwY1SJU-2g">two</ix:nonFraction> performance obligations in the Chiesi Agreements as follows: (i)&#160;the license and research and development services and (ii)&#160;the contingent performance obligation regarding future manufacturing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The Company determined that the license together with the research and development services should be combined into single performance obligation since Chiesi cannot benefit from the license without the research and development services. The research and development services are highly specialized and are dependent on the supply of the drug.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The future manufacturing is contingent on regulatory approvals of the drug and the Company deems these services to be separately identifiable from other performance obligations in the contract. Manufacturing services post-regulatory approval are not interdependent or interrelated with the license and research and development services.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_UINnGcgczk-sYBPTsgtE9A_cont4"><ix:continuation id="Tb_2z1CcaURYk2tdagYT1JkhQ_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The transaction price was comprised of fixed consideration and variable consideration (capped research and development reimbursements). Under ASC 606, the consideration to which the Company would be entitled upon the achievement of contractual milestones, which are contingent upon the occurrence of future events, are a form of variable consideration. The Company estimates variable consideration using the most likely method. Amounts included in the transaction price are recognized only when it is probable that a significant reversal of cumulative revenues will not occur. Prior to recognizing revenue from variable consideration, the Company uses significant judgment to determine the probability of significant reversal of such revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Since the customer benefits from the research and development services as the entity performs the service, revenue from granting the license and the research and development services is recognized over time using the cost-to-cost method. The Company used significant judgment when it determined the costs expected to be incurred upon satisfying the identified performance obligation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Revenue from additional research and development services ordered by Chiesi is recognized&#160;over time using the cost-to-cost method.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Revenue from R&amp;D services</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Revenue from the research and development services is recognized over time using the cost-to-cost method since the customer benefits from the research and development services as the entity performs the service.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></ix:continuation><a id="Tc_XsC_dpGH-0-3132LJijFLQ_1_2"></a><a id="Tc_JYjdPfvfkkObdjiUH6GBIA_1_5"></a><a id="Tc_J9xB77vLgkyjgQ-yTyqUOA_2_0"></a><a id="Tc_lv-ixrgFXUa3QjuAGfUr6w_2_2"></a><a id="Tc_P2XUAPcTtEm2hYO4SwckXw_2_5"></a><a id="Tc_eKP9ahft00GLKd4zfdslKA_3_0"></a><a id="Tc_w0YZI3dZZ0aP__2QdvOs8A_3_2"></a><a id="Tc_TSsa8e23BUuG4h45_4krQg_3_5"></a><a id="Tc_l5EhaN3SKkuypT1elFivhA_4_0"></a><a id="Tc_dcatCJ7rJkmBEOdQ7eagVA_5_0"></a><a id="Tc_15wekQjY6EKRwZ52EsT3Jg_6_0"></a><a id="Tc_ZgVWA9rAzUKoZduVXaE1qw_6_2"></a><a id="Tc_uRPIRYcvUUOgTIYBtM9Myw_6_5"></a><ix:nonNumeric contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw" name="us-gaap:InventoryDisclosureTextBlock" id="Tb_QC1Y4KqbyUGL8h2EnasGMQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;2&#160;- INVENTORIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Inventories at March&#160;31, 2023 and December&#160;31, 2022 consisted of the following:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="Tb_gxBqwKSqHkyvvJ2PgZtqeA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Raw materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="As_Of_3_31_2023_lQ4VofWCfU-ERA4iKttplQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="3" id="Tc_ZiinDupAK0aBSmieYxxh-w_3_3">4,308</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="As_Of_12_31_2022_H53zBT4W7kaDDa9Xye-U_Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="3" id="Tc_vmUHVV_k1EuJofD5uf_ZkQ_3_6">3,508</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Work in progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="As_Of_3_31_2023_lQ4VofWCfU-ERA4iKttplQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="3" id="Tc_y2u4WANPiU2PUPhN_Rv0fA_4_3">1,533</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="As_Of_12_31_2022_H53zBT4W7kaDDa9Xye-U_Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="3" id="Tc_zMzngYuZg0amw_uUZIWSxw_4_6">2,678</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finished goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="As_Of_3_31_2023_lQ4VofWCfU-ERA4iKttplQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="3" id="Tc_hpixRzBm_02GdQRMMCdw8A_5_3">14,462</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="As_Of_12_31_2022_H53zBT4W7kaDDa9Xye-U_Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="3" id="Tc_lg6IStvDEUKy19RrudxAYA_5_6">10,618</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="As_Of_3_31_2023_lQ4VofWCfU-ERA4iKttplQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_8VDMqPHytEanr4QrzS_Pjw_6_3">20,303</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="As_Of_12_31_2022_H53zBT4W7kaDDa9Xye-U_Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_ifOPtyK5yEiTI9Mvov6XKg_6_6">16,804</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:1pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw" name="us-gaap:FairValueDisclosuresTextBlock" id="Tb_TrpGHlskC0uoA_927diMrg" continuedAt="Tb_TrpGHlskC0uoA_927diMrg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;3&#160;&#8211; FAIR VALUE MEASUREMENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received from the sale of an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The fair value of the financial instruments included in the working capital of the Company is usually identical or close to their carrying value.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_TVoO4sNswEOpm12ROnXOdg_1_5"></a><a id="Tc_hxyNoR9R-EadIvlWL2A-dQ_2_0"></a><a id="Tc_aYprr3rvFUCDaSVqvlRXrA_3_0"></a><a id="Tc_PRFgoAEya0iAUNi1JwmoqQ_4_0"></a><a id="Tc_DT1Ajqrz0EWd45EwTjUJyA_4_6"></a><a id="Tc_U1fSaNPFPESUOw-7BFkInw_5_0"></a><a id="Tc_4jKYkoo3rEKhbRPxCVJ3lw_5_6"></a><a id="Tc_O-fsH0RwuU2RL3RlD6iFkA_6_0"></a><a id="Tc_5h0GDHt_bU-fv5jDV191zw_6_6"></a><ix:continuation id="Tb_TrpGHlskC0uoA_927diMrg_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 35.45pt;">Based on a Level 3 measurement, as of March&#160;31, 2023, the fair value of the $<ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="As_Of_3_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_9xvbhmNJFkageC4WyZOI_Q" decimals="-4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="Narr_JDbOxUcFMEecyBDWvkWjIg">28.75</ix:nonFraction>&#160;million aggregate principal amount of the Company&#8217;s outstanding 2024 Notes is approximately $<ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="As_Of_3_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_9xvbhmNJFkageC4WyZOI_Q" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebtFairValueDisclosures" scale="6" id="Narr_gyzQ2m8DgkiorBQfOh7kgg">41.4</ix:nonFraction>&#160;million. The value of these notes was estimated by implementing the binomial model. The liability component was valued based on the Income Approach. The following parameters were used:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_a9VnZ-vJPkiHhaBFIDBw-A" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="Tb_5VpXSaLtPka5V_U9XK6ieA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024&#160;Notes</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Stock price (USD)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_65Ko0I-nrkSGY9fEMAqs6Q" contextRef="As_Of_3_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember__GmWbcoY7kCTcvgHXmTtag" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="Tc_j-HD4Q1WFk2FVOTATrX3hg_2_5">2.10</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_Y_lrd4ffoII0uwy2NmYOCxhg" contextRef="As_Of_3_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_aCnJ8YZWTEKINZXa-WibNQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="Tc_ASZ2wrJiKUSzfR96W1bvSg_3_5">1.42</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Risk free rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_0xGx53TVLESXmSrWd-Jrvw" contextRef="As_Of_3_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_6rulpN2cdUS_aFAtMHgQ0Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="Tc_j8lVUa41HE2oBDCOZI3i2w_4_5">4.19</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:73.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_0xGx53TVLESXmSrWd-Jrvw" contextRef="As_Of_3_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_sRkxswHoFESpgC_hhX6rNw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="Tc_rEhgmp5_eU-qQlgTqfn1tg_5_5">62.47</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:73.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_0xGx53TVLESXmSrWd-Jrvw" contextRef="As_Of_3_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_plx_MeasurementInputYieldMember_fyqadwF3d0u2BkkX4IRliA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="Tc_GNxyxc3xiUeiqSywrssZbg_6_5">12.60</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_8e26df07_0199_4efa_b94b_f1cf525bf56a"></a><a id="Tc__fWgZBseHkeclBD0jvzOog_1_2"></a><a id="Tc_4i4LlpuGVkaDVDO25MFB_g_2_0"></a><a id="Tc_VOMAj1aaIE6qM-Wfj4f1bw_2_2"></a><a id="Tc_-IAu1QVsCkOmxll3-vD9Vg_2_5"></a><a id="Tc_ycGB5Ek13EmHX5l46JettQ_3_0"></a><a id="Tc_8vJgAk5nJE2mqkPylxrnYA_3_2"></a><a id="Tc_-BAWk6nPck-ja-YrZWneGQ_3_5"></a><a id="Tc__mcZ1qLPn0yEJL85mIzlew_4_0"></a><a id="Tc_zHdzUP5WXU6jBZRtuuUUfw_4_2"></a><a id="Tc_pZB9TUJn00idnJjFQwmKyw_4_5"></a><a id="Tc_a0etIDLR0EOGKifcVBuOsA_5_0"></a><a id="Tc__t0TvoVvwUGRqRjodoFTlA_5_2"></a><a id="Tc_f-Ga1S4KkkOeRuEicHpQSA_5_3"></a><a id="Tc_zpz1K0uAR0GkcRChY_impw_5_5"></a><a id="Tc_gVsRmOzFOEaZOqceozUDLA_6_0"></a><a id="Tc_TqagzFQvTUapDJcC6250EQ_6_2"></a><a id="Tc_wcQxs9FLS0CMDZE-OtQCjQ_6_5"></a><a id="Tc_SfuP1GhAVEaoB66WwhU9dw_7_0"></a><a id="Tc_mJizbgNlg0yv6NhfjOeBRg_7_2"></a><a id="Tc_vYC2LLV7JEWS-B4HkJ-J2Q_7_5"></a><ix:nonNumeric contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw" name="plx:RevenueDisclosureTextBlock" id="Tb_qoKBkUvmsEqFiIWISJNzFQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;background:#ffffff;">NOTE&#160;4&#160;&#8211; REVENUES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="Tb_OYaEdCDn0kWemSybqLQKeg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="background:#ffffff;">The following table summarizes the Company&#8217;s disaggregation of revenues:</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Pfizer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="Duration_1_1_2023_To_3_31_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_fttaWimhoUeG-S7zMyaisw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_wm2u4Aq260WnPjd9zUqM0w_3_3">2,266</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="Duration_1_1_2022_To_3_31_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_WcMRAOlFCE6_UAs2eyxXCA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_OxysFihTCEC093iVrabfgw_3_6">3,356</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Brazil</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="Duration_1_1_2023_To_3_31_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_hmYTDCpI-ECukL-F-IOjvQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_T2eMdyDkkU-qbQmarch3gA_4_3">2,800</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="Duration_1_1_2022_To_3_31_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_PBB8cE7vikCPoa7ZmvpzOA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_3VVeDkaKz0iLO7BaTG869g_4_6">5,454</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Chiesi</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="Duration_1_1_2022_To_3_31_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_ChiesiMember_1_EnASsBOky6dNtE7sYeqA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_A9pbqfKChUCJRuOjUE3Aag_5_6">218</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total revenues from selling goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="Duration_1_1_2023_To_3_31_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_1ErUchefYE24icEBkPux0A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_wEtj2LYqikyU1SGzzm3U_g_6_3">5,066</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="Duration_1_1_2022_To_3_31_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_TLlwu1kiM067CBBRXPNrNw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_rQXZ7u811EuksG6mbQAzvA_6_6">9,028</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Revenues from license and R&amp;D services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="Duration_1_1_2023_To_3_31_2023_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_0OKK-_bib0C_UleLAi20GA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_phQLlOmU8EKlL5s8aTSwQg_7_3">4,522</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="Duration_1_1_2022_To_3_31_2022_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_rv5oVU7cTEWzAOzlbF-VFA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_b_BMVLCKqEaV8JcGFR7vdg_7_6">7,057</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="color:#212529;font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="Tb_KhwF9R3VgkmbKbu-wQiI2w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">NOTE 5 &#8211; STOCK TRANSACTIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"><b style="font-weight:bold;background:#ffffff;">At-the-Market (ATM) Offering</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">During the three months ended March&#160;31, 2023, the Company sold, in the aggregate, <ix:nonFraction unitRef="Unit_Standard_shares_4bVAm6lD50yLNxvQT1GIoA" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtmEquityOfferingSalesAgreementMember_aO6xvvEThkasCzfWTSPBgQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_Ev5DBrggDEWJ1L30M6C5dQ">8,212,482</ix:nonFraction> shares of Common Stock under the 2023 Sales Agreement and the 2021 Sales Agreement. The Company generated aggregate gross proceeds equal to approximately $<ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtmEquityOfferingSalesAgreementMember_aO6xvvEThkasCzfWTSPBgQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_7xZDhZfgekmp8krYbsMVpA">14.9</ix:nonFraction>&#160;million in connection with such sales.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw" name="us-gaap:SubsequentEventsTextBlock" id="Tb_KuYWCyxJLEKjGOQ7J1yNvg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTE 6 &#8211; SUBSEQUENT EVENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">During April 2023, the Company sold, in the aggregate, <ix:nonFraction unitRef="Unit_Standard_shares_4bVAm6lD50yLNxvQT1GIoA" contextRef="Duration_4_1_2023_To_4_30_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_tROqvzE5iEKYWMElS1CURw" decimals="INF" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodSharesSalesAgreement" scale="0" id="Narr_UMwW4RbsZ0yttGg6I4hBXg">3,412,268</ix:nonFraction> shares of Common Stock under the 2023 Sales Agreement. The Company generated aggregate gross proceeds equal to approximately $<ix:nonFraction unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw" contextRef="Duration_4_1_2023_To_4_30_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_tROqvzE5iEKYWMElS1CURw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_jVuh8biNZ0iiskU9D6DTtA">7.9</ix:nonFraction>&#160;million in connection with such sales.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt 0pt 10pt 0pt;"><span style="font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_d30392ac_01a9_43ad_9a1c_c82bad98e7fb"></a><a id="Item2ManagementsDiscussionandAnalysisofF"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">2.  Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">AND RISK FACTORS SUMMARY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and the consolidated financial statements and the related notes included elsewhere in this Form</i>&#160;<i style="font-style:italic;">10-Q and in our Annual Report on Form</i>&#160;<i style="font-style:italic;">10-K for the year ended December</i>&#160;<i style="font-style:italic;">31, 2022. Some of the information contained in this discussion and analysis, particularly with respect to our plans and strategy for our business and related financing, includes forward-looking statements within the meanings of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, including statements regarding expectations, beliefs, intentions or strategies for the future. When used in this report, the terms &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;can,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and words or phrases of similar import, as they relate to our company or our management, are intended to identify forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are only predictions and reflect our views as of the date they are made with respect to future events and financial performance, and we undertake no obligation to update or revise, nor do we have a policy of updating or revising, any forward-looking statement to reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated events, except as may be required under applicable law. Forward-looking statements are subject to many risks and uncertainties that could cause our actual results to differ materially from any future results expressed or implied by the forward-looking statements as a result of several factors.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Examples of the risks and uncertainties include, but are not limited to, the following:</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>the risk that the FDA might not grant marketing approval for PRX-102, by the Prescription Drug User Fee Act (PDUFA) action date or at all, and other risks related to the timing, progress and likelihood of final approval by the FDA of the resubmitted PRX-102 BLA;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks related to the timing, progress and likelihood of approval by the EMA of the MAA for PRX-102, and of approvals by other applicable health regulatory authorities;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>the risk that a marketing approval of PRX-102 by either the FDA or the EMA will be conditioned on significant limitations on its use;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>whether, if approved by the FDA, EMA and other applicable health regulatory authorities, the use of PRX-102 will be commercially successful;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>the likelihood that the FDA, EMA or other applicable health regulatory authorities will approve an alternative dosing regimen;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>failure or delay in the commencement or completion of our preclinical studies and clinical trials, which may be caused by several factors, including: slower than expected rates of patient recruitment; unforeseen safety issues; determination of dosing issues; lack of effectiveness during clinical trials; inability to satisfactorily demonstrate non-inferiority to approved therapies; inability or unwillingness of medical investigators and institutional review boards to follow our clinical protocols; inability to monitor patients adequately during or after treatment; and/or lack of sufficient funding to finance our clinical trials;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>the risk that the FDA, EMA, or other foreign regulatory authorities may not accept or approve a marketing application we file for any of our product candidates, and other risks relating to the review process;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks associated with the novel coronavirus disease, or COVID-19, outbreak and variants, which may adversely impact our business;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks related to any transactions we may effect in the public or private equity markets to raise capital to finance future research and development activities, general and administrative expenses and working capital;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks relating to our evaluation and pursuit of strategic alternatives;</div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>the risk that the results of our clinical trials will not support the applicable claims of safety or efficacy and that our product candidates will not have the desired effects or will be associated with undesirable side effects or other unexpected characteristics;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks relating to our ability to manage our relationship with our collaborators, distributors or partners, including, but not limited to, Pfizer and Chiesi;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks related to the amount and sufficiency of our cash and cash equivalents; </div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks relating to our ability to make scheduled payments of the principal of, to pay interest on or to refinance our outstanding notes or any other indebtedness;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks relating to changes to interim, topline or preliminary data from clinical trials that we announce or publish;</div><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;">&#9679;</span></span>risk of significant lawsuits, including stockholder litigation, which is common in the life sciences sector;</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>our dependence on performance by third-party providers of services and supplies, including without limitation, clinical trial services;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>delays in our preparation and filing of applications for regulatory approval; the inherent risks and uncertainties in developing drug platforms and products of the type we are developing;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>the impact of development of competing therapies and/or technologies by other companies;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks related to our supply of drug product to Pfizer;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks related to our expectations with respect to the potential commercial value of our product and product candidates;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks relating to the compliance by Fiocruz, an arm of the Brazilian MoH, with its purchase obligations under our supply and technology transfer agreement, which may have a material adverse effect on us and may also result in the termination of such agreement;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>potential product liability risks, and risks of securing adequate levels of related insurance coverage;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>the possibility of infringing a third-party&#8217;s patents or other intellectual property rights and the uncertainty of obtaining patents covering our products and processes and successfully enforcing our intellectual property rights against third-parties;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks relating to changes in healthcare laws, rules and regulations in the United States or elsewhere;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>and the possible disruption of our operations due to terrorist activities and armed conflict, including as a result of the disruption of the operations of certain regulatory authorities and of certain of our suppliers, collaborative partners, licensees, clinical trial sites, distributors and customers.</div><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Given these uncertainties, you should not place undue reliance on these forward-looking statements. Companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in advanced or late-stage clinical trials, even after obtaining promising earlier trial results or preliminary findings for such clinical trials. Even if favorable testing data is generated from clinical trials of a drug product, the FDA or foreign regulatory authorities may not accept or approve a marketing application filed by a pharmaceutical or biotechnology company for the drug product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Recent Company Developments</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-left:0pt;margin-right:4.3pt;margin-top:0pt;padding-bottom:10pt;text-indent:36pt;background:#ffffff;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>On March&#160;21, 2023, the first patient was dosed in our phase&#160;I First in Human (FIH) clinical trial of PRX-115.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-left:0pt;margin-right:4.3pt;margin-top:0pt;padding-bottom:10pt;text-indent:36pt;background:#ffffff;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>On February&#160;24, 2023, we, together with Chiesi, announced that the CHMP has adopted a positive opinion, recommending marketing authorization for PRX-102. The CHMP opinion was referred for final action to the EC. A final EC decision on the MAA is expected in the beginning of May 2023.</div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt 4.3pt 0pt 0pt;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>On February&#160;21, 2023, we announced our participation in the 19th Annual WORLD<i style="font-style:italic;">Symposium</i>&#8482; 2023, which took place on February&#160;22-26, 2023 at the Hilton Orlando in Orlando, Florida. We hosted an informational booth at the symposium.</div><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 4.5pt 10pt 0pt;">In light of recent developments relating to the COVID-19 pandemic and the focus of healthcare providers and hospitals on fighting the virus and its variants, and consistent with the FDA&#8217;s updated industry guidance for conducting clinical trials issued on March&#160;18, 2020, we and our contract research organizations have made certain adjustments to the operation of our clinical trials in an effort to ensure the monitoring and safety of patients and minimize risk to trial integrity during the pandemic and generally, and we may need to make adjustments again in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We are in close contact with our principal investigators, clinical sites and clinical research organizations, which are primarily located in the United States and Europe, and to date, the COVID-19 pandemic has had a minimal effect on the performance of the phase&#160;III clinical trials of PRX-102 as many of the patients were already treated in home care settings. We were able to complete all three of the clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="font-style:italic;font-weight:bold;">Delisting from Tel Aviv Stock Exchange</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">On December&#160;21, 2022, we announced that that we have decided that it is our company&#8217;s best interest to voluntarily delist our common stock from the Tel Aviv Stock Exchange, or the TASE. The delisting took effect on March&#160;22, 2023, and the last trading day on the TASE was March&#160;20, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">ProCellEx: Our Proprietary Protein Expression System</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">ProCellEx is our proprietary platform used to produce and manufacture recombinant proteins through plant cell-based expressions in suspension. ProCellEx consists of a comprehensive set of proprietary technologies and capabilities, including the use of advanced genetic engineering and plant cell culture technology, enabling us to produce complex, proprietary, and biologically equivalent proteins for a variety of human diseases. Our protein expression system facilitates the creation and selection of high-expressing, genetically-stable cell lines capable of expressing recombinant proteins.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our ProCellEx technology allows for many unique advantages, including: biologic optimization; an ability to handle complex protein expressions; flexible manufacturing with improvements through efficiencies, enhancements and/or rapid horizontal scale-ups; a simplified production process; elimination of the risk of viral contaminations from mammalian components; and intellectual property advantages.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We are the first and only company to gain FDA approval of a protein produced through plant cell-based expression. Our ProCellEx platform uses flexible polyethylene disposable bioreactors and is optimized for plant cell cultures. As opposed to the large stainless-steel bioreactors commonly used for recombinant protein production, our ProCellEx bioreactors are easy to use and maintain and allow for the major advantage of rapid horizontal scale-up.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:229.64pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Plant Cell Production Advantages</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-size:12pt;"><img src="plx-20230331x10q005.jpg" alt="Graphic" style="display:inline-block;height:229.64pt;width:540pt;" /></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">ProCellEx</b><sup style="font-size:7.5pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup><b style="font-weight:bold;">: Protalix&#8217;s Differentiated Plant Cell Protein Expression Platform</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;"><img src="plx-20230331x10q006.jpg" alt="Graphic" style="display:inline-block;height:226.46pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:540pt;" /></b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:109.53pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Product Pipeline</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;"><img src="plx-20230331x10q007.jpg" alt="Graphic" style="display:inline-block;height:109.18pt;left:0%;padding-bottom:0.35pt;position:relative;top:0pt;width:540pt;" /></b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Pegunigalsidase Alfa (PRX-102) for the Treatment of Fabry Disease</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">PRX-102, our lead product candidate, is a late-stage clinical asset in development for the treatment of Fabry disease. We expect PRX-102 to be the primary subject of our development efforts in the short-term. It <span style="letter-spacing:-0.15pt;">is our proprietary, investigational, plant cell culture expressed enzyme, and a chemically modified stabilized version of, the recombinant &#945;-Galactosidase-A protein, a </span>lysosomal enzyme,<span style="letter-spacing:-0.15pt;"> under development for the treatment of Fabry disease. </span>Fabry disease is a serious life-threatening rare genetic disorder. Fabry patients lack or have low levels of &#945;-galactosidase-A resulting in the progressive accumulation of abnormal deposits of a fatty substance called globotriaosylceramide, or Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub>, in blood vessel walls throughout their body. The ultimate consequences of Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> deposition range from episodes of pain and impaired peripheral sensation to end-organ failure, particularly of the kidneys, but also of the heart and the cerebrovascular system. Fabry disease occurs in one person per 40,000 to 60,000 males.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The global market for Fabry disease, that includes Sanofi&#8217;s Fabrazyme<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, Shire&#8217;s (acquired by Takeda Pharmaceutical Company Limited) Replagal<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, and Amicus Therapeutics&#8217; Galafold<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, among others, was $2.2&#160;billion in 2022, is forecasted to be approximately $2.3&#160;billion in 2023 and is forecasted to grow at a CAGR of approximately 11.9% from 2022-2028.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our phase&#160;III clinical program included three separate clinical trials which are referred to as the <i style="font-style:italic;">BALANCE</i> study, the <i style="font-style:italic;">BRIDGE</i> study and the <i style="font-style:italic;">BRIGHT</i> study, all of which have been completed. In addition, the phase&#160;III clinical program included two extension studies in which subjects that participated in our phase&#160;I/II clinical trials and our phase&#160;III clinical trials were given the opportunity to enroll and continue to be treated with PRX-102. As of March&#160;1, 2023, sponsorship of the two open-label extension studies was transferred to Chiesi, and Chiesi is now administering the extension studies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The FDA has indicated that the BLA for PRX-102 for the potential treatment of adult patients with Fabry disease that we, together with Chiesi, resubmitted on November&#160;9, 2022 was considered a complete, class&#160;2 response and set a PDUFA action date of&#160;May&#160;9, 2023. The initial BLA for PRX-102 was submitted to the FDA on May&#160;27, 2020 under the FDA&#8217;s Accelerated Approval pathway, and was subsequently accepted by the FDA and granted Priority Review designation. However, in April 2021, the FDA issued the CRL in response to the initial BLA. In preparation for the BLA resubmission, the Company and Chiesi participated in a Type A (End of Review) meeting with the FDA on September&#160;9, 2021. As part of the meeting minutes provided by the FDA, which included the preliminary comments and meeting discussion, the FDA, in principle, agreed that the data package proposed to the FDA for a BLA resubmission has the potential to support a traditional approval of PRX-102 for the treatment of Fabry disease. The data package in the BLA resubmission, given the change in the regulatory landscape in the United States, includes the final two-year analyses of our <i style="font-style:italic;">BALANCE</i> study and long-term data from our open-label extension study of PRX-102 in adult patients treated with a 2&#160;mg/kg every four&#160;weeks dosage of PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">On February&#160;7, 2022, we, together with Chiesi, submitted an MAA for PRX-102 to the EMA which was subsequently validated by the EMA. The submission was made after the October&#160;8, 2021 meeting we held, together with Chiesi, with the Rapporteur and Co-Rapporteur of the EMA regarding PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The MAA submission includes a comprehensive set of preclinical, clinical and manufacturing data compiled from our completed and ongoing clinical studies evaluating PRX-102 as a potential alternative treatment for adult patients with Fabry disease, including data from our completed 12&#8211;month switch&#8211;over phase&#160;III <i style="font-style:italic;">BRIGHT</i>&#160;clinical trial in adult patients with Fabry disease treated with a 2&#160;mg/kg every four&#160;weeks dosage to support an additional potential treatment regimen for Fabry patients. As part of the EMA review process, we and Chiesi responded to the Day&#160;120 list of questions in September 2022 (following a 3-month clock-stop period) and to the list of outstanding issues of Day&#160;180 in December 2022. An essential portion of the Day&#160;120 response included the submission of the final analysis of the two-year <i style="font-style:italic;">BALANCE</i> study (the final Clinical Study Report), and an interim analysis of our long-term, open-label extension study of PRX-102 in adult patients with Fabry disease treated with the 2&#160;mg/kg every four&#160;weeks dosage. The EMA&#8217;s approval of PRX-102 at this time does not include the 2&#160;mg/kg every four&#160;weeks dosage.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">On February&#160;24, 2023, we, together with Chiesi, announced that CHMP adopted a positive opinion, recommending marketing authorization for PRX-102. The CHMP opinion was referred for final action to the EC. A final EC decision on the MAA is expected in the beginning of&#160;May 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In January&#160;2018, the FDA granted Fast Track designation to PRX-102. Fast Track designation is a process designed to facilitate the development and expedite the review of drugs and vaccines for serious conditions that fill an unmet medical need.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Chiesi, together with Protalix, participated in an Oral Explanation at a meeting of the EMA&#8217;s Committee for Orphan Medicinal Products (COMP) held on March&#160;21, 2023, as part of the Orphan Drug Designation maintenance process. Following the meeting, Chiesi formally withdrew the application for Orphan Drug Designation for PRX-102. The EC first granted Orphan Drug Designation for <span style="font-family:'Times-Roman';">PRX-102</span> for the treatment of Fabry disease in December 2017.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="font-style:italic;font-weight:bold;">Key Trials and Design</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our clinical development program is designed to show that PRX-102 has a potential clinical benefit in all adult Fabry patient populations when compared to currently marketed Fabry disease enzymes, agalsidase beta (Fabrazyme<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>; marketed by Sanofi (acquired Genzyme)) and agalsidase alfa (Replagal<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>; marketed by Takeda Pharmaceutical Company Limited (acquired Shire&#160;Plc)). In preclinical studies, PRX-102 showed significantly longer half-life due to higher enzyme stability, enhanced activity in Fabry disease affected organs leading to reduction of the accumulated substrate and reduced immunogenicity, which together can potentially lead to improved efficacy through increased substrate clearance and significantly lower formation of anti-drug antibodies, or ADAs. Providing a meaningful improvement in the health and quality of life for Fabry patients being treated with PRX-102 represents a significant potential market opportunity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our phase&#160;III clinical program of PRX-102 for the treatment of Fabry disease includes three individual studies; the <i style="font-style:italic;">BALANCE</i> study, the <i style="font-style:italic;">BRIDGE</i> study and the <i style="font-style:italic;">BRIGHT</i> study, all of which have been completed. In 2016, we completed a phase I/II clinical trial of PRX-102, which was a dose range finding study in ERT-na&#239;ve adult Fabry patients. In the phase III clinical program overall, two potential dosing regimens for PRX-102 were analyzed; 1&#160;mg/kg every two weeks, with the potential for improved efficacy and safety offering a potential alternative to existing enzyme replacement therapies, and 2&#160;mg/kg every four weeks, which has the potential to lower treatment burden versus existing treatments and potentially provide a better quality of life for a subset of adult Fabry patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Patients who completed the <i style="font-style:italic;">BALANCE</i>, <i style="font-style:italic;">BRIDGE</i> and <i style="font-style:italic;">BRIGHT</i> studies, and the extension of the phase&#160;I/II study, were offered the opportunity to continue PRX-102 treatment in one of two long-term open-label extension studies. Currently, 126 subjects who participated in our PRX-102 clinical program have opted, with the advice of the treating physician, to continue PRX-102 treatment in one of our long-term, open label, extension studies. Such extension studies include 97 patients in the 1&#160;mg/kg every two weeks extension study (PB-102-F60) with a total cumulative exposure of approximately 400 patient years (10 subjects who completed an extension study from the phase I/II study, 18 subjects who completed the <i style="font-style:italic;">BRIDGE</i> study; 69 subjects who completed the <i style="font-style:italic;">BALANCE</i> study), and 29 subjects who completed the <i style="font-style:italic;">BRIGHT</i> study, in the 2&#160;mg/kg every four weeks extension study (PB-102-F51) with a total cumulative exposure of approximately 110 patient years. Two of such subjects are being treated with 1&#160;mg/kg every two weeks. As of March&#160;1, 2023, sponsorship of the two extension studies was transferred to Chiesi, and Chiesi is now administering the open-label extension studies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In February 2020, we, together with Chiesi, announced an agreement with the FDA for the Initial Pediatric Study Plan (iPSP) for PRX-102. The joint announcement was made after completion of discussions with the FDA and receipt of confirmation from the FDA in an official &#8220;Agreement Letter&#8221; which outlines an agreed-upon approach to evaluate the safety and efficacy of PRX-102 in pediatric Fabry patients in a clinical trial to be performed by Chiesi with our collaborative efforts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><span style="font-style:italic;font-weight:bold;">Phase III BALANCE Study</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The pivotal <i style="font-style:italic;">BALANCE</i> study was a 24-month, randomized, double blind, active control study of PRX-102 in adult Fabry patients with deteriorating renal function that was designed to evaluate the safety and efficacy of 1&#160;mg/kg of PRX-102 administered every two weeks compared to agalsidase beta. Topline results from the completed study were announced in April 2022 and the Clinical Study Report for the <i style="font-style:italic;">BALANCE</i> study was completed in July 2022. The final analysis confirmed the positive topline results and favorable tolerability profile. A total of 78 patients who were previously treated with agalsidase beta for at least one year with an estimated glomerular filtration rate (eGFR) slope at screening worse than -2&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year were enrolled in the study. Patients were randomized on a 2:1 ratio for switching to PRX-102 or continuing on agalsidase beta. A total of 77 patients were treated; 52 with PRX-102 and 25 with agalsidase beta. Approximately 40% of the enrolled patients were female.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The primary endpoint of the <i style="font-style:italic;">BALANCE</i> study is the comparison in the annualized rate of decline of estimated Glomerular Filtration Rate, or eGFR, slope between the agalsidase beta and PRX-102 treatment arms. eGFR is considered a reliable and accepted test to </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">measure kidney function and stage of kidney disease. Additional parameters evaluated include: cardiac assessment, Lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> (a biomarker for monitoring Fabry patients during therapy), pain, quality of life, immunogenicity, Fabry Clinical Events, pharmacokinetics and other parameters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Given the changed regulatory landscape in the United States with the full approval of agalsidase beta in March 2021 based on clinical endpoints, we changed the primary analysis of the <i style="font-style:italic;">BALANCE</i> study from superiority to non-inferiority, as demonstrating superiority is no longer required under FDA guidelines. As part of the September 2021 Type A End of Review meeting, the FDA, in principle, agreed that the proposed analysis of the <i style="font-style:italic;">BALANCE</i> study demonstrating non-inferiority to agalsidase beta to be included in the data package for the PRX-102 BLA resubmission has the potential to support the approval of PRX-102 for the treatment of Fabry disease. The primary endpoint of the <i style="font-style:italic;">BALANCE</i> study compared the eGFR annualized changes (slope) between the two treatment arms in the intent-to-treat (ITT) analysis set (77 patients). The study met its pre-specified primary endpoint and demonstrated that PRX-102 was statistically non-inferior to agalsidase beta.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The median (95% confidence interval) of the eGFR slope in the PRX-102 arm was -2.514&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year (-3.788, -1.240) and -2.155&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year (-3.805, -0.505) in the agalsidase beta arm, demonstrating a large overlap in the confidence intervals of the two arms. The difference in medians (95% confidence interval) is -0.359&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year (-2.444, 1.726). The prespecified non-inferiority margin was met. The final results of the per-protocol analysis set (72 patients) are consistent with the ITT results, with an even smaller difference in medians (95% confidence interval); -0.118&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year (-2.450, 2.213). Additional sensitivity and supportive analyses investigated mean eGFR slopes using other statistical models. These models yielded results similar to the primary analysis and confirming non-inferiority of PRX-102 to agalsidase beta. These results supported the robustness of the methodology used for comparisons of treatment effects in the <i style="font-style:italic;">BALANCE</i> study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The study population (ITT analysis set) was composed of 47 males (61.0%) and 30 females (39.0%), with a mean (range) age of 44.3 (18-60) years. The mean duration of prior treatment with agalsidase beta was approximately six years. At baseline, mean (SD) eGFR was 73.69&#160;ml/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup> (20.32) and median eGFR was 74.51&#160;ml/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>; mean (SD) eGFR slope was -8.10&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year (5.92) and median eGFR slope was -7.25&#160;ml/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">A consistent efficacy response was also observed across biomarkers and functional systems relevant to Fabry disease, as demonstrated via secondary endpoints, where in some cases the trend was in favor of PRX-102 and in some in favor of agalsidase beta, but the actual difference between the two arms is always clinically small, supporting the comparability of the two treatments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Key secondary endpoints included Urine protein creatinine ratio (UPCR) as indicator of proteinuria, plasma levels of lyso &#8211;Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub>, imaging marker of cardiac remodeling (Left Ventricular Mass Index, LVMI, by cardiac MRI), disease severity (by Mainz Severity Score Index, MSSI), pain severity (Short Form Brief Pain Inventory, BPI) and quality of life (EQ-5D-5L). Both treatments showed either a stabilization of clinical parameters (e.g., for eGFR, eGFR slope and UPCR) or prevention of further progression of Fabry disease (e.g., LVMI, MSSI).</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span><i style="font-style:italic;">Secondary measures of kidney function</i>. In addition to eGFR levels and slope, the proportion of patients categorized as having severe proteinuria (UPCR &#8805; 1 gr/gr) in the PRX-102 arm remained stable during the study (at baseline, 7/52 [13.5%] and 6/45 [13.3%] 24-month), while in the agalsidase beta arm, the proportion increased slightly with 3/25 (12.0%) and 4/24 (16.7%), respectively. Mean (SE) UPCR data (post-hoc analysis) for the entire study population remained stable throughout the study with a slight advantage for PRX-102 at 24-months compared to agalsidase beta (Table&#160;1).</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span><i style="font-style:italic;">Biomarkers of Fabry disease</i>. Mean (SE) and median (range) plasma lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> change from baseline to 24 months of treatment in the PRX-102 arm were 3.30 (1.38) and 1.15 (-32.2 to 32.7) nM for PRX-102, and -8.74 (4.85) and -1.50 (-102.3 to 2.4)&#160;nM for agalsidase beta. As expected, a gender difference was noted, with female Fabry patients exhibiting lower values at baseline and no remarkable changes during the study. Overall, the absolute changes of the Fabry biomarkers were minor in both treatment arms and were considered not clinically significant since there was no indication of Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> re-accumulation nor of disease progression.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span><i style="font-style:italic;">Measures of cardiac disease</i>. LVMi was centrally evaluated based on cardiac MRI. An increase in LVMi is indicative of progressing cardiomyopathy, hence preventing an increase in LVMI represents a therapeutic goal in Fabry patients. In the <i style="font-style:italic;">BALANCE </i>study, the change from baseline in both treatment arms was analyzed by absence/presence of hypertrophy at baseline (defined as a LVMI above 91&#160;g/m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup> for males and LVMI above 77&#160;g/m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup> for females at baseline) and by gender (Kawel-Boehm 2015). Similar results were achieved in the two treatment arms after 24 months, with a slight reduction in the mean (SE) LVMi values in the PRX-102 arm -4.238 (5.731) and a small increase in the agalsidase beta arm 2.417 (9.620) for patients with hypertrophy at baseline. Small differences were observed also in those patients without hypertrophy at baseline in both treatment arms.</div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span><i style="font-style:italic;">Measures of systemic disease burden (MSSI)</i>. Further evidence of the stabilization of the disease is provided by the MSSI overall scores, which remained stable throughout the <i style="font-style:italic;">BALANCE</i> study in both arms, with the baseline score in both groups at the low end of the moderate range (means of 23.18&#160;points in the PRX-102 arm and 25.16&#160;points in the agalsidase beta arm), that slightly decreased (improvement by -2.1&#160;points) in the PRX-102 arm and slightly increased in the agalsidase beta arm (+2.0&#160;points). In this case, the CI of the difference in mean changes did not contain 0, suggesting a difference between the two arms in favor of PRX-102.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span><i style="font-style:italic;">Patient reported outcomes</i>. With regards to the patient-reported outcomes (BPI and EQ-5D-5L), the two treatments showed very similar results, with the majority of patients reporting an improvement or no change in both groups, for each domain.</div><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">For an overview of primary and secondary endpoints collected in the <i style="font-style:italic;">BALANCE</i> study, please refer to the Table&#160;1 below.</p><a id="_Ref124326188"></a><a id="_Toc124351688"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Table&#160;</b><b style="font-weight:bold;">1</b><b style="font-weight:bold;">: Summary Table of Comparison of Treatment Benefit Data in the </b><span style="font-style:italic;font-weight:bold;">BALANCE</span><b style="font-weight:bold;"> Study, (Mean (SE) [median]), Efficacy Population</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:auto;width:89.86%;"><tr style="height:11.95pt;"><td style="vertical-align:top;width:26.79%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Parameter</b></p></td><td style="vertical-align:top;width:22.23%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:25.02%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">PRX-102 (N = 52)</b></p></td><td colspan="2" style="vertical-align:top;width:25.94%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Agalsidase beta (N = 25)</b></p></td></tr><tr style="height:13.7pt;"><td rowspan="4" style="vertical-align:top;width:26.79%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">eGFR </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(ml/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>)</p></td><td style="vertical-align:top;width:22.23%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">n</b></p></td><td style="vertical-align:top;width:20.39%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">n</b></p></td><td style="vertical-align:top;width:21.3%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:14.4pt;"><td style="display:none;vertical-align:middle;width:26.79%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"></td><td style="vertical-align:top;width:22.23%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Baseline</p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">52</p></td><td style="vertical-align:top;width:20.39%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">73.46 (2.80) [73.45]</p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">25</p></td><td style="vertical-align:top;width:21.3%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">74.16 (4.19) [74.85]</p></td></tr><tr style="height:14.4pt;"><td style="display:none;vertical-align:middle;width:26.79%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"></td><td style="vertical-align:top;width:22.23%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Month 24</p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">47</p></td><td style="vertical-align:top;width:20.39%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">70.53 (3.19) [69.35]</p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">24</p></td><td style="vertical-align:top;width:21.3%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">72.05 (4.69) [74.48]</p></td></tr><tr style="height:11.95pt;"><td style="display:none;vertical-align:middle;width:26.79%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"></td><td style="vertical-align:top;width:22.23%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change from Baseline </p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">47</p></td><td style="vertical-align:top;width:20.39%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">-3.60 (1.58) [-2.39]</p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">24</p></td><td style="vertical-align:top;width:21.3%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">-1.97 (1.51) [-3.20]</p></td></tr><tr style="height:1pt;"><td rowspan="2" style="vertical-align:top;width:26.79%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">eGFR slope (ml/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/yr)</p></td><td style="vertical-align:top;width:22.23%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Baseline</p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">52</p></td><td style="vertical-align:top;width:20.39%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">-8.03 (0.92) [-6.70]<br />Range: -30.5; 6.3</p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">25</p></td><td style="vertical-align:top;width:21.3%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">-8.25 (0.85) [-7.84]<br />Range: -20.3; -2.8</p></td></tr><tr style="height:1pt;"><td style="display:none;vertical-align:middle;width:26.79%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"></td><td style="vertical-align:top;width:22.23%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Month 24</p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">51</p></td><td style="vertical-align:top;width:20.39%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">-2.38 (1.25) [-2.51] <br />Q1; Q3: -4.8; 0.8</p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">25</p></td><td style="vertical-align:top;width:21.3%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">-2.31 (0.71) [-2.16]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Q1; Q3: -4.6; -0.5</p></td></tr><tr style="height:25.35pt;"><td style="vertical-align:top;width:26.79%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Reaching kidney therapeutic goal<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">a</sup></p></td><td style="vertical-align:top;width:22.23%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Month 24</p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">52</p></td><td style="vertical-align:top;width:20.39%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">41 patients (80.4%)</p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">25</p></td><td style="vertical-align:top;width:21.3%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">20 patients (80.0%)</p></td></tr><tr style="height:14.4pt;"><td rowspan="3" style="vertical-align:top;width:26.79%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">UPCR</p></td><td style="vertical-align:top;width:22.23%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Baseline</p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">52</p></td><td style="vertical-align:top;width:20.39%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">0.441 (0.084)</p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">25</p></td><td style="vertical-align:top;width:21.3%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">0.284 (0.097)</p></td></tr><tr style="height:14.4pt;"><td style="display:none;vertical-align:middle;width:26.79%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"></td><td style="vertical-align:top;width:22.23%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Month 24</p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">45</p></td><td style="vertical-align:top;width:20.39%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">0.480 (0.118)</p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">24</p></td><td style="vertical-align:top;width:21.3%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">0.489 (0.162)</p></td></tr><tr style="height:14.4pt;"><td style="display:none;vertical-align:middle;width:26.79%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"></td><td style="vertical-align:top;width:22.23%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change from Baseline </p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">45</p></td><td style="vertical-align:top;width:20.39%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">0.088 (0.067)</p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">24</p></td><td style="vertical-align:top;width:21.3%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">0.197 (0.085)</p></td></tr><tr style="height:14.4pt;"><td rowspan="3" style="vertical-align:top;width:26.79%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Plasma lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> (nM)</p></td><td style="vertical-align:top;width:22.23%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Baseline</p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">52</p></td><td style="vertical-align:top;width:20.39%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">26.22 (3.78) [15.20]</p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">25</p></td><td style="vertical-align:top;width:21.3%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">32.14 (7.08) [17.60]</p></td></tr><tr style="height:14.4pt;"><td style="display:none;vertical-align:middle;width:26.79%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"></td><td style="vertical-align:top;width:22.23%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Month 24</p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">46</p></td><td style="vertical-align:top;width:20.39%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">29.22 (4.48) [18.80]</p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">22</p></td><td style="vertical-align:top;width:21.3%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">19.65 (3.60) [15.30]</p></td></tr><tr style="height:14.4pt;"><td style="display:none;vertical-align:middle;width:26.79%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"></td><td style="vertical-align:top;width:22.23%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change from Baseline </p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">46</p></td><td style="vertical-align:top;width:20.39%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.30 (1.38) [1.15]</p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">22</p></td><td style="vertical-align:top;width:21.3%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">-8.74 (4.85) [-1.50]</p></td></tr><tr style="height:11.95pt;"><td rowspan="3" style="vertical-align:top;width:26.79%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">LVMI (g/m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>)</p></td><td style="vertical-align:top;width:22.23%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Baseline</p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">40</p></td><td style="vertical-align:top;width:20.39%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">75.97 (5.13)</p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">22</p></td><td style="vertical-align:top;width:21.3%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">82.22 (6.34)</p></td></tr><tr style="height:14.4pt;"><td style="display:none;vertical-align:middle;width:26.79%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"></td><td style="vertical-align:top;width:22.23%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Month 24</p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">35</p></td><td style="vertical-align:top;width:20.39%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">71.56 (5.20)</p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">20</p></td><td style="vertical-align:top;width:21.3%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">82.43 (8.39)</p></td></tr><tr style="height:14.4pt;"><td style="display:none;vertical-align:middle;width:26.79%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"></td><td style="vertical-align:top;width:22.23%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change from Baseline </p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">28</p></td><td style="vertical-align:top;width:20.39%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">-0.64 (2.69)</p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">19</p></td><td style="vertical-align:top;width:21.3%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">0.29 (3.73)</p></td></tr><tr style="height:11.95pt;"><td rowspan="3" style="vertical-align:top;width:26.79%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">MSSI (overall score)<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">a</sup></p></td><td style="vertical-align:top;width:22.23%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Baseline</p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">49</p></td><td style="vertical-align:top;width:20.39%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">23.18 (1.42)</p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">25</p></td><td style="vertical-align:top;width:21.3%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">25.16 (2.14)</p></td></tr><tr style="height:14.4pt;"><td style="display:none;vertical-align:middle;width:26.79%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"></td><td style="vertical-align:top;width:22.23%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Month 24</p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">46</p></td><td style="vertical-align:top;width:20.39%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">22.11 (1.80)</p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">23</p></td><td style="vertical-align:top;width:21.3%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">27.09 (2.30)</p></td></tr><tr style="height:14.4pt;"><td style="display:none;vertical-align:middle;width:26.79%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"></td><td style="vertical-align:top;width:22.23%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change from Baseline </p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">44</p></td><td style="vertical-align:top;width:20.39%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">-2.07 (0.77)</p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">23</p></td><td style="vertical-align:top;width:21.3%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2.04 (1.10)</p></td></tr><tr style="height:11.95pt;"><td rowspan="3" style="vertical-align:top;width:26.79%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">BPI (score for pain at its worst)<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">b</sup></p></td><td style="vertical-align:top;width:22.23%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Baseline</p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">52</p></td><td style="vertical-align:top;width:20.39%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.5 (0.4)</p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">25</p></td><td style="vertical-align:top;width:21.3%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2.6 (0.6)</p></td></tr><tr style="height:14.4pt;"><td style="display:none;vertical-align:middle;width:26.79%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"></td><td style="vertical-align:top;width:22.23%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Month 24</p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">45</p></td><td style="vertical-align:top;width:20.39%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.3 (0.5)</p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">22</p></td><td style="vertical-align:top;width:21.3%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.0 (0.7)</p></td></tr><tr style="height:14.4pt;"><td style="display:none;vertical-align:middle;width:26.79%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"></td><td style="vertical-align:top;width:22.23%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change from Baseline </p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">45</p></td><td style="vertical-align:top;width:20.39%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">-0.1 (0.5)</p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">22</p></td><td style="vertical-align:top;width:21.3%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">0.6 (0.6)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 10pt 0pt;">BPI=brief pain inventory; eGFR=estimated glomerular filtration rate; lyso-Gb<sub style="font-size:6pt;vertical-align:sub;">3</sub>=globotriaosylsphingosine; LVMI=Left Ventricular Mass Index; MSSI=Mainz Severity Score Index; UPCR=Urine Protein Creatinine Ratio.</p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 10pt 0pt;"><sup style="font-size:6pt;line-height:100%;top:0pt;vertical-align:top;">a </sup>Wanner 2018; <sup style="font-size:6pt;line-height:100%;top:0pt;vertical-align:top;">b </sup>Higher scores indicate higher symptom severity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Forty-seven (90.4%) patients in the PRX-102 arm experienced at least one treatment-emergent adverse event (TEAE) compared to 24 (96.0%) in the agalsidase beta arm. The number of events adjusted to 100 years of exposure is 572.36 events for the PRX-102 arm and 816.85 events for the agalsidase beta arm.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Treatment-related adverse events were reported for 21 (40.4%) patients in the PRX-102 arm compared to 11 (44.0%) in the agalsidase beta arm. The number of treatment-related events adjusted to 100 years of exposure is 42.85 events for the PRX-102 arm and 152.91 events for the agalsidase beta arm.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Usage of infusion pre-medication was tapered down during the study, if possible, for all patients. At baseline, 21 (40.4%) patients in the PRX-102 arm used infusion premedication compared to 16 (64.0%) in the agalsidase beta arm. At the end of the study, only three out of 47 (6.4%) patients in the PRX-102 arm used infusion premedication compared to three out of 24 (12.5%) in the agalsidase beta arm. Even with this reduction in use of premedication, there were fewer reported infusion-related reactions with PRX-102: 11 (21.2%) patients in the PRX-102 arm experienced a total of 13 events compared to six (24.0%) patients experiencing a total of 51 events in the agalsidase beta arm. The number of infusion-related reactions adjusted to 100 infusions is 0.5 for the PRX-102 arm and 3.9 for the agalsidase beta arm.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Assessment of immunogenicity, that is, the existence and development of anti PRX-102 antibodies or anti-agalsidase beta antibodies, in the study indicated that for the PRX-102 arm, 18 (34.6%) patients were ADA positive at baseline, of which 17 (94.4%) had neutralizing antibody activity. For the agalsidase beta arm, eight (32.0%) patients were ADA positive at baseline, of which seven (87.5%) had neutralizing antibody activity. Only a small number of patients showed treatment-emergent ADA. At the end of the two-year study, 11 (23.4%) patients who received PRX-102 were ADA positive, of which seven (63.6%) had neutralizing antibody activity, while in the agalsidase beta arm six (26.1%) were ADA-positive and all six (100%) had neutralizing antibody activity. There was little change in the percentage of patients who were ADA positive, with a trend of reduction observed in the PRX-102 arm and stability in the agalsidase beta arm. The proportion of patients with neutralizing ADA decreased in the PRX-102 arm while it remained stable in the agalsidase beta arm.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Out of the 78 randomized patients, six patients discontinued the study: out of the five (9.4%) from the PRX-102 arm, one patient withdrew consent prior to the first infusion, two discontinued due to personal reasons, and two due to adverse events (one due to an unrelated adverse event and one due to a treatment related adverse event); one (4%) patient from the agalsidase beta arm discontinued for personal reasons. There were no deaths in this study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Considering that in the trial, patients in the PRX-102 arm were exposed for the first time to the novel enzyme, tolerability data appear favorable for PRX-102 and in line with what was observed in the previous clinical studies of PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Of the patients who completed the trial from both the PRX-102 and agalsidase beta treatment arms, 69 have opted, with the advice of the treating physician, to receive PRX-102 1&#160;mg/kg every two weeks in the long-term open-label extension study which is now sponsored by Chiesi.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The results of the direct, blinded comparison of PRX-102 to agalsidase beta, for the primary efficacy renal endpoints (i.e., eGFR change, eGFR slope) and for the main secondary endpoints (e.g., urine protein to creatinine ratio [UPCR] LVMI, MSSI, BPI) strongly suggest comparability in treatment effects between the two treatments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">At the same time a potentially favorable safety profile was identified based on lower rates of IRR, lower ADA positivity, and less premedication use in the PRX-102 arm compared to agalsidase beta. Overall, a positive benefit-risk balance was confirmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><span style="font-style:italic;font-weight:bold;">Phase&#160;III BRIDGE Study</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The <i style="font-style:italic;">BRIDGE</i> study was a 12-month open-label, single arm switch-over study evaluating the safety and efficacy of pegunigalsidase alfa, 1&#160;mg/kg infused every two weeks, in up to 22 Fabry patients previously treated with agalsidase alfa for at least two years and on a stable dose for at least six months. The trial was completed in December 2019. Patients were screened and evaluated over three months while continuing agalsidase alfa treatment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Final results of the data generated in the <i style="font-style:italic;">BRIDGE</i> study showed substantial improvement in renal function as measured by mean annualized eGFR slope in both male and female patients. Twenty of 22 patients completed the 12-month treatment duration. Eighteen of the patients who completed the study opted to roll over to a long-term extension study and continue to be treated with PRX-102. In the study, the mean annualized eGFR slope of the study participants improved from -5.90&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year while on agalsidase alfa to -1.19&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year on PRX-102 in all patients. Male patients improved from -6.36&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year to -1.73&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year and female patients improved from -5.03&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year to -0.21&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year. Following the switch to PRX-102, there was a decrease in patients with progressing or fast progressing kidney disease which is consistent with the therapeutic goals for Fabry disease, as identified by Christoph Wanner, et. al., in 2019, and most patients achieved a stable status post-switch.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">PRX-102 was well-tolerated in the <i style="font-style:italic;">BRIDGE</i> study, with all adverse events being transient in nature without sequelae. Of the 22 patients enrolled in the <i style="font-style:italic;">BRIDGE</i> study, the majority of TEAEs were mild or moderate in severity, with two patients (9.1%) withdrawing from the therapy due to hypersensitivity reaction that was resolved. The most common moderate TEAEs were nasopharyngitis, headache and dyspnea.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">An immunogenicity assessment indicated that four out of 20 patients (20%) developed persistent ADAs over the course of the study, of which two had neutralizing activity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;">Baseline characteristics of the 20 patients who completed the study, ranging from ages 28 to 60 years, were as follows: mean eGFR 75.87&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup> in males, and 86.14&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup> in females and plasma lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> were 51.81&#160;nM and 13.81&#160;nM in males and females, respectively. While lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> levels remain slightly high, particularly within the male cohort, continuous reduction in lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> levels was observed of 19.55&#160;nM (32.35%) in males and 4.57&#160;nM (29.81%) in females.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;">Of the patients who completed the trial, 18 have opted, with the advice of the treating physician, to continue receiving PRX-102 1&#160;mg/kg every two weeks in a long-term open-label extension study which now sponsored by Chiesi.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><span style="font-style:italic;font-weight:bold;">Phase&#160;III BRIGHT Study</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The <i style="font-style:italic;">BRIGHT</i> study was a multicenter, multinational open-label, switch-over study designed to evaluate the safety, efficacy and pharmacokinetics of treatment with 2&#160;mg/kg of PRX-102 administered every four weeks for 52 weeks (a total of 14 infusions). The trial, which was completed in June 2020, enrolled 30 adult patients (24 males and 6 females) with mean (SD) age of 40.5 (11.3) years, ranging from 19 to 58 years previously treated with a commercially available ERT (agalsidase beta or agalsidase alfa), for at least three years and on a stable dose administered every two weeks. To determine eligibility for participation in the study, candidates were screened to identify and select Fabry patients with clinically stable kidney disease. The most common Fabry disease symptoms at baseline were acroparesthesia, heat intolerance, angiokeratomas and hypohydrosis. Patients who matched the criteria were enrolled in the study and switched from their current treatment of IV infusions every two weeks to 2&#160;mg/kg of PRX-102 every four weeks for 12&#160;months. Patients participating in the study were evaluated, among other disease parameters, to determine if their kidney disease had not further deteriorated while being treated with the four-week dosing regimen as measured by eGFR and for lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3 </sub>levels as a Fabry biomarker, as well as other parameters. In addition, participating patients were evaluated to assess the safety and tolerability of PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We announced final results from the <i style="font-style:italic;">BRIGHT</i> study in March 2022. The results indicate that 2&#160;mg/kg of PRX-102 administered by intravenous infusion every four weeks was well tolerated, and Fabry disease assessed by eGFR slope and plasma lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> was stable throughout PRX-102 treatment in adult Fabry patients. None of the patients without ADAs at screening developed treatment-induced ADAs following the switch to PRX-102 treatment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">All 30 patients received at least one dose of PRX-102, and 29 patients completed the one-year study. Of these 29 patients, 28 received the intended regimen of 2&#160;mg/kg every four weeks throughout the entire study, while one patient was switched to 1&#160;mg/kg PRX-102 every two weeks per protocol at the 11th infusion. One patient withdrew from the study after the first infusion due to a traffic accident.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">First infusions of PRX-102 were administered under controlled conditions at the investigation site. Based on the protocol-specified criteria, patients were able to receive their PRX-102 infusions at a home care setup once the applicable Investigator and Sponsor Medical Monitor agreed that it was safe to do so. Safety and efficacy exploratory endpoints were assessed throughout the 52-week study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Overall, 33 of 183 total TEAEs reported in nine (30.0%) of the patients were considered treatment related; all were mild or moderate in severity and the majority were resolved at the end of the study. There were no serious or severe treatment-related TEAEs and no TEAEs led to death or study withdrawal. Of the treatment-related TEAEs, 27 were infusion-related reactions (IRRs) and the remainder were single events of diarrhea, erythema, fatigue, influenza-like illness, increases urine protein/creatinine ratio, and urine positive for white blood cells. The 27 IRRs were reported in five (16.7%) patients, all male. All IRRs occurred during the infusion or within two hours post-infusion; no events were recorded between two and 24 hours post-infusion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Study outcome measures show that plasma lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> concentrations remained stable during the study with a mean change (&#177;SE) of 3.01&#160;nM (0.94) from baseline (19.36 nM &#177;3.35) to Week&#160;52 (22.23 &#177;3.60 nM). Mean absolute eGFR values were stable during the 52-week treatment period, with a mean change from baseline of -1.27&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup> (1.39). Mean (SE) eGFR slope, at the end of the study, for the overall population, was -2.92&#160;(1.05) mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year indicating stability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The study suggests that Fabry patients who are currently receiving ERT every two weeks may be successfully transitioned to PRX-102 2&#160;mg/kg every four weeks as an effective and tolerable alternative treatment option. Additional long term data is being collected as part of the ongoing long term extension study of the 2&#160;mg/kg PRX-102 every four weeks dose.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Following a survey of participants using the Quality of Life EQ-5D-5L questionnaire, responses indicate that patient perception of their own health remained high and stable throughout the 52-week study duration, with overall health mean (SE) scores of 78.3 (3.1) and 82.1 (2.9) at baseline and Week 52, respectively, in a 0 to 100 scale. Using the short-form Brief Pain Inventory, or questionnaire, </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">approximately 75% of study participants had an improvement or no change in average pain severity at Week 52 (compared to baseline). The short-form BPI interference items also remained stable during the study. Pain-related results indicate that there was no increase and/or relapse in pain. No Fabry clinical events were reported during the study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><span style="font-style:italic;font-weight:bold;">Open-Label Extension Studies</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our PRX-102 clinical program included two open-label extension studies; one of the 1&#160;mg/kg PRX-102 every two weeks dosage, which we refer to as the F60&#160;Study and the second of the 2&#160;mg/kg PRX-102 every four weeks dosage, which we refer to as the F51&#160;Study. Patients who completed the <i style="font-style:italic;">BALANCE</i> Study, the <i style="font-style:italic;">BRIDGE</i> Study and our phase&#160;I/II extension study were given the opportunity to enroll in the F60&#160;Study and patients who completed the <i style="font-style:italic;">BRIGHT</i> Study were given the opportunity to enroll in the F51&#160;Study. Overall, 97&#160;patients enrolled in the F60&#160;Study; 69&#160;patients from the <i style="font-style:italic;">BALANCE</i> Study, 18&#160;patients from the <i style="font-style:italic;">BRIDGE</i> Study and 10&#160;patients from the phase&#160;I/II study. In addition, 29&#160;patients enrolled in the F51&#160;Study. As of April&#160;30, 2023, 88 patients are actively participating in the F60&#160;Study and 28 patients are actively participating in the F51&#160;Study. Sponsorship of both the F60&#160;Study and the F51&#160;Study were transferred to Chiesi as of February&#160;28, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><span style="font-style:italic;font-weight:bold;">COVID-19 Impact on PRX-102 Clinical Trials</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">To date, the COVID-19 pandemic has had a minimal effect on the performance of the phase&#160;III clinical trials of PRX-102 as many of the patients were already treated in home care settings. We were able to complete all three studies. In a minimal amount of cases, patients who completed a trial were not able to be transferred into an extension study due to the pandemic restrictions, and, accordingly, the main trial was prolonged for the patients to permit the continuation of treatment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><span style="font-style:italic;font-weight:bold;">Phase I/II Study</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our phase&#160;I/II clinical trial of PRX-102, which we completed in 2015, was a worldwide, multi-center, open-label, dose ranging study designed to evaluate the safety, tolerability, pharmacokinetics, immunogenicity and efficacy parameters of PRX-102 in adult patients with Fabry disease. Sixteen adult, na&#239;ve Fabry patients (9 male and 7 female) completed the trial, each in one of three dosing groups, 0.2&#160;mg/kg, 1&#160;mg/kg and 2&#160;mg/kg. Each patient received IV&#160;infusions of PRX-102 every two weeks for 12 weeks, with efficacy follow-up after six-month and twelve-month periods. A majority of the patients who completed the trial opted to continue receiving PRX-102 in an open-label, 60-month extension study under which all patients were switched to receive 1&#160;mg/kg of the drug, the selected dose for our <i style="font-style:italic;">BALANCE</i> and <i style="font-style:italic;">BRIDGE</i> studies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The adult symptomatic, ERT-na&#239;ve Fabry disease patients enrolled in the phase&#160;I/II study were evaluated for Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> levels in kidney biopsies and for plasma Lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> concentration by the quantitative BLISS methodology. Biopsies were available from 14 patients. The outcome of &#8805;&#160;50% reduction in the average number of Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> inclusions per kidney PTC from baseline to Month 6 was demonstrated in 11 of 14 (78.6%) of the patients treated with PRX-102. The overall results demonstrate that PRX-102 reaches the affected tissue and reduces kidney Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> inclusions burden and Lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3 </sub>in the circulation. A high correlation was found between the two Fabry disease biomarkers, reduction of kidney Gb<sub style="font-size:7.5pt;vertical-align:sub;">3 </sub>inclusions and the reduction of plasma Lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> over six months of treatment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Data was recorded at 24&#160;months from 11 patients who completed 12&#160;months of the long-term open-label extension trial that succeeded the phase&#160;I/II study. Patients who did not continue in the extension trial included: female patients who became or planned to become pregnant and therefore were unable to continue in accordance with the study protocol; and patients who relocated to a location where treatment was not available under the clinical study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;">Results show that Lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> levels decreased approximately 90% from baseline. Renal function remained stable with mean eGFR levels of 108.02 and 107.20 at baseline and 24&#160;months, respectively, with a modest annual eGFR slope of -2.1. An improvement across all the gastrointestinal symptoms evaluated, including severity and frequency of abdominal pain and frequency of diarrhea, was noted. Cardiac parameters, including LVM, LVMI and EF, remained stable with no cardiac fibrosis development detected. In conclusion, an improvement of over 40% in disease severity was shown as measured by the Mainz Severity Score Index, or MSSI, a score compiling the different elements of the disease severity including neurological, renal and cardiovascular parameters. In addition, an improvement was noted in each of the individual parameters of the MSSI.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;">The majority of adverse events were mild-to-moderate in severity, and transient in nature. During the first 12 months of treatment, only three of 16 patients (less than 19%) formed ADAs of which two of these patients (less than 13%) had neutralizing antibodies. Importantly, however, the ADAs turned negative for all three of these patients following 12&#160;months of treatment. The ADA positivity effect had no observed impact on the safety, efficacy or continuous biomarker reduction of PRX-102.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_DV_M79"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="font-style:italic;font-weight:bold;">Commercialization Agreements with Chiesi Farmaceutici</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We have entered into two exclusive global licensing and supply agreements for PRX-102 for the treatment of Fabry disease with Chiesi. The agreements have significant revenue potential for Protalix. Under the agreements, Protalix&#160;Ltd. has received $50.0&#160;million in upfront payments and development cost reimbursements of $45.0&#160;million, and is entitled to approximately $1.0&#160;billion in potential milestone payments and tiered royalties of 15%&#160;- 35% (ex-US) and 15%&#160;- 40% (US).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">On October&#160;19, 2017, Protalix&#160;Ltd. and Chiesi entered into the Chiesi Ex-US Agreement pursuant to which Chiesi was granted an exclusive license for all markets outside of the United States to commercialize PRX-102. Under the Chiesi Ex-US Agreement, Chiesi made an upfront payment to Protalix&#160;Ltd. of $25.0&#160;million in connection with the execution of the agreement, and Protalix&#160;Ltd. was entitled to additional payments of up to $25.0&#160;million in development costs in the aggregate, capped at $10.0&#160;million per&#160;year. Protalix&#160;Ltd. is also eligible to receive additional payments of up to a maximum of $320.0&#160;million in regulatory and commercial milestone payments. Protalix&#160;Ltd. agreed to manufacture all of the PRX-102 needed for all purposes under the agreement, subject to certain exceptions, and Chiesi will purchase PRX-102 from Protalix&#160;Ltd., subject to certain terms and conditions. Chiesi is required to make tiered payments of 15% to 35% of its net sales, depending on the amount of annual sales, as consideration for the supply of PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">On July&#160;23, 2018, Protalix&#160;Ltd. entered into the Chiesi US Agreement with respect to the development and commercialization of PRX-102 in the United States. Protalix&#160;Ltd. received an upfront, non-refundable, non-creditable payment of $25.0&#160;million from Chiesi and was entitled to additional payments of up to a maximum of $20.0&#160;million to cover development costs for PRX-102, capped at $7.5&#160;million per&#160;year. Protalix&#160;Ltd. is also eligible to receive additional payments of up to a maximum of $760.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. Chiesi agreed to make tiered payments of 15% to 40% of its net sales under the Chiesi US Agreement to Protalix&#160;Ltd., depending on the amount of annual sales, subject to certain terms and conditions, as consideration for product supply.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;">On May&#160;13, 2021, we signed a binding term sheet with Chiesi amending the Chiesi Agreements in order to provide our company with near-term capital. Chiesi agreed to make a $10.0&#160;million payment to us before the end of the second quarter of 2021 in exchange for a $25.0&#160;million reduction in a longer term regulatory milestone payment provided in the Chiesi EX-US Agreement. All other regulatory and commercial milestone payments remain unchanged. We received the payment in June&#160;2021. We also agreed to negotiate certain manufacturing related matters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;">On August&#160;29, 2022, we entered into the F/F Agreement and the Letter Agreement. Under the F/F Agreement, we agreed to supply Chiesi with drug substance for PRX-102 and, following relevant technology and technical information transfer activities, Chiesi has agreed, among other things, to provide us with commercial fill/finish services for PRX-102, including to support the anticipated global launch of PRX-102. The F/F Agreement will expire December&#160;31, 2025, unless terminated earlier in accordance with its terms and may be extended by mutual agreement in writing for an additional period of seven years. The Letter Agreement changed the obligations of both us and Chiesi under the License Agreements with respect to, among other things, the evaluation, selection and establishment of an initial alternate source of commercial fill/finish services for PRX-102. In addition, the Letter Agreement amended certain provisions of the License Agreements to reflect the appointment of Chiesi as a supplier to our company of commercial fill/finish services and the potential establishment of an initial alternate source of commercial fill/finish services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">As of March&#160;1, 2023, sponsorship of the two extension studies was transferred to Chiesi, and Chiesi is now administering the extension studies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Elelyso</span><sup style="font-size:7.5pt;font-style:italic;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup><span style="font-style:italic;font-weight:bold;"> for the Treatment of Gaucher Disease</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Elelyso (taliglucerase alfa), our first commercial product, was approved by the FDA in 2012 for injection as an enzyme replacement therapy (ERT) for the long-term treatment of adult patients with a confirmed diagnosis of type&#160;1 Gaucher disease. In August 2014, the FDA approved Elelyso for injection for pediatric patients. Elelyso is the first plant cell derived recombinant protein to be approved by the FDA for the treatment of Gaucher disease and is now approved in over 20 markets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Gaucher disease, also known as glucocerebrosidase, or GCD, deficiency, is a rare genetic autosomal recessive disorder and one of the most common Lysosomal Storage Disorders, or LSDs, in the world. It is one of a group of disorders that affect specific enzymes that normally break down fatty substances for reuse in the cells. If the enzymes are missing or do not work properly, the substances can build up and become toxic. Gaucher disease occurs when a lipid called glucosylceramide accumulates in the cells of the bone marrow, lungs, spleen and liver, and sometimes the brain. Gaucher disease symptoms can include fatigue, anemia, easy bruising and bleeding, severe bone pain and easily broken bones, and distended stomach due to an enlarged spleen and thrombocytopenia. Epidemiology of Gaucher disease varies; recent literature provides that prevalence of Gaucher disease ranges from 0.70 to 1.75 per 100,000 in the </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">general population. In people of Ashkenazi Jewish heritage, estimates of occurrence vary from approximately 1 in 400 to 1 in 850 people.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The global market for Gaucher disease, that includes Sanofi&#8217;s Cerezyme<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, Shire&#8217;s (acquired by Takeda Pharmaceutical Company Limited) Vpriv<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, and Sanofi&#8217;s Cerdelga<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, among others, was $1.6&#160;billion in 2022, is forecasted to be approximately $1.6&#160;billion in 2023 and is forecasted to grow at a CAGR of approximately 3% from 2022-2028.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="font-style:italic;font-weight:bold;">Commercialization Agreements for Elelyso</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We have licensed to Pfizer the global rights to Elelyso in all markets excluding Brazil. Pfizer retains 100% of revenue and reimburses 100% of direct costs.<span style="font-family:'Times-Roman';"> </span>We manufacture drug substance for Pfizer, subject to certain terms and conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">For the first 10-year period after the execution of our Amended Pfizer Agreement, we have agreed to sell drug substance to Pfizer for the production of Elelyso, and Pfizer maintains the right to extend the supply period for up to two additional 30-month periods subject to certain terms and conditions. In a subsequent amendment, we agreed that after the completion of the first 10-year supply period, the supply term would automatically extend for a five-year period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We maintain distribution rights to Elelyso in Brazil through a supply and technology transfer agreement with Fiocruz, an arm of the Brazilian MoH.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Uricase (PRX-115)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">PRX-115 is our plant cell-expressed recombinant PEGylated uricase (urate oxidase) &#8211; a chemically modified enzyme under development for the potential treatment of severe gout. We use ProCellEx to express an optimized recombinant uricase enzyme under development for the potential treatment of severe gout which we are designing to lower uric acid levels while having low immunogenicity and increased half-life in the circulation. Pre-clinical data demonstrates stable PK profile and long half-life, low immunogenic risk and high specific activity which supports the potential of PRX-115 to be a safe and effective treatment for severe gout. Results from the one-month multiple dosing toxicity studies in two species demonstrate that PRX-115 is well tolerated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">On March&#160;21, 2023, the first patient was dosed in our phase&#160;I First in Human (FIH) clinical trial of PRX-115, a double-blind, placebo-controlled trial designed to evaluate the safety, pharmacokinetics, pharmacodynamics (reduction of uric acid) and immunogenicity of PRX-115 in patients with elevated uric acid levels (&gt;6.0&#160;mg/dL). The trial is a single ascending dose (SAD) study with up to seven cohorts, and patients are to be randomized 3:1 to receive a single intravenous (IV) dose of PRX-115 or a placebo. The study is being conducted at New Zealand Clinical Research (NZCR) under the New Zealand Medicines and Medical Devices Safety Authority (MedSafe) and the Health and Disability Ethics Committee (HDEC) guidelines, and is expected to enroll approximately 56 patients with no previous exposure to PEGylated uricase.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Gout is the most common inflammatory arthritis in the<span style="direction:rtl;"> </span>United States, affecting<span style="direction:rtl;"> </span>an estimated 9.2&#160;million<span style="direction:rtl;"> </span>adults. Gout is caused by factors that elevate serum uric acid, or sUA, levels, which may include diet or genetic predisposition and environmental factors leading to hyperuricemia and tissue deposition of monosodium urate crystals, tophi, in joints and soft tissues, causing acute and chronic inflammation, and is characterized by recurrent flares. Gout flares lead to substantial morbidity by causing severe pain, reduced quality of life, decreased physical function, increased healthcare costs, and lost economic productivity. Furthermore, gout is strongly associated with metabolic syndrome, and may contribute to myocardial infarction, type&#160;2 diabetes mellitus, chronic kidney disease, or CKD, and premature mortality.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Severe gout is generally described as a state of gout in which there is a presence of monosodium urate crystals with any of the following: frequent recurrent gout flares, chronic gouty arthritis, subcutaneous tophi or disease elements of gout seen via imaging. It is estimated that approximately 2% of the gout patient population is considered to have chronic refractory disease, and we believe the incidence of severe gout is higher.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Currently available urate-lowering therapies, or ULTs, can be effective in treating gout. However, we believe that new effective, safe therapies are needed to treat severe gout and chronic refractory gout regardless of treatment history. One treatment option may be a therapeutic use of the uricase enzyme which converts uric acid to allantoin, which is easily eliminated through urine. The uricase enzyme does not exist naturally in humans. To date, two variants of recombinant uricases are approved for marketing: (i)&#160;Krystexxa<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (pegloticase) for treatment of chronic gout refractory to conventional therapy (gout patients who have contraindication/failure of other lowering uric acid treatments) and (ii)&#160;Elitek<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, indicated for the treatment of tumor lysis syndrome but not gout. Both have a black box warning for anaphylaxis and other major side-effects. In particular, 89% of patients treated with Krystexxa developed an immunogenic response associated with a failure to maintain normalization of serum uric acid levels over a 6-month therapy cycle. In addition, a recent phase&#160;IV study demonstrates that co-treatment with Krystexxa and methotrexate prolongs efficacy and increases </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">tolerability in patients with refractory gout. Krystexxa is no longer marketed in the European Union. The EC withdrew the marketing authorization for Krystexxa in 2016 at the request of the marketing authorization holder which notified the EC of its decision not to market the product in the European Union for commercial reasons.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;">PRX-119</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">PRX-119 is our plant cell-expressed PEGylated recombinant human DNase I product candidate being designed to elongate half-life in the circulation for NETs-related diseases. NETs, Neutrophil extracellular traps, are web-like structures, released by activated neutrophils that trap and kill a variety of microorganisms. NETs are composed of DNA, histones, antimicrobial and pro-inflammatory proteins. Excessive formation or ineffective clearance of NETs can cause different pathological effects. NETs formation has been observed in various autoimmune, inflammatory and fibrotic conditions, diverse forms of thrombosis, cancer and metastasis. According to scientific literature, animal studies have demonstrated that DNase treatment reduces NETs toxicity. Our proprietary modified DNase&#160;I design for long and customized systemically circulating in the bloodstream, may potentially enable effective treatment of acute and chronic conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Intellectual Property</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">A key element of our overall strategy is to establish a broad portfolio of patents to protect our proprietary technology, proprietary product and product candidates and their methods of use. As of March&#160;31, 2023, we hold a broad portfolio of over 80 patents in Europe, the United States, Israel and additional countries worldwide, as well as over 30 pending patent applications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Scientific Presentations</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We hosted an informational booth at the 19th Annual WORLD<i style="font-style:italic;">Symposium</i>&#8482; 2023, which took place February&#160;22-26, 2023 at the Hilton Orlando in Orlando, Florida. Chiesi also participated in the symposium, hosting, among other events, the following presentations:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">&#8220;First results of a head-to-head trial of pegunigalsidase alfa vs. agalsidase beta in Fabry disease: 2<span style="letter-spacing:-0.1pt;">-</span>year results of the phase 3 randomized, double-blind, BALANCE study,&#8221; an abstract (lead author Eric Wallace, M.D., Co-Director of the&#160;University of Alabama at Birmingham Fabry Disease Clinic, <span style="letter-spacing:-0.1pt;">a principal investigator in our phase&#160;III </span>clinical trials of PRX-102) presented by David G. Warnock, M.D., University of Alabama at Birmingham.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">&#8220;Long-term safety and efficacy of pegunigalsidase alfa administered every 4 weeks in patients with Fabry disease: two-year interim results from the ongoing phase 3 BRIGHT51 open-label extension study,&#8221; an abstract presented by John Bernat, M.D., Ph.D., Medical Director of the Iowa Lysosomal Storage Disorders Center, <span style="letter-spacing:-0.1pt;">a principal investigator in our phase&#160;III clinical trials of PRX-102.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Both of the abstracts were also available during the symposium as poster presentations. Copies of presentations are available on our website under the Presentation tab in the Investors section.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Research &amp; Development</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We continuously work on the further development of our ProCellEx plant cell expression technology and bioreactor system. In addition, we are working on the development of new products, each in different initial stages of development, for specific products for which there are unmet needs in terms of efficacy and safety. Our development strategy focuses on the utilization of different modification approaches and development improvements, customized for each protein product, in all stages of expression and development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Critical Accounting Policies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our significant accounting policies are more fully described in Note&#160;1 to our consolidated financial statements appearing in this Quarterly Report. There have been no material changes to our critical accounting policies since we filed our Annual Report on Form&#160;10-K for the year ended December&#160;31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The discussion and analysis of our financial condition and results of operations is based on our financial statements, which we prepared in accordance with U.S.&#160;generally accepted accounting principles. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenues and expenses during the reporting periods. On an ongoing basis, we evaluate such estimates and judgments, including those described in greater detail below. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Results of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Three months ended March&#160;31, 2023 compared to the three months ended March 31, 2022</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Revenues from Selling Goods</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We recorded revenues from selling goods of $5.1&#160;million during the three months ended March&#160;31, 2023, a decrease of $3.9&#160;million, or 43%, compared to revenues of $9.0&#160;million for the three months ended March&#160;31, 2022. The decrease resulted primarily from a decrease of $2.7&#160;million in sales to Brazil and a decrease of $1.1&#160;million in sales to Pfizer, both resulting from timing differences.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Revenues from License and R&amp;D Services</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We recorded revenues from license and R&amp;D services of $4.5&#160;million for the three months ended March&#160;31, 2023, a decrease of $2.6&#160;million, or 37%, compared to revenues of $7.1&#160;million for the three months ended March&#160;31, 2022. Revenues from license and R&amp;D services are comprised primarily of revenues we recognized in connection with the Chiesi Agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Cost of Goods Sold</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Cost of goods sold was $3.1&#160;million for the three months ended March&#160;31, 2023, a decrease of $2.9&#160;million, or 48%, from cost of goods sold of $6.0&#160;million for the three months ended March&#160;31, 2022. <span style="background:#ffffff;">The decrease in cost of goods sold was primarily the result of the decrease in sales of goods.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Research and Development Expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 21.6pt 12pt 0pt;">For the three months ended March&#160;31, 2023, our total research and development expenses were approximately $5.8&#160;million comprised of approximately $3.5&#160;million in subcontractor-related expenses, approximately $1.5&#160;million of salary and related expenses, approximately $0.1&#160;million of materials-related expenses and approximately $0.7&#160;million of other expenses. For the three months ended March&#160;31, 2022, our total research and development expenses were approximately $8.8&#160;million comprised of approximately $5.8&#160;million in subcontractor-related expenses, approximately $2.0&#160;million of salary and related expenses, approximately $0.2&#160;million of materials-related expenses and approximately $0.8&#160;million of other expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 21.6pt 12pt 0pt;">Total decrease in research and developments expenses was $3.0&#160;million, or 34%, for the three months ended March&#160;31, 2023 compared to the three months ended March&#160;31, 2022<span style="direction:rtl;">.</span> The decrease in research and development expenses primarily resulted from the completion of our Fabry clinical program and of a substantial portion of the regulatory processes related to the BLA and MAA submissions for PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 21.6pt 12pt 0pt;">We expect research and development expenses to continue to be our primary expense as we enter into a more advanced stage of preclinical and clinical trials for certain of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Selling, General and Administrative Expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Selling, general and administrative expenses were $3.1&#160;million for the three months ended March&#160;31, 2023, a decrease of $0.1&#160;million, or 3%, compared to $3.2&#160;million for the three months ended March&#160;31, 2022. A decrease of approximately $0.4&#160;million in salary and related expenses was partially offset by an increase of $0.3&#160;million in professional fees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Financial Expenses, Net</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;">Financial expenses, net were $0.5&#160;million for the three months ended March&#160;31, 2023, compared to financial expenses, net of $0.4&#160;million for the three months ended March&#160;31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Income taxes</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Section&#160;174 of the Tax Cuts and Jobs Act, which was enacted in December 2017, eliminated the option to immediately deduct research and development expenses in the year incurred. The amended provision under Section 174&#160;requires us to capitalize and amortize these expenditures over fifteen years (for out of U.S.-based research and development). In the three months ended March&#160;31, 2023, we recorded income taxes of approximately $0.2&#160;million.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Liquidity and Capital Resources</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;">Our sources of liquidity includes our cash and cash equivalents balance. At March&#160;31, 2023, we had $33.0&#160;million in cash and cash equivalents. We have primarily financed our operations through equity and debt financings, business collaborations, and grants funding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;">During the year ended December&#160;31, 2022, we raised gross proceeds equal to approximately $8.7&#160;million from the sale of 7,473,038 shares of our common stock under our ATM program. During the three months ended March&#160;31, 2023, we raised gross proceeds equal to approximately $14.9&#160;million from sales of common stock under our ATM program through the sale of 8,212,482 shares of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;">On August&#160;25, 2021, we completed exchanges, or the Exchanges, of a substantial majority of our then outstanding 7.50% Senior Secured Convertible Notes due 2021, or the 2021 Notes, with institutional note holders of a substantial majority of the 2021 Notes. The Exchanges involved the exchange of an aggregate of $54.65&#160;million principal amount of our 2021 Notes for an aggregate of $28.75&#160;million principal amount of newly issued 7.50% Senior Secured Convertible Notes due 2024, or the 2024 Notes, $25.90&#160;million in cash, and approximately $1.1&#160;million in cash representing accrued and unpaid interest through the closing date. The initial conversion rate for the 2024 Notes is 563.2216 shares of our common stock for each $1,000 principal amount of 2024 Notes (equivalent to an initial conversion price of approximately $1.7755 per share of common Stock, subject to adjustment in certain circumstances. This initial conversion price represents a premium of approximately 32.5% relative to the closing price of the common stock on the NYSE American on August&#160;13, 2021. After giving effect to the Exchanges, $3.27&#160;million aggregate principal amount of the 2021 Notes remained outstanding. On November&#160;15, 2021, all of the then outstanding 2021 Notes&#160;matured and were paid in full.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;">The 2024 Notes were issued pursuant to the Indenture dated as of August&#160;24, 2021 between us, the guarantors party thereto, The Bank of New York Mellon Trust Company, N.A., as trustee and Wilmington Savings Fund Society, FSB, as collateral agent, or the 2024 Indenture. Interest on the Notes are payable semi-annually at a rate of 7.50% per annum. The 2024 Notes will mature on September&#160;1, 2024, unless earlier purchased, converted, exchanged or redeemed, and are guaranteed by our subsidiaries. The 2024 Notes are secured by perfected liens on all of our assets, including those of our subsidiaries. <span style="font-family:'28mugxoulnobhnx';">Under the terms of the 2024 Indenture, we are required to comply with </span><span style="color:#222222;">certain covenants, including the requirement to </span>maintain a minimum cash balance of at least $7.5&#160;million. Failure to comply with such covenants may result in an event of default under the 2024 Indenture and, accordingly, may result in the acceleration of the payment of the notes or in additional interest payments. As of March&#160;31, 2023, we were in compliance with all covenants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We believe that our cash and cash equivalents as of March&#160;31, 2023, together with additional funds raised from the sale of shares under our ATM program subsequent to March&#160;31, 2023 are sufficient to satisfy our capital needs for at least 12&#160;months from the date that these financial statements are issued.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Cash Flows</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Net cash used in operations was $3.0&#160;million for the three months ended March&#160;31, 2023. The net loss for the three months ended March&#160;31, 2023 of $3.1&#160;million was increased by a $1.4&#160;million decrease in contracts liability and a $3.5 million increase in inventories and was partially offset by a $3.8 million decrease in accounts receivable-trade and other assets and $0.5&#160;million in share-based compensation. Net cash provided by investing activities for the three months ended March&#160;31, 2023 was $4.7&#160;million and consisted primarily of proceeds from sale of short-term deposits. Net cash provided by financing activities was $14.2&#160;million resulting primarily from the sale of common stock under our ATM program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="background:#ffffff;">Net cash used in operations was $5.8&#160;million for the three months ended March&#160;31, 2022. The net loss for the three months ended March&#160;31, 2022 of $2.3&#160;million was increased by a $2.6&#160;million decrease in contracts liability, a $2.3&#160;million increase in accounts receivable and other assets and $1.0&#160;million decrease in account payable and accruals, and was partially offset by a $1.4&#160;million decrease in inventories and a $0.8&#160;million in share-based compensation. Net cash used in investing activities for the three months ended March&#160;31, 2022 was $16.3&#160;million and consisted primarily of investment in bank deposits.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Future Funding Requirements </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">As a result of our significant research and development expenditures and the lack of significant revenue from sales of taliglucerase alfa, we have generated operating losses from our continuing operations since our inception. Our outstanding <span style="font-family:'28mugxoulnobhnx';">2024 Notes are </span>secured by a perfected lien on all of our assets<span style="font-family:'28mugxoulnobhnx';">. Under the terms of the 2024 Indenture, we are required to comply with </span><span style="color:#222222;background:#ffffff;">certain covenants, including the requirement to </span>maintain a minimum cash balance of at least $7.5&#160;million. Failure to comply with such covenants may result in an event of default under the 2024 Indenture and, accordingly, may result in the acceleration of the payment of the notes or in additional interest payments. As of March&#160;31, 2023, we were in compliance with all covenants.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We expect to continue to incur significant expenditures in the near future as we increase our research and developments efforts with respect to our product candidates. We cannot anticipate the costs or the timing of the occurrence of such costs. To the extent we need to obtain additional financing, it may be more difficult for us to do so given the volatility of the price of our common stock. Our material cash needs for the next 24&#160;months will include, among other expenses, (i)&#160;costs of preclinical and clinical trials, (ii)&#160;employee salaries, (iii)&#160;payments for rent and operation of our manufacturing facilities, (iv)&#160;fees to our consultants and legal advisors, patent advisors and fees for service providers in connection with our research and development efforts and (v)&#160;payments of principal and interest on our outstanding 2024 Notes. We believe that the funds currently available to us are sufficient to satisfy our capital needs for at least 12&#160;months.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">As discussed above, we may be required to raise additional capital to develop our product candidates and continue research and development activities. Our ability to raise capital, and the amounts of necessary capital, will depend on many other factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the duration and cost of discovery and preclinical development and laboratory testing and clinical trials for our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our progress in commercializing BioManguinhos alfataliglicerase in Brazil;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing and outcome of regulatory review of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims and other intellectual property rights; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs associated with any litigation claims.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We expect to finance our future cash needs through corporate collaborations, licensing or similar arrangements, public or private equity offerings and/or debt financings. We currently do not have any commitments for future external funding, except with respect to the development-related payments and milestone payments that may become payable under the Chiesi Agreements. As of March&#160;31, 2023, shares of our common stock for total gross proceeds of approximately $16.5 million remain available to be sold under our 2023&#160;Sales Agreement. During April 2023, we sold, in the aggregate, 3,412,268 shares of Common Stock under the 2023 Sales Agreement generating gross proceeds equal to approximately $7.9&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Effects of Currency Fluctuations </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Currency fluctuations could affect us through increased or decreased acquisition costs for certain goods and services and salaries expenses. We do not believe currency fluctuations have had a material effect on our results of operations during the three months ended March&#160;31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Off-Balance Sheet Arrangements </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We have no off-balance sheet arrangements as of each of March&#160;31, 2023 and December&#160;31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_9b4c0d00_75a4_4f05_9aa8_2e415e016c80"></a><a id="Item3QuantitativeandQualitativeDisclosur"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">3.  Quantitative and Qualitative Disclosures about Market Risk</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Currency Exchange Risk</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The currency of the primary economic environment in which our operations are conducted is the U.S.&#160;dollar. Most of our revenues and more than 50% of our expenses and capital expenditures are and were incurred in dollars, and a significant source of our financing has been provided in U.S.&#160;dollars. Since the dollar is the functional currency, monetary items maintained in currencies other than the dollar are remeasured using the rate of exchange in effect at the balance sheet dates and non-monetary items are remeasured at historical exchange rates. Revenue and expense items are remeasured at the average rate of exchange in effect during the period in which they occur. Foreign currency translation gains or losses are recognized in the statement of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Approximately 43% of our costs, including salaries, expenses and office expenses, are incurred in NIS. Inflation in Israel may have the effect of increasing the U.S.&#160;dollar cost of our operations in Israel. If the U.S.&#160;dollar declines in value in relation to the NIS, it will </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">become more expensive for us to fund our operations in Israel. A revaluation of 1% of the NIS will affect our loss before tax by less than 1%. The exchange rate of the U.S.&#160;dollar to the NIS, based on exchange rates published by the Bank of Israel, was as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:19.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Average rate for period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.536</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.197</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.360</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:63.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Rate at period-end</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.615</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.176</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.519</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">To date, we have not engaged in hedging transactions. In the future, we may enter into currency hedging transactions to decrease the risk of financial exposure from fluctuations in the exchange rate of the U.S.&#160;dollar against the NIS. These measures, however, may not adequately protect us from material adverse effects due to the impact of inflation in Israel.</p><a id="_5a32759e_5a74_480e_8c2b_45fce53eb63c"></a><a id="Item4ControlsandProcedures_865226"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">4.  Controls and Procedures</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Evaluation of Disclosure Controls and Procedures</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report on Form&#160;10-Q. The evaluation was conducted under the supervision and with the participation of management, including our Chief Executive Officer and Chief Financial Officer. Disclosure controls and procedures are controls and procedures designed to reasonably assure that information required to be disclosed in our reports filed under the Exchange Act, such as this Quarterly Report on Form&#160;10-Q, is recorded, processed, summarized and reported within the time periods specified in the Commission&#8217;s rules and forms. Disclosure controls and procedures are also designed to reasonably assure that such information is accumulated and communicated to our management, including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Based on the evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of the period covered by this Quarterly Report on Form&#160;10-Q, our disclosure controls and procedures were effective to provide reasonable assurance that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified by the Commission, and that material information relating to our company and our consolidated subsidiary is made known to management, including the Chief Executive Officer and Chief Financial Officer, particularly during the period when our periodic reports are being prepared.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Inherent Limitations on Effectiveness of Controls</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent or detect all error and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#8217;s objectives will be met. The design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, within a company have been detected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Changes in Internal Control over Financial Reporting</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">There were no changes in our internal control over financial reporting (as defined in Rules 13a-15f and 15d-15f under the Exchange Act) that occurred during the quarter ended March&#160;31, 2023 that have materially affected, or that are reasonably likely to materially affect, our internal control over financial reporting.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_4b630537_1066_49ba_916f_ffdd013d7a89"></a><a id="PARTIIOTHERINFORMATION_770480"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">PART II &#8211; OTHER INFORMATION</b></p><a id="Item1LegalProceedings_676392"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">1.  Legal Proceedings</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We are not involved in any material legal proceedings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_d06ddd6e_f9f5_47bb_a0a1_6ec9d55b2394"></a><a id="Item1ARiskFactors_983377"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">1A.  Risk Factors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 18pt 10pt 0pt;">There have been no material changes to the risk factors previously disclosed in our Annual Report on Form 10-K for the year ended December&#160;31, 2022.</p><a id="_f9ad971f_2b7a_4e22_a819_fe4e9ed02dfb"></a><a id="Item2UnregisteredSalesofEquitySecurities"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">2.  Unregistered Sales of Equity Securities and Use of Proceeds</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_7eec34dc_1253_475d_a1be_0c42559aa930"></a><a id="Item3DefaultsUponSeniorSecurities_505234"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">3.  Defaults Upon Senior Securities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_966e3751_9a3a_4eca_8883_8a8569ef5519"></a><a id="Item4MineSafetyDisclosure_204781"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">4.  Mine Safety Disclosure</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_456f122b_a221_47f7_9a57_c06b953e1e11"></a><a id="Item5OtherInformation_679200"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">5.  Other Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_11a4c9d6_778c_4de5_9fb0_1794b2af99ac"></a><a id="Item6Exhibits_829552"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">6.  Exhibits</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.00925827%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:6.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:36.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:7.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:8.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:9.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:15.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:13.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:6.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:36.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:7.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:8.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:15.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:13.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:13.5pt;"><td style="vertical-align:bottom;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;width:41.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Incorporated by Reference</b></p></td><td style="vertical-align:bottom;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit Number</b></p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit Description</b></p></td><td style="vertical-align:bottom;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Form</b></p></td><td style="vertical-align:bottom;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">File Number</b></p></td><td style="vertical-align:bottom;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></td><td style="vertical-align:bottom;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Date</b></p></td><td style="vertical-align:bottom;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filed or Furnished Herewith</b></p></td></tr><tr><td style="vertical-align:top;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">1.1</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000155837023002104/plx-20230227xex1d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;background:#ffffff;">At the Market Offering Agreement, dated February&#160;27, 2023, between the Company and&#160;H.C. Wainwright &amp; Co., LLC</span></a></p></td><td style="vertical-align:top;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">1.1</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;">February&#160;27, 2023</p></td><td style="vertical-align:bottom;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">3.1</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420416092335/v435826_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Incorporation of the Company</span></a></p></td><td style="vertical-align:top;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">3.1</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">April&#160;1, 2016</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:22.5pt;"><td style="vertical-align:top;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">3.2</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420416111273/v443094_def14a.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment to Certificate of Incorporation of the Company</span></a></p></td><td style="vertical-align:top;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">Def 14A</p></td><td style="vertical-align:top;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">Appen. A</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">July&#160;1, 2016</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">3.3</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420418054229/tv504383-def14a.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Second Amendment to Certificate of Incorporation of the Company</span></a></p></td><td style="vertical-align:top;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">Def 14A</p></td><td style="vertical-align:top;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">Appen. A</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">October&#160;17, 2018</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">3.4</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000110465919074602/tm1926620d1_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Third Amendment to Certificate of Incorporation of the Company</span></a></p></td><td style="vertical-align:top;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">3.1</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">December&#160;19, 2019</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">3.5</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000155837022013560/plx-20220630xex3d5.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Fourth Amendment to Certificate of Incorporation of the Company</span></a></p></td><td style="vertical-align:top;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">10-Q</p></td><td style="vertical-align:top;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">3.5</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">August&#160;15, 2022</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">3.6</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420416092335/v435826_ex3-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Bylaws of the Company</span></a> </p></td><td style="vertical-align:top;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">3.2</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">April&#160;1, 2016</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:13pt;"><td style="vertical-align:top;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.1</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420412040015/v318898_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Restricted Stock Agreement/Notice</span></a></p></td><td style="vertical-align:top;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">4.1</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;">July&#160;18, 2012</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:13pt;"><td style="vertical-align:top;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.2</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000155837023002102/plx-20221231xex4d7.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Description of Capital Stock</span></a></p></td><td style="vertical-align:top;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">10-K</p></td><td style="vertical-align:top;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">4.7</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;">February&#160;27, 2023</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.3</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000110465920032169/tm2012488d1_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Warrant</span></a></p></td><td style="vertical-align:top;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">4.1</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;">March&#160;12, 2020</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.4&#8224;</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000110465920092375/plx-20200630xex4d8.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Stock Option Agreement (Executives)</span></a></p></td><td style="vertical-align:top;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">10-Q</p></td><td style="vertical-align:top;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">4.8</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;">August&#160;10, 2020</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.5</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000110465920092375/plx-20200630xex4d9.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Stock Option Agreement (Standard)</span></a></p></td><td style="vertical-align:top;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">10-Q</p></td><td style="vertical-align:top;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">4.9</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;">August&#160;10, 2020</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.00925827%;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.6</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000155837021012078/plx-20210824xex4d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Indenture, dated as of August&#160;24, 2021, between Protalix BioTherapeutics, Inc., the guarantors party thereto, The Bank of New York Mellon Trust Company, N.A., as trustee and Wilmington Savings Fund Society, FSB, as collateral agent</span></a></p></td><td style="vertical-align:top;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">4.2</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;">August&#160;26, 2021</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.7</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000155837021012078/plx-20210824xex4d3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Exchange Note (2024)</span></a></p></td><td style="vertical-align:top;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">4.3</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;">August&#160;26, 2021</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">31.1</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="plx-20230331xex31d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Chief Executive Officer pursuant to Rule 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></p></td><td style="vertical-align:top;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">31.2</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="plx-20230331xex31d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Chief Financial Officer pursuant to Rule 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></p></td><td style="vertical-align:top;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">32.1</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="plx-20230331xex32d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Certification of Chief Executive Officer</span></a></p></td><td style="vertical-align:top;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">32.2</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="plx-20230331xex32d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Certification of Chief Financial Officer</span></a> </p></td><td style="vertical-align:top;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">101.INS</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">XBRL Instance Document - <span style="color:#333333;background:#ffffff;">the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document</span></p></td><td style="vertical-align:top;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">101.SCH</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="background:#ffffff;">Inline XBRL Taxonomy Extension Schema Document</span></p></td><td style="vertical-align:top;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">101.CAL</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="background:#ffffff;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></p></td><td style="vertical-align:top;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">101.DEF</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="background:#ffffff;">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></p></td><td style="vertical-align:top;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">101.LAB</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="background:#ffffff;">Inline XBRL Taxonomy Extension Labels Linkbase Document</span></p></td><td style="vertical-align:top;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;">101.PRE</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;"><span style="background:#ffffff;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></p></td><td style="vertical-align:top;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;">104</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;">COVER PAGE INTERACTIVE DATA FILE (formatted as Inline XBRL and contained in Exhibit 101).</p></td><td style="vertical-align:top;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="8" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:10pt 0pt 10pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:10pt 0pt 10pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:10pt 0pt 10pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:10pt 0pt 10pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:10pt 0pt 10pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:10pt 0pt 10pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:10pt 0pt 10pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:10pt 0pt 10pt 0pt;">&#8224;&#160;&#160;&#160;&#160;&#160;Management contracts or compensation plans or arrangements in which directors or executive officers are eligible to participate.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">32</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_fb42ea3a_7937_40ba_a34c_13018e511030"></a><a id="SIGNATURES_574709"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">SIGNATURES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:25.9pt;margin:0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:47.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr style="height:12pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">PROTALIX BIOTHERAPEUTICS, INC.</p></td></tr><tr style="height:10.5pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Registrant)</p></td></tr><tr style="height:15.75pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:15.75pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: May&#160;4, 2023</p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:47.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Dror Bashan</p></td></tr><tr style="height:20.25pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.6%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dror Bashan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Executive Officer)</p></td></tr><tr style="height:17.25pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:13.5pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: May&#160;4, 2023</p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:47.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Eyal Rubin</p></td></tr><tr style="height:13.5pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.6%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Eyal Rubin</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Senior Vice President and Chief Financial Officer, Treasurer and Secretary</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Financial and Accounting Officer)</p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;width:458.2pt;"></span><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">33</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>plx-20230331xex31d1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 5/4/2023 07:35:04 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">EXHIBIT 31.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">CERTIFICATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 10pt 0pt;">I, Dror Bashan, certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt 0pt;">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;I have reviewed this quarterly report on Form 10-Q of Protalix BioTherapeutics, Inc.;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt -0.04pt;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt -0.04pt;">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt -0.04pt;">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 10pt 36pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 10pt 36pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 10pt 36pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 10pt 36pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt -0.04pt;">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt 24.45pt;">a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 0pt 24.5pt;">b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 0pt 24.5pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:98.94%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: May&#160;4, 2023</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;">/s/ Dror Bashan</p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dror Bashan</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>plx-20230331xex31d2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 5/4/2023 07:35:04 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">EXHIBIT 31.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">CERTIFICATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 10pt 0pt;">I, Eyal Rubin, certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt 0pt;">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;I have reviewed this quarterly report on Form 10-Q of Protalix BioTherapeutics, Inc.;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt -0.04pt;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt -0.04pt;">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt -0.04pt;">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 10pt 36pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 10pt 36pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 10pt 36pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 10pt 36pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt -0.04pt;">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt 24.45pt;">a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 0pt 24.5pt;">b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: May&#160;4, 2023</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;">/s/ Eyal Rubin</p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Eyal Rubin</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sr. Vice President &amp; Chief Financial Officer,</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Treasurer</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>plx-20230331xex32d1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 5/4/2023 07:35:03 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">EXHIBIT 32.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">PROTALIX BIOTHERAPEUTICS, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">CERTIFICATION</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In connection with the quarterly report of Protalix BioTherapeutics, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ended March&#160;31, 2023 as filed with the Securities and Exchange Commission (the &#8220;Report&#8221;), I, Dror Bashan, President and Chief Executive Officer of the Company, hereby certify as of the date hereof, solely for purposes of Title 18, Chapter 63, Section&#160;1350 of the United States Code, that to the best of my knowledge:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 24.5pt;">(1) the Report fully complies with the requirements of Section&#160;13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 24.45pt;">(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">This Certification has not been, and shall not be deemed, &#8220;filed&#8221; with the Securities and Exchange Commission.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: May&#160;4, 2023</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;">/s/ Dror Bashan</p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dror Bashan</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>plx-20230331xex32d2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 5/4/2023 07:35:04 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">EXHIBIT 32.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">PROTALIX BIOTHERAPEUTICS, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">CERTIFICATION</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In connection with the quarterly report of Protalix BioTherapeutics, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ended March&#160;31, 2023 as filed with the Securities and Exchange Commission (the &#8220;Report&#8221;), I, Eyal Rubin, Senior Vice President and Chief Financial Officer of the Company, hereby certify as of the date hereof, solely for the purposes of Title 18, Chapter 63, Section&#160;1350 of the United States Code, that to the best of my knowledge:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 24.45pt;">(1) the Report fully complies with the requirements of Section&#160;13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 24.45pt;">(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">This Certification has not been, and shall not be deemed, &#8220;filed&#8221; with the Securities and Exchange Commission.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: May&#160;4, 2023</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;">/s/ Eyal Rubin</p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Eyal Rubin</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Senior Vice President and Chief Financial Officer</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>plx-20230331x10q005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plx-20230331x10q005.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" ',!#@# 2(  A$! Q$!_\0
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M_P"%'U*?=!_Q$7+O^?,__)?_ )(_1NBOSD_X:#^(O_0VW_YK_A1_PT'\1?\
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M+O\ GS/_ ,E_^2/T;HK\Y/\ AH/XB_\ 0VW_ .:_X4?\-!_$7_H;;_\ -?\
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M3_AH/XB_]#;?_FO^%'_#0?Q%_P"AMO\ \U_PH^I3[H/^(BY=_P ^9_\ DO\
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M@ Q3QR _W6!KYLU+PUK?AV-9=0L(A"0#YF]?3)Z^E/U#1&TR&TDU1ETLW?\
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MQ'JSQASY5OF)3QD9SSUKYG\:^$KSP-XHU#0[XJUQ9R%"Z]&'9A]17UZ/VIO
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MZBDK6<J$,(/(EB/S'JV'%0^+?BE\$?$-U>>)K[2KK6-;N(0GV257 W*#C^(
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M;J:$2),(W9/,C.5;!QD>QK[*T3]ICP1X?TY9D\0ZWJ$*0"-=,O8%D<,.G[S
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M4_V:?&_C?Q_K.N:9;V3V%Y*KQ-)=!6("*O([<@URO_#'WQ%_Y]=/_P# Q?\
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M\*/^&/OB+_SZZ?\ ^!B_X5]XT4?7*GD'_$/\H[S_ / E_P#(GP=_PQ]\1?\
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M\*/^&/OB+_SZZ?\ ^!B_X5]XT4?7*GD'_$/\H[S_ / E_P#(GP=_PQ]\1?\
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MYRM^G^78OU?]:+_@_P!;]%J_Q@T/1H[.:4RR6UQIC:J9HP"(X045<\]79PH
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MZ<YKU3XRE%T*PA)P1 M<Q\'$_MKQ3XG9;1K58C'E7'))+9)J[\9[W?-80@Y
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M;^OO_P F']?E_FCT:BH[>=+J".:)MT<BAU.,9!&14E( HHHH **** "BBB@
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MJ7O-W_JW+_\ (H\,\$_"3Q!X<\7^'=0NHH7BBTK5ENVBF!6&XNKF.9(E!Y(
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MP]\1?%?[7J%UIX\--%HATZTM[FX24W$S2QREF,18"+]TH&?F.YB5&,&O\0/
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M_5_D>4:?8M C2%XY(W"8:-LC()./6DA0YF4<EK4\?5A52R<VPG;8Q4F%5;'
M;/\ AFM&W4_V@8SU\@ Y_P"NB"O.T<HZ'6G\=V37R,+_ %%&^]Y2C_R)&:FM
M'*C3_8R&C56"ZWJ8)_AP/P=?\*K&3;;V1!_AD/\ X\:W2LU_74PF]&_ZV&^-
M'$/[,]RN<%[B+C_ML363>7/F?L]>%X1VNU)'_ 9:L?$201_LW0X))>[A!_%G
M/]*P7E/_  IKPQ&3\IF!Q^#U]1/^&_0\.GNO5F)8(191LW&6<C_OHU^V?[&(
MQ^RY\.O^P;_[4>OQ3L%"V46>X8\^[5^U_P"QL-O[,'P['_4-'_H;5Q8%/VTO
M0Z,5_#CZGK\G2L;4ON-]#6S)TK&U+[C?0U[AY9J:1_R#8/H?YFKE4](_Y!L'
MT/\ ,U<H AEO(()HHI9XXY93B-'<!G/L.]35Y[X[^">B?$'QUX3\5ZA=7\-_
MX;E,UK%;3[(I"><.,<\^A&>AXKT*A;:[@]]#S;XH?&/_ (5KXJ\):2VCG4+?
M6[@PS7@N?+^QJ"J[RNP[QN=1C*]:M>)_BNGA[XF^&?"$>FF\;5Q(9;P3[!:X
M4E05VG<6VMW'0USOQD\!7GCOQKX>M8[>?["^FZC;RWL:$K;R/&HC8MV.X CZ
M5QNF>&?&.KW7@SQ/JF@SQ^(;F^N);RUD4E;9([5H85D8#Y59E+9_Z:FDGI=]
M/QZ6_4;6NG;\=[_H>YZ=\0/#>K:S)I-EKEC<ZE&"6MHY@7P.O'?%1:3\2_"F
MO7T-EIWB#3[VZG0R110SJQ=1U(QUZ&O!?"_AW6I=:^&)&F>(_,TJ24:DESIY
MM+.P9H6!CB4* R!N Z[A@#+$GG1\)>!M9L/AM\(;0Z+<VU[8:N\U[&;<J\"L
M9LM(,94'<O)]15-67S2_X)-_RO\ \ ]Q_P"$Y\/G2[+4AK%F;"^<QVMP)ALF
M89RJGN?E;\C7'_#[XY:7XVT'5O$%Q)INE:!:WCVD%R=0,DK['9294,:B,G:"
MH5WR&YQTKS+P[I&N6?A_X9>%I/#>L+?Z!K[/J,YLW%M%'NF*R++C;(I#+RI.
M,\X/%6]*\/Z]HOPX\(PW.E:E:16VOW]Q>RV=@UQ>VL;3SM&\<6UFPVY?F"DA
M6R/6CN^E[+\-1OM_7VM/P1[@GC[PY)X>.NKK=D='!V_;1,/+W9QC/KGM7/WO
MQP\*6WB'PSI4.J6]XVO><8+B&93&HC'?W)^4#U!KQWPSX2\0:<)]7N-&UMM/
ML?',FK26=Y 9;JXM'M419E0<N0YW;5!(((QD8KOM=:76?%W@;6K#PUJMAID=
MQJ,$QDL#&X::$*DSQ+ET5F!^9PI'\0%)[)^GXI/\W;Y?<=;>OYO]%?Y_?Z2G
MC/0I++3KM-6M&M=1E\BSF$HVW$F&.U#W.%8X'H:Q4^*_AW4KJRAT?6]&U S7
MB6LN^_V%=RN0(P$;>_[LX0E> QW<8/B^F:1KJZ#\,?#1\-ZPM[H.NO+J,[V;
MBWB017"JZR8VNK%Q@J2!WP2!5[2_ ^LVWP[^$UH-%NX[JP\1&YO(O((:",QW
M7SN,<#+KR?[P]:?=]+I?)VU#R\F_FK_Y(]ITKXD^%==U.'3M/\0:?>7TRLT<
M$,ZLSA?O8]<=Z!\2?"IUE=)'B#3SJ3S"W6U\]=[2G)" =SP>/:O$].\":W#\
M/_A1:II%U:WUCXE>XN\0%7MHVCN@9'X^5?F3)/J*SIY_L*_!WPU<Z'>G5]/\
M4+YNH/:X@.(K@LZ3?=DWCD["<8.['&6E>27FE]]M?E<3T3?DW]U]/P_$^AO$
M/CCP_P"$Y8HM9UBSTV66-I8TN90K.BD!F [@%ES]:BTGXA>&=>U&&PT[7;"]
MO)HO/CA@G5F=.NX8ZBN5\5>'[R^^.7A#4UL))["TT?4HY+KR]T<4CM!M!;H"
M0&QZX-<!X:\$:SI=E\)Q%HEQ;R6&LZG-=KY!00H\-T$,G'RJQ9!D]<BI6R;_
M *U:_2XWUM_6E_\ @'M5IX_\.:AK;Z/:ZW8SZJH;-HDP+_+][CV[UEVWQ9\-
MP:3:W6K:[HUE+/&TP6WO_.C*!RFY7*H6&1@G:,'([9KQ#1O#NO7&N?#4OI/B
M%;K3-8GEU.%K$V]A8!X9EVQX4"12S##@L.>2":U_@CX'UC2?$OAB?4]%N;5+
M;P]=V[R7-N5$<C7C,$)(X)4YQW%'3[_P3?\ P >E_E^+M_P3U:_^+OAZR\8>
M'/#PO(IY]=@DN+6>.13&57;MQZ[MW&/0UK:9\0/#FM:K-IFGZW8WFHPJ6>VB
MF!8 =3]![5X7X(\->(O#FE_#R230;UI[:QU:R,,EN^V&667,*R@#,:,%^\<
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M&VF5G"KGMGN1CTS6KH'CC2=?\%VOBB.[BATF:V^U-.[C9$H'S;FZ?+@@_2O
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MJBV>NZG;7'C*QOY)=6MDAD,<<,BM.UND,?DJ&V\L,G@G'%$5S-)Z:KY7Y?\
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MKB2-8D)4N< F6,9Q^-<2=)2C8WG&HHMZ&??>=<:OJK)!)(0=HVJ3GGM^5/\
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M.^%XX_$$$R,LEFMH]R6C8'&0,CZYSQ7)1O.I/U-JEH0@_(WO"MG% JV>%DD
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MHZ-T8'J#5.3<G+O?\;_YD)))1?0\]^-D$WBSX,ZPNCV\^HR7EO&]O%!"S22
MLI&$QGISC%>;:KX)U:3X>_&&)-#NVO\ 4-566T46K&6X58H-K)QE@"&P1T(-
M?1L,*6\211($C10JJHP !T I]+9NW7_-/]!W>E^AXIX;67P?XB\6V>O^&M4U
MV;6=1AO+%[;3&N8IHO*C55>4_NXC&RMQ*R>JYS7(V'AW6O#GBG0O$=WH>J/I
MNF^+=6GN5MK*2:=89X'CCE6)%+NA8@$H#C.>F2/IFBA-K7RM^7^0K:6_K9_Y
MGS/X0TS6=*UZQ\6:EX=UD:-;^(-5FEL?[/>2YB$Z*(;H0 %W VLOR*2!)G&
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M><'BO1:**38!1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M[I/[U?[O,IJS:\VON=CZG%Q$P)$B$#J0PJ'4;UK&SGFCMY+V6)-XMH&02/[
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M ,N>,4/2_E_]M_\ (_B$=4GW_P#M?_DOP/KEYXX_OR*O^\P%97_"5Z:?%/\
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M?18S+;V\2D*QNNK=!Q6IXZL_MGQ>U2'(7S($!8]OEK*M$^SV4;AE<BXR0.V
M:\#$Q?UB[VU_]*1Z-+^ K>1Z#X#@EN+V-I@/^/2X4E>G"X%><OXPA^'/B7_A
M'Y8@USK @D7!)V OC''?BO<OAO%_;?@^75C;"$7&F2+D# 5N5_I7AWBWPM<Z
MK\<?"$?]GF8)8VLCW6W.P*,GG\*^PA1C>,I;GS?M79Q07PT"R^*]_);1W<FH
MVGF@VTN#$"R#)/?!]*V_@S%>^.Y5?4].GCEMVD\MS:F**.($;57(_E3[KX>:
MKXO^).H:G8316L'VGS9)YU)\QL *H [ "OJ/PCI7D:9 DP1IE4!V5=H8^PK9
MRYMC-=R?P9X?:)$+J0  !FO6-&L2B*. /:N<T>V ('2NVTZ$+&!CBFE83=R&
MZA X!.:QI+4>;D\FN@NP,D;<$BLN2+G^M5<13G7]V1P,5E36JN>.E;4T7R^_
MK58P9S6;0T8K6 'ICWJ"2P!4Y K>>V![57DMQSZU+07.;O\ 2(-2TR>RF7<K
MJ1GZBO(-:^#TUOY@@U&]=\C:6D)^6O=IK?CC@UCW=O('R>E0T4CY$\0Z%J'A
MSQUX=>!9);BTNA* [X).Y>??I73:]IW@6V\57WB2_OIY8[6U8O8^7L985R6W
M>@SGIZ5Z-<?"Z:X\<'Q!<:G),D3EHK9UR%''&?3(S7S7\2-3FT[Q9X_V,J/'
MHGF)N&0<.1S[4G!3CRM%*3B[H]%GO=1\3ZKI&JF-+BQDOH3;M:L'BC@'W  .
M0,8ZT_X/6\1^-'Q1GDX+&&%?J<'^E>,? GQ-+8>(='LC*\B:C*)$C;=\G[S&
M5]N#@>U>U>$]=FT#Q!XWNDD202^(["T.$!P) P(YZ=*YZ=%TI-ON=,JJFK6\
MB#XD1#_A)4R?^6:+GV*M_C7"+8-=HD$:&222>-451R20P _,UZ%\18R/$X1L
M_P (_0UJ?##0K31M+OO&6KK_ *+IC_Z'&_2>XP=H'J!D5\AB*3JXJ4>FOZ'T
MM"?L\/%K>R,CXM7,GP\\+:#\.(BGVB<KJFK2(V<RL<)&/8!1^0]:B_:8NI[6
M_P#!TMO*T4R12LCH<$'"<BN#\6ZK>>)/%<6IWS^9=W3>;(Q]3*_ ] ,8_"NW
M_:4;??>$5SR+>8_^@UZ*J)T*O)LDK>AAR<M:DI;MML\AT^:<0_:UE=+K^T78
M2JQW!EC0YS]374:#-]EN;YY+AGU"2ZMQ<2DY^]YAV_7@Y/O6!HJ#^R()<X/]
MI7'/TB@_QI]D9(=/UN1@5D6]M&#>^V<C^5>?";C)2\CJJ14ERE;4+96N-9P"
M0;I""1CC$E9^JIMMH@.GV;G_ +ZK9U*Y%S<:E<A01/+$YQVR'_Q-96M ?9UV
M?,!;@9_X$*UO[VGD8RVMZC_VA+,0^#/""@$;G?(_[9K_ (U:N=+^U?$KP]&1
M\D%BLK?\!)(_4"G_ !X26\\.^#(T7?F608R.!LBK>OH!9^.[ZZ.$2ST-F#-P
M,\FOJ+727H> MOO//;[4C<ZEJ,Z2DF2Z\P+CJ3TK]IOV1F9OV;? )?[W]G#.
M?]]J_$>/ L&F"Y(;?NS["OVW_9%.?V;/ )_ZA_\ [.U<&"=ZU1G7BE:$3UB3
MI6-J7W&^AK9DZ5C:E]QOH:]L\PU-(_Y!L'T/\S5RJ>D?\@V#Z'^9JY0 4444
M %%<YXD^(?A[PCK.BZ5J^I)97^LRF"PA>-SYSCMD @?\"(J?5?&^B:)XCTG0
M;V_2#5]5#FSM2C%I0@RQR 0,>Y%&X;&Y6-XI\+VWB[3/[/O)[F*S9@9HK>0(
M)U[H_!RI[@8K8)P,U7T[4(M4LHKJ%9DBD!*BX@>%QSCE' 8=.X% $T4201)'
M&H5$ 55'0 =!3ZIS:Q96^J6VFR7427]RCRPVY;YW1,;F ]!N&3[BK,L@BC=V
M#%5!8[5+'\ .3]!1YA;H/HJ"RO(]0M(;F)95CE4,HFB>)P#ZHX#*?8@&IZ "
MBBB@ HI"<#-9OA[Q)IOBK3OM^E7(N[3S'A\P*R_.C%6&& /!!% &G115&XUR
MQM=16PDN4^W- ]RMLN6D:-2 S!1R1D@?4T 7J*@LKN._M(;F(2K'*@=1-$T3
M@'^\C@,I]B 14] !1110 4444 (1D$=*I:)H]MX?TFUTZS4I;6Z!$#')/J2>
MY)R2?>KU% !115/2=8LM=L5O-/N8[RU9G19HFW*2K%6 /LRD?A0!<HHHH **
M** "BBJ5QK-C::G9Z=-=11W]XLCV]NS?/(J8WD#T&Y<GW'K0!2M_".GVOB^\
M\2H)/[3N[2*RD)?Y/+C9F7 ]<N>:VJ*0D $DX H#K<6BJ>E:O9:Y9)>:?<QW
MEJY95FB;<I*DJ<'V((_"KE !116=XB\0Z?X3T*_UG5KD6>F6$+7%S<%681QJ
M,LV%!)P/04!OHC1HJI<ZI;VNEOJ#>;+;+%YW^CP/*[+C/RH@+,<=@"?:K*.)
M$5AD!AD;@0?R/2@5[ZCJ*S-/\2:;JFKZGI=K="6_TTQB[A"L#$77<G)&#D<\
M$UIT#"BBB@ HHHH Q+GPCI]UXPLO$KB3^T[.SEL8B'^3RY&1FR.YRB\UMUF:
MOXDTW0KO3+:^NA;SZE<?9;1"K'S9=I;;P#CA2<G XK3HZ6_KO^H=?Z]/T"BF
MR.(T9SDA1D[02?R')K&TGQEI.M:O-I5K<2?VE!;17DMK-;R0R)%(65&8.HQD
MHW'7CD4 ;=%8FO\ C/2?"\%W/JL\MG;6B1R2W#VTIB =]B@.%*L=W5021D$@
M BI9/%6EP2PQ3W!M9)[O[#"MU$\)GFVEML>\#?PK'*Y& >>#0!K4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/KWBZ:?2[G35U#35ABGNHRJAB_W.1R17WKJ%@ V-N<U\Z_M$^$_&/B2&73M
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MP7UZ77;V]US5=4:6YAGOWE1Y!;R^9MB+%8_+8[?D"]<')JUI'C745^&WPO\
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MS D2I"=HP1PVU<@].,UV6B^//$$WB6V\%7&H-)KUIK,QN[HPH#+IP!EB;&W
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M^?X<W_R+!*[MUT_'E_\ DD?4E4[_ %FPTIH5O;ZVLVFW>6+B94+[5+-MR><
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MRL&)"X4G)R5('J0?2M*O+?A1I9^('@3P?XJ\0W4NHZV]C"\DHVI&[JS-N"*
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M9.W#?+GC%1R?![PK+IJ6;6=V=ES]L6\_M.Z^V";;LW_:O-\[.WY?O]..E'_
M_3_)@O\ /]3P\^.-:UNX\-+KC3WEYH'CN:Q26X6)9YHTL7D7S!$HCW_/CY0!
MQTKH/!?Q5\6:G/X7UF<:O<VFM78AN["ZL((;"UA8-M:WF $C,I"Y#,^X;L 5
MZAI?P<\'Z*\+6>C^2T6H_P!KJ?M,S?Z7Y7E&4Y<Y)3@YR">2">:GTOX5>&-&
MUF/4[33GCN(7:6")[N9[:W=L[GB@9S%$QR<LB@\GU-$7:U_+\DG][0I:[>?Y
MMK[KG+>.OBJK+X<'AK4)$:7Q'9:?>^99LFZ&0N&0>:@Z[>J\C'45RGBKXC>+
M3XHUS2M-UU-/6/Q;INDP2M:Q2>3;S0!I%P5Y)8Y!.2#[<5[5XH\*:7XSTEM-
MUBU-U:%UE 61XG1U.5='0AD8'D,I!'K7G7B_]GG1-4TZTL]&@^QK+KMIJ^IR
M7-[<2270A&T_O&=G#E<<@CD9)SS2CHU?NONO&_RLG]XY:IV[/[[2_P U]QO_
M  \UO5?^$E\4^&]4U*36SH\D!AU&>*..61)8]VV01*J;E(/*JO!'%>8VOQ \
M7:SXQT?0[?Q VF0ZAXFU73I9X+*W:18(;=I$"[D(W CAB#[AAQ7N?AKPEI?A
M&TDM],@DC65_-EEGGDN)I7Z;GED9G<X &6)Z5FVOPP\,V6KVFIPZ9LOK6]GU
M"&7SY3MGF0I*^"V#N4D8(P.P%-6OKV_'03VTWO\ H_\ @&5\'O$VJ:]I.MV^
ML7G]HW.DZK<:>+UXTC>=$(VLZH H;!YV@#CH*\SU+XK>*K/6]$UBVU&\O-'O
MO$T6BO;BUMX].:%Y3%F-F3SVD!&=V_;D'Y<5[MH7AC3/#0OAIMM]G%]<O=W'
M[QGWRM]YOF)QG'08'M7,2? [P7->Q74FE3.\-\FI01-J%R8;>Y5_,$D47F;(
MR6Y.Q1NR0<@D4)^]%O96O^%_OU!_#)+K>WXV^[0Q_ASJGB7QU-<>)7\1RVFG
MPZG=6C: ;&%H##$[1CY]HE$A*[MV\KSC9WK#\/\ C;Q1/\,;_P")\^N2W5M'
M8WUZ?#+64(A58O,\M$D51*KC8-Q9G!YPHKT6/X7>&H?$)UI+"5+PS_:O+%Y/
M]F\[&/-^S[_*\S_;V;O>FV/PI\+Z=JSZC!IKB5GDD$#W4SVR/(")&2W9S$C-
MDY*J"<G/6I:?+9;V_&W]>A::YKO:_P"'8\VU;QCXM\&:?HMU<^)&UQ]>TF[N
M2C6D")93QVWG*T&Q 3'GC$A<].:;X4\1>+M6T+X>6-WXNOO[0\5Z>-2NM42S
MM UMMA1S% OD[!N+]9%<X!Q[>C:9\'_">DB=;?3)-DML]F(YKR>5(('&&BA5
MW(A4C^&/:*MWGPU\.WWAW2M$>RDCL-*1([$V]W-#/;!%VKLF1Q(IVC&0V2.N
M:NZNW;>W_MW^:];6(5[*_2_Z?\$\)\%Z[K>@Q>(-$MM;GDU2_P#&6HQRW6FV
MD3WDJHJ$M&KJT2$<;BRD#G ]+7A[XE^-?$-WHF@R:Y/IMS_PDM_HMU>FUM7N
M988H@Z%@$,2R#(R57;D?=[5ZM;_ SP79:>+.TTNXLD%Y)?K-::E=0SK/( )'
M$R2"0;@.0&P>XJWHWP@\(>'KJVN-.T=;66WO9-0B*SRD+<2($>3!;!+*!G/!
M.3U)-*-E:_1)?=R_Y/[QOK;NW]_-_FON/+](^)/BK4KF'PE)K<D=[_PD]YHC
M>($M8?M#00QB56V%#$)2&"YV;>,[16UXU\3>*?"NJ^&?"3:SJVH7%]'=7$^M
MZ1I5NUX8XRNQ/+96BW?.-S!,'!PJYX[NY^%/A>ZM;^!M-9!>W[:I++#=31RB
MZ8 &5)%</&<*!\A7]33)?A-X7FTFVT_[!/'';2O/%<PWUQ'=K(_WW^TK()2S
M=R7R>^:2^%7WTOZV5_QU&]W;;7\W;\+(QO _B/Q-XP^&&K23;].\16\EY9V]
MR\48>1HV812M'\RJQ&W<AZ'/ KS6Y_:#ULW-KJ<%S#_8LNC+9F,Q)D:R\7F@
M$]>%*C;TRW2OH+0?#^G^%]*ATW2[5;2RBR5C4D\DDLQ))+,2222222237/+\
M'?!R6$=D-#A^RQZHVLI%YDF!=EMQE^]Z_P /W<<8Q3T;\M/\G^#;]4A+1??_
M )K\DO1L\(\3ZGXG\1>)[K2-2\27<!TCQ+H4*-9VUJA+26R/(3NA;/SDD9Z9
MQTXJQHNI^(O!>A>./$NG^(9DM[7QK/"=)-M T%PCS1(YD8IY@;YB0490/0U[
MIJ?PI\+ZQ<ZK<76FLUQJ=S!>74T=U-&[30J%B=65P4*@ ?)C/?-/;X7^&7T7
M4-);32VGW]Z=1N8C<2DR7!96+[MVX<JIP#CCI3B[._\ 7V/_ )%_@)JZ2_K[
M7^:,_P"+OBS4/"_AO3SI<HM;S4]2M=-6[,8D^S":0*9-IX) SC.1G&0:\]^)
MWAKQ#:^)OA?I\_B^YO;J3Q%,8-5DLK=+F&/[%-D$*@B9OO8;RP.1E3CGVK7_
M  [IWBC29M,U2U6[LI<;HV)4@@Y!# @J00""""".*P]/^%'AC3;C3[B.QGEN
MK"[:^@NKJ^N+B;SC&8B[R2.S2?(Q4!R0!T' J5Y]T_EII^#^\;VMY-?.S/,8
M?B7XCC\/7.DR:S+/K$?B>70HKZ"SB:^NHD0R$QQA/)$H4<LR;  3MZ"L.#XH
M>-IWT_0_[9N+.\7QK'H,M]=VMJ]S):O:R2X=401AP0,%5'09!Y!]IOOA+X6U
M"WN(9-.EC\_4#JK36]Y/#,ET1M,L<J.'C)&1\A P2,8)J#3_ (,>#M*E@EMM
M(,<D.I+JZN;J9B;M8S&)F)<[FVD@YR#G)R>:<=US>7X<M_RE]XY=>7S_ !YK
M?==?<>=1_$7Q1:37GA9M8ENKX^*8M!AU^6UA\Z*%X#.79%18B^%**=FW+*2I
MZ'+UOQYXQ\,:_?:3/XE.JQVOBK1]/BGGLK82?9I\&1'VQA=Q_O  CMBO4O%_
MPTM[W2=531M.TZ2\U.]COKU-2FN%69T  9)(VW02#:I5T!P1]W)S6'X(^ NF
M:8FH7.O6T=S=WFJ6^K""*^N9U@G@ $3>=(PDE;(R2_![C%$-TY=+?.W+?\I?
M?J*6SMU3_P#;O\U]VAQ_AGXA>,8;#P1X@O\ Q')J<.M>(I=%N-,>SMXX1$7F
M".K(@D$B^6O.[:1GY<\U/?>.?&-SHOA[Q9;>)9+*VU+Q3;Z7+HCV=N8DMC=F
M$JK%/,\PA<DEB,$X"D9KUF'X8^&;?3M)L8]-VVNE7_\ :=G'Y\I\JYRQWYW9
M;EVX.1STZ5Y[?? N[U_QA87VHP:7:65EK":PLVGWMWF5XV+(!:.3#$Q.-\BD
MEL'@9X<6E*-^Z^[W;_DQ3U4K=OQ][_./W'0_$O5=?/CKP5H.CZZ^A6NJF[^V
M30V\,LI6.-67R_-1E5@3U((ZY!KA[GQWXOO]8T+PQ#XCELYQXCN='N]8M[2W
M,US"EL958*\;1K(,@$A0N0?E XKT'XB_"Q?B#XM\(ZC<3&.QT=[EY5AN9K><
MF2,*ICDB*LI!'4,#6W:_#?PY9#1Q#IH0Z1.]U9MYTA9974J\C$MF1F#-DON)
M)SUYJ8^?]:_Y%2\OZT?_  #RG5O'7BNR\*^,/%L7B&7RO"U\]DFD26MOY=\D
M)0.TS>7O$DF25\MD49'RFL+XPZMKOC;X>>-]2.N2Z;INEZS%IJ:*;:'RY4CF
MAR[N5,F]BV5VL%QCY3G->VZC\*_"^JZV^JW6FM)<R2I/+&MU,MO-(F-CR0!Q
M%(PP,,RDC YJIXF^"_@_QA>W-SJNER3O<O'+/'%?7$,4TB$%'>..149QM&&(
M)P,9Q3B[--]+??IK^#TZ7):WM_2UT^7?=G >*_B9XBTK0?C/<6^I"&7P]) F
MF,8(C]G#6\3D<K\V68GYL]:W=&U?Q/X^\:^)+>R\22^'[;P]<6MNMHEC#-'>
M%X$E=Y2Z[\'?M7RV3&,G/2NB\4_!?P?XTN[ZXU?2Y+AK^-8KN.*^N((KD+]T
MR1QR*KLO9B"1V-6]7^%GAG7-6&HW=A*;HJB2>3>3PQW"I]P31HX28+V\P-BD
MNE_ZVU_X'F-^1X=X=U37/!EQJTD'B"]OA>?$)[*:.[@MF!CVJ6V[8E(+<#@\
M;1C'.>ETKX@>*6\)>&_'<^MM/;ZSJ,=L_AX6T(MX89)FC4(X3S?-4 $EG*D@
M_**])/PF\*G4Y[_^S7%Q-?IJ;A;N81?:E&!*(P^P-C&< ;L#.<4ZT^%/A>QU
MI=4ATUDG29KE(3=3&UCF8DM*EN7\I')))=4!.3SS1'2,4^EOP23^^S] EJY-
M=;_BV_U7J>1^&_B!XQ_X1SPKXHO?$DE\FH^(9=(FTMK.W2 P?:I8E;<J"3S
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MZ 7D_P#\731^S]X"!S_87/\ U^3_ /Q=>B44[L+(\_7X"^!4.1H0SZ_:IO\
MXNIU^"?@Q  NC8QZ7,W_ ,77<T47861Q)^#'@XG/]D'_ ,"IO_BZ8WP3\&-U
MT;_R:F_^+KN:*+A9'"_\*1\% Y_L;G_KZF_^+KK])TJUT/3H+"RB\FU@79''
MN+;1]22:MT4@L,<55GBW U<(S3&3.:!F?#</9DKM+H3TSTI7UH+_ ,L'_,58
M>W!YP/RJNUH#V'Y4 ,_M\?\ /N_YBD_X2 ?\^[_F*4V(]!^5)]B'H/RH /\
MA(!_S[O^8H_X2 ?\^[_F*/L0]!^5'V(>@_*@ _X2 ?\ /N_YBC_A(!_S[O\
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M'Y4?8AZ#\J #_A(!_P ^[_F*/^$@'_/N_P"8H^Q#T'Y4HL0>P_*@!RZX&/\
MJ'_,5(=2:1<)&5)[D]*C6S /0?E4Z6^,<#\J ([>'!YS15Q$ [44 2T44F:
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M\T9H ;L]J4+BES1F@ QBBEHH C+XIAE'K5.:Z"CK^E4I-0"D\_I0!KF8#O\
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MU@?VFOK^E']IKZ_I0!O^>/\ )H\\?Y-8']IKZ_I1_::^OZ4 ;_GC_)H$X/\
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M ;_GC_)H\\?Y-8']IKZ_I1_::^OZ4 ;_ )X_R://'^36!_::^OZ4?VFOK^E
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M_IK,HH T_P#A)=6_Z"-S_P!_31_PDNK?]!&Y_P"_IK,HH T_^$EU;_H(W/\
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M^$EU;_H(W/\ W]-'_"2ZM_T$;G_OZ:S** -/_A)=6_Z"-S_W]-'_  DNK?\
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ME&);F3.U6=4' )/+$ < ]35VZ\(ZG::=+?&.">TB($DMK=13B// W;&./QH
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M75O^@C<_]_36910!I_\ "2ZM_P!!&Y_[^FC_ (275O\ H(W/_?TUF44 :?\
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M&<Y)&<UQP\0:B$T]/MDNVP)-J,_ZK)R<?C4EEXIU73DD6WO7C620RL, _/\
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M"R+:69CBMF\Y5*JY )X)&,>]27-VM]XXU+17M;4:;]BE_<K"HPRP%PP.,@Y
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4?\ ",ZQ_P! J]_\!W_PK[;HH ^)/^$9UC_H%7O_ (#O_A1_PC.L?] J]_\
M =_\*^VZ* /B3_A&=8_Z!5[_ . [_P"%'_",ZQ_T"KW_ ,!W_P *^VZ* /B3
M_A&=8_Z!5[_X#O\ X4?\(SK'_0*O?_ =_P#"OMNB@#XD_P"$9UC_ *!5[_X#
MO_A1_P (SK'_ $"KW_P'?_"OMNB@#XD_X1G6/^@5>_\ @._^%'_",ZQ_T"KW
M_P !W_PK[;HH ^)/^$9UC_H%7O\ X#O_ (4?\(SK'_0*O?\ P'?_  K[;HH
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M?\(SK'_0*O?_  '?_"OMNB@#XD_X1G6/^@5>_P#@._\ A1_PC.L?] J]_P#
M=_\ "OMNB@#S+X8V\MKX/TR*:-XI53#(ZD$?4&NQ?_5_A45S_P A&;_?_I4K
M_P"K_"@#S7XQ6<]]X4FBMH)+B4S1G9$A9L9]!7A7_",ZQ_T"KW_P'?\ PKZX
MTC_D+?\  3_*NCH ^)/^$9UC_H%7O_@._P#A1_PC.L?] J]_\!W_ ,*^VZ*
M/B3_ (1G6/\ H%7O_@._^%'_  C.L?\ 0*O?_ =_\*^VZ* /B3_A&=8_Z!5[
M_P" [_X4?\(SK'_0*O?_  '?_"OMNB@#XD_X1G6/^@5>_P#@._\ A1_PC.L?
M] J]_P# =_\ "OMNB@#XD_X1G6/^@5>_^ [_ .%'_",ZQ_T"KW_P'?\ PK[;
MHH ^)/\ A&=8_P"@5>_^ [_X4?\ ",ZQ_P! J]_\!W_PK[;HH ^)/^$9UC_H
M%7O_ (#O_A1_PC.L?] J]_\  =_\*^VZ* /B3_A&=8_Z!5[_ . [_P"%'_",
MZQ_T"KW_ ,!W_P *^VZ* /B3_A&=8_Z!5[_X#O\ X4?\(SK'_0*O?_ =_P#"
MOMNB@#XD_P"$9UC_ *!5[_X#O_A1_P (SK'_ $"KW_P'?_"OMNB@#XD_X1G6
M/^@5>_\ @._^%'_",ZQ_T"KW_P !W_PK[;HH ^)/^$9UC_H%7O\ X#O_ (4?
M\(SK'_0*O?\ P'?_  K[;HH ^)/^$9UC_H%7O_@._P#A1_PC.L?] J]_\!W_
M ,*^VZ* /B3_ (1G6/\ H%7O_@._^%'_  C.L?\ 0*O?_ =_\*^VZ* /B3_A
M&=8_Z!5[_P" [_X4?\(SK'_0*O?_  '?_"OMNB@#XD_X1G6/^@5>_P#@._\
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M#XD_X1G6/^@5>_\ @._^%'_",ZQ_T"KW_P !W_PK[;HH ^)/^$9UC_H%7O\
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MQN+&&YB)E WJP<?,,C(/&.>M:DGP?T[_ (5]H?A*&[GALM)EMY8I< NWE.&
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M_"HKG_D(S?[_ /2I7_U?X4 0:1_R%O\ @)_E71USFD?\A;_@)_E71T %%%%
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MSB<@0V+3!8\\D[B<;STXZ<=*5D.\F;/A[Q'%KB2/')!*@<J/L\PF"X./F9>
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M!P5%7*SDK>?Y?YF:NEKY?FOT,*Q_:A@U%=:O(/#5P-(T2S2ZU&YDNE$L;MN
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MMJ7A;5#9SKI2SP7%C(!M&JWKNK#'9'5F'8,">#5)7<5WM\KJ_P" GHI/M?\
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MP5D#R%AN(*JP)."<US?P\^%=YKS2#Q)X5O;E+'PC=PV::CI\BI%<"]E,2HK
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M0,9'<4F[*_S&E=V^1Z_17A'@W]I0WOPHN_$FJZ6\U]I=OI[7BV[!%FDN0G*
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M[QSY385?3DC(KI/!G[0-CX_\4/IFB:;]JM8Y4CDE:]B2Y0-&L@E-LQ#F(A@
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MYT:]>T;3)KMKS4UA1UC#6Y52T989#-Q@=*CT#]G71M%?7O-U"YO8];TM=.O
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MTZ:_NB+:8-!Y:H=J!HQYF2Y&0>WO6MHWAOP]X=T^^\-W?BV?4KS6X2@&HWL
MN&B*; (8T1$  SR$R3RQ8U'XB^&/ACQ=HFB6D^K3I;6UI)IUE-;7,69 X3)!
M*D.P\H'&,=<@BD]]/+];_C8%LK_TM/\ @E#_ (:4\'FVCF0:C+EKA98XK0NU
MOY'E>:9-I(  FC/4]:LW?[0OA.Q6!9C?K<374EJ+4VI\X,B)(Q*YZ;)8V&,D
MAAQUK!T#X.>!8[K688?%MSJEZT=S'?!KVUWPB<0+(2D<:B/_ (]4P, #+<=
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M+^[15VO&(V/*DE9(R!R5(SBO=*IJUB$[A1112*"BBB@ HHHH **** "BBB@
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M3*0P'9.U>H3?!3PI/:K'):W;W"W*W@U ZA<?;1*JE0WVC?YGW25^]T.*JI\
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MRI[T?94]Z -7^U[/_GNM']KV?_/=:ROLJ>]'V5/>@#5_M>S_ .>ZT?VO9_\
M/=:ROLJ>]'V5/>@#5_M>S_Y[K1_:]G_SW6LK[*GO1]E3WH U?[7L_P#GNM']
MKV?_ #W6LK[*GO1]E3WH U?[7L_^>ZT?VO9_\]UK*^RI[T?94]Z -7^U[/\
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M_P#GNM']KV?_ #W6LK[*GO1]E3WH U?[7L_^>ZT?VO9_\]UK*^RI[T?94]Z
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DU&V;I*IK)6U0>M31VZ#UH GN)5NI%V\JN>314L,0'%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>plx-20230331x10q006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plx-20230331x10q006.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" '%!#@# 2(  A$! Q$!_\0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MBBB@ HHHH **** "BBB@ HHHH X[Q]\1X?!5QI>GP6$VL:YJKLEEIUNP4OM
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M-?U>\U.]UG2/!%GJ=A;)<RQQM=!K@QRF-& 8L(TX(P=W3I6:?N\[[7^5F_\
MVUFCB^;E7DOF^7_Y)'VK+(L,;R.0J("S$]@*S_#WB'3_ !5I,.IZ7<K=V,Q8
M1S)T;:Q4_JI%?*2P6NG>%_AIK&EZ_?ZGK'BEO)U9'OY)1>Q.A,K;-V(]A[H%
MQ7->&;34[?PY\)_"&B0V_P#8FM2:M<W,.H:S<V<5W<Q38CB,\:R.#LW,$7&=
MA.>#G5Q:;CU3M\]6_E;;ST,5)-)K9J_R_K\-3[7N]8L["]L[.>;R[B[++ FT
MG>0,GD# _&KM?'&JR^*?"XT'3M0\36-ZJ76JK%%HFJR7:VT8@)6"65D1F9#_
M 'AD5#X6M;KP?I/P4U.Q\0W]G?\ B>PNX=5U#4;Z26)A]B>19&5VVKL9%.0!
MP#G-1]ER]/QO;\C1JS2\F_N>O_ /LVN>USX@>'_#5_-9ZGJ<-G<06,FI2K)G
M]W;(0'D/L"PKY_\ @TUQX(\?^'-.UU;NZU#6;:;[/K>DZ]_:.G:IM&XRO&_S
M1G'(V*%[9K(_:7\,Z;+\3_%%^\<GVP?#W49E87$@&X.B9V[MN,,>,8YSU I3
M]VWFI?\ DL9/\T$?>NO\/XR2_4^L+"_M]4LH+RTE6>VG021RIT93R"*?=745
ME;37$[B."%#([MT50,D_E7R):S6GP<U'P)<Q:GJT.F:EX:N9]5VW3RO(4BW!
MT5R51@>F !6#?[K?QUX2LK>"]TK2O$OAS4I[NTN]?>[N;Q!"KQRRHK%8SD]4
M8 DL,8%.K[G-R]+_ (<W_P B33?,HN76WXV_S/L_0M<LO$ND6NJ:=.+FQND$
MD,J]'4]ZOUXW\"TTSP;^S9HMTK3V]E%IC7,SQRM)(."6*EB>?0=*\$O==N-(
M\4_#;5-%&H:-;^)+._DD.H:\;J[OX?LKR)))"I9$P0IRI7!.,=<552A.45LO
M^#_DQ4[S@I=_^!?\S[?HKXAL++5K#X8?"O\ L^ZFN9/%MSY>K7.K:U<V\4YP
M2D1E59#&&.!\B@GIFOH+X"Z/X@\.MXIT[5]6T:\M8+Q#::7I>JRZB^F QC=#
M))+&C\GYP&!.&ZXQ3<>7F3Z7_"U_S_K0+[>?_!_R/2/$?BC2O".G"_UF^BT^
MS,B0B:8X7>QPJ_4DXK(UOXI^%?#EJMQJ6LPV<3WAL$,B/EYP,E%&,DX].*^1
M_'%C8^*?A7/XLUW6[M?%9\4QV[VSWC;$VW "V_DYV@ <YQGOFIM3\/VGC;XA
M^%UUI[N^!\>ZO9C-[,A6%;;<$4JXV@'TQZ=*S5W^?_I'_P E_75R:C?^ND__
M )'^NGU;X?\ BYX0\5:A]ATG6X;^Y\TP[88W(W@9*[MN.GO785\._"BV;P;X
M:\!RZ&UU!-=:[JGFQ"YE=9MD4FP%2Q!Q^M=3X>L]-D_9\3QK)XOU&/QMK&@7
MTLT!U4C[9< ,9%6!CP8B, 1A2N.<U4K1BY=O\K_H7ROG4._^=CZPU'4;;2+"
MXO;R9;>UMT,DLK]$4#))K(T+Q]H'B>^2STK4H;V=[&'4E6+/-O+N\J3Z-M;'
MTKY;^('BR2[L?AG:1ZP\[77A>_FN(5N2WF@6C89QGYN>Y[UH_LO^&=-A^)FF
MZ@L<@O#\/]"EW&XD(W,LJL=N[;T1>,8'4<DYT4/>DGT_^W_^1,W+W(R757_&
M/_R1]/VWB;3+OQ!=Z)#=))JEI$L\]N.L:-]TGZUJ5\@_%I&\&?$/XP>(M#:>
MTUJ#0K:1;I)I',(<D/($+%>!STP*[SP[9V?@/XU>#M(\+:Q=W^FZUHL]WJ-M
M->/=J^TQ^5<Y8G:7W..,*<<#BLX+G4?/\]7^2*G[C?\ 72/ZL^@J*^7OB2OB
M?QS\===\/HNG-8:9I45S8PZCKUSI@4MG?.ODQ/YA4X^\<#/2N&^)OB?Q-X3L
M/!"0^.%U76M5TE;3Q'?:)(]Y:)8"4*M^C  (WS%=^!GD_P -*/O)/O\ \'_+
M7M\G9M6;7;_@?YZ=WIU1]M45\;Q:#H5QJOQ7EF\8:G&/#UA;SZ6_]JR*+<")
MF$X&[#DD#KD<]*J6]]XA\4ZOXI\0ZG+J+^(=*\#Z5J<%C'=2Q1Q7DD#M(YC4
M@$Y&<$'ITH>B<NUG\FF_T8E=NW?_ #BO_;E_5C[3HKY#\#Z-XL@L/#VN)XM\
M,>&;?5=.GDN[N?Q-<7<M\3"Q\P0S0HB-&WS'8V %.:K^'EO_  ?%_8&I:F_A
M_7M9T&1[;Q1!XB^W:/>E"H:Z<R?/"6W @A0N'XSBFTTVNJ_/7_+U\MQ)W2?1
M_EI_GZ>9]B52M]8L[K4KJPBFWW=J%::/:1M##*\XP<^U>!_ 2=_"WC]_#.J6
M&H6.L76DB\#P:U_:>FW:*R@SHS?O$<E@<$*I!XKAOCSJ.I7'Q&\2Z;%J^H6=
MM)K&AP8M;EX]B/$V\+@\;N^*;7O1BOM?YV_,2>DF^FOX7_(^PJ*\0^#T#>%_
MC-X_\*6=S=2:':6ME=V]O=W#SF*1]X<AG);!P.,T4NB:ZCZM/H='\1/A?J>N
M>--'\7^&[ZPLM=L;9[*1-3MVFM[B!CNVL%(8$')!![FL#Q?\ ]4^*.GZ1I/C
M37X;_0H&EN+RQL;;[,)YR,18V_P1G+#.22%)/%>O7.MV%GJ5II\]Y!%?W89H
M+9Y ))0N-Q5>I R,GWJ[4VTMT_K]=?4J[O?K_7Z:>A\IZ3X+^)6E_'!=/M_$
M-E<:A;^%8+2XU2\LI&AN%$TH5C@C]Z!@]<9/2O1O!/[/">"_%GAS4X]36ZM=
M-TJ\L;B*6/Y[B6XE61I,] ,J>,=Q7LU%5>ZU\_QYO_DF3;MMI^%O\CQCP%\'
MO%OP_M[+0-.\0Z7'X4L9F:V8Z?OOQ"22L+.V4P,XR%S@#FJ<_P !_$6O>.=%
MUS6]8T8OHUW)=VVI:=IWD:A+E658Y6SL*#<,@*,[1FO<ZJ:KJ]CH.GSW^IWM
MOIUC NZ6YNY5BBC'JS,0 /K2OJGU'O==SPJX_9W\0>(O$,.K:_JVB&]M+2YM
MHK_2M/-O<7?FKMS<$':0.NU0!G-:G@/]GZ]\'MKYEUB"Y_M/P[;Z(NR%EV-&
ML@,AYY!\P<>U>U(ZR(K(P96&0P.013J32<7%[/3\_P#-CYG=/^NC_1'Q[K'A
MFY^!$)TC3/$(M-6N?#L&FW9N=+EEAOGCC\M&MF4_+)@ $-Q7=ZGX9U70_P!B
M'5-&O+>;^UD\,7*O!MS)O9';&!_%R./6OH>J.JZW8:''!)J%Y!9I/,EO$9G"
M^9*YVJBYZDD\ 4YMU(RB]Y?\'_,4;0G&2^S_ ,#_ "/ ;3X%^)_B+X7TN?Q3
MX@LY9;71GL]-2WM638TJ -)-D_,V !A<#VJM=_LM:^EGK%E9Z[I$D.KZ-!I4
MUY?6#2W-KY<!B/V=LX56SG!!QDXYKZ)T_6=/U=[E;&^MKUK64P3K;S+(89!U
M1\'Y6'H>:N4YM3OV?ZW?ZBA>"2ZK_@?Y'AO@C]GG4/"UOXC2XUFVN'U;0[;2
M5,<+*(VBA$9<Y/(.,XK0^&WP4U?X=>*-#U&+5K.[M+?P_#HE]$\#AW,3,R21
M'.%R6.0V>*]BHJG)N7-U_P"'_P#DF)12CR+;_AO_ )%'C7CGX+>(-4\8>(]9
M\.:[8Z;%XCT]+#4$O;9I70*NT/$00 <>N157X=?L]7G@=M6,NL070O?#-MH"
M[(67:\0E!D//0^:./:O;Z*SLN5QZ/3\_\V7=W3_KI_DCYXA_92-SHFEZ9J.M
M12QV7AZ/1Q)#"0WFI)O649)XSCBN.\7?"?Q;\0?C5)X?\5ZM;S"Z\'S16U[I
MUH\<$$B7EK(A;<3EF:-21G&!P*^M994@B>65UCC0%F=C@*!U)-9FF^+-%UB2
MUCL=6LKJ6ZA:YMXXKA6>:)6"M(J@Y902!N''(]:OF;GS/S_%2U_%OY"VC;T_
M!K_)'B]U^SIKOC+6]3O_ !EKUA=K>Z)_8X@TVU:)8L-E9 6).>A.>]=O\/?!
MWC30;RS77]<TBZTZQM?L\<6FZ?Y4MR1@"29V)(8 =$P"2<CI7H]%).W]>O\
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M)Z\R]?Q3_-(\R\+?#WQ]I5G#8W?BC28K6TM6M[>6QTM?.E;;A'E,FX9''"@
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M\JIC,14^*;+M[K6H:E.9KJ]N+B4]7DD+$TW3YY&U"US(Q_>KU8^HJI5C3O\
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M=3I]RB7JH#DVSM&%G'O$7X.>E<)H'[7VFWTG@DW^CWMK;^(8+R1V2SNGFC>
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M78Z1P$[8S&/FRH!^4YKZ)\0^!=#\5ZCIE_JE@+F\TUV>UF$CQM&6^\,J1D'
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M#%)\F]CRQ .,GDXKJM!^#G@[PSJ-E?Z;HR6UU9/*]L_GRL(3("'VJS$ ')X
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M#'::->&_L(A+)B"?.=X^;)//0Y%8/B#]EGX5^*K&.SU7P?:WEM'=3WRQO/,
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MH *L:=_R$+7_ *ZK_,57JQIW_(0M?^NJ_P Q2>PUN?K7X?\ ^0#IO_7M%_Z
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MP6LT,.N^%929H=Q4^5)#D!T8J#\V1E>G->VT5<I.>KWNW\VK"24=MK6_%O\
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M.T8&3FNBNM N?"_C;QCX>U_X*ZI\0=;U_6HK_2M<6,16HB^0KYEX/GM]A7.
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M_$S1];\8^*/B5K%AX<U@6NJ^";9+9&T^56:3J8@I7.\=UZCTK&?X*ZCHNM_
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ML[3PCJ^E>$(+(I_:'B?PW;Z5J E# +&'A;$R8!.<#IUKZ[JI)))KJ3%MMI]
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MY+^U/_R)VG?]?7]*]:\/_P#(!TW_ *]HO_0!7DO[4_\ R)VG?]?7]*^)PO\
MO$?4_0\9_NL_0^6Z***^O/A@HHHH **** "BBB@ HHHH 4'!R.M>S_"'X]7/
MAIX=*UV1[G2SA8YR<O!_B*\7HK&K2A6CRS1O1K3H2YX,_0>RO8-1M8KFUE2>
M"50Z2(<A@>]3U\?_  >^,=UX!OELKYWN=#F;YT)R8#_>7V]1_D_6^G:C;:M9
M0WEG,EQ;3*&21#D$5\KB,-+#RL]NY]GA<7#%1NM'U19HHHKD.X**** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@#EM<^&VA>(O&>A^*KVWD?6-&21+.59654#_>RHX/3O74T44;*P=;
MA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<I/\,M!N/B1;^.GM
MY3XBM[!M-CG\YM@@9PY&SIG('-=711L[_P!=@Z6_KN%%%% !1110 4444 %%
M%% !7'>(/A5H7BKQ?I7B/51>7MWI9WV=M+=.;6*3!'F"'.W?@D;L9KL:*.MP
MZ6"BBB@ HHHH **** .5\'_#/0? NL>(=4TBWDAO->N1=WS/*SAY , @'[O'
M85U5%%'9!UN%%%% !1110 4444 %%%% !1110 4444 %9WB'Q!8^%M&NM4U*
M=;:RMD+R2,>@']:T&8*"20 .23VKX$_:N^/[?$+79/#FB7!/AVQ<J\L9XNI!
MU;_=';UZUUX7#RQ,^5;=3AQF*CA*?.]^B.-^/WQRU#XQ^)68,T&A6K%;.U!P
M"/[[#^\?TKRJBBOM*=.-**A%:(_/ZM6=:;G-W;"BBBM#(**** "BBB@ HHHH
M **** "K&G?\A"U_ZZK_ #%5ZL:=_P A"U_ZZK_,4GL-;GZU^'_^0#IO_7M%
M_P"@"O)?VI_^1.T[_KZ_I7K7A_\ Y .F_P#7M%_Z *\E_:G_ .1.T[_KZ_I7
MQ.%_WB/J?H>,_P!UGZ'RW1117UY\,%%%% !1110 4444 %%%% !1110 5ZM\
M$_B_+X'U!=-U&1I-%N&P<G/DM_>'MZUY31652G&K%PEL;4JLZ,U.#U/T+AFC
MN84EB=9(W 974Y!!Z$4^OG']G?XLFWEC\+ZM-^Z;_CRFD/W3_P \R?3T_+TK
MZ.KY&O1E0FX2/N,/B(XFFIQ"BBBN<Z@HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M>E,KZ ^8"BBB@04444 %%%% !1110 445-9V<^H7,=M:PR7%Q(P5(HE+,Q]
M!UI#W(:Z'P-X.UGQGK]I9Z-I\]_/YBDB)"0H!Y)/:O??@]^Q7J_B/R=3\92M
MHNGG#+81X-S(/]H]$'YGV%?8O@WP%H'P_P!+33]!TV'3[=1@E%R[^[,>3^->
M1B<QIT_=IZO\#W<)E56K:=7W5^)JZ1;O::3902#$D4"(P]"% ->9?M&^'-1\
M1>#K<:=:O=O;S^9(D8R0N.N*]7SBEZU\S3J.G-370^OJTE5INF^I^><D;Q.4
M=2CKP588(IM?:'C[X,>'_'B/+)!]@U$CB\MU )/^TO1OY^]?-/CWX.^(/ 4K
MR3V_VS3P?EO+<%EQ_M#JOX\>]?3T,93KZ;/L?'XG 5</KNNYPM%%%=YYH444
M4 %%%% !1110 4444 %%%6+&PN=3NH[:T@DN;B0X6*)2S$_04M@2OHB*&9[>
M5)8V*2(0RLIP01WK['^"?Q"/CSPJOV@_\3"SQ%,?[_HWXUYA\//V9KF\\N]\
M42_98>&%C 09&'^TW0?09_"OH+0_#VG>&K%;33+.*S@7^&-<9]R>I/UKP,?B
M*-1<D=6NI]/EN&KTI<\M$^AHT445XA]"%%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MF$_4_=_7% 'T/1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MFR!%5Y(@SD#&X^IKB/H"CH_PZB%Q]MUF7^T+HG<(C_JT_#O79(BQJ%50JC@
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M?H1D5/7(?"C4O[1\#Z>2?GA!A/\ P$D#],5U] !1145S.MK;RS,"5C4L0.N
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M:W.F6F?M%P24$7^\& (_+FE*E.-[K1?\,.-:G*R35WTZ]SJJ*Y+P=\6?"/Q
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M7]$>_45Q4/QG\%W'B0:!'KT#:P;@VOV01R;_ #?[OW<?CT]ZC;XW^!5\4?\
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M/Q;\87/CR!'TV_T-(=%DN8]Z,P4^9''Z.6YQUKQ[X;> I/'UE'I]C%)!=+X
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MN&9YWTJU:1G^\6,2Y)]\UTE%).R:]/PO^=Q-7:?:_P"/+^5OQ"BBBI&%%%%
M!1110 4444 %?G_^TI<?:/C-XA;!&UT3GV11_2OT K\^?VBO^2Q^)/\ KN/_
M $$5V87XV>#G'\"/K^C/-Z***]0^0"BBB@ HHHH **** "OTH^&?_)/?#O\
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MD8/H17FFB_'/XHG4O"J26MO=S:AXMU336LH[Q"MS%%%(5B9S;@Q+&54[E!+
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MVO;\_P#(^M**\1^&O[2S>)O$%QH7C7PE=?#?5EM&U"!-4O8I89K8=7\T;0I
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MOAGPWX"OVTB+PIH6IQWPUB&=VNKN**4RPQ& H%C.[;N?>V0O"C/!]E7WTO\
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M+J%XX8E7J0ID(WGV7)KQ_P 6_M'^*9M4UFZ\,Z'+=:&/"4>M6<KRPH8V<O\
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MOB-\.=?TK5-*@T/4A#H#:5/;7%[)$/--U-*KAA&>%$@XQSDCC&:TE\5UY_\
MM]O_ &TQBO=:?:/YPO\ ^W'HG@_X\Z)XVURQTW3[6YW76G2:AYD@ $>QMK1L
M.H8&N(MOVCK[6_&WA::TTB:T\)7EAJ=S>2SRQ!E-M,(V?[V<+M)QWWC'0U'X
M?^!?BSX=:IHNKZ&VF:U?BPN+/4(KR=[9 \K[S)&0KY /&TCD=Q6;HO[.GBFS
MT#PQI]^^FW30V6L:=J1BN'C"I>3^8LL7R'<0 ,H<=>O'(]-5Y_?[UOE\.O\
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MME>>)#.J&:1=21Y+H2R0_9BGS ,6(E#;=H'!ZU,=7&/73_VS_.7];G1OI?\
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M#CS+FY<(B9(49)X&20/QKXWO+_7+7P/X\\=#Q3X@;6=(\2O%8Q'59_LL40E
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M_P#H+UT=I_J$^@KG/B""=/T['/\ IT?_ *"U=':_ZA/H* .;^*/_ "(6K_\
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M))&VU?NJY1AO4>C9%;T/PE\)VWBNV\1P:/';ZM;:=_9,,L,CHD=KG(B6,,$
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MUZ_110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% 'P!_P %(_A7K:7>F^.+:ZNKO0B%
MM;JV+EH[63^!PO0!LXSZX'>OA.OW7\3^&M.\8^'M0T35[9+S3;Z%H)X7'#*P
MP?Q]Z_'O]HKX$:G\!?'USH]R'GTN4F33[UEP)HL\9[;AT(H \LHHHH ****
M"BBB@ HHHH **** "BBB@"2VN9K.=)[>5X)D.Y)(V*LI]01TK[#_ &7/VV_&
M.G>)M%\(^)/^*BTZ]G2UBN96Q<09.!S_ !#V-?'%=U\"_P#DL7@__L)0_P#H
M5 '[8UY[\:OB=)\+?"\=_!:"[N9Y/)C#-A5..IKT*O!/VP?^1&TS_K\_]EH
M^9O&GQ#U[Q]?M=:Q?//S\D*G$:>P6N;HHH **** "BBB@ HHHH **** "BBB
M@ HHHH 5':-PR,58'(93@BOMG]FF/Q+)X&%WK]Y+/!.P-E'.,NL8[Y]#VKYV
M^ WPCE^)/B-9[J,KH=DP:X<CB0]HQ_7V^M?<5M;QVEO'!"@CBC4(B*,  =!0
M!+1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !7FOQZ^"&C_ !U\#7.B:BBQWB O
M97F/F@EQP?H>XKTJB@#\.?B-\/=:^%OB^_\ #FO6KVM_:OCY@0LB?PNI[J>Q
MKFJ_8#]IO]F?1_V@O"^UMECXELT8V&H@<@_\\W]4/Z=:_)[QSX&UKX<^);S0
M=>LGL=1M7*.CCAO1E/<'UH P**** "BBB@ HHHH **** "BBB@ KNO@7_P E
MB\'_ /82A_\ 0JX6NZ^!?_)8O!__ &$H?_0J /VQKP3]L'_D1M,_Z_/_ &6O
M>Z\$_;!_Y$;3/^OS_P!EH ^0J*** "BBB@ HHHH **** "BBB@ HHHH *ZOX
M;_#O4OB3XCATRP0B/.Z>X(^2%.Y)JOX#\!ZI\0M>ATS3(BS,<RS$?)$O=B:^
MZ/AK\-]+^&GA]-/T] TK8:XN6'SS/ZGV]!0!I>#O"&G>!] M=(TN$16T"X+'
M[SMW9CW)-;=%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 0W=Y!I]K+<W4T=O;Q*7DEE8*J =
M22> *9IVHVFKV4-Y8W,-Y:3+NCG@<.CCU##@BN=^*W_)-O$G_7C+_P"@UX-X
M>\8^,;#2OA'X9\+:A:V(U?3I_.:[MUE5=H)#^O')P#SWKII475B[/6_Z2?Z'
M)6K^QFDUI9O[G%?^W'U#--';Q/+*ZQQH,L[G  ]2:(9H[B))8G62-QN5T.01
MZ@U\I>,/%GC3Q)\(/B1HNMZM:S:CX?O?L\U[#:J@NH>.-HX4\CD>E/\ $OQ:
M\7_#3P?X)\.IK EU/4K7[0=3MM*$[PP*B[$6$<,><$FM5A)26DE=O3TM>_W&
M,L;&+O*+2L[[:-.UM^Y]0:MK.GZ#:?:M2O;?3[;<$\ZZE6--QZ#)(&33+;Q!
MIEYJ<NG6^HVL^H11B:2UCF5I40]&*@Y /K7RUKWQ+UKXA_ S41KMO*M[8ZO;
MPK=R6AMOM*;@0^P_=/L*Z*#Q0/!7Q;\?ZZ8O._L_PK#<"/\ O%2"!^='U5Q4
MN9ZJ_P""3_47UQ2<7!:.V_FVG^1])T5\E_#?]I#QCJ7BG26U,W&JZ7J1/FVZ
MZ,;=+,$9!28??';)KK_"/C#XK?$9KGQ-H-]I,>BP:BUHFA7$ 4RQHV&8S8+*
M<'.*)8.I!VDTOZM_73S'#'TJBO!-^77:]_ZU\CW\7D!NC;":,W"J',6X;POK
MCKBIJ^9?#=GXJM_VD?'=TNNP)';VD<]Q#]E4^9$4)CC![%>.>]7K[XQ>*H/V
M>K;Q2M_&-;?4TMC/]GCP4,X0C;C'W>^*GZLWR*+^+E_\FV*>+45-RBTH\WS4
M5=GT95"ZUW3;'4K/3KG4+:WO[S=]FM99E66;:,ML4G+8')QTKYW^-WQF\5>&
M/$%Y!H_B.PTV&QMDE%E#9?;)[AB 2),C$8]ZD'BF?QM\3/@9KES&L5Q>VM])
M(J# #>20<?E50PLI)3;T=_\ TEM?D*>,A&4H16J_S2?YGT!KWB;2/"MF+O6=
M4L])M2VP37LZPH3Z98@9JKX>\=^&_%LTL6AZ_IFL2Q+ND2PNXYB@]2%)Q7DO
M[7F/^$)T3-E_:0_M6'_0^/WW/W.>.:YWP7X&U36?BWX>U_3OARGPVTS28YC=
MX,:F[WH55=L8 .#ZTJ="$J3J2=M^W1)_C>V@JV(G"M[.*OHGUZMKIHK6ZGTS
M17SA\-_B9X]U+PUK?C/6]8M;C0-*-RG]GQV:++.5)"DN , 'C ZTR'XD_$KP
MOI7AWQMKNI:;J'AO6;J&&32(;54>U24X5ED'+$>A]:/JLN;ENNGWO9>I;Q<4
MN;E?7[EN]]E]_D?25%?.]YXO^)GBSXA^--)\.:_8:9I^D*DL1N;))7Z9V#CO
MZG-<UXD_:@\1-X.\)PV@&G:YJ;W$=Y>6]E]K,9A(!,<71MV1].:4<+.=N5J[
MM^*O^@2QE.'-S)I*ZOTNG8^K:AN;R"R5&N)HX%=Q&ID8*"QZ 9[GTKY?3X_^
M,Y_@_K.H?/;ZYI]]#;PW]QI_DBYC=OO&)@0#]*I_&#1OB+)_PKR75O%=E)>W
M>M(UMY.GJJVTC("A(_B"_..>N1Z5<<'+G49R2UM^"?ZF<L=%4W.$6]&_TU_X
M%SZRHKPG_A;&M_#_ ,0^,=(\6:E'?FRL5OM.G$"1>8",% % SSZYKTKX7WFM
MWG@#2+[Q+<+/JUS#]HF98UC"AOF5<  <*0*YY4G"//?33\;_ )6U.J%>,Y<E
MM=?E:WYWT-6[\7Z%8:U!H]SK-A;ZM/CRK&6Y19Y,]-J$Y/X"M>O@_P <>.=
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M!+F/EH+A1B:W?'#HW4']#T/%?F#^T+^R3XK^!=]+=")]8\-,Q\G4H$SL'82
M?=/OTH \*HHHH **** "BBB@ HHHH *[KX%_\EB\'_\ 82A_]"KA:[KX%_\
M)8O!_P#V$H?_ $*@#]L:\$_;!_Y$;3/^OS_V6O>Z\$_;!_Y$;3/^OS_V6@#Y
M"HHHH **** "BBB@ HHHH ***.M !78?#7X7ZQ\3=96TTZ(I;(1]HNW'[N)?
M<]S[=:[+X1?LZZMX\EBO]5632]$R#N88DG'HH[#WK[!\->&--\(Z3#INE6J6
MEK$,!4')/J3W/O0!D_#OX;Z1\-M$2PTR+,C &>Y8?/,V.I]O;M75T44 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_(\6\2?LUQ:WXGUC5+7Q3J&E6NL1>7?6<$*-YIQC(<\@>P_.M71/@7'H^H>
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M-K;:-'KFG/JZ\M8+=1F<?5,[OTKYE^'?BC4K+X@-X>\(>,+[QSX=FT^5GGO
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M0?!=/%]_H?VC69[-KRWTFQA>)I<J"B .S')/\6<$<XHULWV_X/\ DPZI=_\
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MGM4>F?M#Z%K.B6.IV6B^([B/4,-90)IC>;=)MW%XQGE0.I)%-73YNO\ G?\
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MTQ;&,(.IKV[P9X[T3X@:,VJ:'=M=6B2O!()89(98I%.&1XY%5T8=U8 U\X^
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MP3\%M,@L]%;5?$FFZ/#%'I*W$<?FW"Q*NSS&;8!NZG., XS7=T4-WBXK2_\
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M:2$+$N]G=W8E5 !^52 ,\"M.5IM?U>Z5OQ1.ZO\ ULW?_P E9];45\X_LO\
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M:J^FC4;&YTNSDB &_;(KP;W9MO4;3EAV%8EU\8-5U30;)I==T#Q$PU_2K?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %<+\=KN?3_@OXYN;:>2UN(=%NWCF
MA<JZ,(6(8$<@CU%=U7-_$CPK+XX^'_B/P]#.EK-JNGSV:32 E4,B%0Q Z@9K
M*JFZ<E'>QM1:C5BY;71\Q0R'P9I?@"Z\-^*-2U>X\0^';J;5#<7[W'GJMN&%
MP%9CY9#$C*X';J*J_#K01>?\*CTK5-=UHZ=XIL[BZU.6759U:]N(E8Q1!]^4
M'4X0J3MKZ+^'/P5\,> /#MM90:+IPOVL8[.^NX;<*;K"!6)[X//'O6WJ/PV\
M+:OX;M_#]YH%A<Z);X\FPD@!BCP<C:.U=4VN>36JO^%Y:?BFO0Y:?-R13TTU
M]=-?71GR]I&M7VL?$*#X?7?B#4)? 4/B"]LX+Y;QTEF$<<;);&X!#-M9Y%SN
MW'9R3@UC>%G7PCX@MK71]:NY=,'Q/AMY;IKICYD9@QLD?/SC=A?FSG ZFOKB
MX^&7A.Z\,1>'9?#VGR:'%C98- OE+]%JO#\(/!-OX>N]"B\+Z7'H]W()9[);
M91%(XQAB.YX'/M41?*T][6^=G%W?KROON7)<R:VO?Y74EI_X%^'I;YH\<>.=
M4?QUX^T^VUZZAT>X\5:=IMS<07+8MH&MT\Q4;/[O+#!(QR3WK?\ &/PY\*:7
M\6/A=8V&NZAK'D>()@]K/K4D[6)^Q3.L?#;@"44_.22,C."0?>['X4>#M,TJ
M]TVU\-:;!87H5;FW2W4),%4*NX=\  ?A44'P>\$6VDVVEQ>%M+CT^VN1=PVZ
MVZ[8YATD'^T/6B#4.7RM^"2_1M>H3][F\T_QO_G^!\T_#G4+OQ[XSTSPMXCU
MO48] DGUBY5$OI('N9DO955/-5@V$0+A01U]*I^$IK_Q]\5/!WAC4?$&K7OA
MJ"]UJUB>"^DA-[;PQQ-&'D0@MM8L-P.?EZ]:^I]1^$_@W5M'&E7GAK3;G3A.
M]R+:2W4H)78L[X]2223[U?LO OA[3KG2[BUT:RMY]+C>&QDCA :V1QAU0]@0
M!FE&RM?L_GY_+;T^X<KMMKJ[^GE\]_4\L^ 4E_XC^&/BK1+C4+J<66JZCI5I
M<33,TR1)*Z1@R9W$J .2<\5X/??%_P 6:YX;N[/3;V\M]5^'>B7[:K,K.2;K
M/D0,P_CQ$SR_-D94'M7VOHOAW3/#D5Q'I=A!81W$[W,JP(%#RN=SN<=2222:
MJZ;X)T#1[[5[VQT>SM;O5V#:A-%" UT0, R'^+@D<TM7OV_&UK_BWZV&FEMW
MO\F[V^ZR/FCQG;P>![K1K/PYKU]J=MK_ (>O9M2@N;Y[M9@L(*W W,=F22/E
MPI]*S_@GXFGTRS\3176JRVMG;?#ZQN8(Y;@JD1VSAI$!. <[<D>U?2VB?"CP
M=X;6_72_#6FV(OU*70AMU7SE/4-ZBH]1^#_@G5QIHO?"VEW(TV+R+,26RGR(
M_P"ZOH..E*7O1E%=5;T^+\N96].@HZ.+?3\=8O\ &W_#GR/X$BO?'.GW#:GK
MVM2+9> [/4(1#J4T?^D;2?-)5@2>._7OFKZ>(?$7P_TSP'KVB:GJ>J:YK_@_
M5+V]2\NGG6XN(K=)(G$9.U2I_N@9'7)-?6NG?#?PMI"2)9:!86J26BV#B*!5
M#6Z_=B/^R/2IH/ GAZVETF6+1K*.3287M[!EA&;:-P%9$_N@@ $>U:5&I.3C
MI>_X\_\ \DON\D**LXMZVM^'+_D_O]3YX^#&D^+X]9\$ZZ-7T&TL-4A,MZ'\
M5W-_/JP90<I;RVZ(C*><1L .F*^I:Y7P]\*_"'A+5YM4T;PYIVFZC-GS+FV@
M"NV3D\UU5$I)[?U_7](F,6MW_7]>H4445!84444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $=Q;Q74$D,\
M:30R*5>.10RL#U!!ZBL67P!X8G@M(9?#FD20V9S;1O8Q%8#G/R#;\O/I110!
MNA0H    X %8UWX+\/:AJJ:G=:#IESJ28VWDUG&\RXZ8<C/ZT44>8>1S.J?!
MW2==^)DGBW54M-4B;3X[%=.O+))40J[,) S$\_-C&WMUKK-6\+Z-KUC'9ZGI
M%CJ-G'@I;W=LDL:XZ85@0***.EOZ[AUO_78DM_#^EVDEL\&FV<+VL9B@:.!%
M,*'JJ$#Y1["J(\ >&!=R70\.:0+J6197F^PQ;W<'*L6VY)! (/J***.MP\B>
M7P?H,R7JR:)ITBWQW72M:1D7!]9./F_'-8GBCX8:7KWA(^&;**WT/1IIHVNK
M:PMEC6:(,&:+"X"A\8)P>"?K110!U\,26\211J%1 %51V I]%% ;!1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
40 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>plx-20230331x10q007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plx-20230331x10q007.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #;!#@# 2(  A$! Q$!_\0
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M_#3PZ-7N;.:]C,RPB*%@&R<\\_2DW;<:5]CK**\Q\3_'C2?#=KX:F%E<7O\
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M^%@+X<CM9F\,W]VFK7%RJGRU91\T>0,#+8.#UKW:BE'W;>7_  /\DP>M_/\
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MX 'I0!TM%<]YK_WV_.CS7_OM^= '0T5SWFO_ 'V_.CS7_OM^= '0T5SWFO\
MWV_.CS7_ +[?G0!T-%<]YK_WV_.CS7_OM^= '0T5SWFO_?;\Z/-?^^WYT =#
M17/>:_\ ?;\Z/-?^^WYT =#17/>:_P#?;\Z/-?\ OM^= '0T5SWFO_?;\Z/-
M?^^WYT =#17/>:_]]OSH\U_[[?G0!T-%<]YK_P!]OSH\U_[[?G0!T-%8,,CF
M9/G;[P[UO4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%9VJNRF/!(^AH T:*Y[S7_OM^='FO\ WV_.@#H:*Y[S7_OM^='FO_?;\Z .
MAHKGO-?^^WYT>:_]]OSH Z&BN>\U_P"^WYT>:_\ ?;\Z .AHKGO-?^^WYT>:
M_P#?;\Z .AHKGO-?^^WYT>:_]]OSH Z&BN>\U_[[?G1YK_WV_.@#H:*Y[S7_
M +[?G1YK_P!]OSH Z&BN>\U_[[?G1YK_ -]OSH Z&BJ&E,623))Y'4U?H **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHI#T- "T5SWFO_ 'V_
M.CS7_OM^= '0T5SWFO\ WV_.CS7_ +[?G0!T-%<]YK_WV_.CS7_OM^= '0T5
MSWFO_?;\Z/-?^^WYT =#17/>:_\ ?;\Z/-?^^WYT =#17/>:_P#?;\Z/-?\
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MW_Q5'_"T?&?_ $-VN_\ @RF_^*H^HR_F#_B).%_Z!Y?>C])**_-O_A:/C/\
MZ&[7?_!E-_\ %4?\+1\9_P#0W:[_ .#*;_XJCZC+^8/^(DX7_H'E]Z/TDHK\
MV_\ A:/C/_H;M=_\&4W_ ,51_P +1\9_]#=KO_@RF_\ BJ/J,OY@_P"(DX7_
M *!Y?>C])**_-O\ X6CXS_Z&[7?_  93?_%4?\+1\9_]#=KO_@RF_P#BJ/J,
MOY@_XB3A?^@>7WH_22BOS;_X6CXS_P"ANUW_ ,&4W_Q5'_"T?&?_ $-VN_\
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MZ'/Q!_X-)_\ XNCZC+^8/^(DX7_H'E]Z/U#HK\O/^%L^./\ H<_$'_@TG_\
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M+^8/^(DX7_H'E]Z/TDHK\V_^%H^,_P#H;M=_\&4W_P 51_PM'QG_ -#=KO\
MX,IO_BJ/J,OY@_XB3A?^@>7WH_22BOS;_P"%H^,_^ANUW_P93?\ Q5'_  M'
MQG_T-VN_^#*;_P"*H^HR_F#_ (B3A?\ H'E]Z/TDHK\V_P#A:/C/_H;M=_\
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MXB3A?^@>7WH_4.BOR\_X6SXX_P"AS\0?^#2?_P"+H_X6SXX_Z'/Q!_X-)_\
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M]/O.AD^-?B&\\!:5KNFZ/I;7=TLKRVMW>E"JH2#M4 LQXK$7XF7?B;QS\/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% "@D$$'!%?HU^SIXP'C3X9:+=LX>X@B^RS?[R<?RQ7YR@9-?HE^
MS9X/_P"$+^&ND6SC;<W,9NYL_P!Y^1^F*\[&VY%W/UCPZ]M_:%7E^#EU];Z?
MJ>MT445XI_1 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M%'_"%Z__ - 6_P#_  '?_"OU4HH^O2_E#_B&N'_Z"9?^ K_,_*O_ (0O7_\
MH"W_ /X#O_A1_P (7K__ $!;_P#\!W_PK]5**/KTOY0_XAKA_P#H)E_X"O\
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MZ*/KTOY0_P"(:X?_ *"9?^ K_,_,U?!NO-TT:^/TMV_PI?\ A"]?_P"@+?\
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M]^&_PK]-Z*/KTOY1_P#$-:'_ $%/_P !7^9^9/\ PBNL_P#0*O/^_#?X4?\
M"*:U_P! F]_[\-_A7Z;44?7I?RA_Q#6A_P!!3_\  5_F?F5_PBFM?] F]_[\
M-_A1_P (EK?_ $";W_OPW^%?IK11]>E_*'_$-:'_ $$O_P !7^9^97_"):W_
M - B]_[\-_A2_P#"(ZW_ - B]_[\-_A7Z:44?7I?RA_Q#6A_T$O_ ,!7^9^9
M?_"(ZY_T"+W_ ,!V_P */^$1US_H$7W_ (#M_A7Z:44?7I?RA_Q#6A_T$O\
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M -\G_&K%% %?%U_>A_[Y/^-&+K^]#_WR?\:L44 5\77]Z'_OD_XT8NO[T/\
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MU_>A_P"^3_C1BZ_O0_\ ?)_QJQ10!7Q=?WH?^^3_ (T8NO[T/_?)_P :L44
M5\77]Z'_ +Y/^-&+K^]#_P!\G_&K%% %?%U_>A_[Y/\ C1BZ_O0_]\G_ !JQ
M10!7Q=?WH?\ OD_XT8NO[T/_ 'R?\:L44 5\77]Z'_OD_P"-&+K^]#_WR?\
M&K%% %?%U_>A_P"^3_C1BZ_O0_\ ?)_QJQ10!7Q=?WH?^^3_ (T8NO[T/_?)
M_P :L44 5\77]Z'_ +Y/^-&+K^]#_P!\G_&K%% %?%U_>A_[Y/\ C5[1Q/\
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MZ%D?^!?_ -C1_P -C'_H61_X%_\ V-?-5%'U>GV%_:6*_G_!?Y'TK_PV,?\
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M:X_Z;G_XFO,06]3_ -\4V0L".6_[YH]G'L/ZU5_F/2!\9'/_ ##8_P#O\?\
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M_$UP08^_Y4\,??\ *ER1[#^L5>YW8^)SG_EP3_OZ?_B:4?$U_P#GQ7_OZ?\
M"N%#'U/Y4X,?4_E1R1#ZQ5[G=#XEN?\ EQ7_ +^G_"E_X62__/BO_?T_X5PP
M8^_Y5(&/O^5')$?UBIW/0++XIO;*P_L]6R?^>I_^)JT/BTY_YAR?]_C_ /$U
MYU&>O^%/!^OY4N2/8/K%3N>B?\+8D_Z!R?\ ?X__ !-'_"V'_P"@<G_?X_\
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M_P"7-?\ OX?\*7_A.V8?\>B_]_#_ (5R :GAL4<J'[:?<W!XC8_\L!_WU_\
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MY;_]_5_QH_M:Q_Y_+?\ [^K_ (T 6Z*J?VM8_P#/Y;_]_5_QH_M:Q_Y_+?\
M[^K_ (T 6Z*J?VM8_P#/Y;_]_5_QH_M:Q_Y_+?\ [^K_ (T 6Z*J?VM8_P#/
MY;_]_5_QH_M:Q_Y_+?\ [^K_ (T 6Z*J?VM8_P#/Y;_]_5_QH_M:Q_Y_+?\
M[^K_ (T 6Z*J?VM8_P#/Y;_]_5_QH_M:Q_Y_+?\ [^K_ (T 6Z*J?VM8_P#/
MY;_]_5_QH_M:Q_Y_+?\ [^K_ (T 6Z*J?VM8_P#/Y;_]_5_QH_M:Q_Y_+?\
M[^K_ (T 6Z*J?VM8_P#/Y;_]_5_QH_M:Q_Y_+?\ [^K_ (T 6Z*J?VM8_P#/
MY;_]_5_QH_M:Q_Y_+?\ [^K_ (T 6Z*J?VM8_P#/Y;_]_5_QH_M:Q_Y_+?\
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MON1P_P#PH/P!_P!"U;?]_)/_ (JC_A0?@#_H6K;_ +^2?_%5W'VZV_Y^(O\
MOL4?;K;_ )^(O^^Q1SS[L/JU'^1?<CA_^%!^ /\ H6K;_OY)_P#%4?\ "@_
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MUK_W]E_^*H_X9U^'/_0K6O\ W]E_^*KO/[6L?^?RW_[^K_C1_:UC_P _EO\
M]_5_QHYY]V'U:C_(ON1PT'[/GP\MIHY8_#%LLB,&5O,D.".G\5;'_"JO"?\
MT!8/^^F_QKH?[6L?^?RW_P"_J_XT?VM8_P#/Y;_]_5_QHYY/J-4*2V@ON1SW
M_"JO"?\ T!8/^^F_QI?^%5^%/^@+!_WTW^-=!_:UC_S^6_\ W]7_ !H_M:Q_
MY_+?_OZO^-+FEW*]E3_E7W'/_P#"K/"G_0%@_-O\:/\ A5GA3_H"P?FW^-=!
M_:UC_P _EO\ ]_5_QH_M:Q_Y_+?_ +^K_C1S2[A[*G_*ON,#_A5WA7_H#0?F
MW^-'_"KO"O\ T!H/S;_&M_\ M:Q_Y_+?_OZO^-']K6/_ #^6_P#W]7_&CFEW
M#V5/^5?<8/\ PJ_PM_T!H/S;_&C_ (5?X6'_ #!H/S;_ !K>_M:Q_P"?RW_[
M^K_C1_:UC_S^6_\ W]7_ !HYI=P]E3_E7W&$/AAX7'_,'A_[Z;_&C_A6/A;_
M * T'YM_C6[_ &M8_P#/Y;_]_5_QH_M:Q_Y_+?\ [^K_ (T<S[A[*G_*ON,+
M_A6/A?\ Z \'YM_C5#4_AOX:B*;-)A7/NW^-=9_:UC_S^6__ ']7_&L_5-2M
M',>VZA;Z2 _UHYI=P]E3_E7W'*_\*]\._P#0*A_-O\:7_A7WAW_H%P_FW^-;
M7VZV_P"?B+_OL4?;K;_GXB_[[%'-+N'LJ?\ *ON,7_A7WAX?\PN'\V_QH_X5
M_P"'O^@7%^;?XUM?;K;_ )^(O^^Q1]NMO^?B+_OL4<TNX>RI_P J^XQO^$ \
M/C_F&1?FW^-'_" ^'_\ H&1?]]-_C6S]NMO^?B+_ +[%'VZV_P"?B+_OL4<S
M[C]E3_E7W&./ 6@#_F&1?]]-_C1_P@6@?] R+\V_QK8^W6W_ #\1?]]BC[=;
M?\_$7_?8HYGW#V4/Y5]QC_\ "!Z!_P! V+_OIO\ &E_X030?^@;%^;?XUK_;
MK;_GXB_[[%'VZV_Y^(O^^Q1S/N'LX?RK[C(_X070?^@;%^;?XTO_  @VA?\
M0.C_ .^F_P :UOMUM_S\1?\ ?8H^W6W_ #\1?]]BCF?</9P_E7W&5_PA&A_]
M Z/\V_QH_P"$)T,?\P^/_OIO\:U?MUM_S\1?]]BC[=;?\_$7_?8HYGW#V</Y
M49?_  A6B?\ 0/C_ #;_ !H_X0K1/^@?'_WTW^-:GVZV_P"?B+_OL4?;K;_G
MXB_[[%',^X>SA_*C+_X0O1/^@?'_ -]-_C2_\(9HO_/A'^;?XUI_;K;_ )^(
MO^^Q1]NMO^?B+_OL4<S[A[.'\J&:9X&T*5'+Z=&V"/XF_P :N_\ "!:!_P!
MR+\V_P :GTO4K1$DW74"\CK(!_6KW]K6/_/Y;_\ ?U?\:.9]P]G#^5&7_P (
M'H'_ $#8OS;_ !I?^$%T'_H&Q_\ ?3?XUI_VM8_\_EO_ -_5_P :/[6L?^?R
MW_[^K_C1S/N'LX=D9G_""Z%_T#H_^^F_QI?^$&T+_H'1_P#?3?XUI?VM8_\
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MG_&KW]K6/_/Y;_\ ?U?\:/[6L?\ G\M_^_J_XT7?<.2'8H_\(?HX_P"7&/\
M-O\ &E_X1#1_^?&/\S_C5W^UK'_G\M_^_J_XT?VM8_\ /Y;_ /?U?\:+ON')
M'L4O^$1T?_GQ3\S_ (TO_"):0/\ EQ3\S_C5S^UK'_G\M_\ OZO^-']K6/\
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MW_&CZM6_E%]:H_S'<>6G]U?RH\M/[J_E7$#XL:>?^7.Y_P#'?\:7_A:^G_\
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M^ORC-?.-D\AE4EG)5L+D].G3TK?M[VXBB!%Q(K, 6.\@D_A7I_5M;I_U=/\
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M_P#G]A_[Y-.'PONQ_P OL/\ WR:AXBD_M#>&J_RG%4^/H:[+_A5]W_S^P_\
M?)J&X^'MS:8#7<39]%-3]8I?S#6'JV^$Y=>AI:Z(>"IQ_P O,?Y&E_X0N?\
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M_P"UT_YYM^=)EK8OTUJI?VNG_/-OSI#JR'^!J0R[2CK5#^U4_N-2C54'\#4
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G*** "BBB@ HHHH *MZ7_ ,?7_ 352K>E_P#'U_P$T ;%%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>plx-20230331.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.2.5.9 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/4/2023 7:35:20 PM-->
<!--Modified on: 5/4/2023 7:35:20 PM-->
<xsd:schema xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:currency="http://xbrl.sec.gov/currency/2021" targetNamespace="http://www.protalix.com/20230331" elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:plx="http://www.protalix.com/20230331" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:srt-roles="http://fasb.org/srt-roles/2021-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:attributeFormDefault="unqualified" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:dei="http://xbrl.sec.gov/dei/2021q4">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets" id="StatementCondensedConsolidatedBalanceSheets">
        <link:definition>00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" id="StatementCondensedConsolidatedStatementsOfOperations">
        <link:definition>00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" id="StatementCondensedConsolidatedStatementsOfCashFlows">
        <link:definition>00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails" id="DisclosureInventoriesScheduleOfInventoryDetails">
        <link:definition>40201 - Disclosure - INVENTORIES (Schedule of Inventory) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical" id="StatementCondensedConsolidatedStatementsOfOperationsParenthetical">
        <link:definition>00205 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency" id="StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency">
        <link:definition>00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiencyParenthetical" id="StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiencyParenthetical">
        <link:definition>00305 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementTables" id="DisclosureFairValueMeasurementTables">
        <link:definition>30303 - Disclosure - FAIR VALUE MEASUREMENT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails" id="DisclosureSignificantAccountingPoliciesDetails">
        <link:definition>40101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails" id="DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails">
        <link:definition>40301 - Disclosure - FAIR VALUE MEASUREMENT (Schedule of Fair Value Assumptions) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails" id="DisclosureFairValueMeasurementAdditionalInformationDetails">
        <link:definition>40302 - Disclosure - FAIR VALUE MEASUREMENT (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureRevenuesDetails" id="DisclosureRevenuesDetails">
        <link:definition>40401 - Disclosure - REVENUES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureStockTransactionsDetails" id="DisclosureStockTransactionsDetails">
        <link:definition>40501 - Disclosure - STOCK TRANSACTIONS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSubsequentEventsDetails" id="DisclosureSubsequentEventsDetails">
        <link:definition>40601 - Disclosure - SUBSEQUENT EVENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPolicies" id="DisclosureSignificantAccountingPolicies">
        <link:definition>10101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureInventories" id="DisclosureInventories">
        <link:definition>10201 - Disclosure - INVENTORIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurement" id="DisclosureFairValueMeasurement">
        <link:definition>10301 - Disclosure - FAIR VALUE MEASUREMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureRevenues" id="DisclosureRevenues">
        <link:definition>10401 - Disclosure - REVENUES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureStockTransactions" id="DisclosureStockTransactions">
        <link:definition>10501 - Disclosure - STOCK TRANSACTIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>10601 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies" id="DisclosureSignificantAccountingPoliciesPolicies">
        <link:definition>20102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureInventoriesTables" id="DisclosureInventoriesTables">
        <link:definition>30203 - Disclosure - INVENTORIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureRevenuesTables" id="DisclosureRevenuesTables">
        <link:definition>30403 - Disclosure - REVENUES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20230331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20230331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20230331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20230331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" />
  <xsd:element name="ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <xsd:element id="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" name="ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" name="GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element name="ChangeInOperatingLeaseRightOfUseAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_ChangeInOperatingLeaseRightOfUseAssets" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <xsd:element id="plx_RevenueDisclosureTextBlock" name="RevenueDisclosureTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element name="NatureOfOperationsPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_NatureOfOperationsPolicyTextBlock" substitutionGroup="xbrli:item" />
  <xsd:element name="SignificantAccountingPoliciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_SignificantAccountingPoliciesTable" substitutionGroup="xbrldt:hypercubeItem" />
  <xsd:element name="AmendedPfizerAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_AmendedPfizerAgreementMember" substitutionGroup="xbrli:item" />
  <xsd:element name="ChiesiUSAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_ChiesiUSAgreementMember" substitutionGroup="xbrli:item" />
  <xsd:element name="ChiesiExUSAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_ChiesiExUSAgreementMember" substitutionGroup="xbrli:item" />
  <xsd:element name="ProtalixBioTherapeuticsIncorporationMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_ProtalixBioTherapeuticsIncorporationMember" substitutionGroup="xbrli:item" />
  <xsd:element name="SignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_SignificantAccountingPoliciesLineItems" substitutionGroup="xbrli:item" />
  <xsd:element id="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" name="CollaborativeArrangementRevenuesExpensesSharingPercentage" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="plx_UpfrontNonrefundableNoncreditablePaymentReceivable" name="UpfrontNonrefundableNoncreditablePaymentReceivable" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="plx_AdditionalAmountsPayableToCoverDevelopmentCosts" name="AdditionalAmountsPayableToCoverDevelopmentCosts" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element name="PaymentOnNetSalesPercentage" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_PaymentOnNetSalesPercentage" substitutionGroup="xbrli:item" />
  <xsd:element id="plx_PfizerMember" name="PfizerMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_MaintainOfMinimumCashBalance" name="MaintainOfMinimumCashBalance" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="plx_ChiesiMember" name="ChiesiMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" name="ChiesiUsAgreementAndChiesiExUsAgreementMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_ShortTermBankDeposits" name="ShortTermBankDeposits" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="plx_IncreaseDecreaseInBankDeposits" name="IncreaseDecreaseInBankDeposits" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="plx_ChiesiAgreementsMember" name="ChiesiAgreementsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_MeasurementInputYieldMember" name="MeasurementInputYieldMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_AtmEquityOfferingSalesAgreementMember" name="AtmEquityOfferingSalesAgreementMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_SaleOfStockMaximumOfferingPrice" name="SaleOfStockMaximumOfferingPrice" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="plx_AtMarketEquityOfferingMember" name="AtMarketEquityOfferingMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_InterestReceivedNet" name="InterestReceivedNet" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" name="AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="plx_StockIssuedDuringPeriodSharesSalesAgreement" name="StockIssuedDuringPeriodSharesSalesAgreement" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="plx_StockIssuedDuringPeriodValueSalesAgreement" name="StockIssuedDuringPeriodValueSalesAgreement" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="plx_ProceedsFromSaleOfShortTermDeposits" name="ProceedsFromSaleOfShortTermDeposits" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="plx_AgreementAmendmentPaymentReceivable" name="AgreementAmendmentPaymentReceivable" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" name="ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="plx_RevenuePerformanceObligationNumber" name="RevenuePerformanceObligationNumber" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element id="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" name="SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="ConvertibleNotesDue2021And2024Member" id="plx_ConvertibleNotesDue2021And2024Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>plx-20230331_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.2.5.9 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/4/2023 7:35:20 PM-->
<!--Modified on: 5/4/2023 7:35:20 PM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="plx-20230331.xsd#StatementCondensedConsolidatedBalanceSheets" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets" />
  <roleRef xlink:type="simple" xlink:href="plx-20230331.xsd#StatementCondensedConsolidatedStatementsOfOperations" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" />
  <roleRef xlink:type="simple" xlink:href="plx-20230331.xsd#StatementCondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="plx-20230331.xsd#DisclosureInventoriesScheduleOfInventoryDetails" roleURI="http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails" />
  <calculationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638188257198337226" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent_638188257198337226" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638188257198337226" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638188257198337226" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638188257198337226" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_ShortTermBankDeposits" xlink:label="plx_ShortTermBankDeposits_638188257198337226" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638188257198337226" xlink:to="plx_ShortTermBankDeposits_638188257198337226" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_638188257198347267" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638188257198337226" xlink:to="us-gaap_AccountsReceivableNetCurrent_638188257198347267" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent_638188257198347267" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638188257198337226" xlink:to="us-gaap_OtherAssetsCurrent_638188257198347267" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_638188257198347267" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638188257198337226" xlink:to="us-gaap_InventoryNet_638188257198347267" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_638188257198347267" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_638188257198347267" order="2" use="optional" weight="1" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638188257198347267" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638188257198347267" order="3" use="optional" weight="1" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638188257198347267" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638188257198347267" order="4" use="optional" weight="1" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_637041422967477240" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638188257198347267" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity_637041422967477240" xlink:to="us-gaap_Liabilities_638188257198347267" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent_638188257198347267" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638188257198347267" xlink:to="us-gaap_LiabilitiesNoncurrent_638188257198347267" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="us-gaap_ConvertibleDebtNoncurrent_638188257198357234" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent_638188257198347267" xlink:to="us-gaap_ConvertibleDebtNoncurrent_638188257198357234" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_638188257198357234" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent_638188257198347267" xlink:to="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_638188257198357234" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638188257198357234" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent_638188257198347267" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638188257198357234" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638188257198357234" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638188257198347267" xlink:to="us-gaap_LiabilitiesCurrent_638188257198357234" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent_638188257198357234" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638188257198357234" xlink:to="us-gaap_AccountsPayableTradeCurrent_638188257198357234" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="us-gaap_AccountsPayableOtherCurrent_638188257198357234" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638188257198357234" xlink:to="us-gaap_AccountsPayableOtherCurrent_638188257198357234" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638188257198357234" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638188257198357234" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638188257198357234" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_638188257198357234" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638188257198357234" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_638188257198357234" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_638188257198367229" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity_637041422967477240" xlink:to="us-gaap_CommitmentsAndContingencies_638188257198367229" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638188257198367229" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity_637041422967477240" xlink:to="us-gaap_StockholdersEquity_638188257198367229" order="3" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637041422967477240" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638188257198367229" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_637041422967477240" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638188257198367229" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638188257198367229" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638188257198367229" xlink:to="us-gaap_OperatingIncomeLoss_638188257198367229" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_638188257198367229" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638188257198367229" xlink:to="us-gaap_Revenues_638188257198367229" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue_638188257198367229" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638188257198367229" xlink:to="us-gaap_CostOfRevenue_638188257198367229" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638188257198367229" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638188257198367229" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638188257198367229" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_638188257198377232" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638188257198367229" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_638188257198377232" order="4" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_638188257198377232" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638188257198367229" xlink:to="us-gaap_NonoperatingIncomeExpense_638188257198377232" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense_638188257198377232" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_638188257198377232" xlink:to="us-gaap_OtherNonoperatingExpense_638188257198377232" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome_638188257198377232" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_638188257198377232" xlink:to="us-gaap_OtherNonoperatingIncome_638188257198377232" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638188257198377232" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_637041422967477240" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638188257198377232" order="2" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637168086008773890" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638188257198377232" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637168086008773890" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638188257198377232" order="1" use="optional" weight="1" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638188257198377232" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638188257198377232" xlink:to="us-gaap_ShareBasedCompensation_638188257198377232" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_638188257198377232" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638188257198377232" xlink:to="us-gaap_Depreciation_638188257198377232" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_638188257198387233" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638188257198377232" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_638188257198387233" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense_638188257198387233" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638188257198377232" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitExpense_638188257198387233" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_638188257198387233" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638188257198377232" xlink:to="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_638188257198387233" order="5" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_638188257198387233" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638188257198377232" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_638188257198387233" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_638188257198387233" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638188257198377232" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_638188257198387233" order="7" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_638188257198387233" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638188257198377232" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_638188257198387233" order="8" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_ChangeInOperatingLeaseRightOfUseAssets" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets_638188257198387233" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638188257198377232" xlink:to="plx_ChangeInOperatingLeaseRightOfUseAssets_638188257198387233" order="9" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories_638188257198387233" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638188257198377232" xlink:to="us-gaap_IncreaseDecreaseInInventories_638188257198387233" order="10" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638188257198387233" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638188257198377232" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638188257198387233" order="11" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638188257198397229" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638188257198377232" xlink:to="us-gaap_ProfitLoss_638188257198397229" order="12" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638188257198397229" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637168086008773890" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638188257198397229" order="2" use="optional" weight="1" priority="7" />
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_IncreaseDecreaseInBankDeposits" xlink:label="plx_IncreaseDecreaseInBankDeposits_638188257198397229" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638188257198397229" xlink:to="plx_IncreaseDecreaseInBankDeposits_638188257198397229" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_ProceedsFromSaleOfShortTermDeposits" xlink:label="plx_ProceedsFromSaleOfShortTermDeposits_638188257198397229" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638188257198397229" xlink:to="plx_ProceedsFromSaleOfShortTermDeposits_638188257198397229" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638188257198397229" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638188257198397229" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638188257198397229" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_638188257198397229" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638188257198397229" xlink:to="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_638188257198397229" order="4" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638188257198397229" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637168086008773890" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638188257198397229" order="3" use="optional" weight="1" priority="8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638188257198397229" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638188257198397229" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638188257198397229" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_638188257198407228" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637168086008773890" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_638188257198407228" order="4" use="optional" weight="1" priority="7" />
  </calculationLink>
  <calculationLink xlink:role="http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails" xlink:type="extended" xlink:title="40201 - Disclosure - INVENTORIES (Schedule of Inventory) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_638188257198477240" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves_638188257198477240" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_638188257198477240" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves_638188257198477240" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_638188257198477240" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves_638188257198477240" order="3" use="optional" weight="1" />
  </calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>plx-20230331_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.2.5.9 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/4/2023 7:35:20 PM-->
<!--Modified on: 5/4/2023 7:35:20 PM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="plx-20230331.xsd#StatementCondensedConsolidatedStatementsOfOperations" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" />
  <roleRef xlink:type="simple" xlink:href="plx-20230331.xsd#StatementCondensedConsolidatedStatementsOfOperationsParenthetical" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical" />
  <roleRef xlink:type="simple" xlink:href="plx-20230331.xsd#StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency" />
  <roleRef xlink:type="simple" xlink:href="plx-20230331.xsd#DisclosureFairValueMeasurementTables" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementTables" />
  <roleRef xlink:type="simple" xlink:href="plx-20230331.xsd#DisclosureSignificantAccountingPoliciesDetails" roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20230331.xsd#DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20230331.xsd#DisclosureFairValueMeasurementAdditionalInformationDetails" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20230331.xsd#DisclosureRevenuesDetails" roleURI="http://www.protalix.com/role/DisclosureRevenuesDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20230331.xsd#DisclosureStockTransactionsDetails" roleURI="http://www.protalix.com/role/DisclosureStockTransactionsDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20230331.xsd#DisclosureSubsequentEventsDetails" roleURI="http://www.protalix.com/role/DisclosureSubsequentEventsDetails" />
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:roleRef roleURI="http://www.protalix.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:href="plx-20230331.xsd#DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" />
  <link:roleRef xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd#eedm" roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended" xlink:title="Extensible Enumeration Domain Members" />
  <link:definitionLink xlink:role="http://www.protalix.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="extended" xlink:title="99900 - Disclosure - Standard And Custom Axis Domain Defaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_1" xlink:title="us-gaap_StatementClassOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1" xlink:title="us-gaap_ClassOfStockDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementClassOfStockAxis_1" xlink:to="us-gaap_ClassOfStockDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementClassOfStockAxis_1 To us-gaap_ClassOfStockDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_1" xlink:title="srt_ProductOrServiceAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_1" xlink:title="srt_ProductsAndServicesDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_ProductOrServiceAxis_1" xlink:to="srt_ProductsAndServicesDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_ProductOrServiceAxis_1 To srt_ProductsAndServicesDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_1" xlink:title="us-gaap_IncomeStatementLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_1" xlink:title="us-gaap_IncomeStatementLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeStatementLocationAxis_1" xlink:to="us-gaap_IncomeStatementLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeStatementLocationAxis_1 To us-gaap_IncomeStatementLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_1" xlink:title="us-gaap_StatementEquityComponentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_1" xlink:title="us-gaap_EquityComponentDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementEquityComponentsAxis_1" xlink:to="us-gaap_EquityComponentDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementEquityComponentsAxis_1 To us-gaap_EquityComponentDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_1" xlink:title="us-gaap_AwardTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AwardTypeAxis_1" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AwardTypeAxis_1 To us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_1" xlink:title="us-gaap_DebtInstrumentAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_1" xlink:title="us-gaap_DebtInstrumentNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_DebtInstrumentAxis_1" xlink:to="us-gaap_DebtInstrumentNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_DebtInstrumentAxis_1 To us-gaap_DebtInstrumentNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_1" xlink:title="us-gaap_TypeOfArrangementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:title="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_TypeOfArrangementAxis_1" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_TypeOfArrangementAxis_1 To us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_1" xlink:title="dei_LegalEntityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_1" xlink:title="dei_EntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="dei_LegalEntityAxis_1" xlink:to="dei_EntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:dei_LegalEntityAxis_1 To dei_EntityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_1" xlink:title="srt_StatementGeographicalAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_1" xlink:title="srt_SegmentGeographicalDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementGeographicalAxis_1" xlink:to="srt_SegmentGeographicalDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementGeographicalAxis_1 To srt_SegmentGeographicalDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_1" xlink:title="srt_RangeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_1" xlink:title="srt_RangeMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_RangeAxis_1" xlink:to="srt_RangeMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_RangeAxis_1 To srt_RangeMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:title="us-gaap_SubsidiarySaleOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_1" xlink:title="us-gaap_SaleOfStockNameOfTransactionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsidiarySaleOfStockAxis_1 To us-gaap_SaleOfStockNameOfTransactionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_1" xlink:title="us-gaap_SubsequentEventTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_1" xlink:title="us-gaap_SubsequentEventTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsequentEventTypeAxis_1" xlink:to="us-gaap_SubsequentEventTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsequentEventTypeAxis_1 To us-gaap_SubsequentEventTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_1" xlink:title="srt_CounterpartyNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_1" xlink:title="srt_RepurchaseAgreementCounterpartyNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_CounterpartyNameAxis_1" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_CounterpartyNameAxis_1 To srt_RepurchaseAgreementCounterpartyNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_1" xlink:title="srt_StatementScenarioAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_1" xlink:title="srt_ScenarioUnspecifiedDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementScenarioAxis_1" xlink:to="srt_ScenarioUnspecifiedDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementScenarioAxis_1 To srt_ScenarioUnspecifiedDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis_1" xlink:title="us-gaap_ShortTermDebtTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain_1" xlink:title="us-gaap_ShortTermDebtTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ShortTermDebtTypeAxis_1" xlink:to="us-gaap_ShortTermDebtTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ShortTermDebtTypeAxis_1 To us-gaap_ShortTermDebtTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:title="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" xlink:title="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByFairValueHierarchyLevelAxis_1 To us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_1" xlink:title="us-gaap_MeasurementInputTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_1" xlink:title="us-gaap_MeasurementInputTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_MeasurementInputTypeAxis_1" xlink:to="us-gaap_MeasurementInputTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_MeasurementInputTypeAxis_1 To us-gaap_MeasurementInputTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis_1" xlink:title="us-gaap_DebtInstrumentRedemptionPeriodAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain_1" xlink:title="us-gaap_DebtInstrumentRedemptionPeriodDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis_1" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_DebtInstrumentRedemptionPeriodAxis_1 To us-gaap_DebtInstrumentRedemptionPeriodDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:label="us-gaap_ChangeInAccountingEstimateByTypeAxis_1" xlink:title="us-gaap_ChangeInAccountingEstimateByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:label="us-gaap_ChangeInAccountingEstimateTypeDomain_1" xlink:title="us-gaap_ChangeInAccountingEstimateTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ChangeInAccountingEstimateByTypeAxis_1" xlink:to="us-gaap_ChangeInAccountingEstimateTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ChangeInAccountingEstimateByTypeAxis_1 To us-gaap_ChangeInAccountingEstimateTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_1" xlink:title="srt_TitleOfIndividualAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" xlink:title="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_TitleOfIndividualAxis_1" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_TitleOfIndividualAxis_1 To srt_TitleOfIndividualWithRelationshipToEntityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis_1" xlink:title="us-gaap_GranteeStatusAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain_1" xlink:title="us-gaap_GranteeStatusDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_GranteeStatusAxis_1" xlink:to="us-gaap_GranteeStatusDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_GranteeStatusAxis_1 To us-gaap_GranteeStatusDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_1" xlink:title="us-gaap_PlanNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_1" xlink:title="us-gaap_PlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PlanNameAxis_1" xlink:to="us-gaap_PlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PlanNameAxis_1 To us-gaap_PlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:title="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:title="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PropertyPlantAndEquipmentByTypeAxis_1 To us-gaap_PropertyPlantAndEquipmentTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" xlink:title="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_1" xlink:title="us-gaap_TypeOfAdoptionMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" xlink:to="us-gaap_TypeOfAdoptionMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1 To us-gaap_TypeOfAdoptionMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="us-gaap_RetirementPlanTypeAxis_1" xlink:title="us-gaap_RetirementPlanTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="us-gaap_RetirementPlanTypeDomain_1" xlink:title="us-gaap_RetirementPlanTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RetirementPlanTypeAxis_1" xlink:to="us-gaap_RetirementPlanTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RetirementPlanTypeAxis_1 To us-gaap_RetirementPlanTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis_1" xlink:title="us-gaap_LongtermDebtTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_1" xlink:title="us-gaap_LongtermDebtTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_LongtermDebtTypeAxis_1" xlink:to="us-gaap_LongtermDebtTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_LongtermDebtTypeAxis_1 To us-gaap_LongtermDebtTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1" xlink:title="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1" xlink:title="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1 To us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1 To us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:title="us-gaap_ClassOfWarrantOrRightAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_1" xlink:title="us-gaap_ClassOfWarrantOrRightDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ClassOfWarrantOrRightAxis_1 To us-gaap_ClassOfWarrantOrRightDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:title="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_1" xlink:title="us-gaap_RelatedPartyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:to="us-gaap_RelatedPartyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1 To us-gaap_RelatedPartyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_1" xlink:title="us-gaap_IncomeTaxAuthorityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_1" xlink:title="us-gaap_IncomeTaxAuthorityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeTaxAuthorityAxis_1" xlink:to="us-gaap_IncomeTaxAuthorityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeTaxAuthorityAxis_1 To us-gaap_IncomeTaxAuthorityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis_1" xlink:title="srt_ConsolidatedEntitiesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain_1" xlink:title="srt_ConsolidatedEntitiesDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_ConsolidatedEntitiesAxis_1" xlink:to="srt_ConsolidatedEntitiesDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_ConsolidatedEntitiesAxis_1 To srt_ConsolidatedEntitiesDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis_1" xlink:title="us-gaap_BalanceSheetLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_1" xlink:title="us-gaap_BalanceSheetLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_BalanceSheetLocationAxis_1" xlink:to="us-gaap_BalanceSheetLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_BalanceSheetLocationAxis_1 To us-gaap_BalanceSheetLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis_1" xlink:title="srt_MajorCustomersAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain_1" xlink:title="srt_NameOfMajorCustomerDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_MajorCustomersAxis_1" xlink:to="srt_NameOfMajorCustomerDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_MajorCustomersAxis_1 To srt_NameOfMajorCustomerDomain_1" order="1" />
  </link:definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseAndServiceMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Revenues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostOfRevenue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingIncome" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical" xlink:type="extended" xlink:title="00205 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_CostOfSalesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency" xlink:type="extended" xlink:title="00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_StockIssuedDuringPeriodValueSalesAgreement" xlink:label="plx_StockIssuedDuringPeriodValueSalesAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_StockIssuedDuringPeriodValueSalesAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_StockIssuedDuringPeriodSharesSalesAgreement" xlink:label="plx_StockIssuedDuringPeriodSharesSalesAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_StockIssuedDuringPeriodSharesSalesAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurementTables" xlink:type="extended" xlink:title="30303 - Disclosure - FAIR VALUE MEASUREMENT (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails" xlink:type="extended" xlink:title="40101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)">
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_SignificantAccountingPoliciesTable" xlink:label="plx_SignificantAccountingPoliciesTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_AmendedPfizerAgreementMember" xlink:label="plx_AmendedPfizerAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_AmendedPfizerAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_ChiesiAgreementsMember" xlink:label="plx_ChiesiAgreementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_ChiesiAgreementsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_ChiesiUSAgreementMember" xlink:label="plx_ChiesiUSAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="plx_ChiesiAgreementsMember" xlink:to="plx_ChiesiUSAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_ChiesiExUSAgreementMember" xlink:label="plx_ChiesiExUSAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="plx_ChiesiAgreementsMember" xlink:to="plx_ChiesiExUSAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" xlink:label="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="plx_ProtalixBioTherapeuticsIncorporationMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="srt_StatementGeographicalAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_BR" xlink:label="country_BR" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_BR" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_ConvertibleNotesDue2021And2024Member" xlink:label="plx_ConvertibleNotesDue2021And2024Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="plx_ConvertibleNotesDue2021And2024Member" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="plx_ConvertibleNotesDue2021And2024Member" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="6" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_AtMarketEquityOfferingMember" xlink:label="plx_AtMarketEquityOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="plx_AtMarketEquityOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_AtmEquityOfferingSalesAgreementMember" xlink:label="plx_AtmEquityOfferingSalesAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="plx_AtmEquityOfferingSalesAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:label="plx_SignificantAccountingPoliciesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_SignificantAccountingPoliciesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_UpfrontNonrefundableNoncreditablePaymentReceivable" xlink:label="plx_UpfrontNonrefundableNoncreditablePaymentReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_UpfrontNonrefundableNoncreditablePaymentReceivable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_SaleOfStockMaximumOfferingPrice" xlink:label="plx_SaleOfStockMaximumOfferingPrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_SaleOfStockMaximumOfferingPrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_AdditionalAmountsPayableToCoverDevelopmentCosts" xlink:label="plx_AdditionalAmountsPayableToCoverDevelopmentCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_AdditionalAmountsPayableToCoverDevelopmentCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_AgreementAmendmentPaymentReceivable" xlink:label="plx_AgreementAmendmentPaymentReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_AgreementAmendmentPaymentReceivable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" xlink:label="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" xlink:label="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_PaymentOnNetSalesPercentage" xlink:label="plx_PaymentOnNetSalesPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_PaymentOnNetSalesPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_RevenuePerformanceObligationNumber" xlink:label="plx_RevenuePerformanceObligationNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_RevenuePerformanceObligationNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_MaintainOfMinimumCashBalance" xlink:label="plx_MaintainOfMinimumCashBalance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_MaintainOfMinimumCashBalance" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails" xlink:type="extended" xlink:title="40301 - Disclosure - FAIR VALUE MEASUREMENT (Schedule of Fair Value Assumptions) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_ConvertibleNotesDue2021And2024Member" xlink:label="plx_ConvertibleNotesDue2021And2024Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="plx_ConvertibleNotesDue2021And2024Member" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="plx_ConvertibleNotesDue2021And2024Member" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_MeasurementInputTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputSharePriceMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_MeasurementInputYieldMember" xlink:label="plx_MeasurementInputYieldMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="plx_MeasurementInputYieldMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMeasurementInput" xlink:label="us-gaap_DebtInstrumentMeasurementInput" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentMeasurementInput" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails" xlink:type="extended" xlink:title="40302 - Disclosure - FAIR VALUE MEASUREMENT (Additional Information) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConvertibleDebtFairValueDisclosures" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureRevenuesDetails" xlink:type="extended" xlink:title="40401 - Disclosure - REVENUES (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseAndServiceMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementGeographicalAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_PfizerMember" xlink:label="plx_PfizerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_SegmentGeographicalDomain" xlink:to="plx_PfizerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_BR" xlink:label="country_BR" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_BR" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_ChiesiMember" xlink:label="plx_ChiesiMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_SegmentGeographicalDomain" xlink:to="plx_ChiesiMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Revenues" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureStockTransactionsDetails" xlink:type="extended" xlink:title="40501 - Disclosure - STOCK TRANSACTIONS (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_AtmEquityOfferingSalesAgreementMember" xlink:label="plx_AtmEquityOfferingSalesAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="plx_AtmEquityOfferingSalesAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="40601 - Disclosure - SUBSEQUENT EVENTS (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_StockIssuedDuringPeriodValueSalesAgreement" xlink:label="plx_StockIssuedDuringPeriodValueSalesAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="plx_StockIssuedDuringPeriodValueSalesAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_StockIssuedDuringPeriodSharesSalesAgreement" xlink:label="plx_StockIssuedDuringPeriodSharesSalesAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="plx_StockIssuedDuringPeriodSharesSalesAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
  </definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>plx-20230331_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.2.5.9 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/4/2023 7:35:20 PM-->
<!--Modified on: 5/4/2023 7:35:20 PM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Document and Entity Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">CONDENSED CONSOLIDATED BALANCE SHEETS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">CURRENT ASSETS:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_ShortTermBankDeposits" xlink:label="plx_ShortTermBankDeposits" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShortTermBankDeposits" xlink:to="plx_ShortTermBankDeposits_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ShortTermBankDeposits_lbl" xml:lang="en-US">Carrying value of deposits held with banks for short period, usually less than one year or the normal operating cycle, whichever is longer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ShortTermBankDeposits_lbl" xml:lang="en-US">Short-term Bank Deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ShortTermBankDeposits_lbl" xml:lang="en-US">Short-term bank deposits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts Receivable, Net, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable - Trade</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US">Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US">Other assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventory, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventories</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Total inventory</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xml:lang="en-US">Assets, Noncurrent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xml:lang="en-US">NON-CURRENT ASSETS:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:to="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_lbl" xml:lang="en-US">Assets for Plan Benefits, Defined Benefit Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_lbl" xml:lang="en-US">Funds in respect of employee rights upon retirement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right of use assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY (NET OF CAPITAL DEFICIENCY)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">CURRENT LIABILITIES:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Accounts payable and accruals:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableTradeCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableTradeCurrent_lbl" xml:lang="en-US">Accounts Payable, Trade, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableTradeCurrent_lbl" xml:lang="en-US">Trade</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="us-gaap_AccountsPayableOtherCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableOtherCurrent" xlink:to="us-gaap_AccountsPayableOtherCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableOtherCurrent_lbl" xml:lang="en-US">Accounts Payable, Other, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableOtherCurrent_lbl" xml:lang="en-US">Other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating Lease, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xml:lang="en-US">Contract with Customer, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xml:lang="en-US">Contracts liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">LONG TERM LIABILITIES:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="us-gaap_ConvertibleDebtNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtNoncurrent" xlink:to="us-gaap_ConvertibleDebtNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtNoncurrent_lbl" xml:lang="en-US">Convertible Debt, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleDebtNoncurrent_lbl" xml:lang="en-US">Convertible notes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:to="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_lbl" xml:lang="en-US">Liability, Pension and Other Postretirement and Postemployment Benefits, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_lbl" xml:lang="en-US">Liability for employee rights upon retirement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">Liabilities, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">Total long term liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">COMMITMENTS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Beginning balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders' equity (net of capital deficiency)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Product and Service [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US">Product and Service [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductMember" xlink:to="us-gaap_ProductMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductMember_lbl" xml:lang="en-US">Goods</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseAndServiceMember" xlink:to="us-gaap_LicenseAndServiceMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LicenseAndServiceMember_lbl" xml:lang="en-US">License and R&amp;D Services</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenues.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">TOTAL REVENUE</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenues</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US">Cost of Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US">COST OF GOODS SOLD</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">RESEARCH AND DEVELOPMENT EXPENSES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Selling, General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">SELLING, GENERAL AND ADMINISTRATIVE EXPENSES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">OPERATING LOSS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingExpense" xlink:to="us-gaap_OtherNonoperatingExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingExpense_lbl" xml:lang="en-US">Other Nonoperating Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherNonoperatingExpense_lbl" xml:lang="en-US">FINANCIAL EXPENSES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncome" xlink:to="us-gaap_OtherNonoperatingIncome_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xml:lang="en-US">Other Nonoperating Income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xml:lang="en-US">FINANCIAL INCOME</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">FINANCIAL EXPENSES, NET</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">LOSS BEFORE TAXES ON INCOME</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">TAXES ON INCOME</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">NET LOSS FOR THE PERIOD</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss for the period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Earnings Per Share, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">LOSS PER SHARE OF COMMON STOCK - BASIC</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Earnings Per Share, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">LOSS PER SHARE OF COMMON STOCK - DILUTED</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING LOSS PER SHARE - BASIC</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING LOSS PER SHARE - DILUTED</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US">Income Statement Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesMember" xlink:to="us-gaap_CostOfSalesMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfSalesMember_lbl" xml:lang="en-US">Cost of goods sold</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and development expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xml:lang="en-US">Selling, general and administrative expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Allocated Share-based Compensation Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Share-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS EQUITY (CAPITAL DEFICIENCY)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Ending balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Beginning balance (in shares)</label>
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_StockIssuedDuringPeriodValueSalesAgreement" xlink:label="plx_StockIssuedDuringPeriodValueSalesAgreement" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_StockIssuedDuringPeriodValueSalesAgreement" xlink:to="plx_StockIssuedDuringPeriodValueSalesAgreement_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_StockIssuedDuringPeriodValueSalesAgreement_lbl" xml:lang="en-US">Equity impact of the value of new stock issued during the period. Includes shares issued in a sales agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_StockIssuedDuringPeriodValueSalesAgreement_lbl" xml:lang="en-US">Stock Issued During Period, Value, Sales Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_StockIssuedDuringPeriodValueSalesAgreement_lbl" xml:lang="en-US">Issuance of common stock under the Sales Agreement, net</label>
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_StockIssuedDuringPeriodSharesSalesAgreement" xlink:label="plx_StockIssuedDuringPeriodSharesSalesAgreement" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_StockIssuedDuringPeriodSharesSalesAgreement" xlink:to="plx_StockIssuedDuringPeriodSharesSalesAgreement_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_StockIssuedDuringPeriodSharesSalesAgreement_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Sales Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_StockIssuedDuringPeriodSharesSalesAgreement_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Sales Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_StockIssuedDuringPeriodSharesSalesAgreement_lbl" xml:lang="en-US">Issuance of common stock under the Sales Agreement, net (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Share-based compensation related to stock options</label>
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_lbl" xml:lang="en-US">Amount of recognized equity-based compensation during the period for restricted stock awards.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_lbl" xml:lang="en-US">Share Based Compensation Restricted Stock Awards Net Of Forfeitures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_lbl" xml:lang="en-US">Share-based compensation related to restricted stock awards</label>
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_lbl" xml:lang="en-US">Share Based Compensation Restricted Stock Awards Net Of Forfeitures Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_lbl" xml:lang="en-US">Share Based Compensation Restricted Stock Awards Net Of Forfeitures Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_lbl" xml:lang="en-US">Share-based compensation related to restricted stock awards (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments required to reconcile net loss to net cash used in operating activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), Unrealized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl" xml:lang="en-US">Financial income, net (mainly exchange differences)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense_lbl" xml:lang="en-US">Pension and Other Postretirement Benefits Cost (Reversal of Cost)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense_lbl" xml:lang="en-US">Changes in accrued liability for employee rights upon retirement</label>
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:to="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_lbl" xml:lang="en-US">Gain (loss) on amounts funded in respect of employee rights upon retirement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_lbl" xml:lang="en-US">Gain Loss On Amounts Funded In Respect Of Employee Rights Upon Retirement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_lbl" xml:lang="en-US">Loss on amounts funded in respect of employee rights upon retirement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xml:lang="en-US">Amortization of debt issuance costs and debt discount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xml:lang="en-US">Decrease in contracts liability (including non-current portion)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Decrease (increase) in accounts receivable-trade and other assets</label>
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_ChangeInOperatingLeaseRightOfUseAssets" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChangeInOperatingLeaseRightOfUseAssets" xlink:to="plx_ChangeInOperatingLeaseRightOfUseAssets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets_lbl" xml:lang="en-US">Amount of Net Change in Operating Lease Right Of use Assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets_lbl" xml:lang="en-US">Change in Operating Lease Right Of use Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets_lbl" xml:lang="en-US">Changes in operating lease right of use assets, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Increase (Decrease) in Inventories</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Decrease (increase) in inventories</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Increase (decrease) in accounts payable and accruals</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</label>
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_IncreaseDecreaseInBankDeposits" xlink:label="plx_IncreaseDecreaseInBankDeposits" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_IncreaseDecreaseInBankDeposits" xlink:to="plx_IncreaseDecreaseInBankDeposits_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_IncreaseDecreaseInBankDeposits_lbl" xml:lang="en-US">Amount of increase (decrease) in deposits held with banks.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_IncreaseDecreaseInBankDeposits_lbl" xml:lang="en-US">Increase (Decrease) in Bank Deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="plx_IncreaseDecreaseInBankDeposits_lbl" xml:lang="en-US">Investment in bank deposits</label>
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_ProceedsFromSaleOfShortTermDeposits" xlink:label="plx_ProceedsFromSaleOfShortTermDeposits" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ProceedsFromSaleOfShortTermDeposits" xlink:to="plx_ProceedsFromSaleOfShortTermDeposits_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ProceedsFromSaleOfShortTermDeposits_lbl" xml:lang="en-US">Amount of cash inflow from sale of short-term deposits.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ProceedsFromSaleOfShortTermDeposits_lbl" xml:lang="en-US">Proceeds from Sale of Short-term Deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ProceedsFromSaleOfShortTermDeposits_lbl" xml:lang="en-US">Proceeds from sale of short-term deposits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_lbl" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_lbl" xml:lang="en-US">Amounts funded in respect of employee rights upon retirement, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash provided by (used in) investing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from issuance of common stock under the Sales Agreement, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Stock issuance proceeds</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl" xml:lang="en-US">Effect of Exchange Rate on Cash and Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl" xml:lang="en-US">EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">BALANCE OF CASH AND CASH EQUIVALENTS AT END OF PERIOD</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xml:lang="en-US">Purchase of property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Operating lease right of use assets obtained in exchange for new operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">SUPPLEMENTARY DISCLOSURE ON CASH FLOWS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest paid</label>
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_InterestReceivedNet" xlink:label="plx_InterestReceivedNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_InterestReceivedNet" xlink:to="plx_InterestReceivedNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_InterestReceivedNet_lbl" xml:lang="en-US">Amount of cash received for interest.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_InterestReceivedNet_lbl" xml:lang="en-US">Interest Received, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_InterestReceivedNet_lbl" xml:lang="en-US">Interest received</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xml:lang="en-US">INVENTORIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US">Inventory Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US">INVENTORIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US">FAIR VALUE MEASUREMENT</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">Fair Value Disclosures [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">FAIR VALUE MEASUREMENT</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:label="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:to="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_lbl" xml:lang="en-US">REVENUES</label>
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_RevenueDisclosureTextBlock" xlink:label="plx_RevenueDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_RevenueDisclosureTextBlock" xlink:to="plx_RevenueDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_RevenueDisclosureTextBlock_lbl" xml:lang="en-US">The entire disclosure pertaining to revenue.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_RevenueDisclosureTextBlock_lbl" xml:lang="en-US">Revenue Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_RevenueDisclosureTextBlock_lbl" xml:lang="en-US">REVENUES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US">STOCK TRANSACTIONS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">STOCK TRANSACTIONS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</label>
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_NatureOfOperationsPolicyTextBlock" xlink:label="plx_NatureOfOperationsPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_NatureOfOperationsPolicyTextBlock" xlink:to="plx_NatureOfOperationsPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_NatureOfOperationsPolicyTextBlock_lbl" xml:lang="en-US">Nature Of Operations Policy</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_NatureOfOperationsPolicyTextBlock_lbl" xml:lang="en-US">Nature Of Operations [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="plx_NatureOfOperationsPolicyTextBlock_lbl" xml:lang="en-US">General</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of presentation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Loss per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue recognition</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US">Schedule of Inventory</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US">Debt Instrument, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_lbl" xml:lang="en-US">Represents the information pertaining to seven point five percentage senior secured convertible notes due 2024.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_lbl" xml:lang="en-US">2024 Notes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xml:lang="en-US">Schedule of Fair Value Assumptions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xml:lang="en-US">Schedule of Company's Disaggregation of Revenues</label>
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_SignificantAccountingPoliciesTable" xlink:label="plx_SignificantAccountingPoliciesTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="plx_SignificantAccountingPoliciesTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_SignificantAccountingPoliciesTable_lbl" xml:lang="en-US">Significant Accounting Policies [Table].</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SignificantAccountingPoliciesTable_lbl" xml:lang="en-US">Significant Accounting Policies [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</label>
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_AmendedPfizerAgreementMember" xlink:label="plx_AmendedPfizerAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AmendedPfizerAgreementMember" xlink:to="plx_AmendedPfizerAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_AmendedPfizerAgreementMember_lbl" xml:lang="en-US">Amended Pfizer Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_AmendedPfizerAgreementMember_lbl" xml:lang="en-US">Amended Pfizer Agreement</label>
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_ChiesiAgreementsMember" xlink:label="plx_ChiesiAgreementsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChiesiAgreementsMember" xlink:to="plx_ChiesiAgreementsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ChiesiAgreementsMember_lbl" xml:lang="en-US">Chiesi Agreements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChiesiAgreementsMember_lbl" xml:lang="en-US">Chiesi Agreements</label>
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_ChiesiUSAgreementMember" xlink:label="plx_ChiesiUSAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChiesiUSAgreementMember" xlink:to="plx_ChiesiUSAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChiesiUSAgreementMember_lbl" xml:lang="en-US">Chiesi US Agreement</label>
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_ChiesiExUSAgreementMember" xlink:label="plx_ChiesiExUSAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChiesiExUSAgreementMember" xlink:to="plx_ChiesiExUSAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChiesiExUSAgreementMember_lbl" xml:lang="en-US">Chiesi Ex-US Agreement</label>
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" xlink:label="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" xlink:to="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_lbl" xml:lang="en-US">n/a</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_lbl" xml:lang="en-US">Chiesi US Agreement and Chiesi Ex-US Agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US">Entity [Domain]</label>
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ProtalixBioTherapeuticsIncorporationMember" xlink:to="plx_ProtalixBioTherapeuticsIncorporationMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember_lbl" xml:lang="en-US">Protalix Bio Therapeutics Incorporation [Member].</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember_lbl" xml:lang="en-US">Protalix Bio Therapeutics Incorporation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_SegmentGeographicalDomain_lbl" xml:lang="en-US">Geographical [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_BR" xlink:label="country_BR" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_BR" xlink:to="country_BR_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_BR_lbl" xml:lang="en-US">Brazil</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Range [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Range [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum</label>
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_ConvertibleNotesDue2021And2024Member" xlink:label="plx_ConvertibleNotesDue2021And2024Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ConvertibleNotesDue2021And2024Member" xlink:to="plx_ConvertibleNotesDue2021And2024Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ConvertibleNotesDue2021And2024Member_lbl" xml:lang="en-US">Represents information pertaining to convertible notes due 2021 and 2024.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ConvertibleNotesDue2021And2024Member_lbl" xml:lang="en-US">Notes 2021 and 2024</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US">Sale of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_AtMarketEquityOfferingMember" xlink:label="plx_AtMarketEquityOfferingMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AtMarketEquityOfferingMember" xlink:to="plx_AtMarketEquityOfferingMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_AtMarketEquityOfferingMember_lbl" xml:lang="en-US">Represents the information pertaining to At The Market equity offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_AtMarketEquityOfferingMember_lbl" xml:lang="en-US">ATM Shares</label>
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_AtmEquityOfferingSalesAgreementMember" xlink:label="plx_AtmEquityOfferingSalesAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AtmEquityOfferingSalesAgreementMember" xlink:to="plx_AtmEquityOfferingSalesAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_AtmEquityOfferingSalesAgreementMember_lbl" xml:lang="en-US">Represents information pertaining to ATM Equity Offering Sales Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_AtmEquityOfferingSalesAgreementMember_lbl" xml:lang="en-US">ATM Equity Offering Sales Agreement</label>
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:label="plx_SignificantAccountingPoliciesLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_SignificantAccountingPoliciesLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SignificantAccountingPoliciesLineItems_lbl" xml:lang="en-US">Significant Accounting Policies [Line Items]</label>
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_UpfrontNonrefundableNoncreditablePaymentReceivable" xlink:label="plx_UpfrontNonrefundableNoncreditablePaymentReceivable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_UpfrontNonrefundableNoncreditablePaymentReceivable" xlink:to="plx_UpfrontNonrefundableNoncreditablePaymentReceivable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_UpfrontNonrefundableNoncreditablePaymentReceivable_lbl" xml:lang="en-US">The amount of upfront, non refundable and non creditable payment receivable under the agreement for licensing rights.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_UpfrontNonrefundableNoncreditablePaymentReceivable_lbl" xml:lang="en-US">Upfront Nonrefundable Non creditable Payment Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_UpfrontNonrefundableNoncreditablePaymentReceivable_lbl" xml:lang="en-US">Non-refundable Payment Receivable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Number of shares issued (in shares)</label>
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_SaleOfStockMaximumOfferingPrice" xlink:label="plx_SaleOfStockMaximumOfferingPrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SaleOfStockMaximumOfferingPrice" xlink:to="plx_SaleOfStockMaximumOfferingPrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_SaleOfStockMaximumOfferingPrice_lbl" xml:lang="en-US">Sale of stock, maximum offering price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SaleOfStockMaximumOfferingPrice_lbl" xml:lang="en-US">Sale Of Stock Maximum Offering Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_SaleOfStockMaximumOfferingPrice_lbl" xml:lang="en-US">Sale of stock, maximum offering price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_AdditionalAmountsPayableToCoverDevelopmentCosts" xlink:label="plx_AdditionalAmountsPayableToCoverDevelopmentCosts" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AdditionalAmountsPayableToCoverDevelopmentCosts" xlink:to="plx_AdditionalAmountsPayableToCoverDevelopmentCosts_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_AdditionalAmountsPayableToCoverDevelopmentCosts_lbl" xml:lang="en-US">The maximum amount payable to the entity to cover development costs under agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_AdditionalAmountsPayableToCoverDevelopmentCosts_lbl" xml:lang="en-US">Additional Amounts Payable To Cover Development Costs</label>
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_AgreementAmendmentPaymentReceivable" xlink:label="plx_AgreementAmendmentPaymentReceivable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AgreementAmendmentPaymentReceivable" xlink:to="plx_AgreementAmendmentPaymentReceivable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_AgreementAmendmentPaymentReceivable_lbl" xml:lang="en-US">Agreement Amendment Payment Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_AgreementAmendmentPaymentReceivable_lbl" xml:lang="en-US">Agreement Amendment Payment Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_AgreementAmendmentPaymentReceivable_lbl" xml:lang="en-US">Agreement Amendment Payment Receivable</label>
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" xlink:label="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" xlink:to="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones_lbl" xml:lang="en-US">Change In Amount Receivable For Achievement Of Regulatory And Commercial Milestones</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones_lbl" xml:lang="en-US">Change In Amount Receivable For Achievement Of Regulatory And Commercial Milestones</label>
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" xlink:label="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" xlink:to="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones_lbl" xml:lang="en-US">The total amount payable to entity for the achievement of regulatory and commercial milestones.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones_lbl" xml:lang="en-US">Additional Amount Payable For Achievement Of Regulatory And Commercial Milestones</label>
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_PaymentOnNetSalesPercentage" xlink:label="plx_PaymentOnNetSalesPercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PaymentOnNetSalesPercentage" xlink:to="plx_PaymentOnNetSalesPercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_PaymentOnNetSalesPercentage_lbl" xml:lang="en-US">Represents the payment as a percentage of future net sales.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_PaymentOnNetSalesPercentage_lbl" xml:lang="en-US">Payment On Net Sales Percentage</label>
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:to="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_lbl" xml:lang="en-US">Collaborative arrangement revenues and expense sharing percentage.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_lbl" xml:lang="en-US">Collaborative Arrangement Revenues Expenses Sharing Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_lbl" xml:lang="en-US">Collaborative Arrangement Revenues and Expenses Sharing Percentage</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Interest rate (as a percent)</label>
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_RevenuePerformanceObligationNumber" xlink:label="plx_RevenuePerformanceObligationNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_RevenuePerformanceObligationNumber" xlink:to="plx_RevenuePerformanceObligationNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_RevenuePerformanceObligationNumber_lbl" xml:lang="en-US">Revenue, Performance Obligation, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_RevenuePerformanceObligationNumber_lbl" xml:lang="en-US">Revenue, Performance Obligation, Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xml:lang="en-US">Long-term Debt, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xml:lang="en-US">Debt Instrument Carrying Amount</label>
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_MaintainOfMinimumCashBalance" xlink:label="plx_MaintainOfMinimumCashBalance" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_MaintainOfMinimumCashBalance" xlink:to="plx_MaintainOfMinimumCashBalance_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_MaintainOfMinimumCashBalance_lbl" xml:lang="en-US">Minimum cash balance required to be maintained under long term debt agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_MaintainOfMinimumCashBalance_lbl" xml:lang="en-US">Maintain of Minimum Cash Balance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" xml:lang="en-US">Raw materials</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" xml:lang="en-US">Work in progress</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" xml:lang="en-US">Finished goods</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Level 3</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xml:lang="en-US">Measurement Input Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputTypeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xml:lang="en-US">Measurement Input Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputSharePriceMember" xlink:to="us-gaap_MeasurementInputSharePriceMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputSharePriceMember_lbl" xml:lang="en-US">Share Price.</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xml:lang="en-US">Expected term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xml:lang="en-US">Risk free rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xml:lang="en-US">Volatility</label>
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_MeasurementInputYieldMember" xlink:label="plx_MeasurementInputYieldMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_MeasurementInputYieldMember" xlink:to="plx_MeasurementInputYieldMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_MeasurementInputYieldMember_lbl" xml:lang="en-US">Yield</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_MeasurementInputYieldMember_lbl" xml:lang="en-US">Yield</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMeasurementInput" xlink:label="us-gaap_DebtInstrumentMeasurementInput" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMeasurementInput" xlink:to="us-gaap_DebtInstrumentMeasurementInput_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMeasurementInput_lbl" xml:lang="en-US">Debt Instrument, Measurement Input</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtFairValueDisclosures" xlink:to="us-gaap_ConvertibleDebtFairValueDisclosures_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures_lbl" xml:lang="en-US">Convertible Debt, Fair Value Disclosures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures_lbl" xml:lang="en-US">Debt Instrument Fair Value</label>
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_PfizerMember" xlink:label="plx_PfizerMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PfizerMember" xlink:to="plx_PfizerMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_PfizerMember_lbl" xml:lang="en-US">Global except for Brazil</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_PfizerMember_lbl" xml:lang="en-US">Pfizer</label>
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_ChiesiMember" xlink:label="plx_ChiesiMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChiesiMember" xlink:to="plx_ChiesiMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ChiesiMember_lbl" xml:lang="en-US">Global except Brazil and Italy</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChiesiMember_lbl" xml:lang="en-US">Chiesi</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US">Schedule of Stock by Class [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US">Class of Stock [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US">Subsequent Event [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Event [Line Items]</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>plx-20230331_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.2.5.9 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/4/2023 7:35:20 PM-->
<!--Modified on: 5/4/2023 7:35:20 PM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="plx-20230331.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.protalix.com/role/DocumentDocumentAndEntityInformation" />
  <roleRef xlink:type="simple" xlink:href="plx-20230331.xsd#StatementCondensedConsolidatedBalanceSheets" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets" />
  <roleRef xlink:type="simple" xlink:href="plx-20230331.xsd#StatementCondensedConsolidatedStatementsOfOperations" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" />
  <roleRef xlink:type="simple" xlink:href="plx-20230331.xsd#StatementCondensedConsolidatedStatementsOfOperationsParenthetical" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical" />
  <roleRef xlink:type="simple" xlink:href="plx-20230331.xsd#StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency" />
  <roleRef xlink:type="simple" xlink:href="plx-20230331.xsd#StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiencyParenthetical" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiencyParenthetical" />
  <roleRef xlink:type="simple" xlink:href="plx-20230331.xsd#StatementCondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="plx-20230331.xsd#DisclosureSignificantAccountingPolicies" roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPolicies" />
  <roleRef xlink:type="simple" xlink:href="plx-20230331.xsd#DisclosureInventories" roleURI="http://www.protalix.com/role/DisclosureInventories" />
  <roleRef xlink:type="simple" xlink:href="plx-20230331.xsd#DisclosureFairValueMeasurement" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurement" />
  <roleRef xlink:type="simple" xlink:href="plx-20230331.xsd#DisclosureRevenues" roleURI="http://www.protalix.com/role/DisclosureRevenues" />
  <roleRef xlink:type="simple" xlink:href="plx-20230331.xsd#DisclosureStockTransactions" roleURI="http://www.protalix.com/role/DisclosureStockTransactions" />
  <roleRef xlink:type="simple" xlink:href="plx-20230331.xsd#DisclosureSubsequentEvents" roleURI="http://www.protalix.com/role/DisclosureSubsequentEvents" />
  <roleRef xlink:type="simple" xlink:href="plx-20230331.xsd#DisclosureSignificantAccountingPoliciesPolicies" roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies" />
  <roleRef xlink:type="simple" xlink:href="plx-20230331.xsd#DisclosureInventoriesTables" roleURI="http://www.protalix.com/role/DisclosureInventoriesTables" />
  <roleRef xlink:type="simple" xlink:href="plx-20230331.xsd#DisclosureFairValueMeasurementTables" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementTables" />
  <roleRef xlink:type="simple" xlink:href="plx-20230331.xsd#DisclosureRevenuesTables" roleURI="http://www.protalix.com/role/DisclosureRevenuesTables" />
  <roleRef xlink:type="simple" xlink:href="plx-20230331.xsd#DisclosureSignificantAccountingPoliciesDetails" roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20230331.xsd#DisclosureInventoriesScheduleOfInventoryDetails" roleURI="http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20230331.xsd#DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20230331.xsd#DisclosureFairValueMeasurementAdditionalInformationDetails" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20230331.xsd#DisclosureRevenuesDetails" roleURI="http://www.protalix.com/role/DisclosureRevenuesDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20230331.xsd#DisclosureStockTransactionsDetails" roleURI="http://www.protalix.com/role/DisclosureStockTransactionsDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20230331.xsd#DisclosureSubsequentEventsDetails" roleURI="http://www.protalix.com/role/DisclosureSubsequentEventsDetails" />
  <presentationLink xlink:role="http://www.protalix.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638188257198687239" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType_638188257198687239" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport_638188257198687239" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentQuarterlyReport_638188257198687239" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_638188257198687239" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport_638188257198687239" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638188257198687239" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_638188257198687239" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_638188257198687239" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber_638188257198687239" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638188257198697249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName_638188257198697249" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_638188257198697249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_638188257198697249" order="7" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_638188257198697249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_638188257198697249" order="8" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_638188257198697249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_638188257198697249" order="9" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2_638188257198697249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2_638188257198697249" order="10" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_638188257198697249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_638188257198697249" order="11" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_638188257198697249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_638188257198697249" order="12" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_638188257198697249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_638188257198697249" order="13" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_638188257198697249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode_638188257198697249" order="14" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_638188257198697249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber_638188257198697249" order="15" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_638188257198697249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle_638188257198697249" order="16" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_638188257198697249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol_638188257198697249" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_638188257198707228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName_638188257198707228" order="18" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_638188257198707228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus_638188257198707228" order="19" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_638188257198707228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent_638188257198707228" order="20" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_638188257198707228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory_638188257198707228" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_638188257198707228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness_638188257198707228" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638188257198707228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_638188257198707228" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_638188257198707228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany_638188257198707228" order="24" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_638188257198707228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding_638188257198707228" order="25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638188257198707228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey_638188257198707228" order="26" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_638188257198717227" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate_638188257198717227" order="27" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_638188257198717227" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus_638188257198717227" order="28" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_638188257198717227" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_638188257198717227" order="29" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638188257198717227" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag_638188257198717227" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_637041422967320790" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_638188257198717227" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_637041422967320790" xlink:to="us-gaap_AssetsAbstract_638188257198717227" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_638188257198717227" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638188257198717227" xlink:to="us-gaap_AssetsCurrentAbstract_638188257198717227" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638188257198717227" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638188257198717227" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638188257198717227" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_ShortTermBankDeposits" xlink:label="plx_ShortTermBankDeposits_638188257198717227" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638188257198717227" xlink:to="plx_ShortTermBankDeposits_638188257198717227" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_638188257198727232" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638188257198717227" xlink:to="us-gaap_AccountsReceivableNetCurrent_638188257198727232" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent_638188257198727232" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638188257198717227" xlink:to="us-gaap_OtherAssetsCurrent_638188257198727232" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_638188257198727232" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638188257198717227" xlink:to="us-gaap_InventoryNet_638188257198727232" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638188257198727232" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638188257198717227" xlink:to="us-gaap_AssetsCurrent_638188257198727232" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract_638188257198727232" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638188257198717227" xlink:to="us-gaap_AssetsNoncurrentAbstract_638188257198727232" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_638188257198727232" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_638188257198727232" xlink:to="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_638188257198727232" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638188257198727232" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_638188257198727232" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638188257198727232" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638188257198727232" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_638188257198727232" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638188257198727232" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_638188257198727232" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638188257198717227" xlink:to="us-gaap_Assets_638188257198727232" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638188257198727232" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_637041422967320790" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638188257198727232" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_638188257198727232" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638188257198727232" xlink:to="us-gaap_LiabilitiesCurrentAbstract_638188257198727232" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638188257198727232" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638188257198727232" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638188257198727232" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent_638188257198737228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638188257198727232" xlink:to="us-gaap_AccountsPayableTradeCurrent_638188257198737228" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="us-gaap_AccountsPayableOtherCurrent_638188257198737228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638188257198727232" xlink:to="us-gaap_AccountsPayableOtherCurrent_638188257198737228" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638188257198737228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638188257198727232" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638188257198737228" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_638188257198737228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638188257198727232" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_638188257198737228" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638188257198737228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638188257198727232" xlink:to="us-gaap_LiabilitiesCurrent_638188257198737228" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_638188257198737228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638188257198727232" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_638188257198737228" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="us-gaap_ConvertibleDebtNoncurrent_638188257198737228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_638188257198737228" xlink:to="us-gaap_ConvertibleDebtNoncurrent_638188257198737228" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_638188257198737228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_638188257198737228" xlink:to="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_638188257198737228" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638188257198737228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_638188257198737228" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638188257198737228" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent_638188257198737228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638188257198727232" xlink:to="us-gaap_LiabilitiesNoncurrent_638188257198737228" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638188257198747228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638188257198727232" xlink:to="us-gaap_Liabilities_638188257198747228" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_638188257198747228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638188257198727232" xlink:to="us-gaap_CommitmentsAndContingencies_638188257198747228" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638188257198747228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638188257198727232" xlink:to="us-gaap_StockholdersEquity_638188257198747228" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_638188257198747228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638188257198727232" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_638188257198747228" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract_637041422967477240" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638188257198747228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_637041422967477240" xlink:to="us-gaap_StatementTable_638188257198747228" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_638188257198747228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638188257198747228" xlink:to="srt_ProductOrServiceAxis_638188257198747228" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_638188257198747228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_638188257198747228" xlink:to="srt_ProductsAndServicesDomain_638188257198747228" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember_638188257198747228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638188257198747228" xlink:to="us-gaap_ProductMember_638188257198747228" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember_638188257198757232" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638188257198747228" xlink:to="us-gaap_LicenseAndServiceMember_638188257198757232" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638188257198757232" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638188257198747228" xlink:to="us-gaap_StatementLineItems_638188257198757232" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_638188257198757232" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638188257198757232" xlink:to="us-gaap_Revenues_638188257198757232" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue_638188257198757232" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638188257198757232" xlink:to="us-gaap_CostOfRevenue_638188257198757232" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638188257198757232" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638188257198757232" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638188257198757232" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_638188257198757232" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638188257198757232" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_638188257198757232" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638188257198757232" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638188257198757232" xlink:to="us-gaap_OperatingIncomeLoss_638188257198757232" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense_638188257198757232" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638188257198757232" xlink:to="us-gaap_OtherNonoperatingExpense_638188257198757232" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome_638188257198757232" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638188257198757232" xlink:to="us-gaap_OtherNonoperatingIncome_638188257198757232" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_638188257198767252" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638188257198757232" xlink:to="us-gaap_NonoperatingIncomeExpense_638188257198767252" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638188257198767252" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638188257198757232" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638188257198767252" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638188257198767252" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638188257198757232" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638188257198767252" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638188257198767252" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638188257198757232" xlink:to="us-gaap_NetIncomeLoss_638188257198767252" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_638188257198767252" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638188257198757232" xlink:to="us-gaap_EarningsPerShareBasic_638188257198767252" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_638188257198767252" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638188257198757232" xlink:to="us-gaap_EarningsPerShareDiluted_638188257198767252" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638188257198767252" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638188257198757232" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638188257198767252" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638188257198767252" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638188257198757232" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638188257198767252" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical" xlink:type="extended" xlink:title="00205 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_411762" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638188257198777241" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_411762" xlink:to="us-gaap_StatementTable_638188257198777241" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_638188257198777241" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638188257198777241" xlink:to="us-gaap_IncomeStatementLocationAxis_638188257198777241" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_638188257198777241" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_638188257198777241" xlink:to="us-gaap_IncomeStatementLocationDomain_638188257198777241" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember_638188257198777241" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638188257198777241" xlink:to="us-gaap_CostOfSalesMember_638188257198777241" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_638188257198777241" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638188257198777241" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_638188257198777241" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_638188257198777241" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638188257198777241" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_638188257198777241" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638188257198777241" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638188257198777241" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638188257198777241" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_638188257198777241" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638188257198777241" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_638188257198777241" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency" xlink:type="extended" xlink:title="00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_676" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638188257198787241" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_676" xlink:to="us-gaap_StatementTable_638188257198787241" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_638188257198787241" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638188257198787241" xlink:to="us-gaap_StatementEquityComponentsAxis_638188257198787241" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638188257198787241" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638188257198787241" xlink:to="us-gaap_CommonStockMember_638188257198787241" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_638188257198787241" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638188257198787241" xlink:to="us-gaap_AdditionalPaidInCapitalMember_638188257198787241" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_638188257198787241" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638188257198787241" xlink:to="us-gaap_RetainedEarningsMember_638188257198787241" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638188257198787241" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638188257198787241" xlink:to="us-gaap_EquityComponentDomain_638188257198787241" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638188257198787241" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638188257198787241" xlink:to="us-gaap_StatementLineItems_638188257198787241" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638188257198787241" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638188257198787241" xlink:to="us-gaap_StockholdersEquity_638188257198787241" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_638188257198787241" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638188257198787241" xlink:to="us-gaap_SharesOutstanding_638188257198787241" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_StockIssuedDuringPeriodValueSalesAgreement" xlink:label="plx_StockIssuedDuringPeriodValueSalesAgreement_638188257198787241" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638188257198787241" xlink:to="plx_StockIssuedDuringPeriodValueSalesAgreement_638188257198787241" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_StockIssuedDuringPeriodSharesSalesAgreement" xlink:label="plx_StockIssuedDuringPeriodSharesSalesAgreement_638188257198787241" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638188257198787241" xlink:to="plx_StockIssuedDuringPeriodSharesSalesAgreement_638188257198787241" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_638188257198797240" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638188257198787241" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_638188257198797240" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_638188257198797240" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638188257198787241" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_638188257198797240" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_638188257198797240" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_638188257198797240" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_638188257198797240" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638188257198797240" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638188257198787241" xlink:to="us-gaap_NetIncomeLoss_638188257198797240" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638188257198797240" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638188257198787241" xlink:to="us-gaap_StockholdersEquity_638188257198797240" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_638188257198797240" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638188257198787241" xlink:to="us-gaap_SharesOutstanding_638188257198797240" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="6" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiencyParenthetical" xlink:type="extended" xlink:title="00305 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY) (Parenthetical)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_738" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638188257198797240" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_738" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638188257198797240" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_638188257198797240" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_738" xlink:to="us-gaap_CommonStockSharesAuthorized_638188257198797240" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_746" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638188257198807240" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638188257198807240" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638188257198807240" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638188257198807240" xlink:to="us-gaap_ProfitLoss_638188257198807240" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638188257198807240" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638188257198807240" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638188257198807240" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638188257198807240" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638188257198807240" xlink:to="us-gaap_ShareBasedCompensation_638188257198807240" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_638188257198807240" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638188257198807240" xlink:to="us-gaap_Depreciation_638188257198807240" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_638188257198807240" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638188257198807240" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_638188257198807240" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense_638188257198807240" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638188257198807240" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitExpense_638188257198807240" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_638188257198807240" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638188257198807240" xlink:to="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_638188257198807240" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_638188257198807240" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638188257198807240" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_638188257198807240" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638188257198807240" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638188257198807240" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638188257198807240" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_638188257198807240" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638188257198807240" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_638188257198807240" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_638188257198807240" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638188257198807240" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_638188257198807240" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_ChangeInOperatingLeaseRightOfUseAssets" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets_638188257198817240" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638188257198807240" xlink:to="plx_ChangeInOperatingLeaseRightOfUseAssets_638188257198817240" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories_638188257198817240" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638188257198807240" xlink:to="us-gaap_IncreaseDecreaseInInventories_638188257198817240" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638188257198817240" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638188257198807240" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638188257198817240" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638188257198817240" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638188257198807240" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638188257198817240" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638188257198817240" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638188257198817240" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_IncreaseDecreaseInBankDeposits" xlink:label="plx_IncreaseDecreaseInBankDeposits_638188257198817240" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638188257198817240" xlink:to="plx_IncreaseDecreaseInBankDeposits_638188257198817240" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_ProceedsFromSaleOfShortTermDeposits" xlink:label="plx_ProceedsFromSaleOfShortTermDeposits_638188257198817240" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638188257198817240" xlink:to="plx_ProceedsFromSaleOfShortTermDeposits_638188257198817240" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638188257198817240" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638188257198817240" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638188257198817240" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_638188257198817240" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638188257198817240" xlink:to="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_638188257198817240" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638188257198817240" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638188257198817240" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638188257198817240" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638188257198827239" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638188257198827239" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638188257198827239" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638188257198827239" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638188257198827239" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638188257198827239" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638188257198827239" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638188257198827239" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_638188257198827239" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_638188257198827239" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638188257198827239" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638188257198827239" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638188257198827239" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638188257198827239" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6381882571988272391" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6381882571988272391" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638188257198827239" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638188257198827239" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_638188257198837241" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638188257198827239" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_638188257198837241" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_638188257198837241" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638188257198827239" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_638188257198837241" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_638188257198837241" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_638188257198837241" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet_638188257198837241" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_638188257198837241" xlink:to="us-gaap_InterestPaidNet_638188257198837241" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_InterestReceivedNet" xlink:label="plx_InterestReceivedNet_638188257198837241" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_638188257198837241" xlink:to="plx_InterestReceivedNet_638188257198837241" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureSignificantAccountingPolicies" xlink:type="extended" xlink:title="10101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_802" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_638188257198847243" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_802" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_638188257198847243" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureInventories" xlink:type="extended" xlink:title="10201 - Disclosure - INVENTORIES">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock_638188257198847243" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_8" xlink:to="us-gaap_InventoryDisclosureTextBlock_638188257198847243" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurement" xlink:type="extended" xlink:title="10301 - Disclosure - FAIR VALUE MEASUREMENT">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_23" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock_638188257198847243" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_23" xlink:to="us-gaap_FairValueDisclosuresTextBlock_638188257198847243" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureRevenues" xlink:type="extended" xlink:title="10401 - Disclosure - REVENUES">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:label="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" />
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_RevenueDisclosureTextBlock" xlink:label="plx_RevenueDisclosureTextBlock_638188257198847243" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:to="plx_RevenueDisclosureTextBlock_638188257198847243" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureStockTransactions" xlink:type="extended" xlink:title="10501 - Disclosure - STOCK TRANSACTIONS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_638188257198847243" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_638188257198847243" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureSubsequentEvents" xlink:type="extended" xlink:title="10601 - Disclosure - SUBSEQUENT EVENTS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_349978" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock_638188257198857239" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_349978" xlink:to="us-gaap_SubsequentEventsTextBlock_638188257198857239" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="20102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_NatureOfOperationsPolicyTextBlock" xlink:label="plx_NatureOfOperationsPolicyTextBlock_638188257198857239" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="plx_NatureOfOperationsPolicyTextBlock_638188257198857239" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_638188257198857239" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_638188257198857239" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_638188257198857239" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_638188257198857239" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_638188257198857239" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_638188257198857239" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="9" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureInventoriesTables" xlink:type="extended" xlink:title="30203 - Disclosure - INVENTORIES (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_101" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_638188257198857239" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_101" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_638188257198857239" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurementTables" xlink:type="extended" xlink:title="30303 - Disclosure - FAIR VALUE MEASUREMENT (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_129" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638188257198857239" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_129" xlink:to="us-gaap_StatementTable_638188257198857239" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638188257198867242" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638188257198857239" xlink:to="us-gaap_DebtInstrumentAxis_638188257198867242" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638188257198867242" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638188257198867242" xlink:to="us-gaap_DebtInstrumentNameDomain_638188257198867242" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_638188257198867242" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638188257198867242" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_638188257198867242" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638188257198867242" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638188257198857239" xlink:to="us-gaap_StatementLineItems_638188257198867242" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_638188257198867242" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638188257198867242" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_638188257198867242" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureRevenuesTables" xlink:type="extended" xlink:title="30403 - Disclosure - REVENUES (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:label="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_637167842398709852" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_638188257198867242" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_637167842398709852" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_638188257198867242" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails" xlink:type="extended" xlink:title="40101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_177" />
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_SignificantAccountingPoliciesTable" xlink:label="plx_SignificantAccountingPoliciesTable_638188257198867242" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_177" xlink:to="plx_SignificantAccountingPoliciesTable_638188257198867242" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638188257198867242" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_638188257198867242" xlink:to="us-gaap_TypeOfArrangementAxis_638188257198867242" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638188257198867242" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638188257198867242" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638188257198867242" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_AmendedPfizerAgreementMember" xlink:label="plx_AmendedPfizerAgreementMember_638188257198877242" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638188257198867242" xlink:to="plx_AmendedPfizerAgreementMember_638188257198877242" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_ChiesiAgreementsMember" xlink:label="plx_ChiesiAgreementsMember_638188257198877242" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638188257198867242" xlink:to="plx_ChiesiAgreementsMember_638188257198877242" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_ChiesiUSAgreementMember" xlink:label="plx_ChiesiUSAgreementMember_638188257198877242" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_ChiesiAgreementsMember_638188257198877242" xlink:to="plx_ChiesiUSAgreementMember_638188257198877242" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_ChiesiExUSAgreementMember" xlink:label="plx_ChiesiExUSAgreementMember_638188257198877242" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_ChiesiAgreementsMember_638188257198877242" xlink:to="plx_ChiesiExUSAgreementMember_638188257198877242" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" xlink:label="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_638188257198877242" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638188257198867242" xlink:to="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_638188257198877242" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_638188257198877242" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_638188257198867242" xlink:to="dei_LegalEntityAxis_638188257198877242" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_638188257198877242" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_638188257198877242" xlink:to="dei_EntityDomain_638188257198877242" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember_638188257198877242" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_638188257198877242" xlink:to="plx_ProtalixBioTherapeuticsIncorporationMember_638188257198877242" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_638188257198877242" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_638188257198867242" xlink:to="srt_StatementGeographicalAxis_638188257198877242" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_638188257198877242" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis_638188257198877242" xlink:to="srt_SegmentGeographicalDomain_638188257198877242" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_BR" xlink:label="country_BR_638188257198877242" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_638188257198877242" xlink:to="country_BR_638188257198877242" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638188257198877242" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_638188257198867242" xlink:to="srt_RangeAxis_638188257198877242" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638188257198887240" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638188257198877242" xlink:to="srt_RangeMember_638188257198887240" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638188257198887240" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638188257198887240" xlink:to="srt_MinimumMember_638188257198887240" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638188257198887240" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638188257198887240" xlink:to="srt_MaximumMember_638188257198887240" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638188257198887240" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_638188257198867242" xlink:to="us-gaap_DebtInstrumentAxis_638188257198887240" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638188257198887240" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638188257198887240" xlink:to="us-gaap_DebtInstrumentNameDomain_638188257198887240" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_ConvertibleNotesDue2021And2024Member" xlink:label="plx_ConvertibleNotesDue2021And2024Member_638188257198887240" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638188257198887240" xlink:to="plx_ConvertibleNotesDue2021And2024Member_638188257198887240" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_638188257198887240" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_ConvertibleNotesDue2021And2024Member_638188257198887240" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_638188257198887240" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638188257198887240" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_638188257198867242" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638188257198887240" order="6" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638188257198887240" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638188257198887240" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638188257198887240" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_AtMarketEquityOfferingMember" xlink:label="plx_AtMarketEquityOfferingMember_638188257198887240" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638188257198887240" xlink:to="plx_AtMarketEquityOfferingMember_638188257198887240" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_AtmEquityOfferingSalesAgreementMember" xlink:label="plx_AtmEquityOfferingSalesAgreementMember_638188257198897241" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638188257198887240" xlink:to="plx_AtmEquityOfferingSalesAgreementMember_638188257198897241" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:label="plx_SignificantAccountingPoliciesLineItems_638188257198897241" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_638188257198867242" xlink:to="plx_SignificantAccountingPoliciesLineItems_638188257198897241" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_UpfrontNonrefundableNoncreditablePaymentReceivable" xlink:label="plx_UpfrontNonrefundableNoncreditablePaymentReceivable_638188257198897241" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638188257198897241" xlink:to="plx_UpfrontNonrefundableNoncreditablePaymentReceivable_638188257198897241" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638188257198897241" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638188257198897241" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638188257198897241" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638188257198897241" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638188257198897241" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638188257198897241" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_SaleOfStockMaximumOfferingPrice" xlink:label="plx_SaleOfStockMaximumOfferingPrice_638188257198897241" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638188257198897241" xlink:to="plx_SaleOfStockMaximumOfferingPrice_638188257198897241" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638188257198897241" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638188257198897241" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638188257198897241" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638188257198897241" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638188257198897241" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638188257198897241" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_AdditionalAmountsPayableToCoverDevelopmentCosts" xlink:label="plx_AdditionalAmountsPayableToCoverDevelopmentCosts_638188257198907242" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638188257198897241" xlink:to="plx_AdditionalAmountsPayableToCoverDevelopmentCosts_638188257198907242" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_AgreementAmendmentPaymentReceivable" xlink:label="plx_AgreementAmendmentPaymentReceivable_638188257198907242" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638188257198897241" xlink:to="plx_AgreementAmendmentPaymentReceivable_638188257198907242" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" xlink:label="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones_638188257198907242" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638188257198897241" xlink:to="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones_638188257198907242" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" xlink:label="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones_638188257198907242" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638188257198897241" xlink:to="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones_638188257198907242" order="10" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_PaymentOnNetSalesPercentage" xlink:label="plx_PaymentOnNetSalesPercentage_638188257198907242" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638188257198897241" xlink:to="plx_PaymentOnNetSalesPercentage_638188257198907242" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_638188257198907242" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638188257198897241" xlink:to="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_638188257198907242" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_638188257198907242" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638188257198897241" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_638188257198907242" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_RevenuePerformanceObligationNumber" xlink:label="plx_RevenuePerformanceObligationNumber_638188257198917240" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638188257198897241" xlink:to="plx_RevenuePerformanceObligationNumber_638188257198917240" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount_638188257198917240" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638188257198897241" xlink:to="us-gaap_DebtInstrumentCarryingAmount_638188257198917240" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_MaintainOfMinimumCashBalance" xlink:label="plx_MaintainOfMinimumCashBalance_638188257198917240" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638188257198897241" xlink:to="plx_MaintainOfMinimumCashBalance_638188257198917240" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails" xlink:type="extended" xlink:title="40201 - Disclosure - INVENTORIES (Schedule of Inventory) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_261" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_638188257198917240" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_261" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves_638188257198917240" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_638188257198917240" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_261" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves_638188257198917240" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_638188257198917240" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_261" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves_638188257198917240" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_638188257198927242" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_261" xlink:to="us-gaap_InventoryNet_638188257198927242" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails" xlink:type="extended" xlink:title="40301 - Disclosure - FAIR VALUE MEASUREMENT (Schedule of Fair Value Assumptions) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_566" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638188257198927242" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_566" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638188257198927242" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638188257198927242" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638188257198927242" xlink:to="us-gaap_DebtInstrumentAxis_638188257198927242" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638188257198927242" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638188257198927242" xlink:to="us-gaap_DebtInstrumentNameDomain_638188257198927242" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_ConvertibleNotesDue2021And2024Member" xlink:label="plx_ConvertibleNotesDue2021And2024Member_638188257198927242" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638188257198927242" xlink:to="plx_ConvertibleNotesDue2021And2024Member_638188257198927242" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_638188257198927242" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_ConvertibleNotesDue2021And2024Member_638188257198927242" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_638188257198927242" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_638188257198927242" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638188257198927242" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_638188257198927242" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638188257199007243" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_638188257198927242" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638188257199007243" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member_638188257199007243" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638188257199007243" xlink:to="us-gaap_FairValueInputsLevel3Member_638188257199007243" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_638188257199007243" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638188257198927242" xlink:to="us-gaap_MeasurementInputTypeAxis_638188257199007243" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_638188257199007243" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis_638188257199007243" xlink:to="us-gaap_MeasurementInputTypeDomain_638188257199007243" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember_638188257199007243" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638188257199007243" xlink:to="us-gaap_MeasurementInputSharePriceMember_638188257199007243" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember_638188257199007243" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638188257199007243" xlink:to="us-gaap_MeasurementInputExpectedTermMember_638188257199007243" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_638188257199017244" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638188257199007243" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_638188257199017244" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_638188257199017244" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638188257199007243" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_638188257199017244" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_MeasurementInputYieldMember" xlink:label="plx_MeasurementInputYieldMember_638188257199017244" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638188257199007243" xlink:to="plx_MeasurementInputYieldMember_638188257199017244" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638188257199017244" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638188257198927242" xlink:to="us-gaap_StatementLineItems_638188257199017244" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMeasurementInput" xlink:label="us-gaap_DebtInstrumentMeasurementInput_638188257199017244" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638188257199017244" xlink:to="us-gaap_DebtInstrumentMeasurementInput_638188257199017244" order="1" use="optional" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails" xlink:type="extended" xlink:title="40302 - Disclosure - FAIR VALUE MEASUREMENT (Additional Information) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_584" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638188257199017244" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_584" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638188257199017244" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_638188257199017244" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638188257199017244" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_638188257199017244" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638188257199017244" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_638188257199017244" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638188257199017244" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member_638188257199017244" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638188257199017244" xlink:to="us-gaap_FairValueInputsLevel3Member_638188257199017244" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638188257199017244" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638188257199017244" xlink:to="us-gaap_DebtInstrumentAxis_638188257199017244" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638188257199027244" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638188257199017244" xlink:to="us-gaap_DebtInstrumentNameDomain_638188257199027244" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_638188257199027244" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638188257199027244" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_638188257199027244" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638188257199027244" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638188257199017244" xlink:to="us-gaap_StatementLineItems_638188257199027244" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount_638188257199027244" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638188257199027244" xlink:to="us-gaap_DebtInstrumentCarryingAmount_638188257199027244" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures_638188257199027244" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638188257199027244" xlink:to="us-gaap_ConvertibleDebtFairValueDisclosures_638188257199027244" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureRevenuesDetails" xlink:type="extended" xlink:title="40401 - Disclosure - REVENUES (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:label="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638188257199027244" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:to="us-gaap_StatementTable_638188257199027244" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_638188257199027244" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638188257199027244" xlink:to="srt_ProductOrServiceAxis_638188257199027244" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_638188257199027244" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_638188257199027244" xlink:to="srt_ProductsAndServicesDomain_638188257199027244" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember_638188257199027244" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638188257199027244" xlink:to="us-gaap_ProductMember_638188257199027244" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember_638188257199027244" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638188257199027244" xlink:to="us-gaap_LicenseAndServiceMember_638188257199027244" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_638188257199027244" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638188257199027244" xlink:to="srt_StatementGeographicalAxis_638188257199027244" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_638188257199027244" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis_638188257199027244" xlink:to="srt_SegmentGeographicalDomain_638188257199027244" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_PfizerMember" xlink:label="plx_PfizerMember_638188257199037243" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_638188257199027244" xlink:to="plx_PfizerMember_638188257199037243" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_BR" xlink:label="country_BR_638188257199037243" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_638188257199027244" xlink:to="country_BR_638188257199037243" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_ChiesiMember" xlink:label="plx_ChiesiMember_638188257199037243" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_638188257199027244" xlink:to="plx_ChiesiMember_638188257199037243" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638188257199037243" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638188257199027244" xlink:to="us-gaap_StatementLineItems_638188257199037243" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_638188257199037243" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638188257199037243" xlink:to="us-gaap_Revenues_638188257199037243" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureStockTransactionsDetails" xlink:type="extended" xlink:title="40501 - Disclosure - STOCK TRANSACTIONS (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable_638188257199037243" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract_1" xlink:to="us-gaap_ScheduleOfStockByClassTable_638188257199037243" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638188257199037243" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638188257199037243" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638188257199037243" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638188257199037243" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638188257199037243" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638188257199037243" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_AtmEquityOfferingSalesAgreementMember" xlink:label="plx_AtmEquityOfferingSalesAgreementMember_638188257199037243" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638188257199037243" xlink:to="plx_AtmEquityOfferingSalesAgreementMember_638188257199037243" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems_638188257199037243" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638188257199037243" xlink:to="us-gaap_ClassOfStockLineItems_638188257199037243" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638188257199037243" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638188257199037243" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638188257199037243" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638188257199037243" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638188257199037243" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638188257199037243" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="40601 - Disclosure - SUBSEQUENT EVENTS (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable_638188257199047243" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable_638188257199047243" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_638188257199047243" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638188257199047243" xlink:to="us-gaap_SubsequentEventTypeAxis_638188257199047243" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_638188257199047243" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_638188257199047243" xlink:to="us-gaap_SubsequentEventTypeDomain_638188257199047243" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_638188257199047243" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_638188257199047243" xlink:to="us-gaap_SubsequentEventMember_638188257199047243" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems_638188257199047243" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638188257199047243" xlink:to="us-gaap_SubsequentEventLineItems_638188257199047243" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_StockIssuedDuringPeriodValueSalesAgreement" xlink:label="plx_StockIssuedDuringPeriodValueSalesAgreement_638188257199047243" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638188257199047243" xlink:to="plx_StockIssuedDuringPeriodValueSalesAgreement_638188257199047243" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20230331.xsd#plx_StockIssuedDuringPeriodSharesSalesAgreement" xlink:label="plx_StockIssuedDuringPeriodSharesSalesAgreement_638188257199047243" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638188257199047243" xlink:to="plx_StockIssuedDuringPeriodSharesSalesAgreement_638188257199047243" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638188257199047243" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638188257199047243" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638188257199047243" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638188257199047243" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638188257199047243" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638188257199047243" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140264514702608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Apr. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33357<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PROTALIX BIOTHERAPEUTICS,&#160;INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">65-0643773<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2 University Plaza<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Hackensack<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07601<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">696-9345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, $0.001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PLX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSEAMER<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,414,917<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001006281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140264513804816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 33,036<span></span>
</td>
<td class="nump">$ 17,111<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShortTermBankDeposits', window );">Short-term bank deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,069<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable - Trade</a></td>
<td class="nump">1,304<span></span>
</td>
<td class="nump">4,586<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other assets</a></td>
<td class="nump">758<span></span>
</td>
<td class="nump">1,310<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">20,303<span></span>
</td>
<td class="nump">16,804<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">55,401<span></span>
</td>
<td class="nump">44,880<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>NON-CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent', window );">Funds in respect of employee rights upon retirement</a></td>
<td class="nump">1,252<span></span>
</td>
<td class="nump">1,267<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">4,704<span></span>
</td>
<td class="nump">4,553<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right of use assets</a></td>
<td class="nump">5,202<span></span>
</td>
<td class="nump">5,087<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">66,559<span></span>
</td>
<td class="nump">55,787<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract', window );"><strong>Accounts payable and accruals:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Trade</a></td>
<td class="nump">5,105<span></span>
</td>
<td class="nump">5,862<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Other</a></td>
<td class="nump">13,471<span></span>
</td>
<td class="nump">12,271<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">1,149<span></span>
</td>
<td class="nump">1,118<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contracts liability</a></td>
<td class="nump">11,790<span></span>
</td>
<td class="nump">13,178<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">31,515<span></span>
</td>
<td class="nump">32,429<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>LONG TERM LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Convertible notes</a></td>
<td class="nump">28,267<span></span>
</td>
<td class="nump">28,187<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent', window );">Liability for employee rights upon retirement</a></td>
<td class="nump">1,617<span></span>
</td>
<td class="nump">1,642<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">4,152<span></span>
</td>
<td class="nump">4,169<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total long term liabilities</a></td>
<td class="nump">34,036<span></span>
</td>
<td class="nump">33,998<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">65,551<span></span>
</td>
<td class="nump">66,427<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">COMMITMENTS</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)</a></td>
<td class="nump">1,008<span></span>
</td>
<td class="num">(10,640)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity (net of capital deficiency)</a></td>
<td class="nump">$ 66,559<span></span>
</td>
<td class="nump">$ 55,787<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShortTermBankDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of deposits held with banks for short period, usually less than one year or the normal operating cycle, whichever is longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ShortTermBankDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1703-114919<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1731-114919<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for pension, other postretirement and postemployment benefits, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1703-114919<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1731-114919<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140264510177264">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">TOTAL REVENUE</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 9,588<span></span>
</td>
<td class="nump">$ 16,085<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">COST OF GOODS SOLD</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(3,085)<span></span>
</td>
<td class="num">(6,034)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">RESEARCH AND DEVELOPMENT EXPENSES</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">(5,847)<span></span>
</td>
<td class="num">(8,767)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">SELLING, GENERAL AND ADMINISTRATIVE EXPENSES</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="num">(3,115)<span></span>
</td>
<td class="num">(3,154)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">OPERATING LOSS</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,459)<span></span>
</td>
<td class="num">(1,870)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingExpense', window );">FINANCIAL EXPENSES</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(649)<span></span>
</td>
<td class="num">(618)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">FINANCIAL INCOME</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">172<span></span>
</td>
<td class="nump">202<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">FINANCIAL EXPENSES, NET</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(477)<span></span>
</td>
<td class="num">(416)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">LOSS BEFORE TAXES ON INCOME</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,936)<span></span>
</td>
<td class="num">(2,286)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">TAXES ON INCOME</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(195)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET LOSS FOR THE PERIOD</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (3,131)<span></span>
</td>
<td class="num">$ (2,286)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">LOSS PER SHARE OF COMMON STOCK - BASIC</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (0.05)<span></span>
</td>
<td class="num">$ (0.05)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">LOSS PER SHARE OF COMMON STOCK - DILUTED</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (0.05)<span></span>
</td>
<td class="num">$ (0.05)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING LOSS PER SHARE - BASIC</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">57,480,009<span></span>
</td>
<td class="nump">45,843,563<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING LOSS PER SHARE - DILUTED</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">57,480,009<span></span>
</td>
<td class="nump">45,843,563<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Goods</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">TOTAL REVENUE</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 5,066<span></span>
</td>
<td class="nump">$ 9,028<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember', window );">License and R&amp;D Services</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">TOTAL REVENUE</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 4,522<span></span>
</td>
<td class="nump">$ 7,057<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><b style="font-size:8pt;font-weight:bold;">(1) Includes share-based compensation</b></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><b style="font-size:8pt;font-weight:bold;">(2) Includes share-based compensation</b></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><b style="font-size:8pt;font-weight:bold;">(3) Includes share-based compensation</b></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140264513358144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of goods sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation</a></td>
<td class="nump">$ 58<span></span>
</td>
<td class="num">$ (6)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation</a></td>
<td class="nump">180<span></span>
</td>
<td class="nump">76<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation</a></td>
<td class="nump">$ 308<span></span>
</td>
<td class="nump">$ 766<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140264513476064">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 46<span></span>
</td>
<td class="nump">$ 368,852<span></span>
</td>
<td class="num">$ (374,934)<span></span>
</td>
<td class="num">$ (6,036)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">45,556,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation related to stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">149<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">149<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures', window );">Share-based compensation related to restricted stock awards</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">687<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">687<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares', window );">Share-based compensation related to restricted stock awards (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">759,482<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,286)<span></span>
</td>
<td class="num">(2,286)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 46<span></span>
</td>
<td class="nump">369,688<span></span>
</td>
<td class="num">(377,220)<span></span>
</td>
<td class="num">(7,486)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">46,316,129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 54<span></span>
</td>
<td class="nump">379,167<span></span>
</td>
<td class="num">(389,861)<span></span>
</td>
<td class="num">(10,640)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">53,790,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodValueSalesAgreement', window );">Issuance of common stock under the Sales Agreement, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">14,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,233<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodSharesSalesAgreement', window );">Issuance of common stock under the Sales Agreement, net (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">8,212,482<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation related to stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">453<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">453<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures', window );">Share-based compensation related to restricted stock awards</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,131)<span></span>
</td>
<td class="num">(3,131)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 62<span></span>
</td>
<td class="nump">$ 393,938<span></span>
</td>
<td class="num">$ (392,992)<span></span>
</td>
<td class="nump">$ 1,008<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">62,002,649<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Common stock, $0.001 par value; Authorized &#8211; as of March&#160;31, 2023 and 2022 &#8211; 144,000,000 and 120,000,000 shares, respectively.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of recognized equity-based compensation during the period for restricted stock awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Restricted Stock Awards Net Of Forfeitures Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_StockIssuedDuringPeriodSharesSalesAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Sales Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_StockIssuedDuringPeriodSharesSalesAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_StockIssuedDuringPeriodValueSalesAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in a sales agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_StockIssuedDuringPeriodValueSalesAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140264517434976">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS EQUITY (CAPITAL DEFICIENCY)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="nump">144,000,000<span></span>
</td>
<td class="nump">120,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140264513503744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (3,131)<span></span>
</td>
<td class="num">$ (2,286)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments required to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">546<span></span>
</td>
<td class="nump">836<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">280<span></span>
</td>
<td class="nump">270<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized', window );">Financial income, net (mainly exchange differences)</a></td>
<td class="num">(91)<span></span>
</td>
<td class="num">(198)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitExpense', window );">Changes in accrued liability for employee rights upon retirement</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement', window );">Loss on amounts funded in respect of employee rights upon retirement</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt issuance costs and debt discount</a></td>
<td class="nump">80<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Decrease in contracts liability (including non-current portion)</a></td>
<td class="num">(1,388)<span></span>
</td>
<td class="num">(2,644)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Decrease (increase) in accounts receivable-trade and other assets</a></td>
<td class="nump">3,823<span></span>
</td>
<td class="num">(2,314)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ChangeInOperatingLeaseRightOfUseAssets', window );">Changes in operating lease right of use assets, net</a></td>
<td class="nump">9<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Decrease (increase) in inventories</a></td>
<td class="num">(3,499)<span></span>
</td>
<td class="nump">1,360<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Increase (decrease) in accounts payable and accruals</a></td>
<td class="nump">353<span></span>
</td>
<td class="num">(1,011)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(2,998)<span></span>
</td>
<td class="num">(5,829)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_IncreaseDecreaseInBankDeposits', window );">Investment in bank deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ProceedsFromSaleOfShortTermDeposits', window );">Proceeds from sale of short-term deposits</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(248)<span></span>
</td>
<td class="num">(229)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Amounts funded in respect of employee rights upon retirement, net</a></td>
<td class="num">(20)<span></span>
</td>
<td class="num">(28)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">4,732<span></span>
</td>
<td class="num">(16,257)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock under the Sales Agreement, net</a></td>
<td class="nump">14,233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">14,233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS</a></td>
<td class="num">(42)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</a></td>
<td class="nump">15,925<span></span>
</td>
<td class="num">(22,097)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD</a></td>
<td class="nump">17,111<span></span>
</td>
<td class="nump">38,985<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">BALANCE OF CASH AND CASH EQUIVALENTS AT END OF PERIOD</a></td>
<td class="nump">33,036<span></span>
</td>
<td class="nump">16,888<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchase of property and equipment</a></td>
<td class="nump">326<span></span>
</td>
<td class="nump">67<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease right of use assets obtained in exchange for new operating lease liabilities</a></td>
<td class="nump">312<span></span>
</td>
<td class="nump">99<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTARY DISCLOSURE ON CASH FLOWS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">1,078<span></span>
</td>
<td class="nump">1,120<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_InterestReceivedNet', window );">Interest received</a></td>
<td class="nump">$ 78<span></span>
</td>
<td class="nump">$ 36<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ChangeInOperatingLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Change in Operating Lease Right Of use Assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ChangeInOperatingLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (loss) on amounts funded in respect of employee rights upon retirement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_IncreaseDecreaseInBankDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deposits held with banks.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_IncreaseDecreaseInBankDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_InterestReceivedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash received for interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_InterestReceivedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ProceedsFromSaleOfShortTermDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of short-term deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ProceedsFromSaleOfShortTermDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossUnrealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123371682&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost (reversal of cost) for pension and other postretirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140264510295472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;1&#160;- SIGNIFICANT ACCOUNTING POLICIES</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">a.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">General</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the &#8220;Company&#8221;) and its wholly-owned subsidiaries, Protalix Ltd. and Protalix B.V. (collectively, the &#8220;Subsidiaries&#8221;), are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&#8217;s proprietary ProCellEx<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> protein expression system (&#8220;ProCellEx&#8221;). To date, the Company has successfully developed taliglucerase alfa (marketed under the name BioManguinhos alfataliglicerase in Brazil and certain other Latin American countries and Elelyso<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> in the rest of the territories) for the treatment of Gaucher disease that has been approved for marketing in the United States, Brazil, Israel and other markets. The Company has a number of product candidates in varying stages of the clinical development process. The Company&#8217;s strategy is to develop proprietary recombinant proteins that are therapeutically superior to existing recombinant proteins currently marketed for the same indications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The most advanced investigational drug in the Company&#8217;s product pipeline is pegunigalsidase alfa, or PRX-102, a therapeutic protein candidate for the treatment of Fabry disease, a rare, genetic lysosomal disorder, which was the subject of a phase&#160;III clinical program. The PRX-102 phase&#160;III clinical program included three separate studies, which are referred to as the <i style="font-style:italic;">BALANCE</i> study, the <i style="font-style:italic;">BRIDGE</i> study and the <i style="font-style:italic;">BRIGHT</i> study, each of which has been completed. The studies were designed to evaluate the potential for improved efficacy and better quality of life for adult patients with Fabry disease and to evaluate the safety of the Company&#8217;s drug/therapy. The phase&#160;III clinical program analyzed two potential dosing regimens: 1&#160;mg/kg every two weeks and 2&#160;mg/kg every four weeks. In addition, the phase&#160;III clinical program included two extension studies in which subjects that participated in the Company&#8217;s phase&#160;I/II clinical trials and phase&#160;III clinical trials had the opportunity to enroll and continue to be treated with PRX-102. As of March&#160;1, 2023, sponsorship of the two open-label extension studies was transferred to the Company&#8217;s development and commercialization partner for PRX-102, Chiesi Farmaceutici S.p.A. (&#8220;Chiesi&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The U.S.&#160;Food and Drug Administration (the &#8220;FDA&#8221;) has indicated that the biologics license application (&#8220;BLA&#8221;) for PRX-102 for the potential treatment of adult patients with Fabry disease resubmitted on November&#160;9, 2022 by the Company, together with Chiesi, was considered a complete, class&#160;2 response and set a PDUFA action date of&#160;May&#160;9, 2023. The initial BLA for PRX-102 was submitted to the FDA on May&#160;27, 2020 under the FDA&#8217;s Accelerated Approval pathway, and was subsequently accepted by the FDA and granted Priority Review designation. However, in April 2021, the FDA issued a Complete Response Letter (CRL) in response to the initial BLA. In preparation for the BLA resubmission, the Company and Chiesi participated in a Type&#160;A (End of Review) meeting with the FDA on September&#160;9, 2021. As part of the meeting minutes provided by the FDA, which included the preliminary comments and meeting discussion, the FDA, in principle, agreed that the data package proposed to the FDA for a BLA resubmission has the potential to support a traditional approval of PRX-102 for the treatment of Fabry disease. The data package in the BLA resubmission, given the change in the regulatory landscape in the United States, included the final two-year analyses of the Company&#8217;s phase&#160;III <i style="font-style:italic;">BALANCE</i> clinical trial of PRX-102, which was completed in July 2022, and long-term data from the Company&#8217;s open-label extension study of PRX-102 in adult patients treated with a 2&#160;mg/kg every four&#160;weeks dosage of PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On February&#160;7, 2022, the Company, together with Chiesi, submitted a Marketing Authorization Application (&#8220;MAA&#8221;) for PRX-102 to the European Medicines Agency (&#8220;EMA&#8221;) which was subsequently validated by the EMA. The submission was made after the October&#160;8, 2021 meeting the Company held, together with Chiesi, with the Rapporteur and Co-Rapporteur of the EMA regarding PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">The MAA submission included a comprehensive set of preclinical, clinical and manufacturing data compiled from the Company&#8217;s completed and ongoing clinical studies evaluating PRX-102 as a potential alternative treatment for adult patients with Fabry disease, including data from the Company&#8217;s completed 12&#8211;month switch&#8211;over phase&#160;III <i style="font-style:italic;">BRIGHT</i>&#160;clinical trial in adult patients with Fabry disease treated with a 2&#160;mg/kg every four&#160;weeks dosage to support an additional potential treatment regimen for Fabry patients. As part of the EMA review process, Chiesi and the Company responded to the Day&#160;120 list of questions in September 2022 (following a 3-month clock-stop period) and the list of outstanding issues of Day&#160;180 in December 2022. An essential portion of the Day&#160;120 response included the submission of the final analysis of the two-year <i style="font-style:italic;">BALANCE</i> study (the final Clinical Study Report), and an interim analysis of the </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Company&#8217;s long-term, open-label extension study of PRX-102 in adult patients with Fabry disease treated with the 2&#160;mg/kg every four&#160;weeks dosage.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On February&#160;24, 2023, the Company, together with Chiesi, announced that the EMA&#8217;s Committee for Medicinal Products for Human Use (the &#8220;CHMP&#8221;) adopted a positive opinion, recommending marketing authorization for PRX-102. The CHMP opinion was referred for final action to the European Commission (the &#8220;EC&#8221;). A final EC decision on the MAA is expected in the beginning of&#160;May 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In addition to PRX-102, the Company&#8217;s product pipeline currently includes, among other candidates:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">PRX-115, the Company&#8217;s plant cell-expressed recombinant PEGylated uricase (urate oxidase) &#8211; a chemically modified enzyme to treat severe gout; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">PRX-119, the Company&#8217;s plant cell-expressed PEGylated recombinant human DNase&#160;I product candidate being designed to elongate half-life in the circulation for NETs-related diseases.</span></td></tr></table><div style="margin-top:10pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Obtaining marketing approval with respect to any product candidate in any country is dependent on the Company&#8217;s ability to implement the necessary regulatory steps required to obtain such approvals. The Company cannot reasonably predict the outcome of these activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On July&#160;2, 2021, the Company entered into an At The Market Offering Agreement (the &#8220;2021 Sales Agreement&#8221;) with H.C.&#160;Wainwright &amp; Co., LLC, as the Company&#8217;s sales agent (the &#8220;Agent&#8221;) which was amended on May&#160;2, 2022. Pursuant to the terms of the 2021 Sales Agreement, the Company was able to sell, from time to time through the Agent, shares of its common stock, par value $0.001 per share (the &#8220;Common Stock&#8221;), having an aggregate offering price of up to $20.0&#160;million (the &#8220;ATM Shares&#8221;). Upon execution of the 2021 Sales Agreement, the Company terminated the ATM Equity Offering<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">SM</sup> Sales Agreement it had entered into on October&#160;1, 2020 with BofA Securities, Inc. (&#8220;BofA Securities&#8221;). During the term of the sales agreement with BofA Securities, the Company sold a total of 3,296,123 shares of Common Stock for total gross proceeds of approximately $13.8&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">As of March&#160;31, 2023, the Company sold a total of 13,980,060 ATM Shares for total gross proceeds of approximately $20.0&#160;million under the 2021 Sales Agreement, thereby completing the ATM program under said agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On February&#160;27, 2023, the Company entered into an At The Market Offering Agreement (the &#8220;2023 Sales Agreement&#8221;) with the Agent. Pursuant to the terms of the 2023 Sales Agreement, the Company may sell, from time to time through the Agent, ATM Shares having an aggregate offering price of up to $20.0&#160;million. As of March&#160;31, 2023, shares of Common Stock for total gross proceeds of approximately $16.5&#160;million remain available to be sold under the 2023 Sales Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On October&#160;19, 2017, Protalix Ltd. and Chiesi entered into an Exclusive License and Supply Agreement (the &#8220;Chiesi Ex-US Agreement&#8221;) pursuant to which Protalix Ltd. granted to Chiesi an exclusive license for all markets outside of the United States to commercialize pegunigalsidase alfa. On July&#160;23, 2018, Protalix Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the &#8220;Chiesi US Agreement&#8221;) with respect to the commercialization of pegunigalsidase alfa in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">Under each of the Chiesi Ex-US Agreement and the Chiesi US Agreement (collectively, the &#8220;Chiesi Agreements&#8221;), Chiesi made an upfront payment to Protalix&#160;Ltd. of $25.0&#160;million in connection with the execution of each agreement. In addition, under the Chiesi Ex-US Agreement, Protalix&#160;Ltd. is entitled to additional payments of up to $25.0&#160;million in pegunigalsidase alfa development costs and to receive additional payments of up to $320.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. Under the Chiesi US Agreement, Protalix&#160;Ltd. is entitled to payments of up to a maximum of $20.0&#160;million to cover development costs for pegunigalsidase alfa and to receive additional payments of up to a maximum of $760.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. To date, Protalix Ltd. has received the complete amount of development costs to which it is entitled under the Chiesi Agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">Under the terms of both of the Chiesi Agreements, Protalix Ltd. will manufacture all of the pegunigalsidase alfa needed under the agreements, subject to certain exceptions, and Chiesi will purchase pegunigalsidase alfa from Protalix, subject to certain terms and conditions. Under the Chiesi Ex-US Agreement, Chiesi is required to make tiered payments of 15% to 35% of its net sales, depending on the amount of annual sales outside of the United States, as consideration for product supply. Under the Chiesi US Agreement, Chiesi is required to make tiered payments of 15% to 40% of its net sales, depending on the amount of annual sales in the United States, as consideration for product supply.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">On May&#160;13, 2021, the Company signed a binding term sheet with Chiesi pursuant to which the Company and Chiesi amended the Chiesi Agreements in order to provide the Company with near-term capital. Chiesi agreed to make a $10.0&#160;million payment to the Company before the end of the second quarter of 2021 in exchange for a $25.0&#160;million reduction in a longer term regulatory milestone payment provided in the Chiesi EX-US Agreement. All other regulatory and commercial milestone payments remain unchanged. The Company received the payment in June&#160;2021. The Company also agreed to negotiate certain manufacturing related matters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">Since its approval by the FDA, taliglucerase alfa has been marketed by Pfizer Inc. (&#8220;Pfizer&#8221;) in accordance with the exclusive license and supply agreement entered into between Protalix Ltd. and Pfizer, which is referred to herein as the Pfizer Agreement. In October 2015, Protalix Ltd. and Pfizer entered into an amended exclusive license and supply agreement, which is referred to herein as the Amended Pfizer Agreement, pursuant to which the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for 100% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">On June&#160;18, 2013, the Company entered into a Supply and Technology Transfer Agreement (the &#8220;Brazil Agreement&#8221;) with Funda&#231;&#227;o Oswaldo Cruz (&#8220;Fiocruz&#8221;), an arm of the Brazilian Ministry of Health (the &#8220;Brazilian MoH&#8221;), for taliglucerase alfa. Fiocruz&#8217;s purchases of BioManguinhos alfataliglicerase to date have been significantly below certain agreed-upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the termination right, the Company is, at this time, continuing to supply BioManguinhos alfataliglicerase to Fiocruz and patients continue to be treated with BioManguinhos alfataliglicerase in Brazil.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">The novel coronavirus disease (&#8220;COVID-19&#8221;), which was declared by the World Health Organization to be a global pandemic on March&#160;11, 2020, has had numerous adverse effects on the global economy. To date, the Company&#8217;s clinical trials have not been adversely affected by COVID-19, although certain practices the Company adopted during the earlier stages of the pandemic in its offices and facilities in an effort to promote social distancing resulted in minor delays in the performance of administrative activities outside of the clinical programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">The Company expects to continue to incur significant expenditures in the near future due to research and developments efforts with respect to the product candidates. Under the terms of the Company&#8217;s outstanding 7.50% Senior Secured Convertible Notes due 2024 (the &#8220;2024 Notes&#8221;)<span style="font-family:'28mugxoulnobhnx';">, </span>the Company is required to comply with certain<span style="color:#222222;background:#ffffff;"> </span>financial covenants, including the maintenance of a minimum cash balance of at least $7.5&#160;million. As of March&#160;31, 2023, the Company is in<span style="background:#ffffff;"> compliance with all such covenants. </span>The Company believes that its cash and cash equivalents as of March&#160;31, 2023, together with additional funds raised from the sale of ATM Shares under the 2023 Sales Agreement subsequent to March&#160;31, 2023 are sufficient to satisfy the Company&#8217;s capital needs for at least 12&#160;months from the date that these financial statements are issued.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;">b.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;">Basis of presentation</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States (&#8220;GAAP&#8221;) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form&#160;10-K for the year ended December&#160;31, 2022, filed by the Company with the U.S.&#160;Securities and Exchange Commission (the &#8220;Commission&#8221;). The comparative balance sheet at December&#160;31, 2022 has been derived from the audited financial statements at that date. There have been no material changes in our significant accounting policies as described in our consolidated financial statements for the year ended December&#160;31, 2022.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">c.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Loss per share</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">Basic and diluted loss per share (&#8220;LPS&#8221;) are computed by dividing net loss by the weighted average number of shares of Common Stock attributable to common stockholders outstanding for each period. The calculation of diluted LPS does not include 36,292,208 shares of Common Stock underlying outstanding options and shares of Common Stock issuable upon conversion of the outstanding 2024 Notes and the exercise of outstanding warrants for the three months ended March&#160;31, 2023, and 33,004,217 shares of Common Stock underlying outstanding options and shares of Common Stock issuable upon conversion of the Company&#8217;s then outstanding 2024 Notes and the exercise of outstanding warrants for the three months ended March&#160;31, 2022 because their effect would be anti-dilutive.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">d.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Revenue recognition</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company accounts for revenue pursuant to Accounting Standards Codification, Topic 606, Revenue from Contracts with Customers (&#8220;ASC 606&#8221;). Under ASC 606, a contract with a customer exists only when: the parties to the contract have approved it and are committed to perform their respective obligations, the Company can identify each party&#8217;s rights regarding the distinct goods or services to be transferred (&#8220;performance obligations&#8221;), the Company can determine the transaction price for the goods or services to be transferred, the contract has commercial substance and it is probable that the Company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Revenues are recorded in the amount of consideration to which the Company expects to be entitled in exchange for performance obligations upon transfer of control to the customer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;">1.&#160;&#160;&#160;&#160;Revenues from selling products</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The Company recognizes revenues from selling goods at a point in time when control over the product is transferred to customers (upon delivery).</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:54pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Revenues from Chiesi Agreements</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The Company has identified two performance obligations in the Chiesi Agreements as follows: (i)&#160;the license and research and development services and (ii)&#160;the contingent performance obligation regarding future manufacturing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The Company determined that the license together with the research and development services should be combined into single performance obligation since Chiesi cannot benefit from the license without the research and development services. The research and development services are highly specialized and are dependent on the supply of the drug.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The future manufacturing is contingent on regulatory approvals of the drug and the Company deems these services to be separately identifiable from other performance obligations in the contract. Manufacturing services post-regulatory approval are not interdependent or interrelated with the license and research and development services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The transaction price was comprised of fixed consideration and variable consideration (capped research and development reimbursements). Under ASC 606, the consideration to which the Company would be entitled upon the achievement of contractual milestones, which are contingent upon the occurrence of future events, are a form of variable consideration. The Company estimates variable consideration using the most likely method. Amounts included in the transaction price are recognized only when it is probable that a significant reversal of cumulative revenues will not occur. Prior to recognizing revenue from variable consideration, the Company uses significant judgment to determine the probability of significant reversal of such revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Since the customer benefits from the research and development services as the entity performs the service, revenue from granting the license and the research and development services is recognized over time using the cost-to-cost method. The Company used significant judgment when it determined the costs expected to be incurred upon satisfying the identified performance obligation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Revenue from additional research and development services ordered by Chiesi is recognized&#160;over time using the cost-to-cost method.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:54pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Revenue from R&amp;D services</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Revenue from the research and development services is recognized over time using the cost-to-cost method since the customer benefits from the research and development services as the entity performs the service.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140264518025296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORIES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;2&#160;- INVENTORIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Inventories at March&#160;31, 2023 and December&#160;31, 2022 consisted of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Raw materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,308</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,508</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Work in progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,533</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,678</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finished goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,462</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,618</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,303</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16,804</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:1pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140264518727904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>FAIR VALUE MEASUREMENT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENT</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;3&#160;&#8211; FAIR VALUE MEASUREMENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received from the sale of an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The fair value of the financial instruments included in the working capital of the Company is usually identical or close to their carrying value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 35.45pt;">Based on a Level 3 measurement, as of March&#160;31, 2023, the fair value of the $28.75&#160;million aggregate principal amount of the Company&#8217;s outstanding 2024 Notes is approximately $41.4&#160;million. The value of these notes was estimated by implementing the binomial model. The liability component was valued based on the Income Approach. The following parameters were used:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024&#160;Notes</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Stock price (USD)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.10</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.42</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Risk free rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.19</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:73.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 62.47</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:73.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12.60</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140264594673888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract', window );"><strong>REVENUES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_RevenueDisclosureTextBlock', window );">REVENUES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;background:#ffffff;">NOTE&#160;4&#160;&#8211; REVENUES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="background:#ffffff;">The following table summarizes the Company&#8217;s disaggregation of revenues:</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Pfizer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,266</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,356</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Brazil</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,800</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,454</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Chiesi</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 218</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total revenues from selling goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,066</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Revenues from license and R&amp;D services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,522</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,057</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="color:#212529;font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_RevenueDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure pertaining to revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_RevenueDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionAndDeferredRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140264594713376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCK TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCK TRANSACTIONS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">NOTE 5 &#8211; STOCK TRANSACTIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"><b style="font-weight:bold;background:#ffffff;">At-the-Market (ATM) Offering</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">During the three months ended March&#160;31, 2023, the Company sold, in the aggregate, 8,212,482 shares of Common Stock under the 2023 Sales Agreement and the 2021 Sales Agreement. The Company generated aggregate gross proceeds equal to approximately $14.9&#160;million in connection with such sales.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140264516725712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>SUBSEQUENT EVENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTE 6 &#8211; SUBSEQUENT EVENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">During April 2023, the Company sold, in the aggregate, 3,412,268 shares of Common Stock under the 2023 Sales Agreement. The Company generated aggregate gross proceeds equal to approximately $7.9&#160;million in connection with such sales.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140264517544784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_NatureOfOperationsPolicyTextBlock', window );">General</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">a.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">General</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the &#8220;Company&#8221;) and its wholly-owned subsidiaries, Protalix Ltd. and Protalix B.V. (collectively, the &#8220;Subsidiaries&#8221;), are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&#8217;s proprietary ProCellEx<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> protein expression system (&#8220;ProCellEx&#8221;). To date, the Company has successfully developed taliglucerase alfa (marketed under the name BioManguinhos alfataliglicerase in Brazil and certain other Latin American countries and Elelyso<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> in the rest of the territories) for the treatment of Gaucher disease that has been approved for marketing in the United States, Brazil, Israel and other markets. The Company has a number of product candidates in varying stages of the clinical development process. The Company&#8217;s strategy is to develop proprietary recombinant proteins that are therapeutically superior to existing recombinant proteins currently marketed for the same indications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The most advanced investigational drug in the Company&#8217;s product pipeline is pegunigalsidase alfa, or PRX-102, a therapeutic protein candidate for the treatment of Fabry disease, a rare, genetic lysosomal disorder, which was the subject of a phase&#160;III clinical program. The PRX-102 phase&#160;III clinical program included three separate studies, which are referred to as the <i style="font-style:italic;">BALANCE</i> study, the <i style="font-style:italic;">BRIDGE</i> study and the <i style="font-style:italic;">BRIGHT</i> study, each of which has been completed. The studies were designed to evaluate the potential for improved efficacy and better quality of life for adult patients with Fabry disease and to evaluate the safety of the Company&#8217;s drug/therapy. The phase&#160;III clinical program analyzed two potential dosing regimens: 1&#160;mg/kg every two weeks and 2&#160;mg/kg every four weeks. In addition, the phase&#160;III clinical program included two extension studies in which subjects that participated in the Company&#8217;s phase&#160;I/II clinical trials and phase&#160;III clinical trials had the opportunity to enroll and continue to be treated with PRX-102. As of March&#160;1, 2023, sponsorship of the two open-label extension studies was transferred to the Company&#8217;s development and commercialization partner for PRX-102, Chiesi Farmaceutici S.p.A. (&#8220;Chiesi&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The U.S.&#160;Food and Drug Administration (the &#8220;FDA&#8221;) has indicated that the biologics license application (&#8220;BLA&#8221;) for PRX-102 for the potential treatment of adult patients with Fabry disease resubmitted on November&#160;9, 2022 by the Company, together with Chiesi, was considered a complete, class&#160;2 response and set a PDUFA action date of&#160;May&#160;9, 2023. The initial BLA for PRX-102 was submitted to the FDA on May&#160;27, 2020 under the FDA&#8217;s Accelerated Approval pathway, and was subsequently accepted by the FDA and granted Priority Review designation. However, in April 2021, the FDA issued a Complete Response Letter (CRL) in response to the initial BLA. In preparation for the BLA resubmission, the Company and Chiesi participated in a Type&#160;A (End of Review) meeting with the FDA on September&#160;9, 2021. As part of the meeting minutes provided by the FDA, which included the preliminary comments and meeting discussion, the FDA, in principle, agreed that the data package proposed to the FDA for a BLA resubmission has the potential to support a traditional approval of PRX-102 for the treatment of Fabry disease. The data package in the BLA resubmission, given the change in the regulatory landscape in the United States, included the final two-year analyses of the Company&#8217;s phase&#160;III <i style="font-style:italic;">BALANCE</i> clinical trial of PRX-102, which was completed in July 2022, and long-term data from the Company&#8217;s open-label extension study of PRX-102 in adult patients treated with a 2&#160;mg/kg every four&#160;weeks dosage of PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On February&#160;7, 2022, the Company, together with Chiesi, submitted a Marketing Authorization Application (&#8220;MAA&#8221;) for PRX-102 to the European Medicines Agency (&#8220;EMA&#8221;) which was subsequently validated by the EMA. The submission was made after the October&#160;8, 2021 meeting the Company held, together with Chiesi, with the Rapporteur and Co-Rapporteur of the EMA regarding PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">The MAA submission included a comprehensive set of preclinical, clinical and manufacturing data compiled from the Company&#8217;s completed and ongoing clinical studies evaluating PRX-102 as a potential alternative treatment for adult patients with Fabry disease, including data from the Company&#8217;s completed 12&#8211;month switch&#8211;over phase&#160;III <i style="font-style:italic;">BRIGHT</i>&#160;clinical trial in adult patients with Fabry disease treated with a 2&#160;mg/kg every four&#160;weeks dosage to support an additional potential treatment regimen for Fabry patients. As part of the EMA review process, Chiesi and the Company responded to the Day&#160;120 list of questions in September 2022 (following a 3-month clock-stop period) and the list of outstanding issues of Day&#160;180 in December 2022. An essential portion of the Day&#160;120 response included the submission of the final analysis of the two-year <i style="font-style:italic;">BALANCE</i> study (the final Clinical Study Report), and an interim analysis of the </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Company&#8217;s long-term, open-label extension study of PRX-102 in adult patients with Fabry disease treated with the 2&#160;mg/kg every four&#160;weeks dosage.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On February&#160;24, 2023, the Company, together with Chiesi, announced that the EMA&#8217;s Committee for Medicinal Products for Human Use (the &#8220;CHMP&#8221;) adopted a positive opinion, recommending marketing authorization for PRX-102. The CHMP opinion was referred for final action to the European Commission (the &#8220;EC&#8221;). A final EC decision on the MAA is expected in the beginning of&#160;May 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In addition to PRX-102, the Company&#8217;s product pipeline currently includes, among other candidates:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">PRX-115, the Company&#8217;s plant cell-expressed recombinant PEGylated uricase (urate oxidase) &#8211; a chemically modified enzyme to treat severe gout; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">PRX-119, the Company&#8217;s plant cell-expressed PEGylated recombinant human DNase&#160;I product candidate being designed to elongate half-life in the circulation for NETs-related diseases.</span></td></tr></table><div style="margin-top:10pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Obtaining marketing approval with respect to any product candidate in any country is dependent on the Company&#8217;s ability to implement the necessary regulatory steps required to obtain such approvals. The Company cannot reasonably predict the outcome of these activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On July&#160;2, 2021, the Company entered into an At The Market Offering Agreement (the &#8220;2021 Sales Agreement&#8221;) with H.C.&#160;Wainwright &amp; Co., LLC, as the Company&#8217;s sales agent (the &#8220;Agent&#8221;) which was amended on May&#160;2, 2022. Pursuant to the terms of the 2021 Sales Agreement, the Company was able to sell, from time to time through the Agent, shares of its common stock, par value $0.001 per share (the &#8220;Common Stock&#8221;), having an aggregate offering price of up to $20.0&#160;million (the &#8220;ATM Shares&#8221;). Upon execution of the 2021 Sales Agreement, the Company terminated the ATM Equity Offering<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">SM</sup> Sales Agreement it had entered into on October&#160;1, 2020 with BofA Securities, Inc. (&#8220;BofA Securities&#8221;). During the term of the sales agreement with BofA Securities, the Company sold a total of 3,296,123 shares of Common Stock for total gross proceeds of approximately $13.8&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">As of March&#160;31, 2023, the Company sold a total of 13,980,060 ATM Shares for total gross proceeds of approximately $20.0&#160;million under the 2021 Sales Agreement, thereby completing the ATM program under said agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On February&#160;27, 2023, the Company entered into an At The Market Offering Agreement (the &#8220;2023 Sales Agreement&#8221;) with the Agent. Pursuant to the terms of the 2023 Sales Agreement, the Company may sell, from time to time through the Agent, ATM Shares having an aggregate offering price of up to $20.0&#160;million. As of March&#160;31, 2023, shares of Common Stock for total gross proceeds of approximately $16.5&#160;million remain available to be sold under the 2023 Sales Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On October&#160;19, 2017, Protalix Ltd. and Chiesi entered into an Exclusive License and Supply Agreement (the &#8220;Chiesi Ex-US Agreement&#8221;) pursuant to which Protalix Ltd. granted to Chiesi an exclusive license for all markets outside of the United States to commercialize pegunigalsidase alfa. On July&#160;23, 2018, Protalix Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the &#8220;Chiesi US Agreement&#8221;) with respect to the commercialization of pegunigalsidase alfa in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">Under each of the Chiesi Ex-US Agreement and the Chiesi US Agreement (collectively, the &#8220;Chiesi Agreements&#8221;), Chiesi made an upfront payment to Protalix&#160;Ltd. of $25.0&#160;million in connection with the execution of each agreement. In addition, under the Chiesi Ex-US Agreement, Protalix&#160;Ltd. is entitled to additional payments of up to $25.0&#160;million in pegunigalsidase alfa development costs and to receive additional payments of up to $320.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. Under the Chiesi US Agreement, Protalix&#160;Ltd. is entitled to payments of up to a maximum of $20.0&#160;million to cover development costs for pegunigalsidase alfa and to receive additional payments of up to a maximum of $760.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. To date, Protalix Ltd. has received the complete amount of development costs to which it is entitled under the Chiesi Agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">Under the terms of both of the Chiesi Agreements, Protalix Ltd. will manufacture all of the pegunigalsidase alfa needed under the agreements, subject to certain exceptions, and Chiesi will purchase pegunigalsidase alfa from Protalix, subject to certain terms and conditions. Under the Chiesi Ex-US Agreement, Chiesi is required to make tiered payments of 15% to 35% of its net sales, depending on the amount of annual sales outside of the United States, as consideration for product supply. Under the Chiesi US Agreement, Chiesi is required to make tiered payments of 15% to 40% of its net sales, depending on the amount of annual sales in the United States, as consideration for product supply.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">On May&#160;13, 2021, the Company signed a binding term sheet with Chiesi pursuant to which the Company and Chiesi amended the Chiesi Agreements in order to provide the Company with near-term capital. Chiesi agreed to make a $10.0&#160;million payment to the Company before the end of the second quarter of 2021 in exchange for a $25.0&#160;million reduction in a longer term regulatory milestone payment provided in the Chiesi EX-US Agreement. All other regulatory and commercial milestone payments remain unchanged. The Company received the payment in June&#160;2021. The Company also agreed to negotiate certain manufacturing related matters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">Since its approval by the FDA, taliglucerase alfa has been marketed by Pfizer Inc. (&#8220;Pfizer&#8221;) in accordance with the exclusive license and supply agreement entered into between Protalix Ltd. and Pfizer, which is referred to herein as the Pfizer Agreement. In October 2015, Protalix Ltd. and Pfizer entered into an amended exclusive license and supply agreement, which is referred to herein as the Amended Pfizer Agreement, pursuant to which the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for 100% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">On June&#160;18, 2013, the Company entered into a Supply and Technology Transfer Agreement (the &#8220;Brazil Agreement&#8221;) with Funda&#231;&#227;o Oswaldo Cruz (&#8220;Fiocruz&#8221;), an arm of the Brazilian Ministry of Health (the &#8220;Brazilian MoH&#8221;), for taliglucerase alfa. Fiocruz&#8217;s purchases of BioManguinhos alfataliglicerase to date have been significantly below certain agreed-upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the termination right, the Company is, at this time, continuing to supply BioManguinhos alfataliglicerase to Fiocruz and patients continue to be treated with BioManguinhos alfataliglicerase in Brazil.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">The novel coronavirus disease (&#8220;COVID-19&#8221;), which was declared by the World Health Organization to be a global pandemic on March&#160;11, 2020, has had numerous adverse effects on the global economy. To date, the Company&#8217;s clinical trials have not been adversely affected by COVID-19, although certain practices the Company adopted during the earlier stages of the pandemic in its offices and facilities in an effort to promote social distancing resulted in minor delays in the performance of administrative activities outside of the clinical programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">The Company expects to continue to incur significant expenditures in the near future due to research and developments efforts with respect to the product candidates. Under the terms of the Company&#8217;s outstanding 7.50% Senior Secured Convertible Notes due 2024 (the &#8220;2024 Notes&#8221;)<span style="font-family:'28mugxoulnobhnx';">, </span>the Company is required to comply with certain<span style="color:#222222;background:#ffffff;"> </span>financial covenants, including the maintenance of a minimum cash balance of at least $7.5&#160;million. As of March&#160;31, 2023, the Company is in<span style="background:#ffffff;"> compliance with all such covenants. </span>The Company believes that its cash and cash equivalents as of March&#160;31, 2023, together with additional funds raised from the sale of ATM Shares under the 2023 Sales Agreement subsequent to March&#160;31, 2023 are sufficient to satisfy the Company&#8217;s capital needs for at least 12&#160;months from the date that these financial statements are issued.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of presentation</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;">b.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;">Basis of presentation</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States (&#8220;GAAP&#8221;) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form&#160;10-K for the year ended December&#160;31, 2022, filed by the Company with the U.S.&#160;Securities and Exchange Commission (the &#8220;Commission&#8221;). The comparative balance sheet at December&#160;31, 2022 has been derived from the audited financial statements at that date. There have been no material changes in our significant accounting policies as described in our consolidated financial statements for the year ended December&#160;31, 2022.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Loss per share</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">c.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Loss per share</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">Basic and diluted loss per share (&#8220;LPS&#8221;) are computed by dividing net loss by the weighted average number of shares of Common Stock attributable to common stockholders outstanding for each period. The calculation of diluted LPS does not include 36,292,208 shares of Common Stock underlying outstanding options and shares of Common Stock issuable upon conversion of the outstanding 2024 Notes and the exercise of outstanding warrants for the three months ended March&#160;31, 2023, and 33,004,217 shares of Common Stock underlying outstanding options and shares of Common Stock issuable upon conversion of the Company&#8217;s then outstanding 2024 Notes and the exercise of outstanding warrants for the three months ended March&#160;31, 2022 because their effect would be anti-dilutive.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue recognition</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">d.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Revenue recognition</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company accounts for revenue pursuant to Accounting Standards Codification, Topic 606, Revenue from Contracts with Customers (&#8220;ASC 606&#8221;). Under ASC 606, a contract with a customer exists only when: the parties to the contract have approved it and are committed to perform their respective obligations, the Company can identify each party&#8217;s rights regarding the distinct goods or services to be transferred (&#8220;performance obligations&#8221;), the Company can determine the transaction price for the goods or services to be transferred, the contract has commercial substance and it is probable that the Company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Revenues are recorded in the amount of consideration to which the Company expects to be entitled in exchange for performance obligations upon transfer of control to the customer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;">1.&#160;&#160;&#160;&#160;Revenues from selling products</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The Company recognizes revenues from selling goods at a point in time when control over the product is transferred to customers (upon delivery).</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:54pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Revenues from Chiesi Agreements</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The Company has identified two performance obligations in the Chiesi Agreements as follows: (i)&#160;the license and research and development services and (ii)&#160;the contingent performance obligation regarding future manufacturing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The Company determined that the license together with the research and development services should be combined into single performance obligation since Chiesi cannot benefit from the license without the research and development services. The research and development services are highly specialized and are dependent on the supply of the drug.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The future manufacturing is contingent on regulatory approvals of the drug and the Company deems these services to be separately identifiable from other performance obligations in the contract. Manufacturing services post-regulatory approval are not interdependent or interrelated with the license and research and development services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The transaction price was comprised of fixed consideration and variable consideration (capped research and development reimbursements). Under ASC 606, the consideration to which the Company would be entitled upon the achievement of contractual milestones, which are contingent upon the occurrence of future events, are a form of variable consideration. The Company estimates variable consideration using the most likely method. Amounts included in the transaction price are recognized only when it is probable that a significant reversal of cumulative revenues will not occur. Prior to recognizing revenue from variable consideration, the Company uses significant judgment to determine the probability of significant reversal of such revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Since the customer benefits from the research and development services as the entity performs the service, revenue from granting the license and the research and development services is recognized over time using the cost-to-cost method. The Company used significant judgment when it determined the costs expected to be incurred upon satisfying the identified performance obligation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Revenue from additional research and development services ordered by Chiesi is recognized&#160;over time using the cost-to-cost method.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:54pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Revenue from R&amp;D services</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Revenue from the research and development services is recognized over time using the cost-to-cost method since the customer benefits from the research and development services as the entity performs the service.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_NatureOfOperationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nature Of Operations Policy</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_NatureOfOperationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140264594713376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Raw materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,308</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,508</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Work in progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,533</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,678</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finished goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,462</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,618</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,303</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16,804</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140264517559088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member', window );">2024 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of Fair Value Assumptions</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024&#160;Notes</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Stock price (USD)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.10</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.42</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Risk free rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.19</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:73.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 62.47</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:73.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12.60</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140264594762512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract', window );"><strong>REVENUES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Company's Disaggregation of Revenues</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="background:#ffffff;">The following table summarizes the Company&#8217;s disaggregation of revenues:</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Pfizer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,266</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,356</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Brazil</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,800</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,454</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Chiesi</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 218</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total revenues from selling goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,066</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Revenues from license and R&amp;D services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,522</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,057</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionAndDeferredRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140264509362768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Feb. 27, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 02, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 13, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 23, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 19, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Oct. 31, 2015</div></th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>agreement </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Stock issuance proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,292,208<span></span>
</td>
<td class="nump">33,004,217<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=plx_AtMarketEquityOfferingMember', window );">ATM Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,980,060<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SaleOfStockMaximumOfferingPrice', window );">Sale of stock, maximum offering price</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Stock issuance proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=plx_AtmEquityOfferingSalesAgreementMember', window );">ATM Equity Offering Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,296,123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,212,482<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Stock issuance proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member', window );">2024 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_MaintainOfMinimumCashBalance', window );">Maintain of Minimum Cash Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_AmendedPfizerAgreementMember', window );">Amended Pfizer Agreement | Protalix Bio Therapeutics Incorporation | Brazil</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_CollaborativeArrangementRevenuesExpensesSharingPercentage', window );">Collaborative Arrangement Revenues and Expenses Sharing Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiAgreementsMember', window );">Chiesi Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_RevenuePerformanceObligationNumber', window );">Revenue, Performance Obligation, Number | agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember', window );">Chiesi US Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_AdditionalAmountsPayableToCoverDevelopmentCosts', window );">Additional Amounts Payable To Cover Development Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones', window );">Additional Amount Payable For Achievement Of Regulatory And Commercial Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 760,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember', window );">Chiesi US Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_PaymentOnNetSalesPercentage', window );">Payment On Net Sales Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember', window );">Chiesi US Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_PaymentOnNetSalesPercentage', window );">Payment On Net Sales Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember', window );">Chiesi Ex-US Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_AdditionalAmountsPayableToCoverDevelopmentCosts', window );">Additional Amounts Payable To Cover Development Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_AgreementAmendmentPaymentReceivable', window );">Agreement Amendment Payment Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones', window );">Change In Amount Receivable For Achievement Of Regulatory And Commercial Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones', window );">Additional Amount Payable For Achievement Of Regulatory And Commercial Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 320,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember', window );">Chiesi Ex-US Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_PaymentOnNetSalesPercentage', window );">Payment On Net Sales Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember', window );">Chiesi Ex-US Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_PaymentOnNetSalesPercentage', window );">Payment On Net Sales Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUsAgreementAndChiesiExUsAgreementMember', window );">Chiesi US Agreement and Chiesi Ex-US Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_UpfrontNonrefundableNoncreditablePaymentReceivable', window );">Non-refundable Payment Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount payable to entity for the achievement of regulatory and commercial milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_AdditionalAmountsPayableToCoverDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum amount payable to the entity to cover development costs under agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_AdditionalAmountsPayableToCoverDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_AgreementAmendmentPaymentReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreement Amendment Payment Receivable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_AgreementAmendmentPaymentReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change In Amount Receivable For Achievement Of Regulatory And Commercial Milestones</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_CollaborativeArrangementRevenuesExpensesSharingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement revenues and expense sharing percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_CollaborativeArrangementRevenuesExpensesSharingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_MaintainOfMinimumCashBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum cash balance required to be maintained under long term debt agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_MaintainOfMinimumCashBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_PaymentOnNetSalesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the payment as a percentage of future net sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_PaymentOnNetSalesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_RevenuePerformanceObligationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue, Performance Obligation, Number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_RevenuePerformanceObligationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SaleOfStockMaximumOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of stock, maximum offering price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_SaleOfStockMaximumOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_SignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_UpfrontNonrefundableNoncreditablePaymentReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of upfront, non refundable and non creditable payment receivable under the agreement for licensing rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_UpfrontNonrefundableNoncreditablePaymentReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=plx_AtMarketEquityOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=plx_AtMarketEquityOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=plx_AtmEquityOfferingSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=plx_AtmEquityOfferingSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_AmendedPfizerAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_AmendedPfizerAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=plx_ProtalixBioTherapeuticsIncorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=plx_ProtalixBioTherapeuticsIncorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_BR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_BR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_ChiesiAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUsAgreementAndChiesiExUsAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_ChiesiUsAgreementAndChiesiExUsAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140264508912928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INVENTORIES (Schedule of Inventory) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 4,308<span></span>
</td>
<td class="nump">$ 3,508<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in progress</a></td>
<td class="nump">1,533<span></span>
</td>
<td class="nump">2,678<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">14,462<span></span>
</td>
<td class="nump">10,618<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventory</a></td>
<td class="nump">$ 20,303<span></span>
</td>
<td class="nump">$ 16,804<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140264514639152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT (Schedule of Fair Value Assumptions) (Details) - 2024 Notes - Level 3<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>Y </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member', window );">Share Price.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input | $ / shares</a></td>
<td class="nump">2.10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input | Y</a></td>
<td class="nump">1.42<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member', window );">Risk free rate</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input</a></td>
<td class="nump">4.19<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input</a></td>
<td class="nump">62.47<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member', window );">Yield</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input</a></td>
<td class="nump">12.60<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure debt instrument, including, but not limited to, convertible and non-convertible debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=plx_MeasurementInputYieldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=plx_MeasurementInputYieldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140264510277296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT (Additional Information) (Details) - Level 3 - 2024 Notes<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Debt Instrument Carrying Amount</a></td>
<td class="nump">$ 28,750<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Debt Instrument Fair Value</a></td>
<td class="nump">$ 41,400<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtFairValueDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtFairValueDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140264514518128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 9,588<span></span>
</td>
<td class="nump">$ 16,085<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Goods</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">5,066<span></span>
</td>
<td class="nump">9,028<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Goods | Pfizer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">2,266<span></span>
</td>
<td class="nump">3,356<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Goods | Brazil</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">2,800<span></span>
</td>
<td class="nump">5,454<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Goods | Chiesi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">218<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember', window );">License and R&amp;D Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 4,522<span></span>
</td>
<td class="nump">$ 7,057<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=plx_PfizerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=plx_PfizerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_BR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_BR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=plx_ChiesiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=plx_ChiesiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140264517501072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK TRANSACTIONS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 02, 2021</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Stock issuance proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,233<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=plx_AtmEquityOfferingSalesAgreementMember', window );">ATM Equity Offering Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued (in shares)</a></td>
<td class="nump">3,296,123<span></span>
</td>
<td class="nump">8,212,482<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Stock issuance proceeds</a></td>
<td class="nump">$ 13,800<span></span>
</td>
<td class="nump">$ 14,900<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=plx_AtmEquityOfferingSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=plx_AtmEquityOfferingSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140264508426496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodValueSalesAgreement', window );">Issuance of common stock under the Sales Agreement, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,233<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Stock issuance proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,233<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodSharesSalesAgreement', window );">Issuance of common stock under the Sales Agreement, net (in shares)</a></td>
<td class="nump">3,412,268<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Stock issuance proceeds</a></td>
<td class="nump">$ 7,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_StockIssuedDuringPeriodSharesSalesAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Sales Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_StockIssuedDuringPeriodSharesSalesAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_StockIssuedDuringPeriodValueSalesAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in a sales agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_StockIssuedDuringPeriodValueSalesAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>plx-20230331x10q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2021"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:plx="http://www.protalix.com/20230331"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="plx-20230331.xsd" xlink:type="simple"/>
    <context id="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_E_QLG5yGnUWYSbAfH9__OQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_IL0F69SjoE2AcVxC9gRdAg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_td4XMHFZWkWCZfhPrs2Yog">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_xvyzPFwz2Ei9WGmzrZtTKA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_sessMVhLlE-60nptH85tHA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_P1TRpg9XL0SipWskVIymPg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember__Fk6t8bO9k-wg-VncCAqpg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_vOwYA9rCf0W5Bz8PPuTQvg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_bMnoYH_kPEuyqw6R4J9L2Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_B-MKROg0kkWsBATWzcCW9g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Ma9XQZkyu0yv3iLSHCbY5g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_J7EBNPBz8ESJc8H_4uZ72w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_fttaWimhoUeG-S7zMyaisw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:PfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_hmYTDCpI-ECukL-F-IOjvQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_1ErUchefYE24icEBkPux0A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_0OKK-_bib0C_UleLAi20GA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_3_31_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_WcMRAOlFCE6_UAs2eyxXCA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:PfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_3_31_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_ChiesiMember_1_EnASsBOky6dNtE7sYeqA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:ChiesiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_3_31_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_PBB8cE7vikCPoa7ZmvpzOA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_3_31_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_TLlwu1kiM067CBBRXPNrNw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_3_31_2022_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_rv5oVU7cTEWzAOzlbF-VFA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtmEquityOfferingSalesAgreementMember_aO6xvvEThkasCzfWTSPBgQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtmEquityOfferingSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtmEquityOfferingSalesAgreementMember_TYdGwaWNbE6JmroON4hlzg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtmEquityOfferingSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_M5gF58pjUEaKAVvefka9Pw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_P_C-vkYM70mz4hoQ7UVhOg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_a9VnZ-vJPkiHhaBFIDBw-A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember__GmWbcoY7kCTcvgHXmTtag">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_6rulpN2cdUS_aFAtMHgQ0Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_sRkxswHoFESpgC_hhX6rNw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_aCnJ8YZWTEKINZXa-WibNQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_plx_MeasurementInputYieldMember_fyqadwF3d0u2BkkX4IRliA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">plx:MeasurementInputYieldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_9xvbhmNJFkageC4WyZOI_Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_vCJMvVrkpEey12nFHwmq_g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtMarketEquityOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-02</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2022_cjzuDz-ZiUubY38dhB0s0A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_x-pm8I0vjUS_ATBiwepawg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_f8-sCIf2RkuxwvCb3yISvA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_O-2jNHV-AUW4fRDBPZldoA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_kovew3nQoUW7X8jAVRvjhw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_3_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_QMhb-FrbfESVBC7w8w5e4A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_3_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_ACjpei32d0mTu26aZxZF-Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_3_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_M9nMRkvbzkONqh4KPar8cg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2023_lQ4VofWCfU-ERA4iKttplQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_Am7rx-rvZUywApMit-lb-A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUsAgreementAndChiesiExUsAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-07-23</instant>
        </period>
    </context>
    <context id="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_z3hwihuoBkC5xNBh7hXP6A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUsAgreementAndChiesiExUsAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-19</instant>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_4_30_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_tROqvzE5iEKYWMElS1CURw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-04-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_o5KTQD_NWEC6IWOAHM7tDQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_H53zBT4W7kaDDa9Xye-U_Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_M0avG7-u206lSf4X6whkbA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_chSQy1P71EiszadyqHEgpA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_pTjg192DOkSYYbGFlFzhqA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="Duration_2_27_2023_To_2_27_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_Q-zSWd_o2UuvPzl41Xf3MA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtMarketEquityOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-27</startDate>
            <endDate>2023-02-27</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_0iU3Zlmqr0On_CGrbCti_Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtMarketEquityOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_NlK07qNF70WUx9TiUtAq1A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtMarketEquityOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2023_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_6M0Qz8IYh02zFSz41wRItw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="Duration_7_23_2018_To_7_23_2018_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_qGhtjJbQ70ugptcYziO39Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-23</startDate>
            <endDate>2018-07-23</endDate>
        </period>
    </context>
    <context id="Duration_7_23_2018_To_7_23_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_VXlGDMYSYka-21A_FiXp3A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-23</startDate>
            <endDate>2018-07-23</endDate>
        </period>
    </context>
    <context id="Duration_10_19_2017_To_10_19_2017_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_Sax1Fe0WOEOjE9gRCUPqYQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-19</startDate>
            <endDate>2017-10-19</endDate>
        </period>
    </context>
    <context id="Duration_10_19_2017_To_10_19_2017_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_D2oITtj5_U2sjJO37_gN5w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-19</startDate>
            <endDate>2017-10-19</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_ZgUoVauLFkSr1Jlp4jtK7Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="Duration_10_1_2015_To_10_31_2015_dei_LegalEntityAxis_plx_ProtalixBioTherapeuticsIncorporationMember_srt_StatementGeographicalAxis_country_BR_us-gaap_TypeOfArrangementAxis_plx_AmendedPfizerAgreementMember_2qZfvaa21UeJuh9OQT_1zQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:AmendedPfizerAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">plx:ProtalixBioTherapeuticsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-10-01</startDate>
            <endDate>2015-10-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_3_31_2022_N1jzYHJ1VECWf3tLdKC1jw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="Duration_5_13_2021_To_5_13_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_18jRabrPoUa3e12IYdZR0w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-13</startDate>
            <endDate>2021-05-13</endDate>
        </period>
    </context>
    <context id="As_Of_5_13_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_egFQOM62D0mceKOHvMGXcw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-13</instant>
        </period>
    </context>
    <context id="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_3yJmheSn6UeRYw8iwyMgIg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-07-23</instant>
        </period>
    </context>
    <context id="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_GyY7-odK10eb47EO_FtixA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-19</instant>
        </period>
    </context>
    <context id="As_Of_4_30_2023_HFiWapI7CUuGG9dGexPKfw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2023-04-30</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <unit id="Unit_Standard_shares_4bVAm6lD50yLNxvQT1GIoA">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Standard_pure_0xGx53TVLESXmSrWd-Jrvw">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Standard_agreement_l_AIB71m8UmKtkYDila2Og">
        <measure>plx:agreement</measure>
    </unit>
    <unit id="Unit_Divide_USD_shares_65Ko0I-nrkSGY9fEMAqs6Q">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Standard_Y_lrd4ffoII0uwy2NmYOCxhg">
        <measure>plx:Y</measure>
    </unit>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_3_31_2023_lQ4VofWCfU-ERA4iKttplQ"
      id="Hidden_qx9a_LJ0kUyO05_Ul4HyJw"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2022_H53zBT4W7kaDDa9Xye-U_Q"
      id="Hidden_-OnFasH4jEy4yn00zm1FBw"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw"
      xsi:nil="true"/>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw"
      id="Tc_vf1keXzUA0SZiNbf-gQFtQ_2_1">0001006281</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw"
      id="Tc_iXthAhY0PUuaLwtaKRluRg_3_1">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw"
      id="Tc_YagIgBr8CkaB3psguOLOnw_4_1">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw"
      id="Tc_r5VQF_iGBk2GkV5ztSH9-w_5_1">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw"
      id="Tc_p4ooJc-Mh0Cy3pka0UDOEw_6_1">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw"
      id="Narr_RTkzTGZXCk2CIM02XYHMUQ">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw"
      id="Narr_hy43Ub5jKkmONkWqhZZCIQ">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw"
      id="Narr_hdq9h3FQVEy1m0ZRBcylkQ">2023-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw"
      id="Narr_l8QwNi_xrE-VUBI9HrQPBg">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw"
      id="Narr_WhTmVY89PU-qBL4qmVMDEQ">001-33357</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw"
      id="Narr_79QOTFIVg0icwM1AhDThbw">PROTALIX BIOTHERAPEUTICS,&#160;INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw"
      id="Tc_2Ko8D2XjVkCuH7sYV9AnTw_1_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw"
      id="Narr_PA6Rn9ejhECmmEjUn1ZDKA">65-0643773</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw"
      id="Narr_rhiNRVwzUUKPTehXZil4vg">2 University Plaza</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw"
      id="Narr_a1hSC4crG0CZtuLsz-aFww">Suite 100</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw"
      id="Narr_ntzWAf97d0y4ET25dorw9g">Hackensack</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw"
      id="Narr_Hy6GUZK_I0KstzRLQNzUKg">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw"
      id="Tc_nLdBbhNsmUWRAv4IDIAcuQ_4_1">07601</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw"
      id="Narr__Km7AmpleE2wm39zx4Tx_Q">201</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw"
      id="Narr_1IZYcxARV0G91a82efDotA">696-9345</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw"
      id="Tc_w6tcv4-CtU6Amj5MCu1zVg_2_0">Common stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw"
      id="Tc__8QDTel_HEaJuO8J6f0gnQ_2_2">PLX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw"
      id="Tc_LzEOxhRwXkii79Op4RWSpw_2_4">NYSEAMER</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw"
      id="Narr_7RLc_SATfU-nz0iL8Yp6kw">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw"
      id="Narr_CbJu1IEStUGdWhkMLVl0xw">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw"
      id="Tc_7ONUbNuYZES6Gg_TekzZZg_2_0">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw"
      id="Tc_vsal4hQgCUSudb3rLgOeqw_2_3">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw"
      id="Tc_TVDrjNV3L02KNUcED2sXXQ_3_3">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw"
      id="Narr_XKDqWtaNckmsHlGKBd51GA">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_4_30_2023_HFiWapI7CUuGG9dGexPKfw"
      decimals="INF"
      id="Narr_rH6KJNkCuE2mhYbOIvyMQw"
      unitRef="Unit_Standard_shares_4bVAm6lD50yLNxvQT1GIoA">65414917</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_3_31_2023_lQ4VofWCfU-ERA4iKttplQ"
      decimals="-3"
      id="Tc_zgVS2BbzHkOmJCqJHG28sA_6_3"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">33036000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2022_H53zBT4W7kaDDa9Xye-U_Q"
      decimals="-3"
      id="Tc_c4qJ2PG9_EGpUPYDC9mMVw_6_6"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">17111000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <plx:ShortTermBankDeposits
      contextRef="As_Of_12_31_2022_H53zBT4W7kaDDa9Xye-U_Q"
      decimals="-3"
      id="Tc_-VJUCHWhi0G8-E0g3gBXdg_7_6"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">5069000</plx:ShortTermBankDeposits>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_3_31_2023_lQ4VofWCfU-ERA4iKttplQ"
      decimals="-3"
      id="Tc_4_GcIXvl_EqRIYTqSDNHNQ_8_3"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">1304000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_12_31_2022_H53zBT4W7kaDDa9Xye-U_Q"
      decimals="-3"
      id="Tc_NB_q3f-FxUWkImM1QwNv_Q_8_6"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">4586000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="As_Of_3_31_2023_lQ4VofWCfU-ERA4iKttplQ"
      decimals="-3"
      id="Tc_NvokxZ8rW0Cy2i4t3yKVBQ_9_3"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">758000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="As_Of_12_31_2022_H53zBT4W7kaDDa9Xye-U_Q"
      decimals="-3"
      id="Tc_1oFk8UTi5kikgVXIZ2lCPQ_9_6"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">1310000</us-gaap:OtherAssetsCurrent>
    <us-gaap:InventoryNet
      contextRef="As_Of_3_31_2023_lQ4VofWCfU-ERA4iKttplQ"
      decimals="-3"
      id="Tc_xfQxwCkE-UOKSuOUfSvk6g_10_3"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">20303000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="As_Of_12_31_2022_H53zBT4W7kaDDa9Xye-U_Q"
      decimals="-3"
      id="Tc_5AehK0rAd0KmNaF_EE6diQ_10_6"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">16804000</us-gaap:InventoryNet>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_3_31_2023_lQ4VofWCfU-ERA4iKttplQ"
      decimals="-3"
      id="Tc_VwoVAwzZG0qd82RSXBcfyw_11_3"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">55401000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2022_H53zBT4W7kaDDa9Xye-U_Q"
      decimals="-3"
      id="Tc_20n8B62hmEaOVkUnWYk6Xw_11_6"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">44880000</us-gaap:AssetsCurrent>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
      contextRef="As_Of_3_31_2023_lQ4VofWCfU-ERA4iKttplQ"
      decimals="-3"
      id="Tc_CeUduVfktUeaLxz0s8miJg_14_3"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">1252000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
      contextRef="As_Of_12_31_2022_H53zBT4W7kaDDa9Xye-U_Q"
      decimals="-3"
      id="Tc_qHsAbiFYskCcnqKveuMs5g_14_6"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">1267000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_3_31_2023_lQ4VofWCfU-ERA4iKttplQ"
      decimals="-3"
      id="Tc_r1F0qVOD30CKs-wQOD7OBw_15_3"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">4704000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2022_H53zBT4W7kaDDa9Xye-U_Q"
      decimals="-3"
      id="Tc_0v_fmIgJU0GebtOW6yMKiA_15_6"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">4553000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_3_31_2023_lQ4VofWCfU-ERA4iKttplQ"
      decimals="-3"
      id="Tc_ABPr-sCTr0Ci3dZEuRUaQg_16_3"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">5202000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2022_H53zBT4W7kaDDa9Xye-U_Q"
      decimals="-3"
      id="Tc_xSJxBlr_lUSX5dFJcLOhaw_16_6"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">5087000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Assets
      contextRef="As_Of_3_31_2023_lQ4VofWCfU-ERA4iKttplQ"
      decimals="-3"
      id="Tc_cePGG0gK5UCD_XfKCXMWCA_17_3"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">66559000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2022_H53zBT4W7kaDDa9Xye-U_Q"
      decimals="-3"
      id="Tc__Y2UMgZk7kCloA1GqsWjVg_17_6"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">55787000</us-gaap:Assets>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="As_Of_3_31_2023_lQ4VofWCfU-ERA4iKttplQ"
      decimals="-3"
      id="Tc_RZT76YgVVke4zj7gvQq3NA_23_3"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">5105000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="As_Of_12_31_2022_H53zBT4W7kaDDa9Xye-U_Q"
      decimals="-3"
      id="Tc_mHp6-_WM2USIsmqCFhozSw_23_6"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">5862000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableOtherCurrent
      contextRef="As_Of_3_31_2023_lQ4VofWCfU-ERA4iKttplQ"
      decimals="-3"
      id="Tc_dINMgE6ALUqUOH1JhzaPuA_24_3"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">13471000</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:AccountsPayableOtherCurrent
      contextRef="As_Of_12_31_2022_H53zBT4W7kaDDa9Xye-U_Q"
      decimals="-3"
      id="Tc_-uxkn8L0hkKd_iyUrzpJbA_24_6"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">12271000</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_3_31_2023_lQ4VofWCfU-ERA4iKttplQ"
      decimals="-3"
      id="Tc_Gv1FYphB4UG-tWyTpUB4Mg_25_3"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">1149000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2022_H53zBT4W7kaDDa9Xye-U_Q"
      decimals="-3"
      id="Tc_-8f0_b6OZkKI8VHMWcF-tg_25_6"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">1118000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="As_Of_3_31_2023_lQ4VofWCfU-ERA4iKttplQ"
      decimals="-3"
      id="Tc_dzyhqZQudEaCyk84FFfEmQ_26_3"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">11790000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="As_Of_12_31_2022_H53zBT4W7kaDDa9Xye-U_Q"
      decimals="-3"
      id="Tc_7HS4088AYUSVuaipdYKvHQ_26_6"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">13178000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_3_31_2023_lQ4VofWCfU-ERA4iKttplQ"
      decimals="-3"
      id="Tc_AdOXDAuKykmLnJ4WVG9qxg_27_3"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">31515000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2022_H53zBT4W7kaDDa9Xye-U_Q"
      decimals="-3"
      id="Tc_dSi_3fxveU6NgEc7-fA5mQ_27_6"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">32429000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="As_Of_3_31_2023_lQ4VofWCfU-ERA4iKttplQ"
      decimals="-3"
      id="Tc_i1WFjrs5Z0qTRTDbvj9LNQ_30_3"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">28267000</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="As_Of_12_31_2022_H53zBT4W7kaDDa9Xye-U_Q"
      decimals="-3"
      id="Tc_bSz_p1gUlEuOCsCSkbKTmg_30_6"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">28187000</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent
      contextRef="As_Of_3_31_2023_lQ4VofWCfU-ERA4iKttplQ"
      decimals="-3"
      id="Tc_PJUxr0rw8kWZFOYDdBkjeQ_31_3"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">1617000</us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2022_H53zBT4W7kaDDa9Xye-U_Q"
      decimals="-3"
      id="Tc_e8PwGEUMZEKTBZdw6N_7Kw_31_6"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">1642000</us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_3_31_2023_lQ4VofWCfU-ERA4iKttplQ"
      decimals="-3"
      id="Tc_cm7f5dRCC0K3yUQvdpFe_w_32_3"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">4152000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2022_H53zBT4W7kaDDa9Xye-U_Q"
      decimals="-3"
      id="Tc_LgrNRFRwu0Kc3u8SqDfsZw_32_6"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">4169000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="As_Of_3_31_2023_lQ4VofWCfU-ERA4iKttplQ"
      decimals="-3"
      id="Tc_r91afrmvG0K23EEWd4CTFA_33_3"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">34036000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="As_Of_12_31_2022_H53zBT4W7kaDDa9Xye-U_Q"
      decimals="-3"
      id="Tc_Gnmpa_7jSEuWchLztLrubw_33_6"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">33998000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="As_Of_3_31_2023_lQ4VofWCfU-ERA4iKttplQ"
      decimals="-3"
      id="Tc_o5qBPGY7EkC0RTNNaD9yYw_34_3"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">65551000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2022_H53zBT4W7kaDDa9Xye-U_Q"
      decimals="-3"
      id="Tc_iHCxgmERk021LcXpDVYbqA_34_6"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">66427000</us-gaap:Liabilities>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2023_lQ4VofWCfU-ERA4iKttplQ"
      decimals="-3"
      id="Tc_xfm0M7WY00WBIubq-ZH53g_38_3"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">1008000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_H53zBT4W7kaDDa9Xye-U_Q"
      decimals="-3"
      id="Tc_8n18JUUZ1UGNIjlxGddM4Q_38_6"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">-10640000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_3_31_2023_lQ4VofWCfU-ERA4iKttplQ"
      decimals="-3"
      id="Tc_c4rDe1x9I0iSaFf9rrsCZg_39_3"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">66559000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2022_H53zBT4W7kaDDa9Xye-U_Q"
      decimals="-3"
      id="Tc_4W9TSwchDE-snhC7PVobKg_39_6"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">55787000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2023_To_3_31_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_1ErUchefYE24icEBkPux0A"
      decimals="-3"
      id="Tc_imnrnIymU0S2LFhpCWxtKQ_3_3"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">5066000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2022_To_3_31_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_TLlwu1kiM067CBBRXPNrNw"
      decimals="-3"
      id="Tc_X1rua7BamkyeuBiU8BaK-Q_3_6"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">9028000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2023_To_3_31_2023_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_0OKK-_bib0C_UleLAi20GA"
      decimals="-3"
      id="Tc_6vC62m0OY0O5dJpEk7191A_4_3"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">4522000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2022_To_3_31_2022_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_rv5oVU7cTEWzAOzlbF-VFA"
      decimals="-3"
      id="Tc_eHEQYr_Ptk-ig6ztv_-7UQ_4_6"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">7057000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw"
      decimals="-3"
      id="Tc_wg1iUyeDMU2XOiVNwOn9IA_5_3"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">9588000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2022_To_3_31_2022_N1jzYHJ1VECWf3tLdKC1jw"
      decimals="-3"
      id="Tc_DPOGyhNJc0mMkELbQ6QmgQ_5_6"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">16085000</us-gaap:Revenues>
    <us-gaap:CostOfRevenue
      contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw"
      decimals="-3"
      id="Tc_weldJHKNTU-LFl_B0NjZQw_6_3"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">3085000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="Duration_1_1_2022_To_3_31_2022_N1jzYHJ1VECWf3tLdKC1jw"
      decimals="-3"
      id="Tc_eCxjacwjWUC54yg3cb-XsA_6_6"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">6034000</us-gaap:CostOfRevenue>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw"
      decimals="-3"
      id="Tc_l3K5Bpo4okmUExRcDvJpSA_7_3"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">5847000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2022_To_3_31_2022_N1jzYHJ1VECWf3tLdKC1jw"
      decimals="-3"
      id="Tc_o7CMDO5nykicD24BOuYAWg_7_6"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">8767000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw"
      decimals="-3"
      id="Tc_fTYVNJWnjESxIeMvtTihVg_8_3"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">3115000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2022_To_3_31_2022_N1jzYHJ1VECWf3tLdKC1jw"
      decimals="-3"
      id="Tc_FWjhg_ga90yHw-Q3cLx8eA_8_6"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">3154000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw"
      decimals="-3"
      id="Tc_Ja8JiVagPEeZFBynBELdXg_9_3"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">-2459000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2022_To_3_31_2022_N1jzYHJ1VECWf3tLdKC1jw"
      decimals="-3"
      id="Tc_nCKtM2FR3UGRuKgx47JuAA_9_6"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">-1870000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingExpense
      contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw"
      decimals="-3"
      id="Tc_swN-AB3tcU2lz8XYcgGj5Q_10_3"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">649000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense
      contextRef="Duration_1_1_2022_To_3_31_2022_N1jzYHJ1VECWf3tLdKC1jw"
      decimals="-3"
      id="Tc_BiYx9QAPwEiLz7-1m3VgiA_10_6"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">618000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingIncome
      contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw"
      decimals="-3"
      id="Tc_vMD5fsUkx0aImZrgpnxjng_11_3"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">172000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="Duration_1_1_2022_To_3_31_2022_N1jzYHJ1VECWf3tLdKC1jw"
      decimals="-3"
      id="Tc_qEjaLKalhkmwHiLqIg4_dQ_11_6"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">202000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw"
      decimals="-3"
      id="Tc_x04bAnZAXUCxAuDg_-YYVg_12_3"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">-477000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_1_1_2022_To_3_31_2022_N1jzYHJ1VECWf3tLdKC1jw"
      decimals="-3"
      id="Tc_MtvVh_JIAUCpk_xTvrGjgg_12_6"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">-416000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw"
      decimals="-3"
      id="Tc_HU-d2JjfTEO3ViosXeJ0DA_13_3"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">-2936000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2022_To_3_31_2022_N1jzYHJ1VECWf3tLdKC1jw"
      decimals="-3"
      id="Tc_bEArjs423Em_5QW5bPyPfw_13_6"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">-2286000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw"
      decimals="-3"
      id="Tc_HfZ0hFX-Jk6AcMdkMljIkA_14_3"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">195000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw"
      decimals="-3"
      id="Tc_u3bjcH7Bi06NXHJZcXxttQ_15_3"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">-3131000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_3_31_2022_N1jzYHJ1VECWf3tLdKC1jw"
      decimals="-3"
      id="Tc_rrDyNmFzhEGpboQOrDqOZg_15_6"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">-2286000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw"
      decimals="2"
      id="Tc_XbRPM9NTTE2SGBFqeB9mAg_16_3"
      unitRef="Unit_Divide_USD_shares_65Ko0I-nrkSGY9fEMAqs6Q">-0.05</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw"
      decimals="2"
      id="Tc_XbRPM9NTTE2SGBFqeB9mAg_16_3_2"
      unitRef="Unit_Divide_USD_shares_65Ko0I-nrkSGY9fEMAqs6Q">-0.05</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2022_To_3_31_2022_N1jzYHJ1VECWf3tLdKC1jw"
      decimals="2"
      id="Tc_rWM_b1ygHE-cNyGvSNu5nw_16_6"
      unitRef="Unit_Divide_USD_shares_65Ko0I-nrkSGY9fEMAqs6Q">-0.05</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2022_To_3_31_2022_N1jzYHJ1VECWf3tLdKC1jw"
      decimals="2"
      id="Tc_rWM_b1ygHE-cNyGvSNu5nw_16_6_2"
      unitRef="Unit_Divide_USD_shares_65Ko0I-nrkSGY9fEMAqs6Q">-0.05</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw"
      decimals="0"
      id="Tc_fLmz2eItK0i3gFFi5N-xNg_18_3"
      unitRef="Unit_Standard_shares_4bVAm6lD50yLNxvQT1GIoA">57480009</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw"
      decimals="0"
      id="Tc_fLmz2eItK0i3gFFi5N-xNg_18_3_2"
      unitRef="Unit_Standard_shares_4bVAm6lD50yLNxvQT1GIoA">57480009</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2022_To_3_31_2022_N1jzYHJ1VECWf3tLdKC1jw"
      decimals="0"
      id="Tc_rM_53rzO9E-2iG51YhlYOg_18_6"
      unitRef="Unit_Standard_shares_4bVAm6lD50yLNxvQT1GIoA">45843563</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2022_To_3_31_2022_N1jzYHJ1VECWf3tLdKC1jw"
      decimals="0"
      id="Tc_rM_53rzO9E-2iG51YhlYOg_18_6_2"
      unitRef="Unit_Standard_shares_4bVAm6lD50yLNxvQT1GIoA">45843563</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_kovew3nQoUW7X8jAVRvjhw"
      decimals="-3"
      id="Tc_EzNc6Yz3eUeEdEtsg1EABg_19_3"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">58000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_M9nMRkvbzkONqh4KPar8cg"
      decimals="-3"
      id="Tc_yFx6awzeZ0mGoZFMt7_exA_19_6"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">-6000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_O-2jNHV-AUW4fRDBPZldoA"
      decimals="-3"
      id="Tc_Sd5VSQRqfEiwi5sNfNoxLA_20_3"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">180000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_ACjpei32d0mTu26aZxZF-Q"
      decimals="-3"
      id="Tc_l7sNONWGjUKCLKMbKlGHzw_20_6"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">76000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_f8-sCIf2RkuxwvCb3yISvA"
      decimals="-3"
      id="Tc_ma9pYR_V1kacfHOinaGwzA_21_3"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">308000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_QMhb-FrbfESVBC7w8w5e4A"
      decimals="-3"
      id="Tc_Q35hpGJO7kqghqualPKGeg_21_6"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">766000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_J7EBNPBz8ESJc8H_4uZ72w"
      decimals="INF"
      id="Tc_v0W510vMt0WtRFcsOlezUQ_6_2"
      unitRef="Unit_Standard_shares_4bVAm6lD50yLNxvQT1GIoA">45556647</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_J7EBNPBz8ESJc8H_4uZ72w"
      decimals="-3"
      id="Tc_GEmucjc6PkWJ_BHsh3d16Q_6_5"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">46000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_vOwYA9rCf0W5Bz8PPuTQvg"
      decimals="-3"
      id="Tc_UbVedHXfxUG6h_aOzpaxOw_6_8"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">368852000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember__Fk6t8bO9k-wg-VncCAqpg"
      decimals="-3"
      id="Tc_BBuCf6nYk0GPH8uxj3_nEA_6_11"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">-374934000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_x-pm8I0vjUS_ATBiwepawg"
      decimals="-3"
      id="Tc_9uZfNvtTaUWLDKnu87ki0g_6_14"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">-6036000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_pTjg192DOkSYYbGFlFzhqA"
      decimals="-3"
      id="Tc_WleW3eJpkE-ue8sCPq4RzA_8_8"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">149000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2022_To_3_31_2022_N1jzYHJ1VECWf3tLdKC1jw"
      decimals="-3"
      id="Tc_wia29lh5n0aIjLSYqa-j3A_8_14"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">149000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares
      contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_M0avG7-u206lSf4X6whkbA"
      decimals="INF"
      id="Tc_yTxTuHFDc0CebaIJf12WuA_9_2"
      unitRef="Unit_Standard_shares_4bVAm6lD50yLNxvQT1GIoA">759482</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_pTjg192DOkSYYbGFlFzhqA"
      decimals="-3"
      id="Tc_Fm6qmMMKekauGaGNgr_hOA_9_8"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">687000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_1_1_2022_To_3_31_2022_N1jzYHJ1VECWf3tLdKC1jw"
      decimals="-3"
      id="Tc__aOAaa015E2h0fQ3YQYZUA_9_14"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">687000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_P_C-vkYM70mz4hoQ7UVhOg"
      decimals="-3"
      id="Tc_wBdLT37iKU-G1EXoD2Ga6w_10_11"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">-2286000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_3_31_2022_N1jzYHJ1VECWf3tLdKC1jw"
      decimals="-3"
      id="Tc_lW4RpCcYTESLhSMWViV8jw_10_14"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">-2286000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Ma9XQZkyu0yv3iLSHCbY5g"
      decimals="INF"
      id="Tc_dgYszTwrTEefeCZ3ZKmo1Q_11_2"
      unitRef="Unit_Standard_shares_4bVAm6lD50yLNxvQT1GIoA">46316129</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Ma9XQZkyu0yv3iLSHCbY5g"
      decimals="-3"
      id="Tc_-p7bq2dsek2ZfOUkYUBgkQ_11_5"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">46000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_P1TRpg9XL0SipWskVIymPg"
      decimals="-3"
      id="Tc_KSOGZykx_UyTrdaOiIVZ2A_11_8"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">369688000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_sessMVhLlE-60nptH85tHA"
      decimals="-3"
      id="Tc_BOiYAS6n-0WPIKxzUnC6dQ_11_11"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">-377220000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2022_cjzuDz-ZiUubY38dhB0s0A"
      decimals="-3"
      id="Tc_r3ASuL4Vd0CiMunRa86oIg_11_14"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">-7486000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_B-MKROg0kkWsBATWzcCW9g"
      decimals="INF"
      id="Tc_exCmImm6ckG9_1mX6eB13g_12_2"
      unitRef="Unit_Standard_shares_4bVAm6lD50yLNxvQT1GIoA">53790167</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_B-MKROg0kkWsBATWzcCW9g"
      decimals="-3"
      id="Tc_Bl3kZf5VE0Cxo1h5VZmyWA_12_5"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">54000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_xvyzPFwz2Ei9WGmzrZtTKA"
      decimals="-3"
      id="Tc_P2rAMuazoE203pp2a_-Xjg_12_8"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">379167000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_td4XMHFZWkWCZfhPrs2Yog"
      decimals="-3"
      id="Tc__ACYK-Pd20esDP0CAegAcA_12_11"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">-389861000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_H53zBT4W7kaDDa9Xye-U_Q"
      decimals="-3"
      id="Tc_5lyVxFwW1EKG6QG6DLI3Ew_12_14"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">-10640000</us-gaap:StockholdersEquity>
    <plx:StockIssuedDuringPeriodSharesSalesAgreement
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_o5KTQD_NWEC6IWOAHM7tDQ"
      decimals="INF"
      id="Tc_mfQTaw5le0imjmuMBx4ODg_14_2"
      unitRef="Unit_Standard_shares_4bVAm6lD50yLNxvQT1GIoA">8212482</plx:StockIssuedDuringPeriodSharesSalesAgreement>
    <plx:StockIssuedDuringPeriodValueSalesAgreement
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_o5KTQD_NWEC6IWOAHM7tDQ"
      decimals="-3"
      id="Tc_08SrCHxp8kSOuA7gdTovBA_14_5"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">8000</plx:StockIssuedDuringPeriodValueSalesAgreement>
    <plx:StockIssuedDuringPeriodValueSalesAgreement
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_chSQy1P71EiszadyqHEgpA"
      decimals="-3"
      id="Tc_NqV6jxOwGEq1opWpDrwcQA_14_8"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">14225000</plx:StockIssuedDuringPeriodValueSalesAgreement>
    <plx:StockIssuedDuringPeriodValueSalesAgreement
      contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw"
      decimals="-3"
      id="Tc_uCYYIpTqs0G6cDDgU858Ig_14_14"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">14233000</plx:StockIssuedDuringPeriodValueSalesAgreement>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_chSQy1P71EiszadyqHEgpA"
      decimals="-3"
      id="Tc_VRE1EH6hzkOBEhNwR_BbuA_15_8"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">453000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw"
      decimals="-3"
      id="Tc_eQIyHVg6mkqN0GliWuwjjA_15_14"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">453000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_chSQy1P71EiszadyqHEgpA"
      decimals="-3"
      id="Tc_sw0RuQ9mA0W5YdBwzczWfA_16_8"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">93000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw"
      decimals="-3"
      id="Tc_3aTISMeIY02cHXcJwyrkeQ_16_14"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">93000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_M5gF58pjUEaKAVvefka9Pw"
      decimals="-3"
      id="Tc_P8Y3vTkndEKkN85PfpLgwQ_17_11"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">-3131000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw"
      decimals="-3"
      id="Tc_iq34XAgSX0mndax1chJPeQ_17_14"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">-3131000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_bMnoYH_kPEuyqw6R4J9L2Q"
      decimals="INF"
      id="Tc_EWUveCzkOkWNPC49U8GrGw_18_2"
      unitRef="Unit_Standard_shares_4bVAm6lD50yLNxvQT1GIoA">62002649</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_bMnoYH_kPEuyqw6R4J9L2Q"
      decimals="-3"
      id="Tc_bcxV9fbgeE6Inish6WBISQ_18_5"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">62000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_IL0F69SjoE2AcVxC9gRdAg"
      decimals="-3"
      id="Tc_bvz4P9KfV02Oer2O2Lt46Q_18_8"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">393938000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_E_QLG5yGnUWYSbAfH9__OQ"
      decimals="-3"
      id="Tc_wMj68Qovokqq15QRkdlpxA_18_11"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">-392992000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2023_lQ4VofWCfU-ERA4iKttplQ"
      decimals="-3"
      id="Tc_MK4tQawPMEGaQZVKn09bvA_18_14"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">1008000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_3_31_2022_cjzuDz-ZiUubY38dhB0s0A"
      decimals="INF"
      id="Narr_H8bJoskOX0yVvO0s2dy3jw"
      unitRef="Unit_Divide_USD_shares_65Ko0I-nrkSGY9fEMAqs6Q">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_3_31_2023_lQ4VofWCfU-ERA4iKttplQ"
      decimals="INF"
      id="Narr_pAwFV1t5yUqbnHUopInOFA"
      unitRef="Unit_Divide_USD_shares_65Ko0I-nrkSGY9fEMAqs6Q">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_3_31_2023_lQ4VofWCfU-ERA4iKttplQ"
      decimals="INF"
      id="Narr_-ES6nSAE10K6xII9lrm-JQ"
      unitRef="Unit_Standard_shares_4bVAm6lD50yLNxvQT1GIoA">144000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_3_31_2022_cjzuDz-ZiUubY38dhB0s0A"
      decimals="INF"
      id="Narr_MtsL9p7LdESJbCeMtxR42A"
      unitRef="Unit_Standard_shares_4bVAm6lD50yLNxvQT1GIoA">120000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw"
      decimals="-3"
      id="Tc_gzcauP7Z5kmh0iwQoP5R9g_4_3"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">-3131000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2022_To_3_31_2022_N1jzYHJ1VECWf3tLdKC1jw"
      decimals="-3"
      id="Tc_HS-NknV5TE2qj63CgMakmA_4_6"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">-2286000</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw"
      decimals="-3"
      id="Tc_f0A_2evQPE-JwMIfEJgG5A_6_3"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">546000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2022_To_3_31_2022_N1jzYHJ1VECWf3tLdKC1jw"
      decimals="-3"
      id="Tc_LVlbcfnMOkKhVtgz0rR9gg_6_6"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">836000</us-gaap:ShareBasedCompensation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw"
      decimals="-3"
      id="Tc_qoQ6W3H33UiJguodkl80JA_7_3"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">280000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2022_To_3_31_2022_N1jzYHJ1VECWf3tLdKC1jw"
      decimals="-3"
      id="Tc_LsRbmJ7dI0WSXAisipJWCw_7_6"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">270000</us-gaap:Depreciation>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw"
      decimals="-3"
      id="Tc_3wEOp56ZCk2-A_IFdxSKDw_8_3"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">91000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="Duration_1_1_2022_To_3_31_2022_N1jzYHJ1VECWf3tLdKC1jw"
      decimals="-3"
      id="Tc_aJUao3I0bUqBYmHbKvpdNA_8_6"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">198000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:PensionAndOtherPostretirementBenefitExpense
      contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw"
      decimals="-3"
      id="Tc_uU_02oSD00OwCv2Q5ytv9A_9_3"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">19000</us-gaap:PensionAndOtherPostretirementBenefitExpense>
    <us-gaap:PensionAndOtherPostretirementBenefitExpense
      contextRef="Duration_1_1_2022_To_3_31_2022_N1jzYHJ1VECWf3tLdKC1jw"
      decimals="-3"
      id="Tc_1whmY-Bhx0ubtX34SjxEFw_9_6"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">75000</us-gaap:PensionAndOtherPostretirementBenefitExpense>
    <plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement
      contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw"
      decimals="-3"
      id="Tc_AzVI7lDt60mv9mS1YcM_Wg_10_3"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">-1000</plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement>
    <plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement
      contextRef="Duration_1_1_2022_To_3_31_2022_N1jzYHJ1VECWf3tLdKC1jw"
      decimals="-3"
      id="Tc_3ygxeR2w00eQFL7WRWqx4A_10_6"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">-10000</plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw"
      decimals="-3"
      id="Tc_p_M9xV-3f0Okhy12-yfOMw_11_3"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">80000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="Duration_1_1_2022_To_3_31_2022_N1jzYHJ1VECWf3tLdKC1jw"
      decimals="-3"
      id="Tc_tEG6KvpY4EONZtsCUiTIJw_11_6"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">75000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw"
      decimals="-3"
      id="Tc_d5i3BkNofES-koPEWXHz2A_13_3"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">-1388000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="Duration_1_1_2022_To_3_31_2022_N1jzYHJ1VECWf3tLdKC1jw"
      decimals="-3"
      id="Tc_mNAipb1tyU-E0q2W_4zgLA_13_6"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">-2644000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw"
      decimals="-3"
      id="Tc_MARbc29eqEa3Cxqobijlag_14_3"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">-3823000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="Duration_1_1_2022_To_3_31_2022_N1jzYHJ1VECWf3tLdKC1jw"
      decimals="-3"
      id="Tc_i49cAhdE40-keWkF5a2lfg_14_6"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">2314000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <plx:ChangeInOperatingLeaseRightOfUseAssets
      contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw"
      decimals="-3"
      id="Tc__dKV5pt8oEGoW-PtLGPHqg_15_3"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">-9000</plx:ChangeInOperatingLeaseRightOfUseAssets>
    <plx:ChangeInOperatingLeaseRightOfUseAssets
      contextRef="Duration_1_1_2022_To_3_31_2022_N1jzYHJ1VECWf3tLdKC1jw"
      decimals="-3"
      id="Tc_tMbbAlo6D0msb6dlBJss7A_15_6"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">2000</plx:ChangeInOperatingLeaseRightOfUseAssets>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw"
      decimals="-3"
      id="Tc_AEMerhhXCEuLbufUgQuCOg_16_3"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">3499000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="Duration_1_1_2022_To_3_31_2022_N1jzYHJ1VECWf3tLdKC1jw"
      decimals="-3"
      id="Tc_xQwi-X0uIk2Wp1_RFthAlg_16_6"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">-1360000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw"
      decimals="-3"
      id="Tc_tY08W5A1W0ab0IT7s_JcXw_17_3"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">353000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="Duration_1_1_2022_To_3_31_2022_N1jzYHJ1VECWf3tLdKC1jw"
      decimals="-3"
      id="Tc_MtmDycDpqECzFBo6B1LBfQ_17_6"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">-1011000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw"
      decimals="-3"
      id="Tc_CyNd8dWwY0uofLESaoSV0Q_18_3"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">-2998000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2022_To_3_31_2022_N1jzYHJ1VECWf3tLdKC1jw"
      decimals="-3"
      id="Tc_vKPDya3bPEmq7XUwYcqxEw_18_6"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">-5829000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <plx:IncreaseDecreaseInBankDeposits
      contextRef="Duration_1_1_2022_To_3_31_2022_N1jzYHJ1VECWf3tLdKC1jw"
      decimals="-3"
      id="Tc_uM_XGJF41Eyx4Nu-c11abw_21_6"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">16000000</plx:IncreaseDecreaseInBankDeposits>
    <plx:ProceedsFromSaleOfShortTermDeposits
      contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw"
      decimals="-3"
      id="Tc_fE9YnMPwRkK0YvySZElVzA_22_3"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">5000000</plx:ProceedsFromSaleOfShortTermDeposits>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw"
      decimals="-3"
      id="Tc_-J0hsjeXkk-UCOV0SwSTlQ_23_3"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">248000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2022_To_3_31_2022_N1jzYHJ1VECWf3tLdKC1jw"
      decimals="-3"
      id="Tc__AyKT-0I8EWTudXW8kKuzA_23_6"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">229000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw"
      decimals="-3"
      id="Tc_XzxymGrzn0u811t7V1T5_A_24_3"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">20000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="Duration_1_1_2022_To_3_31_2022_N1jzYHJ1VECWf3tLdKC1jw"
      decimals="-3"
      id="Tc_hlcOXDXovk2YdS34IktegA_24_6"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">28000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw"
      decimals="-3"
      id="Tc_-BtWtO9GO0eEDHGZxE6qfQ_25_3"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">4732000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2022_To_3_31_2022_N1jzYHJ1VECWf3tLdKC1jw"
      decimals="-3"
      id="Tc_ZRLUrygayU6VHuQR8pdXqQ_25_6"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">-16257000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw"
      decimals="-3"
      id="Tc_VF5vca3efkWefetw0GC-4w_28_3"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">14233000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw"
      decimals="-3"
      id="Tc_wJq6zOC7BUmGJOvWeR75Xw_29_3"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">14233000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents
      contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw"
      decimals="-3"
      id="Tc_hxpNsBKGF0KTWwM2OQCkRw_30_3"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">-42000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents
      contextRef="Duration_1_1_2022_To_3_31_2022_N1jzYHJ1VECWf3tLdKC1jw"
      decimals="-3"
      id="Tc_KZXqToDoGkG81ru957RdJw_30_6"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">-11000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw"
      decimals="-3"
      id="Tc_Z6K_yX-mnUarAOPaxE5Sfg_31_3"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">15925000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2022_To_3_31_2022_N1jzYHJ1VECWf3tLdKC1jw"
      decimals="-3"
      id="Tc_Xf22wY_K6E6Nunx89m_yRg_31_6"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">-22097000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2022_H53zBT4W7kaDDa9Xye-U_Q"
      decimals="-3"
      id="Tc_QlPAnhg5cU6ewJli5juewA_32_3"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">17111000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2021_x-pm8I0vjUS_ATBiwepawg"
      decimals="-3"
      id="Tc_GzQv2w122ECZWBA607SVqg_32_6"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">38985000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_3_31_2023_lQ4VofWCfU-ERA4iKttplQ"
      decimals="-3"
      id="Tc_Yf_vVJ2EZ024awGf7nk4gQ_33_3"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">33036000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_3_31_2022_cjzuDz-ZiUubY38dhB0s0A"
      decimals="-3"
      id="Tc_68jg6tKR9UOnEVgVcfM_ZQ_33_6"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">16888000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw"
      decimals="-3"
      id="Tc__GF_lzmiO0mg04orJ132-Q_4_3"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">326000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="Duration_1_1_2022_To_3_31_2022_N1jzYHJ1VECWf3tLdKC1jw"
      decimals="-3"
      id="Tc_qj6GOg5aUkqurIFZikuvzA_4_6"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">67000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw"
      decimals="-3"
      id="Tc_lKvC3wsYqUi35tEl2uGEzg_5_3"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">312000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="Duration_1_1_2022_To_3_31_2022_N1jzYHJ1VECWf3tLdKC1jw"
      decimals="-3"
      id="Tc_ctciluhnoEqn7cf9K-Z6xQ_5_6"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">99000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:InterestPaidNet
      contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw"
      decimals="-3"
      id="Tc_Nr6iWJtJxkStnAzr1eReDQ_7_3"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">1078000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="Duration_1_1_2022_To_3_31_2022_N1jzYHJ1VECWf3tLdKC1jw"
      decimals="-3"
      id="Tc_SmrebSgHyEWmOcLqYOFmlQ_7_6"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">1120000</us-gaap:InterestPaidNet>
    <plx:InterestReceivedNet
      contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw"
      decimals="-3"
      id="Tc_oT9rkxg-k0mWwLy5sUbwYA_8_3"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">78000</plx:InterestReceivedNet>
    <plx:InterestReceivedNet
      contextRef="Duration_1_1_2022_To_3_31_2022_N1jzYHJ1VECWf3tLdKC1jw"
      decimals="-3"
      id="Tc_-qU7x_JJI0urE_yxYBUvng_8_6"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">36000</plx:InterestReceivedNet>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw"
      id="Tb_UINnGcgczk-sYBPTsgtE9A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;NOTE&#160;1&#160;- SIGNIFICANT ACCOUNTING POLICIES&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;"&gt;a.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;"&gt;General&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the &#x201c;Company&#x201d;) and its wholly-owned subsidiaries, Protalix Ltd. and Protalix B.V. (collectively, the &#x201c;Subsidiaries&#x201d;), are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&#x2019;s proprietary ProCellEx&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; protein expression system (&#x201c;ProCellEx&#x201d;). To date, the Company has successfully developed taliglucerase alfa (marketed under the name BioManguinhos alfataliglicerase in Brazil and certain other Latin American countries and Elelyso&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; in the rest of the territories) for the treatment of Gaucher disease that has been approved for marketing in the United States, Brazil, Israel and other markets. The Company has a number of product candidates in varying stages of the clinical development process. The Company&#x2019;s strategy is to develop proprietary recombinant proteins that are therapeutically superior to existing recombinant proteins currently marketed for the same indications.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The most advanced investigational drug in the Company&#x2019;s product pipeline is pegunigalsidase alfa, or PRX-102, a therapeutic protein candidate for the treatment of Fabry disease, a rare, genetic lysosomal disorder, which was the subject of a phase&#160;III clinical program. The PRX-102 phase&#160;III clinical program included three separate studies, which are referred to as the &lt;i style="font-style:italic;"&gt;BALANCE&lt;/i&gt; study, the &lt;i style="font-style:italic;"&gt;BRIDGE&lt;/i&gt; study and the &lt;i style="font-style:italic;"&gt;BRIGHT&lt;/i&gt; study, each of which has been completed. The studies were designed to evaluate the potential for improved efficacy and better quality of life for adult patients with Fabry disease and to evaluate the safety of the Company&#x2019;s drug/therapy. The phase&#160;III clinical program analyzed two potential dosing regimens: 1&#160;mg/kg every two weeks and 2&#160;mg/kg every four weeks. In addition, the phase&#160;III clinical program included two extension studies in which subjects that participated in the Company&#x2019;s phase&#160;I/II clinical trials and phase&#160;III clinical trials had the opportunity to enroll and continue to be treated with PRX-102. As of March&#160;1, 2023, sponsorship of the two open-label extension studies was transferred to the Company&#x2019;s development and commercialization partner for PRX-102, Chiesi Farmaceutici S.p.A. (&#x201c;Chiesi&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The U.S.&#160;Food and Drug Administration (the &#x201c;FDA&#x201d;) has indicated that the biologics license application (&#x201c;BLA&#x201d;) for PRX-102 for the potential treatment of adult patients with Fabry disease resubmitted on November&#160;9, 2022 by the Company, together with Chiesi, was considered a complete, class&#160;2 response and set a PDUFA action date of&#160;May&#160;9, 2023. The initial BLA for PRX-102 was submitted to the FDA on May&#160;27, 2020 under the FDA&#x2019;s Accelerated Approval pathway, and was subsequently accepted by the FDA and granted Priority Review designation. However, in April 2021, the FDA issued a Complete Response Letter (CRL) in response to the initial BLA. In preparation for the BLA resubmission, the Company and Chiesi participated in a Type&#160;A (End of Review) meeting with the FDA on September&#160;9, 2021. As part of the meeting minutes provided by the FDA, which included the preliminary comments and meeting discussion, the FDA, in principle, agreed that the data package proposed to the FDA for a BLA resubmission has the potential to support a traditional approval of PRX-102 for the treatment of Fabry disease. The data package in the BLA resubmission, given the change in the regulatory landscape in the United States, included the final two-year analyses of the Company&#x2019;s phase&#160;III &lt;i style="font-style:italic;"&gt;BALANCE&lt;/i&gt; clinical trial of PRX-102, which was completed in July 2022, and long-term data from the Company&#x2019;s open-label extension study of PRX-102 in adult patients treated with a 2&#160;mg/kg every four&#160;weeks dosage of PRX-102.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On February&#160;7, 2022, the Company, together with Chiesi, submitted a Marketing Authorization Application (&#x201c;MAA&#x201d;) for PRX-102 to the European Medicines Agency (&#x201c;EMA&#x201d;) which was subsequently validated by the EMA. The submission was made after the October&#160;8, 2021 meeting the Company held, together with Chiesi, with the Rapporteur and Co-Rapporteur of the EMA regarding PRX-102.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;The MAA submission included a comprehensive set of preclinical, clinical and manufacturing data compiled from the Company&#x2019;s completed and ongoing clinical studies evaluating PRX-102 as a potential alternative treatment for adult patients with Fabry disease, including data from the Company&#x2019;s completed 12&#x2013;month switch&#x2013;over phase&#160;III &lt;i style="font-style:italic;"&gt;BRIGHT&lt;/i&gt;&#160;clinical trial in adult patients with Fabry disease treated with a 2&#160;mg/kg every four&#160;weeks dosage to support an additional potential treatment regimen for Fabry patients. As part of the EMA review process, Chiesi and the Company responded to the Day&#160;120 list of questions in September 2022 (following a 3-month clock-stop period) and the list of outstanding issues of Day&#160;180 in December 2022. An essential portion of the Day&#160;120 response included the submission of the final analysis of the two-year &lt;i style="font-style:italic;"&gt;BALANCE&lt;/i&gt; study (the final Clinical Study Report), and an interim analysis of the &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Company&#x2019;s long-term, open-label extension study of PRX-102 in adult patients with Fabry disease treated with the 2&#160;mg/kg every four&#160;weeks dosage.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On February&#160;24, 2023, the Company, together with Chiesi, announced that the EMA&#x2019;s Committee for Medicinal Products for Human Use (the &#x201c;CHMP&#x201d;) adopted a positive opinion, recommending marketing authorization for PRX-102. The CHMP opinion was referred for final action to the European Commission (the &#x201c;EC&#x201d;). A final EC decision on the MAA is expected in the beginning of&#160;May 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;In addition to PRX-102, the Company&#x2019;s product pipeline currently includes, among other candidates:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(1)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;PRX-115, the Company&#x2019;s plant cell-expressed recombinant PEGylated uricase (urate oxidase) &#x2013; a chemically modified enzyme to treat severe gout; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(2)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;PRX-119, the Company&#x2019;s plant cell-expressed PEGylated recombinant human DNase&#160;I product candidate being designed to elongate half-life in the circulation for NETs-related diseases.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:10pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Obtaining marketing approval with respect to any product candidate in any country is dependent on the Company&#x2019;s ability to implement the necessary regulatory steps required to obtain such approvals. The Company cannot reasonably predict the outcome of these activities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On July&#160;2, 2021, the Company entered into an At The Market Offering Agreement (the &#x201c;2021 Sales Agreement&#x201d;) with H.C.&#160;Wainwright &amp;amp; Co., LLC, as the Company&#x2019;s sales agent (the &#x201c;Agent&#x201d;) which was amended on May&#160;2, 2022. Pursuant to the terms of the 2021 Sales Agreement, the Company was able to sell, from time to time through the Agent, shares of its common stock, par value $0.001 per share (the &#x201c;Common Stock&#x201d;), having an aggregate offering price of up to $20.0&#160;million (the &#x201c;ATM Shares&#x201d;). Upon execution of the 2021 Sales Agreement, the Company terminated the ATM Equity Offering&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;SM&lt;/sup&gt; Sales Agreement it had entered into on October&#160;1, 2020 with BofA Securities, Inc. (&#x201c;BofA Securities&#x201d;). During the term of the sales agreement with BofA Securities, the Company sold a total of 3,296,123 shares of Common Stock for total gross proceeds of approximately $13.8&#160;million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;As of March&#160;31, 2023, the Company sold a total of 13,980,060 ATM Shares for total gross proceeds of approximately $20.0&#160;million under the 2021 Sales Agreement, thereby completing the ATM program under said agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On February&#160;27, 2023, the Company entered into an At The Market Offering Agreement (the &#x201c;2023 Sales Agreement&#x201d;) with the Agent. Pursuant to the terms of the 2023 Sales Agreement, the Company may sell, from time to time through the Agent, ATM Shares having an aggregate offering price of up to $20.0&#160;million. As of March&#160;31, 2023, shares of Common Stock for total gross proceeds of approximately $16.5&#160;million remain available to be sold under the 2023 Sales Agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On October&#160;19, 2017, Protalix Ltd. and Chiesi entered into an Exclusive License and Supply Agreement (the &#x201c;Chiesi Ex-US Agreement&#x201d;) pursuant to which Protalix Ltd. granted to Chiesi an exclusive license for all markets outside of the United States to commercialize pegunigalsidase alfa. On July&#160;23, 2018, Protalix Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the &#x201c;Chiesi US Agreement&#x201d;) with respect to the commercialization of pegunigalsidase alfa in the United States.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;Under each of the Chiesi Ex-US Agreement and the Chiesi US Agreement (collectively, the &#x201c;Chiesi Agreements&#x201d;), Chiesi made an upfront payment to Protalix&#160;Ltd. of $25.0&#160;million in connection with the execution of each agreement. In addition, under the Chiesi Ex-US Agreement, Protalix&#160;Ltd. is entitled to additional payments of up to $25.0&#160;million in pegunigalsidase alfa development costs and to receive additional payments of up to $320.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. Under the Chiesi US Agreement, Protalix&#160;Ltd. is entitled to payments of up to a maximum of $20.0&#160;million to cover development costs for pegunigalsidase alfa and to receive additional payments of up to a maximum of $760.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. To date, Protalix Ltd. has received the complete amount of development costs to which it is entitled under the Chiesi Agreements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;Under the terms of both of the Chiesi Agreements, Protalix Ltd. will manufacture all of the pegunigalsidase alfa needed under the agreements, subject to certain exceptions, and Chiesi will purchase pegunigalsidase alfa from Protalix, subject to certain terms and conditions. Under the Chiesi Ex-US Agreement, Chiesi is required to make tiered payments of 15% to 35% of its net sales, depending on the amount of annual sales outside of the United States, as consideration for product supply. Under the Chiesi US Agreement, Chiesi is required to make tiered payments of 15% to 40% of its net sales, depending on the amount of annual sales in the United States, as consideration for product supply.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;On May&#160;13, 2021, the Company signed a binding term sheet with Chiesi pursuant to which the Company and Chiesi amended the Chiesi Agreements in order to provide the Company with near-term capital. Chiesi agreed to make a $10.0&#160;million payment to the Company before the end of the second quarter of 2021 in exchange for a $25.0&#160;million reduction in a longer term regulatory milestone payment provided in the Chiesi EX-US Agreement. All other regulatory and commercial milestone payments remain unchanged. The Company received the payment in June&#160;2021. The Company also agreed to negotiate certain manufacturing related matters.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;Since its approval by the FDA, taliglucerase alfa has been marketed by Pfizer Inc. (&#x201c;Pfizer&#x201d;) in accordance with the exclusive license and supply agreement entered into between Protalix Ltd. and Pfizer, which is referred to herein as the Pfizer Agreement. In October 2015, Protalix Ltd. and Pfizer entered into an amended exclusive license and supply agreement, which is referred to herein as the Amended Pfizer Agreement, pursuant to which the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for 100% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;On June&#160;18, 2013, the Company entered into a Supply and Technology Transfer Agreement (the &#x201c;Brazil Agreement&#x201d;) with Funda&#xe7;&#xe3;o Oswaldo Cruz (&#x201c;Fiocruz&#x201d;), an arm of the Brazilian Ministry of Health (the &#x201c;Brazilian MoH&#x201d;), for taliglucerase alfa. Fiocruz&#x2019;s purchases of BioManguinhos alfataliglicerase to date have been significantly below certain agreed-upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the termination right, the Company is, at this time, continuing to supply BioManguinhos alfataliglicerase to Fiocruz and patients continue to be treated with BioManguinhos alfataliglicerase in Brazil.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;The novel coronavirus disease (&#x201c;COVID-19&#x201d;), which was declared by the World Health Organization to be a global pandemic on March&#160;11, 2020, has had numerous adverse effects on the global economy. To date, the Company&#x2019;s clinical trials have not been adversely affected by COVID-19, although certain practices the Company adopted during the earlier stages of the pandemic in its offices and facilities in an effort to promote social distancing resulted in minor delays in the performance of administrative activities outside of the clinical programs.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;The Company expects to continue to incur significant expenditures in the near future due to research and developments efforts with respect to the product candidates. Under the terms of the Company&#x2019;s outstanding 7.50% Senior Secured Convertible Notes due 2024 (the &#x201c;2024 Notes&#x201d;)&lt;span style="font-family:'28mugxoulnobhnx';"&gt;, &lt;/span&gt;the Company is required to comply with certain&lt;span style="color:#222222;background:#ffffff;"&gt; &lt;/span&gt;financial covenants, including the maintenance of a minimum cash balance of at least $7.5&#160;million. As of March&#160;31, 2023, the Company is in&lt;span style="background:#ffffff;"&gt; compliance with all such covenants. &lt;/span&gt;The Company believes that its cash and cash equivalents as of March&#160;31, 2023, together with additional funds raised from the sale of ATM Shares under the 2023 Sales Agreement subsequent to March&#160;31, 2023 are sufficient to satisfy the Company&#x2019;s capital needs for at least 12&#160;months from the date that these financial statements are issued.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;"&gt;b.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;"&gt;Basis of presentation&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;"&gt;The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States (&#x201c;GAAP&#x201d;) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;"&gt;These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form&#160;10-K for the year ended December&#160;31, 2022, filed by the Company with the U.S.&#160;Securities and Exchange Commission (the &#x201c;Commission&#x201d;). The comparative balance sheet at December&#160;31, 2022 has been derived from the audited financial statements at that date. There have been no material changes in our significant accounting policies as described in our consolidated financial statements for the year ended December&#160;31, 2022.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;c.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;Loss per share&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;"&gt;Basic and diluted loss per share (&#x201c;LPS&#x201d;) are computed by dividing net loss by the weighted average number of shares of Common Stock attributable to common stockholders outstanding for each period. The calculation of diluted LPS does not include 36,292,208 shares of Common Stock underlying outstanding options and shares of Common Stock issuable upon conversion of the outstanding 2024 Notes and the exercise of outstanding warrants for the three months ended March&#160;31, 2023, and 33,004,217 shares of Common Stock underlying outstanding options and shares of Common Stock issuable upon conversion of the Company&#x2019;s then outstanding 2024 Notes and the exercise of outstanding warrants for the three months ended March&#160;31, 2022 because their effect would be anti-dilutive.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;d.&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Revenue recognition&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company accounts for revenue pursuant to Accounting Standards Codification, Topic 606, Revenue from Contracts with Customers (&#x201c;ASC 606&#x201d;). Under ASC 606, a contract with a customer exists only when: the parties to the contract have approved it and are committed to perform their respective obligations, the Company can identify each party&#x2019;s rights regarding the distinct goods or services to be transferred (&#x201c;performance obligations&#x201d;), the Company can determine the transaction price for the goods or services to be transferred, the contract has commercial substance and it is probable that the Company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Revenues are recorded in the amount of consideration to which the Company expects to be entitled in exchange for performance obligations upon transfer of control to the customer.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;"&gt;1.&#160;&#160;&#160;&#160;Revenues from selling products&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The Company recognizes revenues from selling goods at a point in time when control over the product is transferred to customers (upon delivery).&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:54pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;2.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;Revenues from Chiesi Agreements&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The Company has identified two performance obligations in the Chiesi Agreements as follows: (i)&#160;the license and research and development services and (ii)&#160;the contingent performance obligation regarding future manufacturing.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The Company determined that the license together with the research and development services should be combined into single performance obligation since Chiesi cannot benefit from the license without the research and development services. The research and development services are highly specialized and are dependent on the supply of the drug.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The future manufacturing is contingent on regulatory approvals of the drug and the Company deems these services to be separately identifiable from other performance obligations in the contract. Manufacturing services post-regulatory approval are not interdependent or interrelated with the license and research and development services.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The transaction price was comprised of fixed consideration and variable consideration (capped research and development reimbursements). Under ASC 606, the consideration to which the Company would be entitled upon the achievement of contractual milestones, which are contingent upon the occurrence of future events, are a form of variable consideration. The Company estimates variable consideration using the most likely method. Amounts included in the transaction price are recognized only when it is probable that a significant reversal of cumulative revenues will not occur. Prior to recognizing revenue from variable consideration, the Company uses significant judgment to determine the probability of significant reversal of such revenue.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;Since the customer benefits from the research and development services as the entity performs the service, revenue from granting the license and the research and development services is recognized over time using the cost-to-cost method. The Company used significant judgment when it determined the costs expected to be incurred upon satisfying the identified performance obligation.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;Revenue from additional research and development services ordered by Chiesi is recognized&#160;over time using the cost-to-cost method.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:54pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;3.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;Revenue from R&amp;amp;D services&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;Revenue from the research and development services is recognized over time using the cost-to-cost method since the customer benefits from the research and development services as the entity performs the service.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <plx:NatureOfOperationsPolicyTextBlock
      contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw"
      id="Tb_OEW348Bc6EKVcPHgG9dl4Q">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;"&gt;a.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;"&gt;General&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the &#x201c;Company&#x201d;) and its wholly-owned subsidiaries, Protalix Ltd. and Protalix B.V. (collectively, the &#x201c;Subsidiaries&#x201d;), are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&#x2019;s proprietary ProCellEx&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; protein expression system (&#x201c;ProCellEx&#x201d;). To date, the Company has successfully developed taliglucerase alfa (marketed under the name BioManguinhos alfataliglicerase in Brazil and certain other Latin American countries and Elelyso&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; in the rest of the territories) for the treatment of Gaucher disease that has been approved for marketing in the United States, Brazil, Israel and other markets. The Company has a number of product candidates in varying stages of the clinical development process. The Company&#x2019;s strategy is to develop proprietary recombinant proteins that are therapeutically superior to existing recombinant proteins currently marketed for the same indications.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The most advanced investigational drug in the Company&#x2019;s product pipeline is pegunigalsidase alfa, or PRX-102, a therapeutic protein candidate for the treatment of Fabry disease, a rare, genetic lysosomal disorder, which was the subject of a phase&#160;III clinical program. The PRX-102 phase&#160;III clinical program included three separate studies, which are referred to as the &lt;i style="font-style:italic;"&gt;BALANCE&lt;/i&gt; study, the &lt;i style="font-style:italic;"&gt;BRIDGE&lt;/i&gt; study and the &lt;i style="font-style:italic;"&gt;BRIGHT&lt;/i&gt; study, each of which has been completed. The studies were designed to evaluate the potential for improved efficacy and better quality of life for adult patients with Fabry disease and to evaluate the safety of the Company&#x2019;s drug/therapy. The phase&#160;III clinical program analyzed two potential dosing regimens: 1&#160;mg/kg every two weeks and 2&#160;mg/kg every four weeks. In addition, the phase&#160;III clinical program included two extension studies in which subjects that participated in the Company&#x2019;s phase&#160;I/II clinical trials and phase&#160;III clinical trials had the opportunity to enroll and continue to be treated with PRX-102. As of March&#160;1, 2023, sponsorship of the two open-label extension studies was transferred to the Company&#x2019;s development and commercialization partner for PRX-102, Chiesi Farmaceutici S.p.A. (&#x201c;Chiesi&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The U.S.&#160;Food and Drug Administration (the &#x201c;FDA&#x201d;) has indicated that the biologics license application (&#x201c;BLA&#x201d;) for PRX-102 for the potential treatment of adult patients with Fabry disease resubmitted on November&#160;9, 2022 by the Company, together with Chiesi, was considered a complete, class&#160;2 response and set a PDUFA action date of&#160;May&#160;9, 2023. The initial BLA for PRX-102 was submitted to the FDA on May&#160;27, 2020 under the FDA&#x2019;s Accelerated Approval pathway, and was subsequently accepted by the FDA and granted Priority Review designation. However, in April 2021, the FDA issued a Complete Response Letter (CRL) in response to the initial BLA. In preparation for the BLA resubmission, the Company and Chiesi participated in a Type&#160;A (End of Review) meeting with the FDA on September&#160;9, 2021. As part of the meeting minutes provided by the FDA, which included the preliminary comments and meeting discussion, the FDA, in principle, agreed that the data package proposed to the FDA for a BLA resubmission has the potential to support a traditional approval of PRX-102 for the treatment of Fabry disease. The data package in the BLA resubmission, given the change in the regulatory landscape in the United States, included the final two-year analyses of the Company&#x2019;s phase&#160;III &lt;i style="font-style:italic;"&gt;BALANCE&lt;/i&gt; clinical trial of PRX-102, which was completed in July 2022, and long-term data from the Company&#x2019;s open-label extension study of PRX-102 in adult patients treated with a 2&#160;mg/kg every four&#160;weeks dosage of PRX-102.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On February&#160;7, 2022, the Company, together with Chiesi, submitted a Marketing Authorization Application (&#x201c;MAA&#x201d;) for PRX-102 to the European Medicines Agency (&#x201c;EMA&#x201d;) which was subsequently validated by the EMA. The submission was made after the October&#160;8, 2021 meeting the Company held, together with Chiesi, with the Rapporteur and Co-Rapporteur of the EMA regarding PRX-102.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;The MAA submission included a comprehensive set of preclinical, clinical and manufacturing data compiled from the Company&#x2019;s completed and ongoing clinical studies evaluating PRX-102 as a potential alternative treatment for adult patients with Fabry disease, including data from the Company&#x2019;s completed 12&#x2013;month switch&#x2013;over phase&#160;III &lt;i style="font-style:italic;"&gt;BRIGHT&lt;/i&gt;&#160;clinical trial in adult patients with Fabry disease treated with a 2&#160;mg/kg every four&#160;weeks dosage to support an additional potential treatment regimen for Fabry patients. As part of the EMA review process, Chiesi and the Company responded to the Day&#160;120 list of questions in September 2022 (following a 3-month clock-stop period) and the list of outstanding issues of Day&#160;180 in December 2022. An essential portion of the Day&#160;120 response included the submission of the final analysis of the two-year &lt;i style="font-style:italic;"&gt;BALANCE&lt;/i&gt; study (the final Clinical Study Report), and an interim analysis of the &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Company&#x2019;s long-term, open-label extension study of PRX-102 in adult patients with Fabry disease treated with the 2&#160;mg/kg every four&#160;weeks dosage.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On February&#160;24, 2023, the Company, together with Chiesi, announced that the EMA&#x2019;s Committee for Medicinal Products for Human Use (the &#x201c;CHMP&#x201d;) adopted a positive opinion, recommending marketing authorization for PRX-102. The CHMP opinion was referred for final action to the European Commission (the &#x201c;EC&#x201d;). A final EC decision on the MAA is expected in the beginning of&#160;May 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;In addition to PRX-102, the Company&#x2019;s product pipeline currently includes, among other candidates:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(1)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;PRX-115, the Company&#x2019;s plant cell-expressed recombinant PEGylated uricase (urate oxidase) &#x2013; a chemically modified enzyme to treat severe gout; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(2)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;PRX-119, the Company&#x2019;s plant cell-expressed PEGylated recombinant human DNase&#160;I product candidate being designed to elongate half-life in the circulation for NETs-related diseases.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:10pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Obtaining marketing approval with respect to any product candidate in any country is dependent on the Company&#x2019;s ability to implement the necessary regulatory steps required to obtain such approvals. The Company cannot reasonably predict the outcome of these activities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On July&#160;2, 2021, the Company entered into an At The Market Offering Agreement (the &#x201c;2021 Sales Agreement&#x201d;) with H.C.&#160;Wainwright &amp;amp; Co., LLC, as the Company&#x2019;s sales agent (the &#x201c;Agent&#x201d;) which was amended on May&#160;2, 2022. Pursuant to the terms of the 2021 Sales Agreement, the Company was able to sell, from time to time through the Agent, shares of its common stock, par value $0.001 per share (the &#x201c;Common Stock&#x201d;), having an aggregate offering price of up to $20.0&#160;million (the &#x201c;ATM Shares&#x201d;). Upon execution of the 2021 Sales Agreement, the Company terminated the ATM Equity Offering&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;SM&lt;/sup&gt; Sales Agreement it had entered into on October&#160;1, 2020 with BofA Securities, Inc. (&#x201c;BofA Securities&#x201d;). During the term of the sales agreement with BofA Securities, the Company sold a total of 3,296,123 shares of Common Stock for total gross proceeds of approximately $13.8&#160;million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;As of March&#160;31, 2023, the Company sold a total of 13,980,060 ATM Shares for total gross proceeds of approximately $20.0&#160;million under the 2021 Sales Agreement, thereby completing the ATM program under said agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On February&#160;27, 2023, the Company entered into an At The Market Offering Agreement (the &#x201c;2023 Sales Agreement&#x201d;) with the Agent. Pursuant to the terms of the 2023 Sales Agreement, the Company may sell, from time to time through the Agent, ATM Shares having an aggregate offering price of up to $20.0&#160;million. As of March&#160;31, 2023, shares of Common Stock for total gross proceeds of approximately $16.5&#160;million remain available to be sold under the 2023 Sales Agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On October&#160;19, 2017, Protalix Ltd. and Chiesi entered into an Exclusive License and Supply Agreement (the &#x201c;Chiesi Ex-US Agreement&#x201d;) pursuant to which Protalix Ltd. granted to Chiesi an exclusive license for all markets outside of the United States to commercialize pegunigalsidase alfa. On July&#160;23, 2018, Protalix Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the &#x201c;Chiesi US Agreement&#x201d;) with respect to the commercialization of pegunigalsidase alfa in the United States.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;Under each of the Chiesi Ex-US Agreement and the Chiesi US Agreement (collectively, the &#x201c;Chiesi Agreements&#x201d;), Chiesi made an upfront payment to Protalix&#160;Ltd. of $25.0&#160;million in connection with the execution of each agreement. In addition, under the Chiesi Ex-US Agreement, Protalix&#160;Ltd. is entitled to additional payments of up to $25.0&#160;million in pegunigalsidase alfa development costs and to receive additional payments of up to $320.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. Under the Chiesi US Agreement, Protalix&#160;Ltd. is entitled to payments of up to a maximum of $20.0&#160;million to cover development costs for pegunigalsidase alfa and to receive additional payments of up to a maximum of $760.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. To date, Protalix Ltd. has received the complete amount of development costs to which it is entitled under the Chiesi Agreements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;Under the terms of both of the Chiesi Agreements, Protalix Ltd. will manufacture all of the pegunigalsidase alfa needed under the agreements, subject to certain exceptions, and Chiesi will purchase pegunigalsidase alfa from Protalix, subject to certain terms and conditions. Under the Chiesi Ex-US Agreement, Chiesi is required to make tiered payments of 15% to 35% of its net sales, depending on the amount of annual sales outside of the United States, as consideration for product supply. Under the Chiesi US Agreement, Chiesi is required to make tiered payments of 15% to 40% of its net sales, depending on the amount of annual sales in the United States, as consideration for product supply.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;On May&#160;13, 2021, the Company signed a binding term sheet with Chiesi pursuant to which the Company and Chiesi amended the Chiesi Agreements in order to provide the Company with near-term capital. Chiesi agreed to make a $10.0&#160;million payment to the Company before the end of the second quarter of 2021 in exchange for a $25.0&#160;million reduction in a longer term regulatory milestone payment provided in the Chiesi EX-US Agreement. All other regulatory and commercial milestone payments remain unchanged. The Company received the payment in June&#160;2021. The Company also agreed to negotiate certain manufacturing related matters.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;Since its approval by the FDA, taliglucerase alfa has been marketed by Pfizer Inc. (&#x201c;Pfizer&#x201d;) in accordance with the exclusive license and supply agreement entered into between Protalix Ltd. and Pfizer, which is referred to herein as the Pfizer Agreement. In October 2015, Protalix Ltd. and Pfizer entered into an amended exclusive license and supply agreement, which is referred to herein as the Amended Pfizer Agreement, pursuant to which the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for 100% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;On June&#160;18, 2013, the Company entered into a Supply and Technology Transfer Agreement (the &#x201c;Brazil Agreement&#x201d;) with Funda&#xe7;&#xe3;o Oswaldo Cruz (&#x201c;Fiocruz&#x201d;), an arm of the Brazilian Ministry of Health (the &#x201c;Brazilian MoH&#x201d;), for taliglucerase alfa. Fiocruz&#x2019;s purchases of BioManguinhos alfataliglicerase to date have been significantly below certain agreed-upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the termination right, the Company is, at this time, continuing to supply BioManguinhos alfataliglicerase to Fiocruz and patients continue to be treated with BioManguinhos alfataliglicerase in Brazil.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;The novel coronavirus disease (&#x201c;COVID-19&#x201d;), which was declared by the World Health Organization to be a global pandemic on March&#160;11, 2020, has had numerous adverse effects on the global economy. To date, the Company&#x2019;s clinical trials have not been adversely affected by COVID-19, although certain practices the Company adopted during the earlier stages of the pandemic in its offices and facilities in an effort to promote social distancing resulted in minor delays in the performance of administrative activities outside of the clinical programs.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;The Company expects to continue to incur significant expenditures in the near future due to research and developments efforts with respect to the product candidates. Under the terms of the Company&#x2019;s outstanding 7.50% Senior Secured Convertible Notes due 2024 (the &#x201c;2024 Notes&#x201d;)&lt;span style="font-family:'28mugxoulnobhnx';"&gt;, &lt;/span&gt;the Company is required to comply with certain&lt;span style="color:#222222;background:#ffffff;"&gt; &lt;/span&gt;financial covenants, including the maintenance of a minimum cash balance of at least $7.5&#160;million. As of March&#160;31, 2023, the Company is in&lt;span style="background:#ffffff;"&gt; compliance with all such covenants. &lt;/span&gt;The Company believes that its cash and cash equivalents as of March&#160;31, 2023, together with additional funds raised from the sale of ATM Shares under the 2023 Sales Agreement subsequent to March&#160;31, 2023 are sufficient to satisfy the Company&#x2019;s capital needs for at least 12&#160;months from the date that these financial statements are issued.&lt;/p&gt;</plx:NatureOfOperationsPolicyTextBlock>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_vCJMvVrkpEey12nFHwmq_g"
      decimals="INF"
      id="Narr_mvrK0y0Dc0W5YIVIXo9G4w"
      unitRef="Unit_Divide_USD_shares_65Ko0I-nrkSGY9fEMAqs6Q">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <plx:SaleOfStockMaximumOfferingPrice
      contextRef="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_NlK07qNF70WUx9TiUtAq1A"
      decimals="-5"
      id="Narr_HEB57ZT8UE2ztI6jOYPS4Q"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">20000000.0</plx:SaleOfStockMaximumOfferingPrice>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtmEquityOfferingSalesAgreementMember_TYdGwaWNbE6JmroON4hlzg"
      decimals="INF"
      id="Narr_K8txZ77RqEaEAKA3dRzzgg"
      unitRef="Unit_Standard_shares_4bVAm6lD50yLNxvQT1GIoA">3296123</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtmEquityOfferingSalesAgreementMember_TYdGwaWNbE6JmroON4hlzg"
      decimals="-5"
      id="Narr_W7VAPu2gvEGamXDbyQ6kEg"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">13800000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_0iU3Zlmqr0On_CGrbCti_Q"
      decimals="INF"
      id="Narr_MiHdWXx5qE-TcD0NECwfnA"
      unitRef="Unit_Standard_shares_4bVAm6lD50yLNxvQT1GIoA">13980060</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_0iU3Zlmqr0On_CGrbCti_Q"
      decimals="-5"
      id="Narr_R_rP9CiOYkaoJr3pBs1LPg"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">20000000.0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <plx:SaleOfStockMaximumOfferingPrice
      contextRef="Duration_2_27_2023_To_2_27_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_Q-zSWd_o2UuvPzl41Xf3MA"
      decimals="-5"
      id="Narr_pmPh69CnTkOV0K2V_7cFdw"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">20000000.0</plx:SaleOfStockMaximumOfferingPrice>
    <plx:SaleOfStockMaximumOfferingPrice
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_0iU3Zlmqr0On_CGrbCti_Q"
      decimals="-5"
      id="Narr_g1nPVdHiOUKt328GpwJJvw"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">16500000</plx:SaleOfStockMaximumOfferingPrice>
    <plx:UpfrontNonrefundableNoncreditablePaymentReceivable
      contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_z3hwihuoBkC5xNBh7hXP6A"
      decimals="-5"
      id="Narr_hTjdU3JA-kyL72QF05F5rA"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">25000000.0</plx:UpfrontNonrefundableNoncreditablePaymentReceivable>
    <plx:UpfrontNonrefundableNoncreditablePaymentReceivable
      contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_Am7rx-rvZUywApMit-lb-A"
      decimals="-5"
      id="Narr_yk-zk8kN5Eu5agSQQ7_bxw"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">25000000.0</plx:UpfrontNonrefundableNoncreditablePaymentReceivable>
    <plx:AdditionalAmountsPayableToCoverDevelopmentCosts
      contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_GyY7-odK10eb47EO_FtixA"
      decimals="-5"
      id="Narr_o88oCtwjAU-7fE_-qMDKYg"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">25000000.0</plx:AdditionalAmountsPayableToCoverDevelopmentCosts>
    <plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones
      contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_GyY7-odK10eb47EO_FtixA"
      decimals="-5"
      id="Narr_encmai31kkOKTJhvtgx8VQ"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">320000000.0</plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones>
    <plx:AdditionalAmountsPayableToCoverDevelopmentCosts
      contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_3yJmheSn6UeRYw8iwyMgIg"
      decimals="-5"
      id="Narr_Wx5nOk-AmUykDHtmAdyzfA"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">20000000.0</plx:AdditionalAmountsPayableToCoverDevelopmentCosts>
    <plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones
      contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_3yJmheSn6UeRYw8iwyMgIg"
      decimals="-5"
      id="Narr_1toyQ7ROAUqS1-9tny_gbw"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">760000000.0</plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones>
    <plx:PaymentOnNetSalesPercentage
      contextRef="Duration_10_19_2017_To_10_19_2017_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_Sax1Fe0WOEOjE9gRCUPqYQ"
      decimals="INF"
      id="Narr_LJt5NBe6vkGtXg93qQnekg"
      unitRef="Unit_Standard_pure_0xGx53TVLESXmSrWd-Jrvw">0.15</plx:PaymentOnNetSalesPercentage>
    <plx:PaymentOnNetSalesPercentage
      contextRef="Duration_10_19_2017_To_10_19_2017_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_D2oITtj5_U2sjJO37_gN5w"
      decimals="INF"
      id="Narr_3yx1FjAqw0qeNYOS5GsYGw"
      unitRef="Unit_Standard_pure_0xGx53TVLESXmSrWd-Jrvw">0.35</plx:PaymentOnNetSalesPercentage>
    <plx:PaymentOnNetSalesPercentage
      contextRef="Duration_7_23_2018_To_7_23_2018_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_qGhtjJbQ70ugptcYziO39Q"
      decimals="INF"
      id="Narr_zipq38pT1UiOcRS76p_Yew"
      unitRef="Unit_Standard_pure_0xGx53TVLESXmSrWd-Jrvw">0.15</plx:PaymentOnNetSalesPercentage>
    <plx:PaymentOnNetSalesPercentage
      contextRef="Duration_7_23_2018_To_7_23_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_VXlGDMYSYka-21A_FiXp3A"
      decimals="INF"
      id="Narr_omOn1kForUWt3D2x1ZK2YA"
      unitRef="Unit_Standard_pure_0xGx53TVLESXmSrWd-Jrvw">0.40</plx:PaymentOnNetSalesPercentage>
    <plx:AgreementAmendmentPaymentReceivable
      contextRef="As_Of_5_13_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_egFQOM62D0mceKOHvMGXcw"
      decimals="-5"
      id="Narr_JEeCCJWYIkCbedPA3i4FnQ"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">10000000.0</plx:AgreementAmendmentPaymentReceivable>
    <plx:ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones
      contextRef="Duration_5_13_2021_To_5_13_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_18jRabrPoUa3e12IYdZR0w"
      decimals="-5"
      id="Narr_Kfk_-Nre-Uedb_JE_ZzELg"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">25000000.0</plx:ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones>
    <plx:CollaborativeArrangementRevenuesExpensesSharingPercentage
      contextRef="Duration_10_1_2015_To_10_31_2015_dei_LegalEntityAxis_plx_ProtalixBioTherapeuticsIncorporationMember_srt_StatementGeographicalAxis_country_BR_us-gaap_TypeOfArrangementAxis_plx_AmendedPfizerAgreementMember_2qZfvaa21UeJuh9OQT_1zQ"
      decimals="2"
      id="Narr_D3-qlLT_rEqLrEPjy9zXVA"
      unitRef="Unit_Standard_pure_0xGx53TVLESXmSrWd-Jrvw">1</plx:CollaborativeArrangementRevenuesExpensesSharingPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_3_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_ZgUoVauLFkSr1Jlp4jtK7Q"
      decimals="4"
      id="Narr_RenMmz2meUKs_LbRa-5eNg"
      unitRef="Unit_Standard_pure_0xGx53TVLESXmSrWd-Jrvw">0.0750</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <plx:MaintainOfMinimumCashBalance
      contextRef="As_Of_3_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_ZgUoVauLFkSr1Jlp4jtK7Q"
      decimals="-5"
      id="Narr_lQeZma1e2kqrXGFnvq96zg"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">7500000</plx:MaintainOfMinimumCashBalance>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw"
      id="Tb_3tjqtk-fxEmlfXM_Os346Q">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;"&gt;b.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;"&gt;Basis of presentation&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;"&gt;The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States (&#x201c;GAAP&#x201d;) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;"&gt;These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form&#160;10-K for the year ended December&#160;31, 2022, filed by the Company with the U.S.&#160;Securities and Exchange Commission (the &#x201c;Commission&#x201d;). The comparative balance sheet at December&#160;31, 2022 has been derived from the audited financial statements at that date. There have been no material changes in our significant accounting policies as described in our consolidated financial statements for the year ended December&#160;31, 2022.&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw"
      id="Tb_9j_Sp_bU50-Zw_BYNw4JFA">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;c.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;Loss per share&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;"&gt;Basic and diluted loss per share (&#x201c;LPS&#x201d;) are computed by dividing net loss by the weighted average number of shares of Common Stock attributable to common stockholders outstanding for each period. The calculation of diluted LPS does not include 36,292,208 shares of Common Stock underlying outstanding options and shares of Common Stock issuable upon conversion of the outstanding 2024 Notes and the exercise of outstanding warrants for the three months ended March&#160;31, 2023, and 33,004,217 shares of Common Stock underlying outstanding options and shares of Common Stock issuable upon conversion of the Company&#x2019;s then outstanding 2024 Notes and the exercise of outstanding warrants for the three months ended March&#160;31, 2022 because their effect would be anti-dilutive.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw"
      decimals="INF"
      id="Narr_iwlsqMoVuESG1PYiGZ9kFw"
      unitRef="Unit_Standard_shares_4bVAm6lD50yLNxvQT1GIoA">36292208</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2022_To_3_31_2022_N1jzYHJ1VECWf3tLdKC1jw"
      decimals="INF"
      id="Narr_JqexpDW1YU-RMym9YD3spQ"
      unitRef="Unit_Standard_shares_4bVAm6lD50yLNxvQT1GIoA">33004217</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw"
      id="Tb_2z1CcaURYk2tdagYT1JkhQ">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;d.&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Revenue recognition&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company accounts for revenue pursuant to Accounting Standards Codification, Topic 606, Revenue from Contracts with Customers (&#x201c;ASC 606&#x201d;). Under ASC 606, a contract with a customer exists only when: the parties to the contract have approved it and are committed to perform their respective obligations, the Company can identify each party&#x2019;s rights regarding the distinct goods or services to be transferred (&#x201c;performance obligations&#x201d;), the Company can determine the transaction price for the goods or services to be transferred, the contract has commercial substance and it is probable that the Company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Revenues are recorded in the amount of consideration to which the Company expects to be entitled in exchange for performance obligations upon transfer of control to the customer.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;"&gt;1.&#160;&#160;&#160;&#160;Revenues from selling products&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The Company recognizes revenues from selling goods at a point in time when control over the product is transferred to customers (upon delivery).&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:54pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;2.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;Revenues from Chiesi Agreements&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The Company has identified two performance obligations in the Chiesi Agreements as follows: (i)&#160;the license and research and development services and (ii)&#160;the contingent performance obligation regarding future manufacturing.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The Company determined that the license together with the research and development services should be combined into single performance obligation since Chiesi cannot benefit from the license without the research and development services. The research and development services are highly specialized and are dependent on the supply of the drug.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The future manufacturing is contingent on regulatory approvals of the drug and the Company deems these services to be separately identifiable from other performance obligations in the contract. Manufacturing services post-regulatory approval are not interdependent or interrelated with the license and research and development services.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The transaction price was comprised of fixed consideration and variable consideration (capped research and development reimbursements). Under ASC 606, the consideration to which the Company would be entitled upon the achievement of contractual milestones, which are contingent upon the occurrence of future events, are a form of variable consideration. The Company estimates variable consideration using the most likely method. Amounts included in the transaction price are recognized only when it is probable that a significant reversal of cumulative revenues will not occur. Prior to recognizing revenue from variable consideration, the Company uses significant judgment to determine the probability of significant reversal of such revenue.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;Since the customer benefits from the research and development services as the entity performs the service, revenue from granting the license and the research and development services is recognized over time using the cost-to-cost method. The Company used significant judgment when it determined the costs expected to be incurred upon satisfying the identified performance obligation.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;Revenue from additional research and development services ordered by Chiesi is recognized&#160;over time using the cost-to-cost method.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:54pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;3.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;Revenue from R&amp;amp;D services&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;Revenue from the research and development services is recognized over time using the cost-to-cost method since the customer benefits from the research and development services as the entity performs the service.&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <plx:RevenuePerformanceObligationNumber
      contextRef="As_Of_3_31_2023_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_6M0Qz8IYh02zFSz41wRItw"
      decimals="INF"
      id="Narr_A27zUIzSbE-bXwY1SJU-2g"
      unitRef="Unit_Standard_agreement_l_AIB71m8UmKtkYDila2Og">2</plx:RevenuePerformanceObligationNumber>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw"
      id="Tb_QC1Y4KqbyUGL8h2EnasGMQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;NOTE&#160;2&#160;- INVENTORIES&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;Inventories at March&#160;31, 2023 and December&#160;31, 2022 consisted of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Raw materials&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,308&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,508&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Work in progress&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,533&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,678&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Finished goods&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14,462&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,618&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total inventory&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20,303&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 16,804&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="font-size:1pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw"
      id="Tb_gxBqwKSqHkyvvJ2PgZtqeA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Raw materials&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,308&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,508&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Work in progress&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,533&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,678&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Finished goods&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14,462&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,618&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total inventory&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20,303&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 16,804&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="As_Of_3_31_2023_lQ4VofWCfU-ERA4iKttplQ"
      decimals="-3"
      id="Tc_ZiinDupAK0aBSmieYxxh-w_3_3"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">4308000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="As_Of_12_31_2022_H53zBT4W7kaDDa9Xye-U_Q"
      decimals="-3"
      id="Tc_vmUHVV_k1EuJofD5uf_ZkQ_3_6"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">3508000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="As_Of_3_31_2023_lQ4VofWCfU-ERA4iKttplQ"
      decimals="-3"
      id="Tc_y2u4WANPiU2PUPhN_Rv0fA_4_3"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">1533000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="As_Of_12_31_2022_H53zBT4W7kaDDa9Xye-U_Q"
      decimals="-3"
      id="Tc_zMzngYuZg0amw_uUZIWSxw_4_6"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">2678000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="As_Of_3_31_2023_lQ4VofWCfU-ERA4iKttplQ"
      decimals="-3"
      id="Tc_hpixRzBm_02GdQRMMCdw8A_5_3"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">14462000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="As_Of_12_31_2022_H53zBT4W7kaDDa9Xye-U_Q"
      decimals="-3"
      id="Tc_lg6IStvDEUKy19RrudxAYA_5_6"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">10618000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="As_Of_3_31_2023_lQ4VofWCfU-ERA4iKttplQ"
      decimals="-3"
      id="Tc_8VDMqPHytEanr4QrzS_Pjw_6_3"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">20303000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="As_Of_12_31_2022_H53zBT4W7kaDDa9Xye-U_Q"
      decimals="-3"
      id="Tc_ifOPtyK5yEiTI9Mvov6XKg_6_6"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">16804000</us-gaap:InventoryNet>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw"
      id="Tb_TrpGHlskC0uoA_927diMrg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;NOTE&#160;3&#160;&#x2013; FAIR VALUE MEASUREMENT&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;The Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received from the sale of an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;The fair value of the financial instruments included in the working capital of the Company is usually identical or close to their carrying value.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 35.45pt;"&gt;Based on a Level 3 measurement, as of March&#160;31, 2023, the fair value of the $28.75&#160;million aggregate principal amount of the Company&#x2019;s outstanding 2024 Notes is approximately $41.4&#160;million. The value of these notes was estimated by implementing the binomial model. The liability component was valued based on the Income Approach. The following parameters were used:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&#160;Notes&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Stock price (USD)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.10&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.42&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk free rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4.19&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 62.47&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12.60&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="As_Of_3_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_9xvbhmNJFkageC4WyZOI_Q"
      decimals="-4"
      id="Narr_JDbOxUcFMEecyBDWvkWjIg"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">28750000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="As_Of_3_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_9xvbhmNJFkageC4WyZOI_Q"
      decimals="-5"
      id="Narr_gyzQ2m8DgkiorBQfOh7kgg"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">41400000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_a9VnZ-vJPkiHhaBFIDBw-A"
      id="Tb_5VpXSaLtPka5V_U9XK6ieA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&#160;Notes&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Stock price (USD)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.10&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.42&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk free rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4.19&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 62.47&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12.60&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="As_Of_3_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember__GmWbcoY7kCTcvgHXmTtag"
      decimals="2"
      id="Tc_j-HD4Q1WFk2FVOTATrX3hg_2_5"
      unitRef="Unit_Divide_USD_shares_65Ko0I-nrkSGY9fEMAqs6Q">2.10</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="As_Of_3_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_aCnJ8YZWTEKINZXa-WibNQ"
      decimals="2"
      id="Tc_ASZ2wrJiKUSzfR96W1bvSg_3_5"
      unitRef="Unit_Standard_Y_lrd4ffoII0uwy2NmYOCxhg">1.42</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="As_Of_3_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_6rulpN2cdUS_aFAtMHgQ0Q"
      decimals="2"
      id="Tc_j8lVUa41HE2oBDCOZI3i2w_4_5"
      unitRef="Unit_Standard_pure_0xGx53TVLESXmSrWd-Jrvw">4.19</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="As_Of_3_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_sRkxswHoFESpgC_hhX6rNw"
      decimals="2"
      id="Tc_rEhgmp5_eU-qQlgTqfn1tg_5_5"
      unitRef="Unit_Standard_pure_0xGx53TVLESXmSrWd-Jrvw">62.47</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="As_Of_3_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_plx_MeasurementInputYieldMember_fyqadwF3d0u2BkkX4IRliA"
      decimals="2"
      id="Tc_GNxyxc3xiUeiqSywrssZbg_6_5"
      unitRef="Unit_Standard_pure_0xGx53TVLESXmSrWd-Jrvw">12.60</us-gaap:DebtInstrumentMeasurementInput>
    <plx:RevenueDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw"
      id="Tb_qoKBkUvmsEqFiIWISJNzFQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;background:#ffffff;"&gt;NOTE&#160;4&#160;&#x2013; REVENUES&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;background:#ffffff;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;&lt;span style="background:#ffffff;"&gt;The following table summarizes the Company&#x2019;s disaggregation of revenues:&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:61.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Pfizer&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,266&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,356&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Brazil&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,800&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,454&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Chiesi&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 218&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total revenues from selling goods&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,066&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,028&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Revenues from license and R&amp;amp;D services&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,522&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,057&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="color:#212529;font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</plx:RevenueDisclosureTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw"
      id="Tb_OYaEdCDn0kWemSybqLQKeg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;&lt;span style="background:#ffffff;"&gt;The following table summarizes the Company&#x2019;s disaggregation of revenues:&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:61.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Pfizer&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,266&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,356&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Brazil&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,800&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,454&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Chiesi&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 218&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total revenues from selling goods&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,066&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,028&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Revenues from license and R&amp;amp;D services&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,522&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,057&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2023_To_3_31_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_fttaWimhoUeG-S7zMyaisw"
      decimals="-3"
      id="Tc_wm2u4Aq260WnPjd9zUqM0w_3_3"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">2266000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2022_To_3_31_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_WcMRAOlFCE6_UAs2eyxXCA"
      decimals="-3"
      id="Tc_OxysFihTCEC093iVrabfgw_3_6"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">3356000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2023_To_3_31_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_hmYTDCpI-ECukL-F-IOjvQ"
      decimals="-3"
      id="Tc_T2eMdyDkkU-qbQmarch3gA_4_3"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">2800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2022_To_3_31_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_PBB8cE7vikCPoa7ZmvpzOA"
      decimals="-3"
      id="Tc_3VVeDkaKz0iLO7BaTG869g_4_6"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">5454000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2022_To_3_31_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_ChiesiMember_1_EnASsBOky6dNtE7sYeqA"
      decimals="-3"
      id="Tc_A9pbqfKChUCJRuOjUE3Aag_5_6"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">218000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2023_To_3_31_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_1ErUchefYE24icEBkPux0A"
      decimals="-3"
      id="Tc_wEtj2LYqikyU1SGzzm3U_g_6_3"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">5066000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2022_To_3_31_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_TLlwu1kiM067CBBRXPNrNw"
      decimals="-3"
      id="Tc_rQXZ7u811EuksG6mbQAzvA_6_6"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">9028000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2023_To_3_31_2023_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_0OKK-_bib0C_UleLAi20GA"
      decimals="-3"
      id="Tc_phQLlOmU8EKlL5s8aTSwQg_7_3"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">4522000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2022_To_3_31_2022_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_rv5oVU7cTEWzAOzlbF-VFA"
      decimals="-3"
      id="Tc_b_BMVLCKqEaV8JcGFR7vdg_7_6"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">7057000</us-gaap:Revenues>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw"
      id="Tb_KhwF9R3VgkmbKbu-wQiI2w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NOTE 5 &#x2013; STOCK TRANSACTIONS&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"&gt;&lt;b style="font-weight:bold;background:#ffffff;"&gt;At-the-Market (ATM) Offering&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"&gt;During the three months ended March&#160;31, 2023, the Company sold, in the aggregate, 8,212,482 shares of Common Stock under the 2023 Sales Agreement and the 2021 Sales Agreement. The Company generated aggregate gross proceeds equal to approximately $14.9&#160;million in connection with such sales.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtmEquityOfferingSalesAgreementMember_aO6xvvEThkasCzfWTSPBgQ"
      decimals="INF"
      id="Narr_Ev5DBrggDEWJ1L30M6C5dQ"
      unitRef="Unit_Standard_shares_4bVAm6lD50yLNxvQT1GIoA">8212482</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtmEquityOfferingSalesAgreementMember_aO6xvvEThkasCzfWTSPBgQ"
      decimals="-5"
      id="Narr_7xZDhZfgekmp8krYbsMVpA"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">14900000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw"
      id="Tb_KuYWCyxJLEKjGOQ7J1yNvg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NOTE 6 &#x2013; SUBSEQUENT EVENTS&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;During April 2023, the Company sold, in the aggregate, 3,412,268 shares of Common Stock under the 2023 Sales Agreement. The Company generated aggregate gross proceeds equal to approximately $7.9&#160;million in connection with such sales.&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <plx:StockIssuedDuringPeriodSharesSalesAgreement
      contextRef="Duration_4_1_2023_To_4_30_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_tROqvzE5iEKYWMElS1CURw"
      decimals="INF"
      id="Narr_UMwW4RbsZ0yttGg6I4hBXg"
      unitRef="Unit_Standard_shares_4bVAm6lD50yLNxvQT1GIoA">3412268</plx:StockIssuedDuringPeriodSharesSalesAgreement>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_4_1_2023_To_4_30_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_tROqvzE5iEKYWMElS1CURw"
      decimals="-5"
      id="Narr_jVuh8biNZ0iiskU9D6DTtA"
      unitRef="Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw">7900000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Tc_yTxTuHFDc0CebaIJf12WuA_9_2"
          xlink:label="Tc_yTxTuHFDc0CebaIJf12WuA_9_2"
          xlink:type="locator"/>
        <link:footnote id="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" xlink:label="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Common stock, $0.001 par value; Authorized &#x2013; as of March&#160;31, 2023 and 2022 &#x2013; 144,000,000 and 120,000,000 shares, respectively.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_yTxTuHFDc0CebaIJf12WuA_9_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_mfQTaw5le0imjmuMBx4ODg_14_2"
          xlink:label="Tc_mfQTaw5le0imjmuMBx4ODg_14_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_mfQTaw5le0imjmuMBx4ODg_14_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_v0W510vMt0WtRFcsOlezUQ_6_2"
          xlink:label="Tc_v0W510vMt0WtRFcsOlezUQ_6_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_v0W510vMt0WtRFcsOlezUQ_6_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_dgYszTwrTEefeCZ3ZKmo1Q_11_2"
          xlink:label="Tc_dgYszTwrTEefeCZ3ZKmo1Q_11_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_dgYszTwrTEefeCZ3ZKmo1Q_11_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_exCmImm6ckG9_1mX6eB13g_12_2"
          xlink:label="Tc_exCmImm6ckG9_1mX6eB13g_12_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_exCmImm6ckG9_1mX6eB13g_12_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_EWUveCzkOkWNPC49U8GrGw_18_2"
          xlink:label="Tc_EWUveCzkOkWNPC49U8GrGw_18_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_EWUveCzkOkWNPC49U8GrGw_18_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_eCxjacwjWUC54yg3cb-XsA_6_6"
          xlink:label="Tc_eCxjacwjWUC54yg3cb-XsA_6_6"
          xlink:type="locator"/>
        <link:footnote id="_decff55c_b6f1_4b4f_9c4c_20bfc2a1e99e" xlink:label="_decff55c_b6f1_4b4f_9c4c_20bfc2a1e99e" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:b style="font-size:8pt;font-weight:bold;">(1) Includes share-based compensation</xhtml:b></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_eCxjacwjWUC54yg3cb-XsA_6_6"
          xlink:to="_decff55c_b6f1_4b4f_9c4c_20bfc2a1e99e"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_weldJHKNTU-LFl_B0NjZQw_6_3"
          xlink:label="Tc_weldJHKNTU-LFl_B0NjZQw_6_3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_weldJHKNTU-LFl_B0NjZQw_6_3"
          xlink:to="_decff55c_b6f1_4b4f_9c4c_20bfc2a1e99e"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_o7CMDO5nykicD24BOuYAWg_7_6"
          xlink:label="Tc_o7CMDO5nykicD24BOuYAWg_7_6"
          xlink:type="locator"/>
        <link:footnote id="_8530ca94_6c84_4f48_984f_7cc5a2959400" xlink:label="_8530ca94_6c84_4f48_984f_7cc5a2959400" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:b style="font-size:8pt;font-weight:bold;">(2) Includes share-based compensation</xhtml:b></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_o7CMDO5nykicD24BOuYAWg_7_6"
          xlink:to="_8530ca94_6c84_4f48_984f_7cc5a2959400"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_l3K5Bpo4okmUExRcDvJpSA_7_3"
          xlink:label="Tc_l3K5Bpo4okmUExRcDvJpSA_7_3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_l3K5Bpo4okmUExRcDvJpSA_7_3"
          xlink:to="_8530ca94_6c84_4f48_984f_7cc5a2959400"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_FWjhg_ga90yHw-Q3cLx8eA_8_6"
          xlink:label="Tc_FWjhg_ga90yHw-Q3cLx8eA_8_6"
          xlink:type="locator"/>
        <link:footnote id="_64475d15_2bf5_4e75_bed3_14deb6a39d55" xlink:label="_64475d15_2bf5_4e75_bed3_14deb6a39d55" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:b style="font-size:8pt;font-weight:bold;">(3) Includes share-based compensation</xhtml:b></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_FWjhg_ga90yHw-Q3cLx8eA_8_6"
          xlink:to="_64475d15_2bf5_4e75_bed3_14deb6a39d55"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_fTYVNJWnjESxIeMvtTihVg_8_3"
          xlink:label="Tc_fTYVNJWnjESxIeMvtTihVg_8_3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_fTYVNJWnjESxIeMvtTihVg_8_3"
          xlink:to="_64475d15_2bf5_4e75_bed3_14deb6a39d55"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>39
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M> X]1OJ\FB4)^AR!$1:)$IX%]%^JY3:*-.4NK1(VNA$S]W++M=QFR47J0[O
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MX1846=N<311?F\[SB2OL8\TPPK\:('0 WE]QKMXF^@'%GY?1+U!+ P04
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MIP>N$@J_5&;%?Z-C9BJ<E_^[5!**I0?P_=R@?/:_T ;-'VUY\W]02P,$%
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M=O\X7=Y\@GF6H>8RA\O:+Q1 /XT(9?.HZ!X5"),4[9MT?-A,E163+V"42#O
MI3>R/->8,XL=&';B*.X,AC&8@M&=@<H<AGAA856R@IJHM4<Y4E@P04%3PB.U
MO04FTZTS^M/9A>6.@APE:LJ9OJ:'7"MCH-(J04RIC,>:"; *6$6V9TX-C>(%
M/D2#[BDUEA!N1E -B9)R,S'6W!8TK:ANXY)WWWKG<*?U2M2Y'S"&6&IIFRYL
MK>T,FS:M^QK>#$"ZXIQ+ P(S@O:ZGX\#T,U0:0Y65;Z1'Y2EL>"W!<UAU"Z
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M)\<!Z,[ZW<*JVMOM05DRKY^6U"U1NP ZWRAE=PN7H.^_B]]02P,$%     @
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M=GIRKYU]=7D^3U<M"KTOA+J?")2YATZW@.@0S$G"%Q<Z):9I"W'7)#Y9IC2
MF#($NF;A#8*$1+P8O1@TVS$&(U:M*"_Q4?(9OU%'YA<087I]1LNBH12.DOW'
M YZ7=21\P.K?RJ,2W)VVG'K16U'0A%]]'E.R^VDZP'XU [NK<!(HNY:MQZ#V
MK0:?E/@K]D$]QP&SS+\&9+MY-9R T#0GIN<;#R+@H-517Z5JQX1I,:5)P(Y*
M+ R%,I [O17FDC>?/[NR#(5+052=A*EEITV"M]E*E:L)N"H"D_2#EVY (VC^
M(Y@8; O3QB5NFMRNF"_WKAF_^E0B%6;\#>.K;<209<+WQ /9J"L2M_OX40JU
M0I%NN^"_AWW:,JR-11F4PJM08QO6OYI$,79;]6^[.WLX[%3;VKSS/H;W7*)#
MO*8NZK:L2I/MLCR.N&8;HP$>EWKXT=^M9@(9_5^< /2M<M*3%4\ :]=IX/D?
M,JF&"VY&QXDM59&Z@DU:V^;#(-O7-!4-FYYLL[S;:XIYYG>WG$G1^&JU-GO%
MUNW/1/0DP5F6F35-X.JG_%1<D=^7UK=*Q(.QVB]UI00>3>QG)3)P7S_HM%VZ
M-8K&,*/A[L!<=QK<YQX/L-IF#&X.-Q1]+>6+:A_'EAL_7G1^U'2&Y'8.PVL"
MZ, 6<0/W^3B&W&D?(6(*N(&/ ' "6C=IE#;(O#."ZVN4/AJ@ES'=3GT2)PV-
M;LUT1QC"O&U,JQWB::Y)Y1QD6+4-C>$-1TH6O:8RV+'<7$?P 94-6#I$E!&S
MW6RT,K8Z[.&YR5@YD8UDY&L(H<'7Z,\/J;T3Z*ZO<.\<YOB%7[*=(X6Y\\EG
M"XQ$]!8I-(NB^]63!/RK>Q@HE<YG"#J<_>X& O<XBHYS"9;0CHFL0K,^@:K?
M-C6&< %UW*/MO*H:J4]#Q"1N]M\5+;WB$;;1F <MDH(#"'S9+XFM:B7B@)P+
M0WOD5ML0,_";R9G^3CJ7 R(H3YGF+G)K7B_RRK5[?\&_L2](VZ"IUUO+3H9+
M?J.T;D0WJ7/.B6[;#IESM*20+)NA>S'3CR+Q?JX*$T6%_6?M!C U]6EB-OZH
MTT48&.A&-HYY-XU/2>$>WKG.Z?D(;>_8M0;PLRWZ/0+"K!]5J&AW;_/^)6OW
MS*![=A[6#'<:F^;C]N-F87N-[);)6[=Z0D-3AY4YI)^-HMQT)9OV2S8H1,<_
M*3^&U92[' )R0;T,]F5Q@W:^"3Q$WKL?!H?=-"$:5GM8!#R3XMLAT6S/CPOE
M>(N+K_RBPKMVI\ZW_X_WXUWQ/Z",O7GI4?3W2[#U@O]*BW4OP[@_9=)\VOPA
MF*G[^R?MX^ZOR"!C7E"?.E-S+!T-3YX?N PH_%*9%?\UE)FI<$[^[U))7"@]
M@._G!MF[_X4V:/X\SMO_!5!+ P04    " #:@Z16!Y4!EI$"   9!@  &0
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M[4;:I.GDS_!F'NK_?D<+"0Q3#77M&SU!1#-C&D/QLN[K+5=Z2M3;3(]E%"9
MGZ=</TMKF 3=H(_^ E!+ P04    " #:@Z16$%^+OMP"  #K!@  &0   'AL
M+W=O<FMS:&5E=',O<VAE970Q-RYX;6RM5=M2VS 0_94=EZ$PDXD=.S?(988
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M>""KUEH96I2NG3T*;9JC&^;F-4)I'<QZ*H3>&C9 \[[-_P!02P,$%     @
MVH.D5EJ91.;+"P  %X\  !D   !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL
MO=WM3]M( @;P?V646YVZ4I?$+X'0 R2(YVVU4%3:O0^G^V"2@5AU[*SM %WU
MC[^Q8V(F,4/<>]*5NB4A\QL3'LS$C^.>/*;9UWRF5$&>YG&2G_9F1;'XT._G
MDYF:A_E!NE")_LQ=FLW#0M_,[OOY(E/AM!HTC_ON8'#8GX=1TCL[J>Z[SLY.
MTF411XFZSDB^G,_#[-N%BM/'TY[3>[[C4W0_*\H[^F<GB_!>W:CBR^(ZT[?Z
M:V4:S5621VE",G5WVCMW/LAA-:!ZQ)^1>LQ??$S*+^4V3;^6-^3TM#<HMTC%
M:E*41*C_>E!C%<>EI+?CKQKMK><L![[\^%EGU1>OOYC;,%?C-/YW-"UFI[U1
MCTS57;B,BT_IHU#U%S0LO4D:Y]7_R6/]V$&/3)9YD<[KP7H+YE&R^CM\JI^(
M%P-<]Y4!;CW W1C@OS:#5P_P-F=P7AG@UP/\73=I6 \8[CK@L!YPN#% /WGM
M X[J 4<; X:O?=&C>L!H8X#WVB8=UP..JSBLOG_5-S\(B_#L)$L?258^6FOE
M!U6"JM'Z>QXE9=AOBDQ_-M+CBK,;R:\DD^/SJ\_D?#S^^.7JL[SBY/KC'W(L
MZ0UY%Z@BC.+\5_(+Z9-\%F8J)U%"OB11D;_7=^J//\_291XFT_RD7^A-*N'^
MI)Z>KZ9W7YG>(9=I4LQR0I.IFK:,%_;QGF5\7S\5Z^?#?7X^+EPKR-3M 7&/
MWA-WX'KDRTU WOWR:\MVC>W,[\OX@ S<BG&>F9=/X>JO%CBPPY?A-^)XIMNB
MT!TVSZT89V1AF)WY."D.B'-<,4<6AN_ >$[%#-LR\-93DCT/;[YE)+S/E-)[
MY6*G9UWN/H7[%FCDSEO_''K5#-YK/X?1?1+=19-0;_#Y9)(NDR)*[LEU&D>3
M2$_TGS_T "(+-<__V[+]%RO=;]?+WY@?\D4X4:<]_2LQ5]F#ZIW]\Q_.X>!?
M;=E&8@$2HTB,(3&.Q 02DR#,B+6_CK5OT\_&Z7RNES0W13KY^IY<AQE),WTK
M+-24_!G&2T6NE;ZC_"DBWU_\8+5%W#I3UX@CL0")423&D!A'8F*%C2JL7)$_
MG T.!@/GI/_P,KMO/<H(Y7 =RJ$UE%4:293GRS"9*++(THE2K:N7"RO4-7-(
M+$!B%(DQ),:1F%AAAR_2Y/BNYVUD#C2E$<W#=30/K=$\U[_VIU&\+%\!DALU
M66914?[ZIT^3>*E7N.0N2^=$[U472[T3+5\MIG>$AEFB%PMYLR]]3\[GY1)"
M[U-?WY]:MZ1KMI%8@,0H$F-(C",QL<*&+[+M';K'KCL8;<2[Y8'>8."[SE'[
M7O5H'=TC>W0_7Z["UQHVZ]BN84-B 1*C2(PA,8[$!!*3(,P([6@=VM%>7W:-
MD+%&8@$2HTB,(3&.Q 02DR#,B/7Q.M;'UGWQU7)^J]<">FWP?,1.+W;UZN%=
ME-3W_&I=&ECUKK%&8@$2HTB,(3&.Q,3QUF]\QSL>#0:'@XVE 6A6([+.H#D2
M/?AIQPKL4W5-<*V]\6(U@$Y*H1J#:ARJ":@F49J9XA=]BF,_N!#&JMKQKF(\
M#Y^B^7*N[[E36;FT6&311+5&UMEZ=>H.]']FR,:[/2RP;V7G+"(U!M4X5!,M
M3Z]S.-Q\>B5J4C-D;A,R%W4$RRYUWA,BM0"J4:C&H!J':J+6WM@'2-2D9DB;
M1LNQ-@O5 0'ZUS(JOI&/SWN_<N^8D_/G;JXUL- J"ZH%4(U"-0;5.%034$VB
M-#/73:7E^'L]9N! BRRH%D U"M485.-034 UB=+,@#?UF&/OQ_[?HP=VOG/
MA]L'K-WC0\?U-I>\T$H,JC&HQJ&::'F"1Z[C^B-W<SVQCV;,::HQQ]Z-=5GT
M0KNM6C->$WBC[9=<T-H*JC&HQJ&::'MZ_>/MU2QH4C-]3;OEV.LM=^#ZY"HM
M7MGE0?LMJ!9 -0K5&%3C4$U -8G2S/@V/9>SWZ++@39=4"V :A2J,:C&H9J
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MNC8U6JLAS'S%A1+ZE&B<2J8/SW</C[_FT[L%.E_H.Y*M*2"^1%.V ::X^+A
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M?79%46F+CN)I7MT67.E:F3<W^N\$A9F@GZ^X+DIEQQ3,ZG\G_ M02P,$%
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MJ9!Y4!=C^5)!I@)D?T2IV%34 /7;Q_\/4$L#!!0    ( -J#I%9J88&<\ (
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M\( A452]!_?>1V'SG@HWOW"-GP!02P,$%     @ VH.D5I>*NQS     $P(
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MJ_A/LKX[M_SK+]5V+8Q4]N#/NM\!LT]02P$"% ,4    " #:@Z16!T%-8H$
M  "Q    $               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4
M Q0    ( -J#I%9_ BSK[P   "L"   1              "  :\   !D;V-0
M<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( -J#I%:97)PC$ 8  )PG   3
M          "  <T!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @
MVH.D5@BW]Q[L!0  Y!\  !@              ("!#@@  'AL+W=O<FMS:&5E
M=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( -J#I%81EUC.E 4  /86   8
M          " @3 .  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4
M    " #:@Z165LQ'5!<%  "K$P  &               @('Z$P  >&PO=V]R
M:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ VH.D5K/0L#%/ P  R P
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M965T."YX;6Q02P$"% ,4    " #:@Z16X,,FH:D"  !S!@  &
M    @('A1   >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @
MVH.D5D_:8'E0!0  U@P  !D              ("!P$<  'AL+W=O<FMS:&5E
M=',O<VAE970Q,"YX;6Q02P$"% ,4    " #:@Z16UX@E9\X"  #B!@  &0
M            @(%'30  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4
M Q0    ( -J#I%8$OBL0K@(  .4%   9              " @4Q0  !X;"]W
M;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ VH.D5@H'"A^# @
MBP4  !D              ("!,5,  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX
M;6Q02P$"% ,4    " #:@Z16[.AS-407   J1P  &0              @('K
M50  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( -J#I%8'
ME0&6D0(  !D&   9              " @69M  !X;"]W;W)K<VAE971S+W-H
M965T,34N>&UL4$L! A0#%     @ VH.D5N;%;>5Q @  ] 4  !D
M     ("!+G   'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( -J#I%;OL0CQ%@(  "\$   9              "
M@:V'  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @ VH.D
M5OV84$P: P  3PP  !D              ("!^HD  'AL+W=O<FMS:&5E=',O
M<VAE970R,BYX;6Q02P$"% ,4    " #:@Z16[7%<%N<"   '"0  &0
M        @(%+C0  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0
M   ( -J#I%9J88&<\ (  (\*   9              " @6F0  !X;"]W;W)K
M<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ VH.D5KRZ9F4K P  [A(
M  T              ( !D),  'AL+W-T>6QE<RYX;6Q02P$"% ,4    " #:
M@Z16EXJ[',     3 @  "P              @ 'FE@  7W)E;',O+G)E;'-0
M2P$"% ,4    " #:@Z16]69,.;@"  "Q$   #P              @ '/EP
M>&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ VH.D5J_LDZ4X 0  'P\  !H
M             ( !M)H  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L!
M A0#%     @ VH.D5O[?4.AO 0  %A   !,              ( !))P  %M#
G;VYT96YT7U1Y<&5S72YX;6Q02P4&     "  ( "7"   Q)T

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>67</ContextCount>
  <ElementCount>136</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>29</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="plx-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="plx-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="plx-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="plx-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00205 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="plx-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="plx-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00305 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiencyParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="plx-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="plx-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>10101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSignificantAccountingPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="plx-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>10201 - Disclosure - INVENTORIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureInventories</Role>
      <ShortName>INVENTORIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="plx-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10301 - Disclosure - FAIR VALUE MEASUREMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureFairValueMeasurement</Role>
      <ShortName>FAIR VALUE MEASUREMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="plx-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10401 - Disclosure - REVENUES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureRevenues</Role>
      <ShortName>REVENUES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="plx-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>10501 - Disclosure - STOCK TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureStockTransactions</Role>
      <ShortName>STOCK TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="plx-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>10601 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="plx-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>20102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="plx-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>30203 - Disclosure - INVENTORIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureInventoriesTables</Role>
      <ShortName>INVENTORIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureInventories</ParentRole>
      <Position>15</Position>
    </Report>
    <Report instance="plx-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>30303 - Disclosure - FAIR VALUE MEASUREMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureFairValueMeasurementTables</Role>
      <ShortName>FAIR VALUE MEASUREMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureFairValueMeasurement</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="plx-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>30403 - Disclosure - REVENUES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureRevenuesTables</Role>
      <ShortName>REVENUES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureRevenues</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="plx-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>40101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="plx-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>40201 - Disclosure - INVENTORIES (Schedule of Inventory) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails</Role>
      <ShortName>INVENTORIES (Schedule of Inventory) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureInventoriesTables</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="plx-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>40301 - Disclosure - FAIR VALUE MEASUREMENT (Schedule of Fair Value Assumptions) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENT (Schedule of Fair Value Assumptions) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureFairValueMeasurementTables</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="plx-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>40302 - Disclosure - FAIR VALUE MEASUREMENT (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENT (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureFairValueMeasurementTables</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="plx-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>40401 - Disclosure - REVENUES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureRevenuesDetails</Role>
      <ShortName>REVENUES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureRevenuesTables</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="plx-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>40501 - Disclosure - STOCK TRANSACTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureStockTransactionsDetails</Role>
      <ShortName>STOCK TRANSACTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureStockTransactions</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="plx-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>40601 - Disclosure - SUBSEQUENT EVENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSubsequentEventsDetails</Role>
      <ShortName>SUBSEQUENT EVENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureSubsequentEvents</ParentRole>
      <Position>24</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept EffectOfExchangeRateOnCashAndCashEquivalents in us-gaap/2021 used in 2 facts was deprecated in us-gaap/2022 as of 2022 and should not be used. plx-20230331x10q.htm 14</Log>
    <Log type="Warning">[ix-0514-Hidden-Fact-Not-Referenced] WARN: 2 fact(s) appearing in ix:hidden were not referenced by any -sec-ix-hidden style property: us-gaap:CommitmentsAndContingencies -  plx-20230331x10q.htm 9</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-Q" original="plx-20230331x10q.htm">plx-20230331x10q.htm</File>
    <File>plx-20230331.xsd</File>
    <File>plx-20230331_cal.xml</File>
    <File>plx-20230331_def.xml</File>
    <File>plx-20230331_lab.xml</File>
    <File>plx-20230331_pre.xml</File>
    <File>plx-20230331xex31d1.htm</File>
    <File>plx-20230331xex31d2.htm</File>
    <File>plx-20230331xex32d1.htm</File>
    <File>plx-20230331xex32d2.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>plx-20230331x10q005.jpg</File>
    <File>plx-20230331x10q006.jpg</File>
    <File>plx-20230331x10q007.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="205">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>45
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "plx-20230331x10q.htm": {
   "axisCustom": 0,
   "axisStandard": 12,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2021-01-31": 205,
    "http://xbrl.sec.gov/dei/2021q4": 30
   },
   "contextCount": 67,
   "dts": {
    "calculationLink": {
     "local": [
      "plx-20230331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "plx-20230331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "plx-20230331x10q.htm"
     ]
    },
    "labelLink": {
     "local": [
      "plx-20230331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "plx-20230331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "plx-20230331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 225,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 2,
    "http://xbrl.sec.gov/dei/2021q4": 5,
    "total": 7
   },
   "keyCustom": 22,
   "keyStandard": 114,
   "memberCustom": 12,
   "memberStandard": 17,
   "nsprefix": "plx",
   "nsuri": "http://www.protalix.com/20230331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00090 - Document - Document and Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.protalix.com/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10301 - Disclosure - FAIR VALUE MEASUREMENT",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.protalix.com/role/DisclosureFairValueMeasurement",
     "shortName": "FAIR VALUE MEASUREMENT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "plx:RevenueDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10401 - Disclosure - REVENUES",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.protalix.com/role/DisclosureRevenues",
     "shortName": "REVENUES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "plx:RevenueDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10501 - Disclosure - STOCK TRANSACTIONS",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.protalix.com/role/DisclosureStockTransactions",
     "shortName": "STOCK TRANSACTIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10601 - Disclosure - SUBSEQUENT EVENTS",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.protalix.com/role/DisclosureSubsequentEvents",
     "shortName": "SUBSEQUENT EVENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "plx:NatureOfOperationsPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "20102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "menuCat": "Policies",
     "order": "14",
     "role": "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "plx:NatureOfOperationsPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30203 - Disclosure - INVENTORIES (Tables)",
     "menuCat": "Tables",
     "order": "15",
     "role": "http://www.protalix.com/role/DisclosureInventoriesTables",
     "shortName": "INVENTORIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_a9VnZ-vJPkiHhaBFIDBw-A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30303 - Disclosure - FAIR VALUE MEASUREMENT (Tables)",
     "menuCat": "Tables",
     "order": "16",
     "role": "http://www.protalix.com/role/DisclosureFairValueMeasurementTables",
     "shortName": "FAIR VALUE MEASUREMENT (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_a9VnZ-vJPkiHhaBFIDBw-A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "plx:RevenueDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30403 - Disclosure - REVENUES (Tables)",
     "menuCat": "Tables",
     "order": "17",
     "role": "http://www.protalix.com/role/DisclosureRevenuesTables",
     "shortName": "REVENUES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "plx:RevenueDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "link:footnote",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230331x10q.htm",
      "contextRef": "As_Of_3_31_2023_lQ4VofWCfU-ERA4iKttplQ",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "Unit_Divide_USD_shares_65Ko0I-nrkSGY9fEMAqs6Q",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "menuCat": "Details",
     "order": "18",
     "role": "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_4bVAm6lD50yLNxvQT1GIoA",
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230331x10q.htm",
      "contextRef": "As_Of_3_31_2023_lQ4VofWCfU-ERA4iKttplQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40201 - Disclosure - INVENTORIES (Schedule of Inventory) (Details)",
     "menuCat": "Details",
     "order": "19",
     "role": "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails",
     "shortName": "INVENTORIES (Schedule of Inventory) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230331x10q.htm",
      "contextRef": "As_Of_3_31_2023_lQ4VofWCfU-ERA4iKttplQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw",
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230331x10q.htm",
      "contextRef": "As_Of_3_31_2023_lQ4VofWCfU-ERA4iKttplQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230331x10q.htm",
      "contextRef": "As_Of_3_31_2023_lQ4VofWCfU-ERA4iKttplQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230331x10q.htm",
      "contextRef": "As_Of_3_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember__GmWbcoY7kCTcvgHXmTtag",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_65Ko0I-nrkSGY9fEMAqs6Q",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40301 - Disclosure - FAIR VALUE MEASUREMENT (Schedule of Fair Value Assumptions) (Details)",
     "menuCat": "Details",
     "order": "20",
     "role": "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails",
     "shortName": "FAIR VALUE MEASUREMENT (Schedule of Fair Value Assumptions) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230331x10q.htm",
      "contextRef": "As_Of_3_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember__GmWbcoY7kCTcvgHXmTtag",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_65Ko0I-nrkSGY9fEMAqs6Q",
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230331x10q.htm",
      "contextRef": "As_Of_3_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_9xvbhmNJFkageC4WyZOI_Q",
      "decimals": "-4",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40302 - Disclosure - FAIR VALUE MEASUREMENT (Additional Information) (Details)",
     "menuCat": "Details",
     "order": "21",
     "role": "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
     "shortName": "FAIR VALUE MEASUREMENT (Additional Information) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230331x10q.htm",
      "contextRef": "As_Of_3_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_9xvbhmNJFkageC4WyZOI_Q",
      "decimals": "-4",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw",
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40401 - Disclosure - REVENUES (Details)",
     "menuCat": "Details",
     "order": "22",
     "role": "http://www.protalix.com/role/DisclosureRevenuesDetails",
     "shortName": "REVENUES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "plx:RevenueDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_fttaWimhoUeG-S7zMyaisw",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw",
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40501 - Disclosure - STOCK TRANSACTIONS (Details)",
     "menuCat": "Details",
     "order": "23",
     "role": "http://www.protalix.com/role/DisclosureStockTransactionsDetails",
     "shortName": "STOCK TRANSACTIONS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "plx:StockIssuedDuringPeriodValueSalesAgreement",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40601 - Disclosure - SUBSEQUENT EVENTS (Details)",
     "menuCat": "Details",
     "order": "24",
     "role": "http://www.protalix.com/role/DisclosureSubsequentEventsDetails",
     "shortName": "SUBSEQUENT EVENTS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230331x10q.htm",
      "contextRef": "Duration_4_1_2023_To_4_30_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_tROqvzE5iEKYWMElS1CURw",
      "decimals": "INF",
      "lang": null,
      "name": "plx:StockIssuedDuringPeriodSharesSalesAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_4bVAm6lD50yLNxvQT1GIoA",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CostOfRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_kovew3nQoUW7X8jAVRvjhw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00205 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_kovew3nQoUW7X8jAVRvjhw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230331x10q.htm",
      "contextRef": "As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_J7EBNPBz8ESJc8H_4uZ72w",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230331x10q.htm",
      "contextRef": "As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_J7EBNPBz8ESJc8H_4uZ72w",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "link:footnote",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230331x10q.htm",
      "contextRef": "As_Of_3_31_2023_lQ4VofWCfU-ERA4iKttplQ",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "Unit_Divide_USD_shares_65Ko0I-nrkSGY9fEMAqs6Q",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00305 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY) (Parenthetical)",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiencyParenthetical",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "link:footnote",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230331x10q.htm",
      "contextRef": "As_Of_3_31_2023_lQ4VofWCfU-ERA4iKttplQ",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_4bVAm6lD50yLNxvQT1GIoA",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_o1wQ3wLAXUuu4roj6AqHIw",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://www.protalix.com/role/DisclosureSignificantAccountingPolicies",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10201 - Disclosure - INVENTORIES",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.protalix.com/role/DisclosureInventories",
     "shortName": "INVENTORIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023_3ZFN94cj-0ejRZ34pFxPUw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 29,
   "tag": {
    "country_BR": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Brazil"
       }
      }
     },
     "localname": "BR",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Document and Entity Information"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount payable to entity for the achievement of regulatory and commercial milestones.",
        "label": "Additional Amount Payable For Achievement Of Regulatory And Commercial Milestones"
       }
      }
     },
     "localname": "AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones",
     "nsuri": "http://www.protalix.com/20230331",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_AdditionalAmountsPayableToCoverDevelopmentCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum amount payable to the entity to cover development costs under agreement.",
        "label": "Additional Amounts Payable To Cover Development Costs"
       }
      }
     },
     "localname": "AdditionalAmountsPayableToCoverDevelopmentCosts",
     "nsuri": "http://www.protalix.com/20230331",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_AgreementAmendmentPaymentReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement Amendment Payment Receivable",
        "label": "Agreement Amendment Payment Receivable",
        "terseLabel": "Agreement Amendment Payment Receivable"
       }
      }
     },
     "localname": "AgreementAmendmentPaymentReceivable",
     "nsuri": "http://www.protalix.com/20230331",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_AmendedPfizerAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended Pfizer Agreement [Member]",
        "label": "Amended Pfizer Agreement"
       }
      }
     },
     "localname": "AmendedPfizerAgreementMember",
     "nsuri": "http://www.protalix.com/20230331",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_AtMarketEquityOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to At The Market equity offering.",
        "label": "ATM Shares"
       }
      }
     },
     "localname": "AtMarketEquityOfferingMember",
     "nsuri": "http://www.protalix.com/20230331",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_AtmEquityOfferingSalesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to ATM Equity Offering Sales Agreement.",
        "label": "ATM Equity Offering Sales Agreement"
       }
      }
     },
     "localname": "AtmEquityOfferingSalesAgreementMember",
     "nsuri": "http://www.protalix.com/20230331",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change In Amount Receivable For Achievement Of Regulatory And Commercial Milestones",
        "label": "Change In Amount Receivable For Achievement Of Regulatory And Commercial Milestones"
       }
      }
     },
     "localname": "ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones",
     "nsuri": "http://www.protalix.com/20230331",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_ChangeInOperatingLeaseRightOfUseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Change in Operating Lease Right Of use Assets.",
        "label": "Change in Operating Lease Right Of use Assets",
        "negatedLabel": "Changes in operating lease right of use assets, net"
       }
      }
     },
     "localname": "ChangeInOperatingLeaseRightOfUseAssets",
     "nsuri": "http://www.protalix.com/20230331",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_ChiesiAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Chiesi Agreements [Member]",
        "label": "Chiesi Agreements"
       }
      }
     },
     "localname": "ChiesiAgreementsMember",
     "nsuri": "http://www.protalix.com/20230331",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_ChiesiExUSAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chiesi Ex-US Agreement"
       }
      }
     },
     "localname": "ChiesiExUSAgreementMember",
     "nsuri": "http://www.protalix.com/20230331",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_ChiesiMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Global except Brazil and Italy",
        "label": "Chiesi"
       }
      }
     },
     "localname": "ChiesiMember",
     "nsuri": "http://www.protalix.com/20230331",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_ChiesiUSAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chiesi US Agreement"
       }
      }
     },
     "localname": "ChiesiUSAgreementMember",
     "nsuri": "http://www.protalix.com/20230331",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_ChiesiUsAgreementAndChiesiExUsAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "n/a",
        "label": "Chiesi US Agreement and Chiesi Ex-US Agreement"
       }
      }
     },
     "localname": "ChiesiUsAgreementAndChiesiExUsAgreementMember",
     "nsuri": "http://www.protalix.com/20230331",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_CollaborativeArrangementRevenuesExpensesSharingPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement revenues and expense sharing percentage.",
        "label": "Collaborative Arrangement Revenues Expenses Sharing Percentage",
        "verboseLabel": "Collaborative Arrangement Revenues and Expenses Sharing Percentage"
       }
      }
     },
     "localname": "CollaborativeArrangementRevenuesExpensesSharingPercentage",
     "nsuri": "http://www.protalix.com/20230331",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "plx_ConvertibleNotesDue2021And2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to convertible notes due 2021 and 2024.",
        "label": "Notes 2021 and 2024"
       }
      }
     },
     "localname": "ConvertibleNotesDue2021And2024Member",
     "nsuri": "http://www.protalix.com/20230331",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement": {
     "auth_ref": [],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (loss) on amounts funded in respect of employee rights upon retirement.",
        "label": "Gain Loss On Amounts Funded In Respect Of Employee Rights Upon Retirement",
        "negatedLabel": "Loss on amounts funded in respect of employee rights upon retirement"
       }
      }
     },
     "localname": "GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement",
     "nsuri": "http://www.protalix.com/20230331",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_IncreaseDecreaseInBankDeposits": {
     "auth_ref": [],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in deposits held with banks.",
        "label": "Increase (Decrease) in Bank Deposits",
        "negatedLabel": "Investment in bank deposits"
       }
      }
     },
     "localname": "IncreaseDecreaseInBankDeposits",
     "nsuri": "http://www.protalix.com/20230331",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_InterestReceivedNet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash received for interest.",
        "label": "Interest Received, Net",
        "terseLabel": "Interest received"
       }
      }
     },
     "localname": "InterestReceivedNet",
     "nsuri": "http://www.protalix.com/20230331",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_MaintainOfMinimumCashBalance": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum cash balance required to be maintained under long term debt agreements.",
        "label": "Maintain of Minimum Cash Balance"
       }
      }
     },
     "localname": "MaintainOfMinimumCashBalance",
     "nsuri": "http://www.protalix.com/20230331",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_MeasurementInputYieldMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Yield",
        "label": "Yield"
       }
      }
     },
     "localname": "MeasurementInputYieldMember",
     "nsuri": "http://www.protalix.com/20230331",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_NatureOfOperationsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature Of Operations Policy",
        "label": "Nature Of Operations [Policy Text Block]",
        "verboseLabel": "General"
       }
      }
     },
     "localname": "NatureOfOperationsPolicyTextBlock",
     "nsuri": "http://www.protalix.com/20230331",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "plx_PaymentOnNetSalesPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the payment as a percentage of future net sales.",
        "label": "Payment On Net Sales Percentage"
       }
      }
     },
     "localname": "PaymentOnNetSalesPercentage",
     "nsuri": "http://www.protalix.com/20230331",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "plx_PfizerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Global except for Brazil",
        "label": "Pfizer"
       }
      }
     },
     "localname": "PfizerMember",
     "nsuri": "http://www.protalix.com/20230331",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_ProceedsFromSaleOfShortTermDeposits": {
     "auth_ref": [],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale of short-term deposits.",
        "label": "Proceeds from Sale of Short-term Deposits",
        "terseLabel": "Proceeds from sale of short-term deposits"
       }
      }
     },
     "localname": "ProceedsFromSaleOfShortTermDeposits",
     "nsuri": "http://www.protalix.com/20230331",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_ProtalixBioTherapeuticsIncorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Protalix Bio Therapeutics Incorporation [Member].",
        "label": "Protalix Bio Therapeutics Incorporation"
       }
      }
     },
     "localname": "ProtalixBioTherapeuticsIncorporationMember",
     "nsuri": "http://www.protalix.com/20230331",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_RevenueDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure pertaining to revenue.",
        "label": "Revenue Disclosure [Text Block]",
        "terseLabel": "REVENUES"
       }
      }
     },
     "localname": "RevenueDisclosureTextBlock",
     "nsuri": "http://www.protalix.com/20230331",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenues"
     ],
     "xbrltype": "textBlockItemType"
    },
    "plx_RevenuePerformanceObligationNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue, Performance Obligation, Number",
        "label": "Revenue, Performance Obligation, Number"
       }
      }
     },
     "localname": "RevenuePerformanceObligationNumber",
     "nsuri": "http://www.protalix.com/20230331",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "plx_SaleOfStockMaximumOfferingPrice": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of stock, maximum offering price.",
        "label": "Sale Of Stock Maximum Offering Price",
        "terseLabel": "Sale of stock, maximum offering price"
       }
      }
     },
     "localname": "SaleOfStockMaximumOfferingPrice",
     "nsuri": "http://www.protalix.com/20230331",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to seven point five percentage senior secured convertible notes due 2024.",
        "label": "2024 Notes"
       }
      }
     },
     "localname": "SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member",
     "nsuri": "http://www.protalix.com/20230331",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementTables",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of recognized equity-based compensation during the period for restricted stock awards.",
        "label": "Share Based Compensation Restricted Stock Awards Net Of Forfeitures",
        "terseLabel": "Share-based compensation related to restricted stock awards"
       }
      }
     },
     "localname": "ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures",
     "nsuri": "http://www.protalix.com/20230331",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Compensation Restricted Stock Awards Net Of Forfeitures Shares",
        "label": "Share Based Compensation Restricted Stock Awards Net Of Forfeitures Shares",
        "terseLabel": "Share-based compensation related to restricted stock awards (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares",
     "nsuri": "http://www.protalix.com/20230331",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "sharesItemType"
    },
    "plx_ShortTermBankDeposits": {
     "auth_ref": [],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value of deposits held with banks for short period, usually less than one year or the normal operating cycle, whichever is longer.",
        "label": "Short-term Bank Deposits",
        "terseLabel": "Short-term bank deposits"
       }
      }
     },
     "localname": "ShortTermBankDeposits",
     "nsuri": "http://www.protalix.com/20230331",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_SignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.protalix.com/20230331",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "plx_SignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Significant Accounting Policies [Table].",
        "label": "Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTable",
     "nsuri": "http://www.protalix.com/20230331",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "plx_StockIssuedDuringPeriodSharesSalesAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Sales Agreement",
        "label": "Stock Issued During Period, Shares, Sales Agreement",
        "terseLabel": "Issuance of common stock under the Sales Agreement, net (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesSalesAgreement",
     "nsuri": "http://www.protalix.com/20230331",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "sharesItemType"
    },
    "plx_StockIssuedDuringPeriodValueSalesAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in a sales agreement.",
        "label": "Stock Issued During Period, Value, Sales Agreement",
        "terseLabel": "Issuance of common stock under the Sales Agreement, net"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueSalesAgreement",
     "nsuri": "http://www.protalix.com/20230331",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_UpfrontNonrefundableNoncreditablePaymentReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of upfront, non refundable and non creditable payment receivable under the agreement for licensing rights.",
        "label": "Upfront Nonrefundable Non creditable Payment Receivable",
        "terseLabel": "Non-refundable Payment Receivable"
       }
      }
     },
     "localname": "UpfrontNonrefundableNoncreditablePaymentReceivable",
     "nsuri": "http://www.protalix.com/20230331",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r230",
      "r273",
      "r281",
      "r295",
      "r296",
      "r309",
      "r315",
      "r322",
      "r344",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r230",
      "r273",
      "r281",
      "r295",
      "r296",
      "r309",
      "r315",
      "r322",
      "r344",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r164",
      "r275",
      "r310",
      "r320",
      "r345",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r164",
      "r275",
      "r310",
      "r320",
      "r345",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r223",
      "r230",
      "r272",
      "r273",
      "r281",
      "r295",
      "r296",
      "r309",
      "r315",
      "r322",
      "r344",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r223",
      "r230",
      "r272",
      "r273",
      "r281",
      "r295",
      "r296",
      "r309",
      "r315",
      "r322",
      "r344",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r165",
      "r166",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r311",
      "r321",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r165",
      "r166",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r311",
      "r321",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Accrued Liabilities, Current [Abstract]",
        "terseLabel": "Accounts payable and accruals:"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableOtherCurrent": {
     "auth_ref": [
      "r4",
      "r29"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.",
        "label": "Accounts Payable, Other, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "AccountsPayableOtherCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableTradeCurrent": {
     "auth_ref": [
      "r4",
      "r29"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Trade, Current",
        "terseLabel": "Trade"
       }
      }
     },
     "localname": "AccountsPayableTradeCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r110",
      "r168",
      "r169",
      "r298"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, Net, Current",
        "terseLabel": "Accounts receivable - Trade"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r231",
      "r232",
      "r233",
      "r338",
      "r339",
      "r340",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r81",
      "r82",
      "r85",
      "r86"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition",
        "terseLabel": "Share-based compensation related to stock options"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments required to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r82",
      "r83",
      "r84"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Allocated Share-based Compensation Expense",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r199",
      "r261",
      "r307",
      "r308",
      "r334"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization of debt issuance costs and debt discount"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Arrangements and Non-arrangement Transactions [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r92",
      "r101",
      "r125",
      "r155",
      "r158",
      "r162",
      "r170",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r240",
      "r244",
      "r253",
      "r319",
      "r342",
      "r343",
      "r353"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r2",
      "r3",
      "r39",
      "r125",
      "r170",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r240",
      "r244",
      "r253",
      "r319",
      "r342",
      "r343",
      "r353"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "CURRENT ASSETS:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Noncurrent [Abstract]",
        "terseLabel": "NON-CURRENT ASSETS:"
       }
      }
     },
     "localname": "AssetsNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "verboseLabel": "Basis of presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r58"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "verboseLabel": "SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r54",
      "r55",
      "r56"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "verboseLabel": "Purchase of property and equipment"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r0",
      "r28",
      "r53"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r48",
      "r53",
      "r57"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "BALANCE OF CASH AND CASH EQUIVALENTS AT END OF PERIOD",
        "periodStartLabel": "BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r48",
      "r89"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r34",
      "r65",
      "r96",
      "r104"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "COMMITMENTS"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r338",
      "r339",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiencyParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiencyParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r217",
      "r218",
      "r219"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Contracts liability"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtFairValueDisclosures": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Convertible Debt, Fair Value Disclosures",
        "terseLabel": "Debt Instrument Fair Value"
       }
      }
     },
     "localname": "ConvertibleDebtFairValueDisclosures",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtNoncurrent": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.",
        "label": "Convertible Debt, Noncurrent",
        "terseLabel": "Convertible notes"
       }
      }
     },
     "localname": "ConvertibleDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfRevenue": {
     "auth_ref": [
      "r42",
      "r125",
      "r170",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r253",
      "r342"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.",
        "label": "Cost of Revenue",
        "negatedLabel": "COST OF GOODS SOLD"
       }
      }
     },
     "localname": "CostOfRevenue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of goods sold"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r12",
      "r13",
      "r14",
      "r93",
      "r94",
      "r99",
      "r127",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r262",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementTables",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r14",
      "r94",
      "r99",
      "r200"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-term Debt, Gross",
        "verboseLabel": "Debt Instrument Carrying Amount"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r32",
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "verboseLabel": "Interest rate (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentMeasurementInput": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure debt instrument, including, but not limited to, convertible and non-convertible debt.",
        "label": "Debt Instrument, Measurement Input"
       }
      }
     },
     "localname": "DebtInstrumentMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r33",
      "r127",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r262",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementTables",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent": {
     "auth_ref": [
      "r11",
      "r91",
      "r100",
      "r220",
      "r221",
      "r222",
      "r314"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans.",
        "label": "Assets for Plan Benefits, Defined Benefit Plan",
        "terseLabel": "Funds in respect of employee rights upon retirement"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r51",
      "r63"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "verboseLabel": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "verboseLabel": "Schedule of Company's Disaggregation of Revenues"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r117",
      "r133",
      "r134",
      "r135",
      "r136",
      "r137",
      "r141",
      "r143",
      "r145",
      "r146",
      "r147",
      "r149",
      "r247",
      "r248",
      "r276",
      "r279",
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "LOSS PER SHARE OF COMMON STOCK - BASIC"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r117",
      "r133",
      "r134",
      "r135",
      "r136",
      "r137",
      "r143",
      "r145",
      "r146",
      "r147",
      "r149",
      "r247",
      "r248",
      "r276",
      "r279",
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "LOSS PER SHARE OF COMMON STOCK - DILUTED"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r59",
      "r60"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Loss per share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.",
        "label": "Effect of Exchange Rate on Cash and Cash Equivalents",
        "terseLabel": "EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r69",
      "r108",
      "r113",
      "r114",
      "r115",
      "r128",
      "r129",
      "r130",
      "r132",
      "r138",
      "r140",
      "r150",
      "r171",
      "r216",
      "r231",
      "r232",
      "r233",
      "r235",
      "r236",
      "r246",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r282",
      "r283",
      "r284",
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "auth_ref": [
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "auth_ref": [
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "verboseLabel": "Schedule of Fair Value Assumptions"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r192",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r249",
      "r269",
      "r270",
      "r271",
      "r305",
      "r306",
      "r312",
      "r313",
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "FAIR VALUE MEASUREMENT"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "verboseLabel": "FAIR VALUE MEASUREMENT"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r192",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r249",
      "r271",
      "r305",
      "r306",
      "r312",
      "r313",
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r192",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r269",
      "r270",
      "r271",
      "r305",
      "r306",
      "r312",
      "r313",
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": {
     "auth_ref": [
      "r52",
      "r351",
      "r352"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), Unrealized",
        "negatedLabel": "Financial income, net (mainly exchange differences)"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossUnrealized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r40",
      "r90",
      "r97",
      "r106",
      "r155",
      "r157",
      "r161",
      "r163",
      "r277",
      "r303"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "LOSS BEFORE TAXES ON INCOME"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r173",
      "r174"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r174"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r126",
      "r139",
      "r140",
      "r154",
      "r234",
      "r237",
      "r238",
      "r280"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "TAXES ON INCOME"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "verboseLabel": "Increase (decrease) in accounts payable and accruals"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Decrease (increase) in accounts receivable-trade and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r274",
      "r333"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "verboseLabel": "Decrease in contracts liability (including non-current portion)"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Decrease (increase) in inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r119",
      "r122",
      "r123"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Interest paid"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "INVENTORIES"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "verboseLabel": "INVENTORIES"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventories"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r22",
      "r62"
     ],
     "calculation": {
      "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r1",
      "r37",
      "r319"
     ],
     "calculation": {
      "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventories",
        "totalLabel": "Total inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r24",
      "r62"
     ],
     "calculation": {
      "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r23",
      "r62"
     ],
     "calculation": {
      "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Work in progress"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r30",
      "r125",
      "r170",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r241",
      "r244",
      "r245",
      "r253",
      "r302",
      "r342",
      "r353",
      "r354"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r21",
      "r95",
      "r102",
      "r319",
      "r337",
      "r341",
      "r350"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity (net of capital deficiency)"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "verboseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY (NET OF CAPITAL DEFICIENCY)"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r31",
      "r125",
      "r170",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r241",
      "r244",
      "r245",
      "r253",
      "r319",
      "r342",
      "r353",
      "r354"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "verboseLabel": "CURRENT LIABILITIES:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r8",
      "r14",
      "r15",
      "r125",
      "r170",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r241",
      "r244",
      "r245",
      "r253",
      "r342",
      "r353",
      "r354"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
        "label": "Liabilities, Noncurrent",
        "totalLabel": "Total long term liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "LONG TERM LIABILITIES:"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseAndServiceMember": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use intangible asset and performance of related service. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License and R&amp;D Services"
       }
      }
     },
     "localname": "LicenseAndServiceMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "auth_ref": [
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.",
        "label": "Expected term"
       }
      }
     },
     "localname": "MeasurementInputExpectedTermMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "auth_ref": [
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.",
        "label": "Volatility"
       }
      }
     },
     "localname": "MeasurementInputPriceVolatilityMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "auth_ref": [
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.",
        "label": "Risk free rate"
       }
      }
     },
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputSharePriceMember": {
     "auth_ref": [
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using share price of saleable stock.",
        "label": "Share Price."
       }
      }
     },
     "localname": "MeasurementInputSharePriceMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r121"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM FINANCING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r121"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r48",
      "r49",
      "r52"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r41",
      "r52",
      "r98",
      "r105",
      "r109",
      "r111",
      "r112",
      "r115",
      "r125",
      "r131",
      "r133",
      "r134",
      "r135",
      "r136",
      "r139",
      "r140",
      "r144",
      "r155",
      "r157",
      "r161",
      "r163",
      "r170",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r248",
      "r253",
      "r303",
      "r342"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "NET LOSS FOR THE PERIOD",
        "verboseLabel": "Net loss for the period"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "FINANCIAL EXPENSES, NET"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r155",
      "r157",
      "r161",
      "r163",
      "r303"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "OPERATING LOSS"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r264"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "verboseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r264"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r263"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "verboseLabel": "Operating lease right of use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r38",
      "r319"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingExpense": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Expense",
        "negatedLabel": "FINANCIAL EXPENSES"
       }
      }
     },
     "localname": "OtherNonoperatingExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncome": {
     "auth_ref": [
      "r118"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income",
        "terseLabel": "FINANCIAL INCOME"
       }
      }
     },
     "localname": "OtherNonoperatingIncome",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "auth_ref": [
      "r331",
      "r332"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "negatedLabel": "Amounts funded in respect of employee rights upon retirement, net"
       }
      }
     },
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent": {
     "auth_ref": [
      "r16",
      "r78",
      "r79",
      "r80"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability, recognized in statement of financial position, for pension, other postretirement and postemployment benefits, classified as noncurrent.",
        "label": "Liability, Pension and Other Postretirement and Postemployment Benefits, Noncurrent",
        "terseLabel": "Liability for employee rights upon retirement"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost (reversal of cost) for pension and other postretirement benefits.",
        "label": "Pension and Other Postretirement Benefits Cost (Reversal of Cost)",
        "terseLabel": "Changes in accrued liability for employee rights upon retirement"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock under the Sales Agreement, net",
        "verboseLabel": "Stock issuance proceeds"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Goods"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r109",
      "r111",
      "r112",
      "r120",
      "r125",
      "r131",
      "r139",
      "r140",
      "r155",
      "r157",
      "r161",
      "r163",
      "r170",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r239",
      "r242",
      "r243",
      "r248",
      "r253",
      "r277",
      "r303",
      "r316",
      "r317",
      "r330",
      "r342"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r9",
      "r10",
      "r64",
      "r103",
      "r278",
      "r319"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r87",
      "r107",
      "r361"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "negatedLabel": "RESEARCH AND DEVELOPMENT EXPENSES"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r108",
      "r128",
      "r129",
      "r130",
      "r132",
      "r138",
      "r140",
      "r171",
      "r231",
      "r232",
      "r233",
      "r235",
      "r236",
      "r246",
      "r282",
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueRecognitionAndDeferredRevenueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "REVENUES"
       }
      }
     },
     "localname": "RevenueRecognitionAndDeferredRevenueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r299",
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue Recognition, Policy [Policy Text Block]",
        "verboseLabel": "Revenue recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r116",
      "r125",
      "r152",
      "r153",
      "r156",
      "r159",
      "r160",
      "r164",
      "r165",
      "r167",
      "r170",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r253",
      "r277",
      "r342"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues.",
        "terseLabel": "TOTAL REVENUE",
        "verboseLabel": "Revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r265",
      "r318"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Operating lease right of use assets obtained in exchange for new operating lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r5",
      "r25",
      "r26",
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "verboseLabel": "Schedule of Inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventoriesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r35",
      "r66",
      "r67",
      "r68",
      "r70",
      "r71",
      "r72",
      "r73",
      "r74",
      "r75",
      "r76",
      "r151",
      "r201",
      "r202",
      "r203",
      "r205",
      "r209",
      "r214",
      "r309",
      "r329",
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "negatedLabel": "SELLING, GENERAL AND ADMINISTRATIVE EXPENSES"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, general and administrative expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Compensation",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r36",
      "r69",
      "r108",
      "r113",
      "r114",
      "r115",
      "r128",
      "r129",
      "r130",
      "r132",
      "r138",
      "r140",
      "r150",
      "r171",
      "r216",
      "r231",
      "r232",
      "r233",
      "r235",
      "r236",
      "r246",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r282",
      "r283",
      "r284",
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementTables",
      "http://www.protalix.com/role/DisclosureRevenuesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED CONSOLIDATED BALANCE SHEETS"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS EQUITY (CAPITAL DEFICIENCY)"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r128",
      "r129",
      "r130",
      "r150",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementTables",
      "http://www.protalix.com/role/DisclosureRevenuesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r17",
      "r18",
      "r69",
      "r76"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "verboseLabel": "Number of shares issued (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r18",
      "r19",
      "r20",
      "r61",
      "r319",
      "r337",
      "r341",
      "r350"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "verboseLabel": "STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCK TRANSACTIONS"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r77",
      "r124",
      "r202",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r215",
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "STOCK TRANSACTIONS"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r260",
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r260",
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r260",
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r260",
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r266",
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "verboseLabel": "SUPPLEMENTARY DISCLOSURE ON CASH FLOWS"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Type of Arrangement and Non-arrangement Transactions [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r142",
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING LOSS PER SHARE - DILUTED"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r141",
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING LOSS PER SHARE - BASIC"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 6
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(7)(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123453770&loc=d3e1703-114919",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123453770&loc=d3e1731-114919",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=123371682&loc=d3e55415-109406",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r323": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r324": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r325": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r326": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r327": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r328": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(25))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123453770&loc=d3e1703-114919",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123453770&loc=d3e1731-114919",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(26))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>46
<FILENAME>0001558370-23-008132-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-23-008132-xbrl.zip
M4$L#!!0    ( -J#I%9_$9UU<@L  )E=   0    <&QX+3(P,C,P,S,Q+GAS
M9.U<67/;.!)^WZK]#UB];.9!UF%[MNR*9XJ6Y(0UEN25Y.S,TQ1$0A(J%,
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M9%I$&TV>)QF5C<)R72,,]FPVXV)I-#K %G+K%YE NZP)K%M!&\V<82\%^XC
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M6^F4I6R&QGEZX,42;2)AXNI92#I^ H+I-$AC [7,?, .C+4NDM*[EOX"[$8
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M0OHX?LB3L( .U#.#4WH2EE2AZ38\3/TD+##4W%5"S+;/T0W4,Y0#.?&'EGN
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M[K9 T<3$]$\KX$'+=.HD+S50<[3V5Z:[!&3HSCQD?5LAQZ9ST^"[#[UMW]Q
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MI*5238XZ"%45Q,9Y9<R]OKB.6$O_$,I^2(@/[%L?L]H>P48Z*$L?1+][2PQ
M9)AQ?A=MK/\%FJ(4M2.94$6.%0V_M?ZW8PJ3I-W\%2NG,T<"?S$@Y2D=DYH"
M.B<3Z.W"8B'94>B+ 03:*?2RZQ[V[5S<J9\7=4\)W)CE%! /0RL($U(+Z;V8
MV"8CX(T7=P@O /1\G+GU6[HW_6\%E2917V&&4UZU(MWUV68XI"(=KT#Z.VYH
MMXSHGOA>ZI)8X;SW:L]@;B%AFTXJ_SL3XF!*?P F^[[?S*H]-44-_>+:Z!B'
M#NF7N]YP:OS:NW\<& ^#WNQQ&ARD&#^%_9X.1N28LF)00Y=:KA]441&?AO
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M'//(TLZN)AA9 -A!C35F_*9K40IB2B6P*H5V;;[54,ZF%(C33I ]2I[-*IS
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M)^M AU<'RXE11IV.X@RFB5^10Q=MNM!O"TE2T+;-"P35"%% 6 U'6*F!?X?
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MV;]M$1![L^T[)I'FSDA;G"H!519OR1>,8AF@@_U<:;*FG&H"I8374DV@'Z=
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M10[JN44I<$!VP +9,![@<\X$^P9<L/]P-LCZP >)@!'B,S\76'&;F72V3@,
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M/5*M5)OD%/ER1@59?M++CXM*NJXO\YQ3_&H%ZH(B*4B2G*;!BL]]D(_4 Z
M'7H![=V]6911UN/9O9=17@K$UTYWQQ 8PMM\-B+J7^LS82._W]?.6ON+?@4-
M D1&1)!!--?>)"T%8U9*R;NJ>]1?TDUN[HP9GBO/%'/Q& ;B(1.1_*.8C6R0
MW/L&]J(43D [!LIJ;\N6[GWJ$:F@D@/NB ALIVNW:V'0UJ$)<Z/>X#TO4U**
M&64(:XU:#/WJ4H='7D]4S,BE,N/HZ8)-K5L"R"/R*8E3M.S,(_AOOH-<(/6=
M7W'K!1'<F5IL\MH?$R]]OO1",$2%H9O!W2\'-NP7"X$)%F4):&=(5Z"%K!DD
M>12@;#OW^SZ !UZSF#Q"@H0@RWX0N0YA#!?BP!9\T*HR]<%QI.48<7,4"!,5
MH@,6R=$0UX7RQ?I[[\LM\]V2P O3.>51UY0F+]KD?QM$G#7"7J3J2M&.Y7R]
ML&5)X8WGB".VT?A"2MP1C_3Q)_\$/DX"X-%R@3#; F$(1O/W./EM%MTE\9JF
MW:S&A(EL-NU"*>U&CX9G.&T\F2P'< F;LW/LH=E.9]$*>79)S%9.V8O$L)]K
MMABFS]3_%,=^-_LQ82+;3[M02OO1H^'93QM/)OLI< E''IKY=):L%.<),!"-
MYYQO=FMZ[;Q-XIBKBVZLVODYVW,^09Q?&-G^#D_$YPWP@,(LVNWSARQ+@N1
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M#_X>! :%F>S'S>&BL->I]$F^B6-*'X?C.I,7SZ7['/:+-(<%KIZG3*AV.LR
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MR_/SZP^JLMU5#B#&@;GG:H:[B' 9D39T4/H%#E=5TT?\59B9PUABCAK:,"_
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MEV\/K3A\< _B?S."30YV"[PD_ W\T#UI4FO+2TF'8L"OL6#8O]O!2Q^Q@WB
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M(&Q#C@W]V"H0^OZ)9TF\/W)LE,@FH5)9*K&=5YJ:I-*"'!O;>?1NL_WQ5QM
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M4$L*,)'V3GVS/&C-5YUR@"6E@RS4&J(3[>?3F#GTOV?#!W__?U!+ P04
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MINC;!S[X S: :[M_Q*\M+)D@V4>\9.WE)7;%2];%[[_[0#=__ST"@8X9KA-
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M2ER%$VS+DGF7ZE/96D-<$".\74\;"WNX*TLOS;Z,:LFN.)@B+C$TL"/K&6?
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MP]$<GOJS%9?AG/3@>VS\3P,A/K^8XSNR^2,2R/>YI4GBXDC1*([T]'P1WW/
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MO\ZRU8H_DUGUCDO:):9A,4LG;+HSUEM/:"7S"SVKZFYFI%'%C%J8\*C6^LX
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MMK*DKF-3*A;D>)>*F3MF[N^X2VW?66,8 #Q[9\VQ9Q_FGJ&+M/Q^6'3.0"_
MW<2:ZO9];N8AI#@R,SZM8$>,#/_W<%O3"6:VY=\.H_"WITH]G2KVMS6' W>R
MGFZ$]X1,'"NHH_QV%;[0Y "RO^Z9FBIG-)>8U:A9B;]5)Q/:<P<L?Y<OS"ZP
M,%]@OOH5[VM25Z-02@H*S=#L&MUPNTVAJR;$.D];Q2 8V[4+S 2&-=)M_Y^+
M!'6!K:H-_7-AS8-K9S(RW6#]_07FZ"-(D(F?Z.GZ^!I)).^8Z!_Q01SY0- ]
M;P$IV=#M";C ?+A.\%>PYW72Q++7D,ET9YD?2J,;X>XFGR.3/J^Q*"N1HBYQ
MBOW[YV-"'&ZGCAASQS)^4!EGOZN,$^1:R$DMSU#+M$(WN:&>R>BIVP5(J-KG
M"[E!W]V0U5Q*$W-CM=K*"*E1N8'2F=F+WP1W21#$"T)^3G;U6CV1^ZX7) +@
MC;".[@PAN<,0V,-I)]\1IK[9G#\]4.<-<!46=B'?<A%)S,8Q&Y\FB.;K[+IC
M>WX=[B0*W$C2<!_)K+>1/3MLHG&C"OEFW\)SR82(]ZA>^M;L:1S:89E+G$T=
M?(.-C-:XWG-YPX"#"7S, P: J@G*M-X4HE(\W02QV?"ES88WWY$5^P=.X1_8
MB&?]7CHK(! FG@<MB#UX1FLYHW [M37QKEYH*7=RII*OH!)$%+08+BF<CKT"
ML7C'KH'3*RE_*-^5M'9'=1/9N=H<%D9EHC:K3#4DWU!?H2^9Y$M>OS-T"*R*
MM^N^#V(GP-E:3X?6,+X!WAQ-G0@%B@_EZ060F;K#>3OI-7%A05IT0"V*C71-
M2R$E@F.2QU,A8LD\8\F,W14?TP3>))J$FQTF5<5BAM:PU[@MM$E;J"+19$/]
MGL"_O+^BX$PA:5POO/4K-EV.;+J<,&4^"IZ+4T\_ H!W-%5D(\@+:/#L0;IY
MMS:?"4,QH4I%>2*I77DZ9,/"QU +(?%+"J=B7T8,")_LZSCU]", ",?3@%Y!
M!(8'_2+N\29>'%7TK":*K&G5$"(@Y8>]3+[HW3PK[T<R?(;B!KJ-&2ME,/:"
M' #/(@Q>APS1C$'J>.<QKQAHC9G;X&?+=@Z_,Y-D7;Y-&]W%#%V7 -46AKFD
M\9=BMF*9CF7Z&5TDENDC'L*\(M0D[B33+-D?B;K4&*I.LS5D;T.A1L<N]&4R
M^97]+LE=^5ZU?"B2_XEI8I&A2^1,LV]&ADB&FT2 ,+&8Q&(2];"-PQ'FG,SZ
M]2->JAY0D2J)N(+ USEA_;()$-&:=,S<WV3.<06!$Q^_9^%(POM]/>"/@1&@
M6[_!:&R["P"P<)_WL<G81=\'EA=>_!SKM%]:IXUK"T355YT!7<L!9AHX\$50
MM75GY>C*NAYZL_[<K[B.\:SK2P"J.6ETAX$*]-)\B?O)D7730U?JAAD%)$/&
MI_"QO'\-J_3L_=B'$/B[O,]WK&S+'PJ&<U><@DG99T*!#T,,29;[*H?L*X6F
MZKEC.,1%6!8)540:(YWE$G/ X127[XA:7R80*,XX^) 2LI$O!$ ![YCB1L3V
M!_EX1!:_:T@9"A>*?F)6DS*<E)YI!(/T#?J2.V8&8RRF9RRF<?K!QW2'=\HI
M/M6ZHT+O1L5SH!-(3791+EH\DM-5)B+S4G3NUW"%2)!>>@"?B=E ]]?>#^0/
MF< W!X[6B\S<(V<*G3HP)LY0.#4F'B]9<B/@)23?=30]J:OZ(#2J]F BGZYZ
M"5]0/%RP*+,M3NJJ7H.F4UB4D;F$0XQ])3% Q!D+7T=I>B]"S.6;>=KV-%N5
M;QDS>V.4I+X^0PBQJC>5_#+.E>T,ACASX<!1SA248M.=H%)=44"QHZ4NG&">
M$8"K(^<N[*LS"ZJY'-XK,JJ0T6Z[1>&VW!2@,<<AQ85EH37W4AV\6)QC<7Y3
MUL+W%.=CIRWLD6>M1:KE7GO(#07;Y8G<G=\<-'I(GMDP"8D[@I[Q[0V0V Z+
M[IGU=TI/B!8=8JF(I2(*<1\1"NF,;/)!J<"G"Z6"4A!EC*]D,%F1A&)>*F7$
MNOR??U&I7YA84PM*"_M1$15,RF("7RTH? G+B-F"4! K0NNO.%LA/I"-1-Q$
M!!8T9N*S9^(31Q4\,[FG4XPMME@WC773V&*+I2*6BMAB^T86VR95?,MRB_/%
M8^4UML!B)OXJ3!Q;8)^P;D_O@AOKB_ B.)03I1N&-]%M_SK6+;^T;OG%+X*+
MP++'W/]-N#]ZJ<U'W<9.&V)ZT#M*OZ,D?H58LSA)]R"WC%97>E\H4\^7PZVW
M%8YM]1J-(:"7 ZXWK=U1%5Z#PPKS7 B<B:-%8P&-E!EW_K&>[Y+047[,)K1F
MF53E@C^Z$[)]=RG/D(2&>29)]J5,M'.W95=Z07B=6JRTQTK[^9JL7TRK""7R
M><PR"Y5R3V3YDGJG2GGBIK_4JQ.H5:PJC5&7-'?$FS,BQMBQ?'\'H_RK*26O
M"'AB,A\ZR1+>'Q9-S5JHWG)\TPD%'%46(R_)%P7\K%P3^PN$V)8>RO$AKR[]
MCBCU92 I]EH<L#Y':2U=B^<1*#<ELJUQ/TVKN4307"AC-4V7>QK)K(J9$G2<
MYAH+:NR].':=C#=(:B+9Q;4.*[6'Q4*RD2\WC6PB""4UK$)*$,DO[,!8:0\"
M;(OFYM_K#8O8W(FK!<7EQ,Y57=D(=-,*^L+$AP0&WAN@T%PN^G?MVL04=6$Q
M3-+9;%<<U30RK"I&$)=<ZJ7+!V.@B($B+BMV9NK2'R(%EY=I/)GD6ZK<F.C6
MV&P5I_D0*=C0@TIPA]>:3AO[\>B"]-B]<HSB1-%"MOB6]+-0=4H/HO@\7/&F
M=)OA)\7%<%1R;NAF(Y>ZFT,;+ZPZ1A&7#!''D<2"'5^5'BG5Y$V2;<J61G7G
M4Z"RE9YH<(DNSR"3):P_1I&7-/F2H_7,W3>GDO'88(ON07:<S1Y+12P5$2!#
MG,T>X6SVDE3)88I8+\?Y[/$I;/3")2*PH#$3GST3Q_GLG^$?OC]"#T>-4MD=
M-SB@7S@R,XT5RO@J\C-P"&])8@9T@A=O(+:(9G;@^4P;OU/J2J8S':1*E9I&
MX<@O3"9?N8(X%NQ8L"-F^T5 L(]Z5OUFR>[(2VU,]%1;G$B"+\C#3E$9]9!D
MLZ%D$U_G_JN5 G)_:(_HB8'1V'878'U3J(]-QG!Y/1!8'D 7K<;V06P?G-S(
M/7=%HPH<'XZ2=\PP&ZGJ^L&#A,%/T0<K.40?I($#NE: [CSVMTZV7@2QZHTZ
M]W!OEAPVVUFIE3'3PP&HH?F$200L<43M));L,Y;L.(G@@S>4'UVT0;(ZRXEJ
MN2T6E73;G+$5C2O.T'S"K .6_LIE$SXO9S$R<XZ<C77JT)4X^^#4\/G9R9(O
MXJ$QXKJ,61<$O$@MU-K4'&>!!O&01*H.?4DP\87F,4C$F0=?2,?Z$Y0H];Q*
M/5N?3?"B04V2\EVFZ[=#E&!#E& /'^P7@:P#VX4Z4@"\49QW$(<GQWD'T5!R
MWFKH>2E"[WJC:0XODI0H-DU:4+*\1H45+"GZ$J?8V(D3RW:<>A EW>2MPIUS
M1F-=XP:R.&D:_=(R*'F3S@P)-\H^H"Y3J:]</.*1CA([;V*[[!,B8TX]\PC
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M"BI%U1"WM"(J]M#$I_U?+"3HJRE',K!M2+\<<("GVQ E>7-D.98?>&'Z[?-
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M7(/1._0]9R6(3[FW400@%)&]$&QHQ,.?FH=O'\4*Q89& 9L;Z=WLPKEC*!I
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MP-KUL3WI3]MV@8.F6-J)GB5S07,L*B3V[>7V]N&S+Y9:_I;8ONA*;=IK.?Y
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M2._MV,C?6QJ.IRLBW%J8X)?W@U\(TU"N7&L#J2W147>>)87- ,&V=.\#QPC
MGQR9"CZ'R!T35/N6X4W,?2'E2/W[HN<9ZBZ9?NV@P*>+?<_7X3,GJK[V$,/[
M/8Z\O5^.7;6&='K3I'&!"+_8&RJ,H?%L6^ :]LW+KN"QQ_4A,]K]]P\C;:\?
MX$3[<IM]B>0EI/M"1KL2OEV)4"R<^Q*A6#CW)7>7B>0EA/M"W=&OUM6/]N6/
M]N6#*3]O.BTW(T+V T2XJ&*]*04"$<H/D@1ZU.C#__<C]>-WR9.Z=<IT]CVA
MQ_>GC/5F!@!$ _YA9A(L;F%^IH2PMZ#M\W)2A"JA0Y7L6P1X30:\>/GS?P."
ML,</^G?Q@W)XX>O@1T,PQ)E#K@3EGDNA/+>S995&C.,Q#IWZ!HQ#1]KG(MHG
M;,E1K[%&M]]JU?$1,M,9$95FB>LTF%Z%:Z(R;I7F@.WV<(NC9O%DPR.BR:'B
M'@.N/D!_.)Q GZ\3TE=*-_O#6$]$!C(B0B02D4@$HHW?G@R.#?)5R/"9O%ZW
M+W++AC:F8.+,P(6A+^!TMX2@2018VO(")<Q^!A<EE)P=]&*_XJT4,@2+_%85
MO1:R):CL9@$T2;9L Y@53;0- TAYVVKJU@A8+4&63MP\X<LE7MW-98Z<3\FD
M;E2I!!UO\TE\;8V^T)VU2/"_J."[!LRMEQDJT;]T*:[?%OWE4[K,35-"7UG:
M1J7T*"OV:H=R9M,__DD'RV9]O>#2-XH>N88=!TTYR)S:E%!1T34"2P>R\FSX
MBV":P#()?6P)L@8D= $ N,78$#\2&IR#_NP!JBQ@"IZK0U/D#;_F#=\<6*]B
M.(9PW:%2*)>U)3MH?=RD;P(&X0'GHD%%\PHSEG1C#R-U! )U%P.V)W2,6EL5
M$FMSM.S+B93%JK1=9G=3/H7-2RK82" "D0A$+A9%N_G*0P4CE[5+SPLCHB7*
MJCW3=':I9<1)KA9_3&_052QHJN9RES-5OPJ*?*88)/G1@\YBI5NH<]U^A]VW
MJW(OSGZ.5(K0*H]OMN97+ZQ\BP;)$:O?8LUG*T?ZUF6%&_#P<797%$#Z[ &D
M"DI> Z9%+ 19BIRUR%F+(CZ?/N+CR30Z)FB"4PU[FD9:'E:MZD;I6AJS,RC0
M 454#0+53H^1F8L4IXN@X9M#0Q3'"4$<YVUPZ,X-,.Y.[[?L<,Z)]>6(*\U5
M! ZH=&6,HLDH//.5PC//#4$#B$!>@?,9@Y]R!Z/$D"@C+ PVW4+=["&[XTKF
M:=C6>SE#V4SC"CD?KNO;E-D?KT<,GT4VW24-NDB\OZ!X1WE?U[++WB_@\64_
ML^&KU0II&RR_W8SR_96&BNBA/C<72>S\[-&YJ'9XN&J'AW=FG[>JN22;"U78
M(M%W"V2^FP:JK(&X6TWGO0Q.OG]GPE_Q/!U5/'<WX@M7/(\JE@=GU^1Z;->9
M28\C7JA?[EXI9^J^2N8W@MSG9</_M(J]4Y@848'J5LK-2JE28)H]IE#@^DUT
MI;X%B5"HL%U4=#OIU3UV[*NF/8?+$<_A"AX'YO*"*9O<I 4-04@._#Q&D[J0
M/O($VFR:Q4"U8J/2YM,65!*B#,P>G$!>U47%M1''?+_2U,KB5-PI<7.4;_7,
MJ<7F&,>NQ371&>N5<3P:1OT@ +0]%W!JEF&#LZ% @$>?;_<!%M#&.-Q).?^)
M$[YM(@[[1'@;A;GB0AN$+/2F@&YB<!,WPPWJ:;P'V^ .<.PPD<SFQ31;&XBM
M^VDY)ZG)=G '3H][80?>5QY[KUM^/ \^.O*02 =-^-<=!"RC4#>\XB)D+^46
MO, O>QOQH%FP]G+>+=R=<GO",[\RT" #J5?R4PYRE4HZ6LG0+;BS&R(OZ]!2
MA=L(;+C?9HRH:.(=\1.Q$A 12JI;8BU;,T*V3,*TQZ8LR8(!(2>&359D[='D
MWP7'S,6_47__A6\4HR^L9_ YV[B^1K=.CK^]GT'=DN[P%PYSNAL\F\+1R[J^
MYWAOC&'#>BSKBYD [0$1KP9:S([]#0="_UNTD6FM:_A9$H#/U?&-9_QR.!"B
M!;*RY1V6:V1)& !^/$;FMX6^Y%$)W9RV@*R9Q%CP/=)'!"KSMXGO5\,Y6H*Q
M16LK %5E-_\U[470F,[<04_WR S'*LMCE^?"".40)^!DDLC.MA?_>#,BP&8!
MU8:)YF]N3>@L$#]=JNUGX)'LCNCI!/(P8O[9$S,![;,HPJ=,;+AY'J7@.M'N
M3%5;A(1 EXK4B4#\A#RF .2E0.,8&/A)""P17S4$;6K+VDPW\5CGV[+[;3C7
MO"'L9-6A/ER@ #_2$96).DH=)AB,WM ,Q,H.;38>RJJ0'TS]0G24G:W$YQ^N
M5P8-$D.V=#2!O_!M*?PAM.XMS#QP5%FP131OZ('AJU/63+ P'<< :(2P@)NS
M0GX<_*Y#+N0.NF]"$2GXMR[R[*!4.#2!4F@: G!HX]#$^:()-^W97@F$9L_'
M<(1SHU^R18N 5).P\XA[O:P@ Z(W0N]Q"C_QG$U()2PB?DF #T ;?_26/3^;
M%M1X8+HE9).P=.][1VSN%YB]D&!R(/'TB9" . M2'&XQHJ@.&5<V,5U./@)?
M>]0L^)T]OWD[82)ND^%Z14<=G].:?@5 $8'F.N0205I![QQ?JEM!KI&G>!J(
MKH:]W^43T( W:B$O .)61-(%F-H:_+H*P<V3KQ@!5]GJ/,0IDH80=PJ$#IM]
MFCE+PAANC,N:Z!D&W(H8,87Z!ST%R9()B:&B(=ALB$'4EL49L19,A\#V^ GB
M,'J60"Q0\0C7<ZE4#DP$)S,UA+G#..Z$WQH,B2.J-JJO:>&2FR98"(C#X-9!
M$Q])@S,1Q#K0-P3HYBMB%7=>_Y5/.(CHQJPL_KUO_/S?_\C_X.>Y*N2-+W4J
MQ;+O.UC^WO6U\GW/_RH@P'E#@CD+V$,!TD8JXEZ'3NXZB34PD$(R(28Y*P0K
M0;41)="[%SKR9E'X!^VO/'?1!$R0,R Z<QP#"\(4L;0%%(Q!;U;EB<,0@F2K
M**G/DI%/[.CR(YYP%OGLI:8P <Z#3K$O8NW_.+RX=9;RUE8+4"*V.[2ZM>Y;
MD01],BSS4RB'FOF+<,W\^?0_RA3.",!IHF^L 5 <^*># R:Z;3@C[J#U0B 3
M#XF@L^'OY\$U B$X,4=YNEL#Y<O90U<*7#1#43OH>"UP?.XE&?>]^3_^5T-=
M!H4<K^:EV;E#9H+#?OIBH1L6.L78XIW2#&@;N6:+XTR@C\>NY,,IX5UVQ?".
M8##H^\H+4C$"N3LQPER@0*-ASN3%7MU!.D!MK\5580PU4) D&!<,03,/$GF2
M1]XTL! 1H1&,N72/<849?(<,.71OQ<E$]VYQQ]SM+1EGR-Z,N1[>HR9J#@%+
MNB[A5141R#/2'.X;5H]H73]]MFJIR.R-8@0#KJ+"F"=@HQ(9K:H^A;8W@8PC
M#0GD8J&ZZFR_Z'S]\" ?P?:8?Y"I(_1_6_JAJ6./Y[)E.89L$X(+,B><=>8P
MH]#$>.O?8RA9^A1@LP0_T-F0&.8,%+F6H1:!3Q/V>!>#G"V8IEO2$KT2\9V#
M/": _$&TBOT20[C'=5B9Z1-G>$/8^N>2</ &TALO%I+EB!QK;+UZZW%9$VX"
M6MK^270&/XKTV:SN/F'.9:#QJR+O'CZ!P<8;CM-;L[4 EX[F[+[%!$O;L4H$
M^)4%&N\2"KT1#800HZ&/6\C,0=+; 2L9LJ,#]GB'[XA[?8V +(: A(&FE(HF
M1\7V#Y)-T\;D++CDA$]Q"5AW</]GH5/_"WU]3UEWY3XR86R$S@'6L8C*'N<@
M$KI,@!V'8W< K<*5R>>@)Q"][<)%+X;XR2);=>*N\"]B#AP[%W.(;Q>ZB%#/
M.8S"(.4_"_&^#B7+1G8LV@99.J*P9Q_XS B 5JC*\$O(&L60@]@>+<)[(.1[
MZ @>%HH?)"/2P.?(D+YPBZ?0'/%)*.1':/D(H@+M9VSNZN8Q<V$]&R D%OAG
MLJDCHQ>!.3+F#,'15/ /@L=G</G/1?ME<\Z1A:/IN<HHN*E3Z$@[?W,+/^Q=
MG:FM"M"_V1(J:@B)PDTO."='A$:G4BK2%O$M$ Q'P9L']^(U;0@UW?N-MV.=
MZ*./WT[=&U9HYE4;2B2"+4=855V;QJ&4S!U"30Q]?G*&+RJ]K7]3$-\?8^J1
MSA5>,E"<3QT[!EH]:*L.3[V2#N,TH@3&A@UEPYF.@X-T[#W@?D!5 9D2KA?+
MV-8,(INKT9D3BJO!G%9<KOBP-JI"![W\!H":$;I"$'^A;P+M6N\!;./P@,..
M'\$O%!SWK-1%!_@=U\0^2"/ZUER0H-9!9W)X&"=:^AZ)L@X2[8'B*"@"5.E%
MK><!7$? D@ULPT%-/>[[Q!4+.#$D<8*!PI!7V/YG%@S<##])]@+MJ&H#S!#;
MKP!6RCB> #SQBQT$$:.IH-D3J*YM V,J$BST!%E%GOE+$G:04AS7T*8Z^O+^
MN9Z!Z3HB/@(1.,YQ@%%!A3NHX4,<'SJ^R]OQ4&P_[7?,EJ+=SK%S2&OH"L"G
M(DL:?X0:S7P0W/;>HO.-9P 7!)@31MMO8XY? 1U<)63?G+ ?7;<,$]9YOS>G
M@+IV^!K;-FX,:6_*>SZT)TN.C2(=-&C1L\LH:)*ILA-Y@Z)MXG@.(LC>9G"L
MT9\3Z/[H:[2% I&(.[LBHL,72&L4D4)1)>FO_9N]9^JV9:+<+QQ^0T85UE:'
MUV=)]+(B$ _O@@O5"+@:ES:(<&YL.##SO>UUI"9]TN9^R5&<CKZ439_;Y2C2
M#X8U'&_#>6;!XZ0N_DL'H.G^Y6A!-^?$D.>!5SMG$$=G9B=^#WT.1R;*X8AR
M.*(<CN^7PP&1R@V#.9;GJQD0WKGZ!_(@Z)??\?K9_0=.^NE+R:??_G]NX>P]
MH]AO.S]OV29(O[S;.KF5&T0GO7CH._P@0=.@$A']\0'70\$TA=_&;I(3?'>=
M&JB26\Z)CXD_OK?A$H@^))8_5EBX;[0.)^B2OG"<+8?G5R@*#-4[<N7Q$=D<
M.(;,X411./+%?+Z6>YP''^\] SM#^S,5--2U2IP W'/?#"_*,6+\$V8+A[-D
MQGT"6\!Y[X[!XT01D-,!K0VP60#1%R\?0^M2T]#$?:$^)\1W'3[PG16@%>_#
M"N\ZL#N<2+KF'C1X!6B)3MWSVL,1["^\F@_TM?^SI;Z6=H(G <5\"RWA7Q-Y
M R2_B>!9,XXR/Y4WY!+N>5;-'\WZ'(E&/ZF_WLCT"=@B?Z2<WS9D,#-1J1>8
M246'VR)0U;B;KP&EPG_NW6++6Q6#J(U2(!!.V/AD5-_@L^&_"-?[1([[#,S=
M\_2Y+LD3&9T-:KOMW D"(S"&[OP*'3%.X;;_C;R!O5452#RZ.IM^)RZEP\FE
MN0]PZ8$S_?PZP_JLV#Q$08*I*!#O<<S%?\R-#!#TIYF@3N+XQ-K5#:)LB"@J
M[2FR)MLSX]CF@]]T#0V4Z?$2&Y_VB2@OU1$;G)>W,W!EQ&<ZVHOS8YL"A0Q0
M:@5*:M"V)VB&#"YMZV9 X<0;":!RX/@PX/2QLUMJ$3U31@$L',G!:5D A66<
M+)U]R-^TP )9 DM;=L]RG2+1* 5LMI_ML[0C$=E *#PDF+H&"8YFC@P=YSU0
M:B%G #>Z@$[Y4!(?+B1]/0,/G0&XQEW,=YSFK0"[*-@4P:0G& LOT(EK$]P$
M&D8XNHT.@C !_68/CA)W!16'JMT!AP@UVM?[NX)[4#R$M%P[M;C_CS!?_ UG
M<!<CZO5"S$MC"619X0=#:_C96U%4W#H1"!>0(>B<W1X..&-N\*IE&Z:-LQ=U
M+Y=MOH_[G%K',9GP\Y%"0&%#" 0Q-UHJN\H%_W=FZ/;4L?3Q'&.$.1,,)[:&
M<D"1K8J="5U48BAHB,+U-B#^]?HMS:*,SOOP'4WG>7PZ5=/)2EPSE&YYE)M
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M[L.\:PRE>-58O1C7/SA7/=W_FVE8? =96MC*0K\U9 V9?*YM]2>N6%?84"5
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M(?)TGH3KGSAB[2;B'27;'@Y[" _P46LS"3LX3M6GGKZ DIDFTS'"6RGVL%"
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MDMH_@F&6:V\FQ@PF/SY51JWMP07 8O-3_V#8O!@ QM3TTK0'/(,P;+2E>4)
M8YQP8@-P$S5Y@DQ4>S1VB-&HMMT]V_5&J,V//$LXO%3L.*)!()Y+S?P--J!P
MF;3+:M>%9X3603PSS*$T(%4[6O0G 71"M':NA+1'?[%'[>*1S&B?N5^+E^\/
M+^QW0V-S9W=[\ZK8N=%IVR'_2,>U]A+WR#ZS=.O /<(WXOPM>."CY_KJ3Y #
M=G"F3-*3V"*]H85N_6S\S[&Q%QY>&/6S\]/V/Q\:]JJ%[I-KH5LMM7[3'F0<
M=BF5ZXG5]81ZPU6PM<CJ6I[:M;1^V_ZZ3_M>5N2RNI;5M=R?B]5_TPZP3_M>
M*J5*:W4O"[N7>;.S[]*-'PT(2VP7>RO_7GB/LAD0>9#&H8M1_I:,#R\" WZ%
M!*8PX.5 9$ZB>&HP8@7C"3<_G).QH*^-60EYWQZL9^;MXO[Y$M?/2=K'[6>%
M^6=V?W(KO(Y#S[R068]KI\?;ZP_%3QZUXFWZG ]8'/[H#1.?C!1=06$%A40V
M/L'>?6FXW%&TLVU?VI:@N&LP-'P1G#?J'[SR;M'U+X[??FGWN_N=[T'CTPL,
MOZIG]I,D"'KJ9#(6F47R#QPCH Y1=LB5SM^./O=,[TOS8NO$O!R\^V=T L=+
M!W(K/QWRS[\\#N&6XT*F;\5WV[5/^N>=B\K.V<%)Y\3_ISH<\(S;2DDO+Z;R
M$%6>E\(#GJ9#84Z=IAL/MA?^Z+G81TM47AZ3+3\!<?7HU[DZ\M*4DN>D@<2Y
M7U_.'=^J]?O>[FXYNII4/HZ^'&Q=#P<KU2-Y0/'X$V#Q*F=HRWW?^O+U\TGW
MP^['K_\8Q<]V[^.GI2D?G>.OE2O_O?WA]/A'_ZC=^*SW+H_EB'N]5%M0+ZHG
MY6]9.51>_7V$U4-]+%3$HK07:F.NO"DOPX_P"T[Y%PV7IP6%%^%?B;6;,<C1
M\_+UV^MZ]>1LKWO\S^C8_VP5W_N7+S&U_:<5')0C.R!&=I$L11 >@321:S;\
MR!E_K)C6Z?&YL=,)]]\-/I67I^A\:SEGIT9-?]>M>)O;6P=?=ZMV!;LE@Z)3
M*^GM%^5EF8]#_OG"/"EG'J;5('M["4;H,W.C/"TA]-23!%X.$)[6D9^Q'V6E
M:=Q+TZ  3L+IY7+!T<5U</7.V^D>CP=;Y\/A/PW_X]72E R_.QR,QO5S<5K\
M_LD9G'SONWHX.*^CDM&HE&K-Y^M.6;)*\?1=)E]LX5@OU%I<>4I>AD?@66@F
MOSUVK#PE+UA_P:WGOR31(1?H3[X;UM5.U2I'E<V+BW]JNT>.W5F:QO+VX_7D
MVJQ>VZ?"_GX\N?*#X&L/N^AB_*=2:KRL[)-?4V*6U4KW]JJ;;&\R;!(S3P/=
M='.;Y[/S1>_SYW?&G87.6Z+2L/KEYGE9;[?/:Z)OG/?:M=YY7S?[]4J]UZ\W
MC'POHO/^Y\'7S4"\NQ"FL[E=_G;YX\##WDZ5J4Y(=FW/&4=OSRZ,[;/M@TI]
M?V?S?#"KM]/9P7[GFVX8N]W&]_WBY_ZW6E_O7<&34VL6=SN1_NDLV+HX&%T[
M3K5XN=T^DUEGV2<GYMO->O="KW9'[_ZI.[7&>Q&&GV;UBVI=OA]T+NKN^VYE
M]/WB<.)<^^X7["PU_?;-SN>+AGMH7A2_&<4O_M?/KGC[B</..2B-S*_Z][U#
MMSSIOM]KU4>[/QQQ-:L'U8]WUH_3P_KG?TX;WS:_'H51='K:QR>GWC[^NMD^
M.7WOELNVY;[_MO/I:O1A(GW!N5Y991'N;N\=E;L';S_8??-L,SH(.K.Z59V'
MY9-+[^SRZO3MT?>C;Y[E[9PX^.34V_O%MX9^7/MP<7$@CJ*N;;X;?SJ6 Z!R
M)QK_T#^4H\Y1^>V%>;0U_')NC\97;$YFGQR<!4>C@Q\[!UWCZ\%W4W@_3K?W
M9G; .OEN#'[L?+H\.37&V^_-K4:E7NY^@B>G]GEE?KH.VCM[Q^6M_>VOW>)!
M^&GKVR<6#=DGC_O1H?YVV#GK&MYFH_'Y:GC:MJ[.F]-O'[VW?_0&'YU!>7+9
M^#CL?SL0FT<#>'+J[9=?MBI[>V?-]]W/Q\7-VKN+]\7WE4_PI'K[@EIK@[Q^
M<X2J1KKSSG1;E>_>A\V+T\M1T/V^8^]^WCU^_Q&@NJBV*AG&=7.!3%JB]NG_
M-M)]LVO9OME'W;/NQ]/N<5Q%\\0:JL\\S?)[K ,6J,9:L!3.:B+DN*'=SL$7
MHVMM;;OEB\]B=#SI?=_[]$$,%HX74SU8,[">"<ELOR7962<:P9K4]'96NS K
M PKL&>4S,((WOT67GH:^ZJ.PP+KP7[ G6JM[>8+WHI>:JSX*3_%>JJ7*K8.G
M5A>S8F2K>UDQLB=_+ZN+>9H74RFU5P+F"=X+EG2L[F5A]S)GKL-=]N3OT-CJ
M=H7G01K0++Z/E>DY")&_7M5?_20@JD"94P. GW.KGA,:>[8/7PP#K>OBB)_]
MS&R"!VT)=I>\>?1TB@=LZK,PYO_;]#EBOOO(M'8;G-;^8V>AA/]^@P.Q;!.^
M/BT=ES0+':E^P(.SO"@P7"M8_\]K>\66I]ERY6?9LEZ'73TZJCQL![7J@_'<
M%9(H=]KTB/-GCB25E6!>">;'$LQ/*R'TL ^/^0_&,)_8Z9:?[LH^NR<&AG\]
MQ,$XK/)2$GGO.\SKCBR+P _/#WW/BLSPP#\6_J5M9BM[Y)>J@L>G+824M?I6
M> . [Q O(<ZF97I4Z;-A:'RV1T/O5+PM'C=_[$\,.\@4_!2K<^3/RN2.9-)6
M-<Z4O1I5HEKG>Z51_NP>?K/:/TZ_[Y>O\* @, N51F,QF;(KEO&B6<:CG>Q)
ML8Q*FF54%LPR/IO[1YT#9V>KVS@_[005,;G^9ZNS")9Q<#T)=NSAR59WJ]RN
MVF>^T>L/D&4T7OU=+53K"V(9[:<GA)X$#T$E^XGQD&4UHGK\2,.F;_RPG>?@
M=GBR\N_9"[N[THY>H&1;I#)LXFA??W*^>70^''TYV=X:[Q:[6]'%7G&GN'OP
M[?+3(F3:247L6Y/MBXO3XO?>IQ&&=*H#G/1-:G"KO*""L17-/U.:7\XQGA3-
M+U*;3='\X>9FR^PV+^V+K4//:'X=78Y_'"Q$CZV>G8GM"^/#C[*]=]#<-$[>
MMAKM = \Z+'U0JT^/6?Z.7J.GZ[2^BP9WTMP_6X-;1'8*S_.POTXCQ@[>V37
M\&.??#[)2:5@E8?H#+.BB-^<(I[LR7\;71(]HRSAY./Z>=?M' >;!Q>3AO4Q
M[#:#+^+[0C3*3GO<^][_L#4\W7I_%!U\.^U6.P8V2@.-LJ*W5G[1E5_T-_&+
MGGBAX<1UU%K?]T9:(!P'B[('GF<%+\]]\EA)-B1O,L*E"L+%\B(L5W\Q<E5J
MFH]]SB<E17_-"ZMW_5-S*/I?NI6:;78W+PZCZ_)"Q.)5-_Q6V?ORW;Z8G.K'
M;W_\&%5/S[$;5Q4=+>5%YABLN,-OP1V>R#F?%'?X-1W[9,^YBO0+>[_<:&YM
M;A[]<_@QUW+XH;B#_^F?K\VHI>O=Z")XVQCU/G5^7&*3)U":VX5R98%J\TI'
M?DINV-\^)?<HHRX[0*!N(#1@ ]K1OXW1>&,;5&BBVX?3GI\8!)Z.R+S+@?,2
MI>@]O;F_NV"=5^W>8T+NN);\5HK8\L&'#\7SGMTK;YV?.F*O8U?*;Q>B@(^'
MG_:<@]%IJ_O!V:L'+>/D^.H3]B<$!;Q6J%<6- ]QQ6!6#.9GG.._.X.95W._
MB<'XEW7O[+1IGG0__^@<_'!Z.\6SG84PF-[YYO[9WM:'[UWCK/7>?+MSU+RT
MD,& #M\LE.L+FA"R<GT_3]?WKVOZRVI:?FNS5]-S//_-'Q6]4J^TTVO$2V1Z
M;\N/;ND->V-_\T<[XJ(.]71;GS^7YO$+[@]\''KFQ1!H4_A!]WL$N\')$[?U
MCOXPO-II'U7/!A>CWH=>5+SZ9.]6KI;8(U@"^[82\(\')UVMKJE>T<<G!UL?
MM).CSL?CSM;)[L''!7>-QON-R6S.AM>=L!@.17'?\"]$J*UU3O;7M8-^'U[K
M#I:W:\ MZJL\%/#_L17.R*-6.&)&*QP-T:V0;KF,*0]6@7M["$TU71:%^RI4
MP=#P17!>ZYUU1@UGNUZ>['V\OOQTHK_=]3IS&6U*=3J.>H%MV88_.0:5YJ!/
M:!^G$73"$>.^ C0^%'1@VX('D?"L^X/&]>5E]V1X801;/_J?3XX/-P>9+/7=
MCSMSZ%FTA]T@B(3%X#Z$=WO6,1T>;I&^"O)33SX:OG_>O:QO;_J#P7;W\WM]
MKUK>;VS5K4^O_FX50$@5:JUI0T]CF&+7:[@DN$V-7@\W )1/UX3PTNC@6GQR
M<DK)+_7\ER7M)'7E ^$*G+YN)?>M 7('@3;V/=!++$">[Y'A:*&G&6/X[!I@
M$@IGHOUKN7;\<E&B6)\#(PXEI'9\;X2W;[@F;(SOB[87(T,CA0S-ZZ_;PZ_]
M@;@8C5L7_I=>L'\V[KSZ6Z^5IN<",]4"OW 0TD"A #E7,-RO['"H!9$)_X.'
M+<U42Q8MC^!6 $\ Q%VP0L)@AOR)OGS>FER_W^M^^/;VX%/SO3[Y>+FL'O65
M.>1/(Y$_IYO'W4^GW8\G&DXM.%FT^"E/,?+.V+>=I\&H:RGLJ)U7R]-4F;K_
MJ4&:N>\E'89'!]\O?W3K=O?#E\_[7>=8WSH]NIJ?->/XC%O9<I8+S.3-I_M7
MGVM'O>!K>1*&;P>-W=IP\Y\!ELS6=*RTGXYS_1QO?O+L]W$N>@D,]]M9-&SU
M[(]?R[8=7)RVMQO;)R$PW.8B^.W"]>B',-CC35IV,':,"9Y SLBX]XX=VQ5%
MV;9UWBW30?'+G_8X4!?45*]7TQ&&CRZ88<YVJ^)K%M'L];8N4!LXSB[?M/7_
M_I],<]K8F"A*?X5TJ:9.(J%;(<?00!2Y]ZW1AY>],9PK8Q*H>2.M4J6F$BW>
MQ&Y9/+M6+[5:?VK)/Q$"4^##02@I(&4&G?"OLJ-.Y&=W-."5-Q%ZX\5=0P[M
MJBFT,S0PA8##_0'FY$PLQ'\#Z@/S<3*8*#]Z]3>-W6$^3T-B@A@'C?O@81:F
MLX E![I9U7*U73',\[)NM,]K5<,Z;QNZ>6ZV*CW#:K=$L]][]7=J9-5N*$:5
M?<,%K$#9$J #( H"6!ZX?\<UG$E@!UY_1_[H48U[W&NJ&][-CZ8]IV-?4+]G
M^'VEI&G)4>/Q0,F1R>I1A\;;VK$!#*8-TA/NS2*H<[A>!)$3TB,'8\%B+WA@
MW>[.YG#W!=M6YQ1='YVC+]KQ2>>DNX_JZ%'W;>=H>_?C6VWGX.@S_+.X=W#P
M ?^.GSF^ \KX6E][_?>=CW4^;FM'N\<?M)W.ULG!T3&HQ?O[L)TE*,,2/+>V
M)?WB1:"(>9%C:< 6V>Q-)DQ96>PP4MCA1;[6CS'$S&"(GV"(%V,(Z& # <O[
MK %D?Q^H@H<@-KYA2:HA(?7NUB>)%<!#+DZ/!6W#="+TUP@G$%?P/L&:/FQ[
M!S@2=EN5='0K8/1R\1.] 7Z,>^VX+BJ21V+L^:$&!YUSL0^HG]%V)\#;I$MI
M6YBDX=UW'>EW EH^]D;$4G%!VV75#\&/.JD!.H45'_J&.RQH8P,#+Y%C^* /
MTYW O8U!2T-M&8\,.HW+4 Y"U+('$SH#?M6+ GA)$,CK=M*7Y X*ZA("_,$5
MZ-%%Q_,N$*-2UX>OE#;82!@N?$L8<RSUQ$JSHPY(@X(!O= 0,-D]$S^E=V<\
MU;TVAX8[$/0X?*VWJ[6"9L!V1P3X@B;O(OV@VG5NFVA6^/2AN$;H,#87M)YP
M;-$/\%<HU C%/5^!RN:S,SU%8>2+DO9Y*,#."%)WXQ,VL7$*3&X4D/%<*6\8
ML*!IC]$JI4_ G);?T&LOISX604BFS=3GM.?\IZ;A3GWDT9#9J05,Y WY#^G(
M4Y^.C$G^(T2AJ<\\@I?A3'WA"\N>WBR8;=]FG(&Y5O[3*[ YIC[#!]5GB#PX
M]X N:SSTC8!MT, &Q@N$:8_X2@P:IS>1R*U(PI2&IR2#42Q0X0?$:$(F;'C<
MMO"4_<DM)  HH7X#+S, LQWG-HKIX;2_WC=)HH@T@=$'\\'P>W@8WT.]G_"0
M*>+0MR]Q\RG*V(/_R%& 8+<"VTA(I%TGXSH0MVT!3^FYP##D9='KF GT'=P8
M@N72%E<!0E#NPR(((C3QYR/#$E/\AFE$$Y<Q9T]8/H@08G!@IA;X_@1["4+C
M0@#7U[R>HPX%2T5C>A] Q!< $/@-:**:Y>'/AL:ET QM#(+%G.#VZ&$\HWJ<
MV!=>\8U P'>HT\K]PH]-VS>C$3P$NX0#H'61G!W-WJ$-)B_=6;P0<  "!O*)
M9$U\QC/AQGP!:]$FW80?6/*=!6!'I@ I;^ B$\0-7WR/;+@6Z4(QQF,X)>G>
MCG%50H%UVZVF,&N$Y_?!RN>;B& ;/DH5PB!"5.(*FFD -Z,;![L_HI(H%ORP
MAF6C"UE#GN3#)0+&4-XG09;O6CT,+ K^B6S1(_(#_F9IO8E416[>,_P_N0;1
M+X#%ARWT82N>CVX%>SGZ5??:@#V+&-EO@IL4B2 XHI  #NJ*Y@#7"8E?%+*J
MUQO:>\HD>H#=QX'8U$=Q:#ME9<8*N.TB#WLS*W2N7!ZV2QZ,'CJK-T:P@!R-
MT<BM08;K=$X'NB7:C69;N244 !G+\*^=[8XV0H6:X#7P@1( J3!,B/A 3KU+
M@[BF=GCT3U$O5PH*>0X!.TS?'A-CV/:C@78*X-%V!.L%:X?;ISN==4TZ !73
M8#;,C,8C?95O5&DYDO."N"56 >\?^$H3<NP+$,]#S[,0&Y"#.<D6Y:[P0 I5
M 'M[@ "XK-R\MKG7V9@VB'^/V_]90.=!W-V/0;S?Z61Q@ZXU^4F O^%K3O'+
MH3 <DD\#4(^!G8#@BL*AQS+TM[V>+'$:L\@0(*L0&> J; )LC/5^?#NHIJ'(
MBNU&Y/ZP?S#X[3Y<@BM9HS0=T8D,+!^DS6\+?+!D$9A@;BCD3:0D += 8$UX
MUGV1F<4.B?'DZI+;&8V$;[+X#B(3-)N@'SF_[1T@J%*<)RVC&/YH%LP%?@:U
MO$^X/A ]H"^YY-D$E16U4?PE@,_];:'>-VP']454XD$T3%3@EK 35"Q2I3VV
MS1RAIIR3 \,7)FP%LTMACV#9"Y8>\8<AJJ9  ZR<2S6:M%JBK9Q.F7(0O-$"
MT-.(M\'YV<B&WZ#I3XH@:.HV;@LVX$=VB%O< 'T0)!'85\(ENRV$DU"RRP:<
M"ZU_VXUGM,NK5]\[AGF!'PO0J4W$#?*]6!SESIUF W9I</ '16@ :P9\ $ 3
M>-,(&"KY*$"A<N$J,-$#L7$2!TF1LR 6&V.4=JGE ,B1BQ@+KZ4=P)9&: ;"
MRVWW$GT0 T3Q0#K.X.\PPB-QMP2P"K6>9Z#MC18?J;IL5:L3P,M##X>[Y X!
M>[9#-'$9K+"^A7%=BN1***#FQD:7+PP)<-C%:_A<02^(^B!;Z%[Z8")1JI<G
M[4R1W8@$Y>]*<C/5<&)QA83'(3*#O+Z)LR$UH<INF&2F>G["YK*: S)*C@R#
M_6,[9/21G1A3,54' %W"G:&6'MR@G,L+9<V:L(VR (+?]QZE+1H$'@AQ9%#D
M=D$ N7 1Z+;W@3@O;3\B/[$PT%L"T-\Z.-O=+NIM^",**5Y*$+\T@"S(]Y P
M3,,"'AD@(8+I;D@'D'(/_^: 3UDRB,_ ==W D#ZS*T'@8XZN1-HXZ@$UD&=2
MNNX$I>-)@B&^Z1MP44 ,8XP*I!E8XE81F*E*-V:!!'.\,6<UHN202A\GSC@<
M$;#@O#;)!-0Z4)BY@9245YY/?A?YNM5]QEP&T5R R1,9<=AK'/D!W!:)&AD%
M,-,*74P.SR#OHKK*NUCE7=R5=_';L8%IO2@=ZIY6(-F\0RTHB,84.*:,T\0X
M-!W#'G'\B2T"8/T"M53#G,CXMA'>H 4EBU-4@X(-(J   $L5BDLH6SZO!&",
M !ZF702V)=*_8<TJ<F.[QAP:F-H'EP<JO;D2ZUDQD#94*"!(G_)3(.J']CA)
M>3!Q BQP.H,-2@OEKMV+R&@B \</03*G34T.&.2#!3P=AU"$VT&N[B3M-#9&
MV'.=<Q>4U6?&%H5I!*P>T3]0Q0)!C@QR0UM!\4;,O@!&80Z%%3D Y[$QX3"<
M]+.#ONIB@!)=P 5\?DR.&F 9(J!TF3C&F3*WP;C @"E9XIR\HRP_8D!X@AY<
MZN(MB>=T+YRP0J8 P=<>(;S'^%8V' 3R"=< <QS$A,%AU[Q<(K%RA1Y'UXOH
M.GPV/H+A#$BG0*%+[82?>4!=- W:>R9!SP3Y%(P3\,_2HF[:<WZ/]U2YLI>7
MND-.,4E%-XPKM!6";-)17)4*O%[E:2ACVP[(X\GY].R)[B-%(F>#K0<"77P;
MOV?8&)F))<:8>T/([*9S1CA*8OM6$:7KA/-DL/*7TP:XYY04%:B9B<REH.0&
M/I4*1Q5RU!2O\=N*8'++!RI3$C@0 #HQB_LV-<;EH*MR]G%V7-IU*$.(&S*E
M$1,WT8%^8S:%\FU0GBH&]^%D(=XY/R[UY5A A9.Q(([GB]0O?]LK(R!+AUT_
MXR:"/S&2PN[9. R@?.FA,(<N6/R4X!B'SCDM[G>.C4]IH4@)Q$](ZV0$E28<
M?,OJ^PI::6BETVNG\@-)QU2)HZG M(8N.)$/%:080,I@7H$[$R.A>*FM).2.
M[9E^]*- 06A_I-@FCX"$I[1][UV!KP53,<:1#XHHI@W$N9>!S#M,83YY,!3'
MD YPS HT5#EG.I(@<S-5QJ"*+"@7.=9H,FNGL(,3>"K[3^I#N1 JE1C&+_IM
M[SXA&D40<)O2K".\X& :HP@I1"8'5%6(57-0.-!WBF!M-XA\0AS3PPCYX/=-
MRV&^%*AR2X22[?81@ 3#M.(9UUQA&J^;]K2A'>=@[F_$UP3**]T.F!9)E4NB
M_[ ?HX?_QI>HY>@N2--*.&&L"V$8--9R52(/4*C G 13_>KVC0P,#.FGCK02
M^+,,<V!'G/-CHJZ)AEY!\R-'J#QY4GF)7TK&A17G0%4T](6P(JY<^EV]'@KG
MF;(<@7Y2/QJG<WM2A6561/49P/]]#SW4J4@G!SC]$?JP/;?OV-DRGUP..;G0
M,V^B7/SD3:@;,Q'>E/4@TTO54W*STK!$OV[B ,9@:^+OE0V1T?C,FY<VI3QD
M7,7DO(P"N$5!N>Y+]MC<[*!YB\E)"+9 9"VV@C9)2@W1FPUX8U(=1T05?*R(
M>.JWMQ7-;"EK(PZ;#^&*8;6(&@D2<'JVEU(\ /LBA![\A+0,] D+#)2D73*!
M"#&L2:N"[H'[H9($E'E%>/] 3">.82V&S#M*,63?&U$AB28,'Z]=7F0<*\IZ
MZ?HV>4#9(B:M)?>:DH;-(##QLV]<>ARR"3'9"BU?=/'90:H3QDQ_'QK?&2.D
MD,[*??!,'DSCH0PZ(W\W\./LU:B**E4LE]YD:3D%LK>5[QX)#(_'#4>V$T,Y
M*7E^8.Z<Y\4<LZZ5JM/L686UT^)RBF7/;+@V#Q?76S_'Q0_<=,^T2J9G6M_V
M@5&K-,DK8,26)RLC27U!VX)_MPNF"3X+W[R+ (S:VL[NN_4\DU39RWI]!C=<
MW4KV5G9$SX^ ]<B+J:F+N1*%7)4VQQ8+<9P@E?2\]6[_$+@IYF)Z8VK!HW&2
MP"6*3+@<])3Z@K-T2=JF> 5SEQ^26R3U&;*]#RXMUR#<\ 6P:^37^*@LJS%5
MO1_5%&R5M([\IKM%C7&HXIGE"56!V$&2IROE1D_ M;G2.;D/7 [!4'H^23JU
M59+.*DEG64DZ]^%@*4@19]3*<T3N%L':](2UI7@821CJ?H EM7824M/;P/-D
MIX?/!T=[V[>W8SB>C!#DD>P#T:JU*AOJ?5SN"]JK5'2]J;U5BI4&;T^3+/6=
M[83PW('O@ J+X5WUSX*V _1K6P95C ^]@/BMF^[\@-5O'N"$6BM0>UN^=7 7
M8M2S^M>N"\8/%GB2AXG4K50\8MIOJ9*3X0H!.T:88^FJQB5@$^$R*?L[B?;A
M4P Z2F2EDK(^OE4U?.4D:*I;@'<FF<YD:8'M!]87:2HJ@1I4Y]BAPQ7GEC(S
M)MH@@KNBG%RJ2W%1F9U1JL'U'53YEE*4]!9A15DBK27SAMP04["2]%[/'X 1
M]$-:IF364#&Y,CT-ZQMLAD$H(1=;LC>EJ^'/7'2X4JJ:IPET]'%JF2S!(.F-
M3B29KM9/U62@:Q;6&P$BR"PY3VIGZ%<:4(V)E;38S5R?3$AV)G&%/UD=@L,#
ME'R2/A#YHA35ROX:2S$6/@O9Z$'#5M&"^ZV889+@E23"9"IB4E8]V?/9.J39
MEZJX"*.Q#9O""A[@E49*A\DZCW#5;H2..X8C%N)3:\O9A(/JV]! U8TN#G:2
M.-OIBE)1=)7HD]+,=W=G&9JJBI :$W 9!U^WQ),K;,EC.-AN:,+5.GR:(;:T
M(9H%2QS)A?MC\.-D\WJJQDM0IPSNT2R7S]O,RVDT>I/$ER)BAD&Y#88_F^YD
MJ)\(1^M< FOFYI>J'\TB>[;G41JDINI#E)&:E9S4E)H_)PX1OT$UVU+?V-3/
M(M4D)6://4'FF\P%@UN\])P(R$86I"$\U.\PO8728!@Z>+$W0"ANX7/2.>ZR
MV6#%H"6YFZ!RV@JM*(U "0W'P$WYAL7NE(G"?5R7C(_TK\L%92,\MF/BT/>V
MA.-TK]]H!P [^!-8A C1H03_#@405)<;:R"_/YZ ^!HMK>=8O#F%$N/4]E2>
M!K="PE1!\O8(&=MS(ZQ6Y$H6P(@>Y@N&5!D(9\+,-= L!D-J3A6"L'.<8L_
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M<&4Z:L_#7_8T /C 0O*E@ZM8+36HH*G> K95K  T'E1(OG3X/:R0?.G0*H+
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M:N!>\,:))OI]0"US F] :@8A-?9LXCQV290*Y!26\D_^$8!V)];I5M5B*"I
MN@.'L&C-9!%1&L B$;ECQ](="]LR$X\L^96U_Z+;]G_D_RV0C[>@;1[NK@-D
M?;@H4&Z":# 00(=\TK1@C#$)C@) "?"@<-6NTF.2)X(EJ<ZL304&<@QD&P:H
M VB: XG 21*V$!A] 8< N/11ZB(/ ,8%S_5MQ#*2T7"CCD<&%7!QNO_=HZ."
M_"RE:9"ZA'?B@-J>,P?19+O#YY;#$] HN=]%@38OU:F><$7?#HN :!>P/<=
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MA"%[3?@-4BF6^@_9#+ECQ!QF29$1FQ6OK$A S0-,.N$;8:)#S(ELTDX,HAY
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MD01K[+X\6\Y;0XJP!SIWY/-"^ O;8^<$^SB53R%%'Q3YAQ,5\42(P?B$+P;
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MR.?(&PA2*1))#TA^FX_9YO9U23N-U>EDE4+\/7/BO1!4F*&1*DSY5[U<4JW
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M+"RPX7Z$ZGYGT-S,W:G"'JPG=J,^:&F1SR%+>0V*%[KL'(DGJD0^]L8.4BZ
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M'F>18!-\(PJ]P!M1$R\L1$?3%5["QH<:7"?Y8;K''N9S\.^.0?'&G+MM^:N
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MJC;RBYT;=,6>!P8";J*9\FW *\0N-W2U>,J4Z0%(17O;M@8ZK?<#'8DX&)"
M+#RO=#(=QM'2L5 K8T N1)8FR"?43X)H&,_^PEILH&_E=:2G!NJ7'Z)WNQJU
M^ST.H&7=>8F!:+?U:IM7++\3O?Q9;$5FJO)V&A.XK!V;^7S\ZQVEQV9ZV#.L
M!E<Z#X(8KQS4_.X;"#]=0W<\RN,X\@F4EP-=E">P,_WFE)L =BZXPX[K531+
M,:<'D8+/<72H1GI\2X<<ATN]M,KR1$I0>^1ZO(\P@JQO'.(1U.K-Z2/BD89W
M.6(8^(;.!E&CU;5'Z'LWB]J[-6:2KSX7CJHAX-@MZK+[',NJ:11"X#^KR=#
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M^\[&V3'$!$'R>[_"YU%#IT I@@Y$J]L8X0MUGF(*986)CEN1,IA\#>)H DH
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MPZ1=4_OK=$'J[V\UKK[J^N/H,#;%66' 8_:.-R=RGEMK3W-8F"=K"A,XR"F
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M)%GY#%3<7%=DU=MH, 7X.B^K+P>I5O2(4#\ ?!I A5#'/A3JR J+<1*95!/
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M&#+41EN"5>&[E+DI-2&E)A;W*QK'"W[4VL-WD+K)A[H G^_5V*RYI(XON+E
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MD:0\B#Z(R=4LF%Q'"484*,80<(S!L"678E6*5?ZB8UL;[;U9BE7KV.EO&NF
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MP#[LAL$DKT@HP**4$]97IE:K(0V_@@7!(F$2Q V1'GZC<;Y&,)7>"H%+O@)
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MBZ>H #-7/97[E:FYG"\<_1H%_I*ZT:SP8A#Y=^K_7:?C\.__'U!+ P04
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ML/T:V+74>N7&/Q.2 PR7A,Q41[Y[,N'&,CG1@,QSTMHP(Z1D+!EN_8RG$J#
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MK(UDUTI_]]_/O6PN?92X;!K7PVY@M4B'3=6N$WR9&6_5&>\K45I9<RV1%.W
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M4EB'X,0*4% X9S3E0U9?WYI79:-B/O.'-I<<W#0TQDM"_+QD.50]DX^3SN<
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M?\#]&0=!<9IP=B\X P/@"&;% $A#$/3H$&\, $5J!:^.[ $#.B3]%0G"E&>
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MX]ML*<<X&X ;3;$\B1NNZ=]("D@^_"CZ;EU:QL/YDZ X.(&#86A=0/_SD=Q
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M';^OE?35,("D=^Q*J%'S\D!55-B;&_8=YVV 1ZXP$KH.QO%OZEEAFA49;81
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M8L]+*(QKZI%9_//*82RWSU3XC!]].WF<MV!/UU8_B3M)@< +L-.G]0MN.?;
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M^LI?@MJO6;1)/QDIM_/*+'2CO9A78]I^(MECF>-*^%9.\]E7Y=U6:M08:.(
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MR%G"+YD>N:"\0'43 :P[#>-0I)V17H9YR9^3%^(D#Q^(<W']VPBDM+[Q035
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M"'ZQ.:PN24FL *<H3A0OQ]75$W?A7/34XQD?';@(3@K"*I!<#Y;,W@'BQ>\
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M9^,?;\Y,'$M'Q)KW^0[]6$YO&0_O@$!YNO=/VB YHM(5O@^ $+GX!ASR[0<
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M->RK@0!=XW$I!N 4_-U)MB_7<5L?0L E-8.H@3>2!MA]DH<T1T*IR#94WQY
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M9.95ORD_UM,XQY2_%:2'5QKUEBX\_#)' :#V[I[[KR?VD(L"'\&V@(HM'Z*
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MF<)%YUP&[W5)U@0:T[\M=PGU,4 !(:T.#C)945P^OP9E5VM><5*?N%">5^;
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M0YYS)=JT$4X'%*SVA]$C0QMSZ ^N5QGC>N:</OVK7C"4HS,[I9]_ F%E3+9
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M  EW^OXM1<9O[B0<*&6=\_#++^-%ZQX)@?T];+]AEW-GC7>--E],;Q\ ,,C
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M'SJ7MS@^"2^7G63+@CA\>I(RS<D"BJ^,K"?S$N<PJ2K4F"+->Q(F _@9II@
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MQH?*8#N&L!RY^Y^H2;7/+<>,C=:I?$7.*#S2-& 48I@&>5VG9\"YNE;NDX@
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M$2DRL)N&Z3/[=YI:*1N=C.HGHO@XB[OXJIA0:*K:TGOBQ2<^2=8-U,(MU86
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M$8I$.:2 V PW1I>>\I6CC@\0FG]LWY<-<LT'TX8F2;;1O9/IQD7HC;_S99\
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M?$HD;X.@]W)'W#\M>((4\.\2+K1!2CX"8->/ ++IG,C*:KY'P ;9=/O>VB.
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MU?Z_2MPL6?QN,^5I'M,\PH#E.1^\@%2A3"MUG^7H[B.K("#OXD[]5>-/[$=
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M4/Y*[Z]7K_UEF\KQTC8E:#V;ID5FC:Q]XN=< -.X) <I&ZD^.BW?'WP'!,L
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M.E"M\)FK0[/V]-)^OUK2_'>FG(Y2(4R6<:#WP:WVQ9[M))AH[U52"NJK"O5
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MYRQ2;4<^ ;[MA"QR*7<O$O&B/NQF,D0>> PI+7T[\RHG>/LZ2>*%2)7J=*O
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ML^V]Q)-CD!];5X,ZOD#77K3-SEY,B/9=<+PVL&;U:7DR1?&!I9L*XP[*>MZ
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MDN>1?9_8U0 I8_8NM2O-@9&"#L;?@"R]H)=;Y4>"AG@;R3'7N433DGPE)L@
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M>"1_1KWJK*.N$.']T*<O?+N27C&K0Z]/Q0V;)O1<B/8> (]6,O?^N#0M[#\
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MNWK:A_\YJG!Q/3]Y((0J?8*XUT2O;623H_KP+21OD5Z$^V@V,M 89"[#C7$
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MCL:PT:-JEV_JD3:A+V@0G(]**1EHDM*/!?7<OAG'VA_#JEV!.[U:S[76P)C
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MIHICH>\Z ?PBF-P0&ROKN(U+^D_+S A]"/]!5D9&YI6X>6>*PQ4C6\9$=:^
M&G/$)WF1S_GL6/C^8AO+]J6S_U05A6C$S1G\_9ISY5,INU6<F,8\7#A25<-4
M([D'[C)]W916(0.W]55YZ\#0/Z//GVJLP@UQ%ZO,6OD+,ECZ?^0[JI4@[7K]
M# )H3(3ZP#'507\PDM.SF.IBQ+B>K;IB>?)9K"FPE%YNN0TE'MS[KYQ+>R(L
M#Y?6:4/&SKI<(<3.UV299*DDN<RU1L8476[.3Y-86$RW:5 #X=_G].F[+4G@
MP,#>91+(],67T]D:(9SSK22EML=;U$]#(S',S]N8/_.%SG8DQ6F8"]ZBFQX
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M2W91A1.+BW; ],1"_F7^TV,6TW)R-XZ6S0G=GA<T.K+T#_/_!5!+ P04
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M7$L42#$B%^=WY@&;M81_#H_0 &9/WDM*[;)/=6&$.^@T7@RQ.&_]6H4L%M(
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MY #^)/4B0G_Y\LEUN_$R'H #L321BO>6^# 0I@U+_41?3^K3X'2OJ9GD7N%
M]8XR^\?WZH'9)AFG[Z)3BM"PW\%:8/1.W1K9H:\1WJ%[ B<IE3CR,!-NE'F"
MT/.VRM5^Q^;ZMG/WM06/!.AOQS5(;:C0D[F)2 .B 2;0G'#EZ,-4 "S-.S<H
M?)[4,]=5JE#B/4=[YW;\Y([DB\E%S (ZQ.60&B<@BE[S7%:YZF?0(]_;J1).
MOD4!?!(]>S8)55#TK9-)JZ3^X._L$P;!ON.W]UG]N1G,2_R(/;?#S)W61F!=
M6C2U"?R^EE\SI,([V/>VOB;Z>0/@@[$?<RS/.*-'^_?7@G;WQTF)=UJW(I)!
M0K!]A]^GFB&*IE=(\FR?O.!,?B"=S#FU8J>9 ;J#,\=IK4%$$;_]WN5%4\@E
M$G?JEC9^+;PFX29Q8HM3]7-0X[%%SIGHE+JF:7V4;LK[G;,/#,U!P*T,H(+-
M2PK )J:IA0(H]U76&Y=D8*$7^Z3,G-PV$ROA!S*..5,SV8N83KFMM<\');4W
M9AR XEMYV&R%1FL<)0V8*0#'=A?)QUNM+%_2<^=,3HS4/G.S%ZM(:Y@72>$0
MIOWZ 2T[Z,%2.@'NVAKD!5@;+U$ D<H\Q-!"1YY+J I&,>)S*4<* ,,],?KB
MGN-;%>"3BJLK'$.RJW6*08M*QAV<-:=^7,\(&LGP&"X7%P6<^*?3=]]'*R;.
M3/3V*A94^9E"W$'_H/TD-">:-=]6S%MRU.A*/H0 ]03_MF\^<YW.@3HLU*XC
M5]$DAM;=U4[XP"DIZ83W/O09T6I)[)9SJYCFF#=;-O98;S+51NZ/^#SM&]-4
MR12M1R<TEPL($1TGBH:+!ASSZ\&,A(]3$)%M$58(DS/CG+7U?9M>/HU*K<&P
MI^P[PYX@*T-M!:L!4A(I)?24!#G)4=D,OCQ5<*%C;JA*1F4,;76(6\P.W0+[
MAWNR'\,EQDATV 0ZHH$^N0N/CO%BX.+F'+KD^:H#K+QG;_UHOJOWS?O?U)_U
MZ;J#TM7I9D_WDRF V8OKWD<>C:7&BEU-=#C/K<8MZ)R0+3IV>P<3WD_./,AM
M:HH" B\@1.OU_P-__Q.#!K@D%IU]F^CO#J:)@JK:Y0UZ<NE>L_G]JQ&^P+=A
M[1!' 3@E7/,S5\.GUM@IVMX=;58K[2S0A#FXY3V@7SN.-7C;>[\Y\*BII78\
M6 GZJ*D%G]4;![X;LJ/M%6-AY&1O&&\F<U>.=QXN8O"I\:@EWY%MC,AK- Z5
M*8?^@T#&=([_S3KR><J2N!JE>CMW6*Z-V=!V#+4+(:6+==N0ONJ,@OU5S@60
M[07'^3LWF"Y ,82DC1G P9X3I+/\\RU2K4K_%EZ5U3F\'FCFDW[V%"HW!14O
M\8ON[9&W&8HJ3&%+JQS\NLB_Z'KP6VK?-A^SRPB5(8CURBF*X$G.G"8HUB>6
M&^4%NS7IT@QRF,@/2;_(ZTHN_8=(:F*"#7ZXAZM<H2U8:$RD)HOQ=QGB+(O[
MGG^ZJW'PW_*)GXDA/HQ6'$+1VOO@:96L"B/;/8.3\KU&4,DQ%7D,=)WOHR"$
M:X.>OCFQ+!R6DJY,I)F!_R5Y$6$ESO)28? 81,FN5,I\44<:H*:- K W#_5#
M+\['4@#,P3=FK(BB#R7IK3AF]AX@YF8U[ZF&/J!'B*LL+*/2'%6NB@DKLSO)
M&!(%=VX$H+'/C?EC"N7GU-^)FH3SBF)HK3//%P[+WF0F!>$H@.0'Y+H#\55H
M\X(Y!?#;&JD;4+T],!Q'OOR+D$347^K.L%?F>T<K.97IWY3P/N#,9*:HYU^]
M]$5K\!<T'74P"[HU?^O7QI@^=86!:H(EL0@[7Q=#\L3.SEHEA)VV9I4ZM0I&
MNY=L< H#G8]"]/EE !SO/.04-*[JN^0UCHA"Q98@[,1 $!'X$ZHZ=7CN##P'
M6EMTF>6)?8:G^RD'!H5Y?GCB'FMB?#QAM44!S)S/7N!/"@F1T[B<9M 91$*
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MJ$W@CVKB\")8K8/-]E$M0?^;3 38NE<YKYKAD32WJG(-(3L![]#UA&B.4:J
M8[C:"ZV)'>!G>CQ69E\L9N0$S-X"/K%O,ERN@1_ F4CB]<2V1M[.*&\(@QXV
M2&FJW0NB=*7DT\FX95N;<!G[@Q,_ZOV%DE(A-/DZ2TZ1Q%GX<5S->;"2.?S1
MV?#/<K(*5+X)_XV8P<ONY.%(][@.K/KN?*9/_W+RWXP2]S,=DB@B1*Z0,)3
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MFJJ64,.:Z-4IDVPZ$WFMB'L?=XU1O10 3:OXO-_5D_?PK!TON6]KSSQ>J2R
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M2M*8LCHV2[Z+O=?I-!EV6A6: OD!YR) >_FT@6A(T6KG/\)7J&_7W%'ES3/
MJZ9)21OLCI_D'1>XT/M)?X"9=T+,P_M]):)).O_Y+](>R(8\W]]DN:E'<A]J
MG//4YE3$?V\U$54JSEFP;R>G114;]KO!! 6-9+UPH/+_IH3%_\>'EZ//R6D6
M$18L&F-P':GOX/V%2N#BZL.DK[6J+4E=F":SC+K( F-8?HJTB@D_ J!;.3G%
MD4IE2 N-$M,+WV*9M6G,LANVC_$;9'5*_0)KM6+\&4#:3VHEY?#ASLP9(!ZI
M+]:AV>E3-SY^CK01CQT[770]<9[IR&'TRK["/,BZ+O0H"=\=X_L+G.3KKP63
MJI>[O/= T1,NF;BYWYUSG0RDS<%>D6!$1C,XI)I%7&Y]B2]/._$XYXH(+K(X
M/J=;M!;*O/[+T0!,+<BL9N5SVTM(V/8M_1?(C3=IB(34WB6K?92)F5'>P%U]
M5W &:'WD7D29,\7#7SXT>[DU?M*$J+CNA]D<,#"QWR+'J^%]5#WQR5GEV?S$
MT,79W+(913 6Y]D/5R8N*0PO?[OIM\.H_M8)\H/,1_3(-]]L4+1+QCIK*1S&
M=#<*_WA\^0(5X"J^ ;D2>!L/#=F&2\A(7%OHI>\1<Y57CM \N+^<Z3$N>SFG
MPX#&W-?E^$EDU]22=NNW(=FREN94*OY^=\D9P#/6%,Y!W\8'Y]AR0I?M[58-
M_S*Y7Z=3(+(18(F24D5)=PN%!PL0:WJH+/C5,J]BHN>Z@<]M/5>[T_O3*@(J
M!I98F9$K<QO!-X@&<$O?4-/0UT@OFO'*#QPOGG;<\KJ7I\![::0MR (##U-E
MP@?'!10XD%C93<U*C3!L\^DF*C$I$K#> H%KY/LR0_0ON8TH,(TL%\_UU@TU
MM]N)&O;>P!),]=UXR1M!-DA_QU39W>."]<_F8OV>(+:4>OT]%,I/?G,DI^*C
M,/X9FDM9VA;J)YGZX2U?3_/<\)BB=*4.@U]E %8K[>?6 BM>->L]LB%89=*3
M>"M,Y+2/K55#>%"0CM<#.8YJ+VXB.F-:!N===IP?VBQ91KU%0.74UW[&7HB;
M@_YVLUIH.E4@*Q*$I\8V;7CTTB06@0Y1S5G>O4VH5H6-I!'+[^]R_Q8H43).
M9H $Z">/SM<KW]XZ^U4$1]4B7Z:<CC 1X7E.JLS_SNU(K]=.G:QM-#O5&PQV
M'MNTVBM\Y<NU,?0NRZFGG8]H7';.3FO9FYVV4NJE9.-_2B[TTDFLYG[EC8]!
M3B#'G?$:OW<QG*T/J/R?#A2R\N,GEQ.BI7D3*X&N_0>R_ET84-C!R)4A3(SS
M]2F5:ZZ!L\HW!>:JE*(6/3)C38)<KDG(!D'J2>CVK&92TJ'8_IVLQ+C:@( *
M;Z2UCTV6 0U^-\P31!L\9L/Z:U06?"@.V6ZRZE/IS^PV4'ZXD=UX7#E[%.-9
M0Y#O E*>0;L_SUK2XC(HEH^?"MD=T4VU@.C)C'CYSX=ZUGK/\&0YCJD_HSV*
M>K?>5" ?V[80AKR:IZ+>8E4>!:D9UT20!MSJGXN^&NC:,!]ASMP8LMX[WBH+
M#AK:P%@6&5T?S*BO'Y422IL,!"[V$%QB/GAY?)!K<66:=KW4R-_M.12(%/WT
M<XHL2_"Q23*:D-CQC#,"QBC@*KD5QDP .X)!6%]>Y)@J U%T$1:)W WXX>N_
MT(F+4*;LBL-RO96@#*:Q(,9 >=JTBHV-PGLS6RYCCC?\JH,IW]]D[OSY0]VY
M)V3*"M^>G3U\T628Y13PNJ$]J\F2C)X++%FB0'KX5::41?)N-OQ2C63#1"P9
MR8G=#W<?@]"\A^E:VQ@P;R*NM_-MD"JKN2V4C>XOM8Y#6K&WA,+W6?=>)SX^
M8#M ?PEF($KU^*OF%&RB&#A2+/VOX)*S)G\:CFI$,,)*RHP#[^/+2<%1[U R
MXN"?PPURS+T[,32A>8'Y[\\ ;9G'E74Q^>7?/(T06'00KFC3M971/F#0C <R
MU>^-(NWNJ;J&8L(DE@R^V+!19R=[(PMF"LC,]'TCF69*:35),%W$3R=41%E>
MX,6FYI9T\&ISDXY5T]]/)B'S6[_9#MX1F=3U;4TF-4,X2/FWZ?M;^RB;%T(>
M9C+]OE;@A"_KG#(ET3"#[R4X2.Z!!]>>!P\/975_:/^X3-F>TF--MYI_#*49
M/]UI7X*4]#]6F %E[#C+'EM0UD;2M6!%@=K(5DBE;TT/,ITV+V]3@C$_RF=%
M)-/IW[8H39 C4QPJ#A';^C+=).LH%\LE@[OAXB.Q.8,2$[J]^$NPYD:\HEF[
M;\PB]%.@!;RPH93H/K5K;,0S<G^K,7Z[M -(H"TD<'3 :(@U9C43AY#K%@LV
M*,%HCC<#%Z]'OV8NIWOS&_O-C=D*;LV1$C\U7@FW"=>C-]ROD W8\H8'J*9+
ML*\-H]AKH)5$O<6LX3S78S,AJX<G\;-1)HL>"VV@H[)PR6"^C5]_Y+7OU-G%
M,KF:AUI7I'8*7-F8:M:OJX^O4B^PRAB\V[V'Y3(P%9!7TTC  6WNX%.2EL0Y
MRP]CU .<63?<$U+?=W]QKT@6))P8E7P)V]32<2B )H]+IG#GB^G>]&_<(V\C
M-P--2GL\2L"HU$]KVG(+-R-(A!A[3L$3D_7T?!P<C* +O%6\:;RARCU1BY#;
M?"[RD&O>UKIJET\%RGV\<<Y%+;'[YBU)SV/GG)CIG39HXAE&S^$=TTB*Y=9W
MPMB'*VMB M2N;UK>YTC73+\'G/TS]#V$DP>D%,E_F-?3LS?OU7)8HT_!R:Z_
M_V5L-14T=M!J"7('DW*4S@"=&J6^]%K$W!]$B$D38K0VXWV 4I/(H[H:>8;<
MTT4/"[.%Z_]:92L"!5O&ZDZS=->,6H 9W^V:I>F\-24$:<BMF>_:\_'H+A@#
M45L]57-,QLE)Y=&;9[\ P+]TH8U5(@@6JZ.D4Y5 Y7]P'/RCLC3$V<?9U>5=
MFEVJN\[6X,$9P+ZH3N%=+A?()GW#YX,S5!51PM+Q^MMCD^:-BN3Y@_&5\0-5
M?X)-,C\"C\#6-E2/")D[13P'? MA>G%C+L#,#.,L$<A#8,+@4E)%.D)\7P*K
M6&ND=Q+B]Y%SA'7QN7RB,<;"L\WV99"(?@I</B>((TMT-P>I5*W&8#+=>OE'
M1_E&<REXLSDB WS$8W&^*R;4YGI=_:\_%UVH(0VLK"!)D5*KCK\2U]:\J:4>
MP9;^.7*!"J.>,!8'*#[+-[3/S%\@BL/8TRFRI5.0*3QF4)1319QNJ;+L#'!5
M.[KU0T"1?C%:/_>^;L--4 PPX [@O5;(ZE,#Y6-XP7LBRZ)8H,'YB_1$NZ$Z
M9ZI]5NIL"W)POD8M7,F*R+-H<-/IF'NJ %.FUZ:+E>:M>>S*>R,VF<[%C6P^
MTF;9HZYO8,V. M<O6*K.XMHPF'ON"N"RR:W*TX/VLO:%E),]$+TYL0MKUME"
M\<8N#Y5L,$IT=ZXD>2; !T-GT5,_4GNX*U,7H;R:$*A*OGRV8F+O*L%JY_-\
M_4['MO@ZQ6!Q)%0V3DF[JNW?4F/]V,,C-G#^_'4E6L9&V#M]ZWJB+29 7]IL
M/$D[O+PN(+*E[;,IF!T,Y,E8%:7[-,Z)T\=NM*=:-P.S]/;&=ZXL;HHTOQS8
MK3CAA<I#6PD@^HUZ-*/J(P<44WA=1H7Q\TG/DT)$??KRL- 'J_(TX:4[K6.#
MG6.B'4 8+_3CIJU%U50!\)5DQD"4\EZ!]QJ=<CJII0-TA7P+OSW7$.FI((-L
MY$S1M/=YN]'4+QAPZ24HG)_5X)H>IF#LM4/B7Q?^\>$DVJ>S@R[S+;L>4XD]
M6H^,S *<)F?JSP",%Q97[BJT2!Q,#<Y7D[W.)5P@DF#_8D)9?8E^2!>X.H5S
M]EQ';Q]Q%R6X%:G^T^.LEO??!VD'\A%85>\1[3$479ZRC(F4:;%LPM._*^[Y
M]0K#ZLM>Q<H6>*7?"PI-#8U39"5(@$KSE:74OXER*%J "*=+7[O3KW&907T.
M@\^]O0M*>@K,VJP/)2<U^0!L<;KX+#9]"3.RP%;1WX44?L^MYKAUY$FP:1 H
M.>:UH:9K]I?_<2XJ1+#OMNW,N7XXKZ?@BTLSYM.3OR20Y36YF%,OU^JY&^GM
M[]Z.;&_F4RIE2#@#P*Z-9?H5)@Q&EVP7#P<E$#Q:GF]OZYUS#/\D_9_1QTPC
M__<Q?,6&?]UJ5 #??/C?^M2'F>4)#XT87_\,T2_R#'J,;SAJRQ[O'R>_O=KX
MY:U6WD7RTCP2,6$V:1E$YJZ(:ULI_PST^Z?#$Q^;_YZ;W 0?@T5 ]PP"SY'&
MYL$98/UVZU]]A<YAT:D5\]*ZIES#A3YU+_>4K[7QKJ725I)Y2^(5=KO;BK*U
MJ=)0ED_A!NX!IN>T_X-#H)KW@.LSNY]$U_.M=<4[0U#3+%%P^$GOTJ;3%]+%
M>!A^\Y;;T;P="$?_T^<*C%1+5D*^_U)5;/*J5 ' <.'E_[F"C%#V@GAQNEB>
MA=#;S^6/&-U]@ADS7J15UH)U?>0JT6(D_LGI<TE3'X-%RT&J;31$*L8R6;^^
M:P[18(A/_NM[\*5"9N/U!='9&SZVF6P?8ZELHY:9OW-T <G?;R=V Q23;*!+
M3#$D[]#VA3Z.XU"A%;7;.1Y -9:L/#Q_Y4 /<-!&O>-T"R3]C[;O2RNPA/AS
M>3#(?5@M0M UYH -]M^F^?41!^1MP.6_]C>?829.0],_1P-(JYT$67J>@.)A
MVW39A."P]Z\/_P3>G4#4!C(5)0;[JH>= 7[K7#KH\3HX[T'30Q$U.RA]T53V
M_I.M$&F=%O&J@J"K#O!T&0.4$);N2SE/CR4D4B9+HU//[\AN'&=C(?O,>GKA
MZ8I;;S#.A_L,@&/)6U=CE1&X-E=MV15$EZ&\7Y[]_N72L2&.?J*J-R# S+9S
M4E\+=71@IF#Z*"XSHWK<)KTE&+I6M75@QO*!4-1A"?NB]@MW2!2>;#UND&OA
M?9"@BG]LQ>!_<%SD< ;@:F6#$Y,/&-6Z35,5FQ,1=M9=PEX7OJ#ZIEG, ^[E
M#)SBQIL0]47DP7I* %\!6[=OY!+H$UD,>WE4%G+#<F8S]LFI$IUS_@'#DUO0
MFV*!>N<#JC(AG%1LN]FGY,5=&H!\5JNW73F9\WE)#.ELCVO38Y!OFVO'P?W@
M]A:^.K8.;0+Z]\VYC90-;(QHAA$ 59JBM#^N'%@T4V6NF-,39#/;ERW[;_Q4
M;F%$:U2MUGG'Q>@I39KRP.O$5S[7FDJ/I#<K$)@FU87LE.1#/0,5&/!GZU'7
M$GMHOJ]95^K"7:3GEEZ;Z:2]CG.*(40,1<\Z]XACW)OQHV\ -C5<V237>DO1
MILG)H]#2'L=!\^T&M)7SHIHD6/?;4D %!_G!DF5F>9)9D.*Q8JEX(MZG)^<*
M^4GBJAK35CTJ-H4\$,W%I5W)>5&[$=NZBQW!R><2[9],T(5[Q4F_)C!F=1NJ
MY&]N-]I?F^ZP[K[HSV+"S28BJZ\Y/TN@7,V^_4VL.5YW@!(07-0X:M47UZKO
MA1F))&4W?4Q0F:]+:WSV[69X52;S%06R4W?&DD&/ 8,O2)L ^U*[>\W*UX:
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MVN>Q3%?74[DCHP5LQ@\OIP<]_CCZIOKNR2.NZX\0&ME..Z5BQKV*SK7-4AU
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M1V7\..5IT&6/'&;H,E\1%'D )=$CM<'47-7/G^,A6!CYBR6"X@&B,#JMII.
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MK80[5;FH!5]59U4F9K#'IK^T=F"-OOMM$[NXI;L_Y6XUGDSS+QO9[#53&\X
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MG/L):*7HY,=&44#@X1E :%M7?&W_5'N#!(HC?U!9;DYR\-?Z!"DKUWK.(*Q
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M+]!#94[J'.;0:Y%KEBO(MX&CYI7AM2^$=9A/[(/E0E[CMI#11J-*?E1CO3.
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MCT8W_>MB[_/93GSU,TP1RG.V2MBU"24D80HKEN8].E/]G6:%+8$@+NKH+:/
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MRDS\%,W@XMTXRU5YTO]]KQ.^-"[0^<2"M4--MT OXSOM4A;@!H#QW.!5\BD
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MI)QO! S#!,73J,RR' IZ">'*BGQMS"KPD+TU@7<^[EU"^2+OUC!V:& W[CA
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MY6V$60LGT4SCVH;^!K,?[=@, _VUD^5.(++T]6QS*=?]1SLRO7=$P\[#E$B
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MY&^A=*0-&UN?7JW7>OU4LL!/+$'BXA8)D/RSU_%L<I6#F$D",*%A9F;RQ01
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M#6*:X^T&[<O'7]M5W&(W2%^4GM0UGCF882N(Z0KGCWYFR,%LXZ)>;I(;U7+
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MSA.RJVYJAKCI WD+@]4UCM4NI(-4TGT^UL1,W-_]'"V&LI2I(/AB[3HMU-C
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M,A>SQ2#FU%9H-+$V.8AFS./RM87:[,O)<MAM]TV+3@?6UV=[*63\0-.C*W5
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M.YS5C6#?LV0+ZV[4^;S2@&GN$WWX14LUQ2"-K"]>I$M50NV6WH-/7J,,EB0
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M:1<*^+E^<+F8L7\J!,DBB.\&\6*UDU8NJ=>,9\3H>K7A;R>T^+2?C@%D>7
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MS"J-4FF/!#4H\L2Y1CST^?$B7JE]%G)B;_:YMQ'3T/ 3PFL>?NNJ*1 5+QU
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MBE$%X*SXTY'.FMJ\M92)(1O>8'H(MPSPA[S+DV]31[^?WP.NZ=^N#:!@Z,X
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M44I##.$PPB&MW=]_ZN_,3+D>S*EQQ^1O9@C2.K..W=C(J!=]!H >=[7Y \\
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M9'M[""U)T*!L(2);:3:$7:EB^2P()84BNZ?%CKL'MR1G08D36SLGK9:F"8M
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MW9)852 !UIAF]SOSH7IW;"9U T0V('30=AN\LZ<.)JG,!9SF;B'*X[H:#<X
M4YH=9CQA]3ZYTP:!3GEV:9>'"4T*A=:]B)_!P,]U8YTLOY4?\6[M:$.:6DZS
MI+:<Q@28F.<M\P<*4_MTRY^TS2T;&5S4$3H6N+.D>5E\U,M0&RK<.546AW+Q
MH?,+1$U)NHBF >2*%ST#:J)#;GV1-P:ACK2"$BD:)NI6B=3D<U-K<JB9"6N+
MXR?WXIFBFYYA7ZPC;06&]SDK#&Z^/0.XQ%^(MWPLQA8; E4Y^,&S':=Q<Y[R
M@#3P#7?D:6 #;#<U/00?;()%D,NS;^TY3'X]>X) T/+!46K^XL%! I9DUMT.
M)0ZLQZQB91!V)Y*T(^=]R4O0<F=2@W63*DH>)+$2-QJRPN5M]/]T30_4Q%RW
M_<X:^8R#%LQ-X[X0,[<O31#E)Y G8?-VF]^ERVS. '1G@(2D[* A 4E26/D/
MN[\(1_ <_\@>)- 6XE=J"_E66V IZG8K=#7WU2GPN5UDID;Y<!.P:"/)^0SP
MBA0"96CR1I:)C"S["C@;R"8=+KHPOQ=N74_=:M(D*CT@KN27@%Q'FC/S48\+
MU#\O]NKFVN32EH&:GPUK7+1</_27&%-[6+AI:1O"![[OU:-E8-/SC/6/DJX)
M5Z&DT05\^@@X_Q2&:)L@'!76E,SOY]0N!ARJP<X%J@O!0@YH;:$GXL9#SN-S
M=,K.!N(O9VJ2#K,[._U=.3E9S2Z+!WME\P;DV45!3D,<C/$ON-P7T6&9:R>/
M;>C*NM]QLT;B4I$KU3I$;T6,AJ5V93/6GT'NP-OP(H/H7A:[R_V@_'S)>(MY
M$>9*T<;$IY+YWG6KQ1<A=B_)4J>Y'*'>F>+CMTC2L:-<"I/7^^6NN:W<U+[L
MS2?-R<7%59STW <Q<7!2A1D,[$BNLL,B,*A>:)SFA&N3%Y@4KLTS4%J@/4SV
M7P'_*[GU;2&^2.7FY^Q+QX0C?X^);\1I?'B,6F#!U+HM-_7WB)7>$%2!KAZ-
M0RY9]]^-+Y&@#TYX$)?B:+_+R @<>DL6$1FKRM"B@'X,(IP@4NF'G**.D,*E
MWZ^F@Z=_+[K*6B#M*DM;@B\7_J>]BY<4XQ(X :R4PBSR#B84Y]W?&GQ],>!U
MRB7'W'_56"H]AL'LB-,+@Z).4T&4 :7V+#ZX&PEH8Z!^:>V83W8M:\HC;=.L
MX;4$M.1SS9,>$2_"&F24PDVZM=EY!KA< K>O:3=LKBL'3Q-&OQ+>).B92I)%
MQ%YF?NM\C-,,]A?_I!#>,BHM+:P]$I8H-7WYD9/H[EBY1K5Z5FN,-'9A!ZX6
MT%M4-?[AEW0%A]U^V(,9MWA$LLHT4E]SHN)4\FF0R-P\D7/3HWL?-B7703V/
M^.^23(;5GFJ'NOVPLIE<3YI^S%8>'2(Z$_GRN$CPH=7!&8!7S6)A.D8 QI$A
M]Z)JG**B4<]GZ5#YZP#-FLOU6:[VZ]5X^%]K9E^%TJ*@O@0(5GO5C.2-0KB=
M?E/\DM=*[_*SIPYG\N"2_^&VC6DNT4QW?)NBHK[<M]N9"[[AC)_]2,B\_5SA
MS6QKASVJ*']TT.ZT9?X$MO_>1N84+GA:OKQJ0]K*)S'AM/-+-Q2!>1NC!A*5
MH\]UGUJ$1G7?E'Z2R[=*-^A232I=:28?X@(5]J ^'35,V=9]4Z:1A9^UI<4>
MB(BB0HTN"&\[929CSTL-<"4-#V/82!$ CBO0P9CDSM5V?3?OC?+XE[*17Z[O
M:,;2L?8!1.K$(5X[8Y&CX1M,LNK(<[D6X/>N;&,Y#OXQIWAV)>[M,AD%ZVJ;
M&#B9E,G85U8WP]6$^Q![GS4F/<0VJ7K 8/+#EK:;'O(DY1<?+8'?V$Z5>':W
MF2Q:0HE).,\&PY5L< FY_9]W0UBQ%.60D;EMI.>E[K\??6;<-/7H J_^VPK]
M H=&R5/*6]G.%J,_PKAZRAY3V;9BE-K5.5M][LV ('GME[QK@VM O!T O8>V
M,=VP%WJJ'HH-W5MFF+G2#57G%'++(40SJ5$9S;_&0N%(:4]=#8?ML^E56T%X
M-X&]DZ[/MU2L;RHGI$$8)GG?*Z_;F'5!_;?&U>1P)]?R:NI)5PJ0<6HZ#'QW
M2D5"!#H(=%D'/PR80MP'2\ I5!&2U!D@2K-B^8;%0R\V-QVV#Z]4[UQH#G\S
M*33:<I=L>6)9.>05>.>&QP_G^U]\AA\T.SRZKIL[#[EQ!KB \LI!])/!Y_N<
MTCE;-A^+(3+QQ YMS'-1$& ?G":[;]?4'P-GPAF@PBN_)G:,3>6R[19?4O02
MS4B#7Y 0.:D]4XYT);* 3EV\;8Y]&%JM4@K#)6[M'^96/G+8C>B9TOY7NSC1
M#&JSI:DA;D?"M?!<J(PRA8,P\/>O@)L2>0#9P2"/9^BV4Y4F!SR,&21?2VM7
M'@ZJKWJO5AU[=S'VZ.: "__8<ZMI4NU1\E:]XL'H5@,&Y]%-D3O1(7^TD,\P
M.NY:?#F\?]E/6JB*.)<-.4T3:/M#\+CCYR$#8%7<[^E_B$-,677XU#0H-GJ@
MK%TLC5"\UH:H*5^/9Q_6A_T<M3S\;OF]H =<X]4&70Y7V!#@)"LIA6M5?\F4
M'(=1U)W+D,=JP:P*VI?>>3_CT0*D7Q%Y:<M)%J%RU5:.C';Z5P^&228OU@Q;
MO=$N_RFD/9 +C[CPRU3$<^]'('2'XHD(1SP/L%NE0HYMP[_XQG7-J8X[DE_C
M2Q\=_V%B<KD_97B:A1)),&2SLG+1729)"+DKEC'>Q^J@X$ZD'%^#=@W5EL_Z
M2>VV0AG"AG>XK*TGNR7$Q.4X.\*#Z[VEY5J52\EG ,<3MT+?@'Z2=I%;KK,2
MYMW/$1'=/CWLDE1,GX9]=.:=KHP357,+L6\H [2+4A#7"$J))RA< G1GMGYZ
M-[B^;6E!5L@X/]5FJUF^(0B&>C5Q&%BZ.S$O&@A2'0U2A#\=DQ^\NO'&CNFJ
MFDZI7DZWZ[ME!EII#G>J4W],4\$5M\,PWSU0^!F VSY6\(:E[[;5L&=O,Y-9
MD@%U*%&KXN/F];*28N$,%"0ZICO!=.\,\"'5,2//]P7(T(BP2#PH\7*V_K%B
M)AK;M8CJ\_?H]+1E(T-09#,3DL).#[:T;$/<&*D:\KQ<1<NPN/NIQ.:FH95=
M%G4:=MIX_%,C"[L;E(X9'R@8V&%X- %,LUBLKTE^W"TOS<\/>G1U(2HUM; P
M^^5EXU^ 5]>]=-O^;_0'_=GDA5.&^RP0G-JQ2C<L'Q9-Z3GO3J?K!H\5 ;?[
M78?U\D5&[TAU%M2J71\\>#.6]F(8IB#(9:G?8)KA5O 8BEJ#@%EBS=M<A9[.
M*__Z/<#T]'K4X,'CT<5*7VDU'3=AZ63(ZTM#TU?GKI6N[BZF.WQEY6+Z$CL+
M6;MSIVP["'.N?"L]%=68LJREN)N"%\JJU_>+SP"<OE\@4\W4KYY?'6M^GDAR
M_-QQ+^?F0\ZXZ[FV!UMH,)TFRV.NV_E>(53WIJTW2?'UWDQDUJSB[W'PT[#_
M&,T>;M< G 7*:9,44_#7T/A16'938IL'U+-<\>F]!?[2[8\21@.;Q_.4^?Y/
M>L7JF 5$(H7I;MJ"(JJ$C-89HSS&]U07&][:F[=TTM6%U7I4B]1;W/USH>L2
M)/WZIMIKXA\93O)JF\8M)/F7FL8ATP$(^+Z.]1>)V>K]=,S1FD<4H5C&A"2=
MEK/!8Q-#F'KH4]3WJBHRKE\NQ$DHD-V<RM8@<0:P"3MTIY;X287_FU:O#DO&
MG<1Q&'@L9(@M6?]=.P.\IKN?D!$IVOW5)V?U POH:>IV"QM%S2Z4RF)X368@
MAV,E($ZM<_D,4)*0Q?5[O9&[W]/?M-*AS$JA,Z9MIJU"36N,F::8_?5@]B63
M*1_(BE@2 IMU5-F]AYZ<F.C2C"P'E8'D-90:$E= 8H*W"4H2O":U_'^[;8&]
MYP$[00%$XXQ-G<E4&8-;!>:3/9Z/2KT3&66].VS@:B(<K3U)?Y4OH[-NW<[<
MV.*/TN>H40/X?P[(SLEJRML_#^BJJ*,\^*>3^T&]_J78T""!35M)DE&U=%;>
MKQ3O%A9,I;E6QF^^Y0%!FHJ?BQ.-P/F_!RIJ=Z&2:@Y^>>2/\QU* C='JWNM
M%.;!(KD,W-'UC'4]2]''WNALF6W"7N/M;>EE<ZGOCT42Z]MR@A,-=?)<#OP/
MOD$*UP^O^=A[<2&Y\2H6S'O"4S5?ZM,@('( %4*4BUHV14S$!*&WU6H7G'Y9
M83X=UT8IJ#_NQ-I*CRFLC^ #TGI-0MLO TXGA%;Y/W0^;SE-S6EN)-=K4D08
MLX@_I7)K'4ZX-%]/\HKI#)[T;0UHV"83/%\:S)D&ENX0R.P<B[4!E$,-CPG-
MMU9Y-K=6VS#,7H)778C@^/7[,<OYB?H-(2QEPU\<CWCYSV%'X#VP'H$KX ?#
M>5I2B@TO8SZ];GH(E;RETQP0VMZSX\IKY!ZT/N#6&>#%#M]96=DL/MFFP@RK
MA9/==_:J,3([EEOP8=+C Z5&<JAX%+5[\23CB@SS!KAP1HLC793+!* ]^<65
MFWM54'\H[L 4JV!W(8:V8_X&K+I9!]3X\?#A^,((KBI0S#SY"S2&J[B(X2/C
M?;.A/5.P>W<R%(6#!$YH_=Y5Q6AV(YJ.*C8/%.]C0Q6*H0'=9E.'45Z1A*4&
M$L-L(LUR6RM2(=3\,A_"OV&0/:@?V2))_E1(1B[:("6VX;?%0^<&5%\GFT'G
MW@?.(B:GR=C*8<.-TE.7>H3,QD*:%<+R/UODEZ:]^EMS7V,S?%D1!^K[8ZE$
M.YV"QR>]9FI/6+Z&O%*>_UT6_@M3$6)[%4,.N.^; UDB!G;ERAM(?67RE&Y4
MA2V@"VE]OJ.#<M"99BN;IXBTD]__P4AW%N4UV:V,HC.$KQB"@[T6ID/>50V;
MM_OQ%:^1>E0H5]&RE:?1_SRWPP[N\Z=\1O^C&#H4:]3#\+I2]MJQZT/"[+6"
M0H^^PS]0U8O7-H#RI0%>9X!PRK#A'';]#,!PI B?+:'V\,36XCY?+6L1W_0@
M5V"?\V111#@Y-N]\ W1=+H=&U:U=V!R4;W#ZYRY_*E623RJ=/=&,@E*>'RJ9
MWG%(-%^\3BHWHZ'WNW2AMH#)\OA15+4XI]<R6?X,(-^"4S?)REI$["+\=H-R
M3[C/LW)C%NMZT&UJ_\AV&74Z(+<WQ]*&^^V T>_EYSU,WZ\T6W6= :ZH 1=A
M3)L-GJE:,:$3:)>)R@W3FH32@:M\VS3B6^A+!V4;46%)X95K\E,I]V>.%,X
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MK-:Y8C][N 'DL /XOO&5NIG2GOHD?C)]6OM EOW#JJ;0],[NNA;;A08V"0
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M@8KR#8" ?AZA^OD"_O:B.@3Z>)3FV/$3M*! R6G@$!4U]:'#U =>@W<]P/O
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M>U"A4HA)N ^9^V@0]Y&P&W>:AB.PJZ+;;BI1J0+/XR<&/UU[TXNY)%F>^O[
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MHS=B<*.ZI%'5B>>($AF_"%=5DQ_<HP"L%. RX3@_TCAQQGUV.H]O^6%I[XL
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M5>SJS3J%#U>V8=&JFK/W9:T%$<L=R##^/7+-MONR8\H*1L8ERXH+4H/#^E.
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M[<!FX*.$)F0_)J1,RR02<DJP1+8."M"@L?<._;&)?%&5E>PUNY.R&1Q('*$
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MZ@>=.>P_%.<_E+Q:U 8-\6Z<$(FZ;4UQ\3+S;MD_%.<_E'R?&;&6 C#PT%*
M6^O[/7M*"IZV%. OS]L_%/U?0@K[3TC_=$@&O11@>IE\R&9C>C*J$7%F85RF
MQ\X1RF!=MF?_1?.+]]*VGMK[.(ZL)]*#"W9Q%RWTN&NU#?UH,O/U^SA9S;O*
MFB4"_9 /'-)865G-$RI7* #T2V]R(/_'O:^HF!I1^"(6]Z4AO\QQ2@OC%XGB
MD.-R<7*)#1'(&AFOB<A_)L-H PE.Q=]/0)3*?BJZCI]=I9%<C".+O1A^UY>8
M...\FW_&>44J117+9%!1\=G)U0C>.Q\P[&[23V9RE^RYT#^]L:5R;PI1R/G<
MA#7J:0:?^:/CG=>ES"OXZ8<O(L\XV]2O.R,5_1_BC^:YB 4.BS4.,4P9=8[@
M=UZ^5^1<KB $X2I5""%TH>7EY1A4;EQUR58LE8#>V4<BQ\[O!VZ R84?+XF%
M'W.VHZ=-&R_,7!3W<ZK<?^1-]#MK'BS_^O!F[=E&X=XR]0QH@#5VBP(<WFT=
M<L<>FLOLFTLY>RE,J:7$9L2IH[K8>H"GA+"5P_(E<$>^K.B+CX&_4ABWI&W2
MX.4B+&?VVKL:"6/GQU5/+_1.E%. U^X&'VO?^XA_O'5^ST3L[03"J\P5^UKL
MB_LO4:Z<<VE9EXF'^ O%.HK.4^FEUI[\-A.S8$)*$$U*M]D.7W8MF5XV5@*C
M"34VZGE_^S#*_6&_Z H1S8NE ':<XO':*1VT^ZTJXJ:#>$D-%<$UE972?CN'
MX?E&SB?S,+RG_Q3=\1>5F<7'Q6P0A<;Q7?1C]1)L]UHX^>:B\0B]8$Q]C+C_
M"^9^BY [97UK^C]P/AR_^ #";$X[LC:Y>$AMO-"WBLZ4+)B'$U-9!;^E7>CJ
M<"$+C7/S_JB';$X'^1*1'W\E-,_9$TZ[&!63%I'PH<*P5]>:W\J!+[,N0-D]
M3:*KE6KYCKUUBS5Y53)OCS$@(V;2)4=2\G):KZKV\[<]O&CHY\W]3C]8D.>%
M*AQ+1/YBA5SDH),R?YN-D^O#[*3SJP]IA:<*6:?,L %5#C@*8.3-_W&BHF?-
MSA1SX7TH=W)B%.?QYFFQG,G$[V.7<%U^%*!$C']52*? ^WZZT<WI$PLK>BD\
MG)*-]_C3>\@T5OJ7![QDV(,(MNS#;@;N4EG\UYXK44NR301>6FRH="&KPV<,
M><T)$31:^Z7IP[9V::HJPRT99M(H^3B<4*.'09/V7JY^9'R&5<];R2O!QX0^
M&J4SQ:/.\9Z?_M)YR@92"V$I\<=E^(HBZ18L-/KR5U*K/L*QPNO)>F>1N8\C
M34;$ABTI -7*4[%%1S<24G<0(1/]N,SVCAFB*/>5W\BK&[5D@?YG^S)6-_=4
M_6U,\JR'S0;":0V:,O5:"SL$?FF(YO!ZYS#T<$Q0?1E!JB1VR]/%K3>J1\R4
M1ZQQF<=E58M:25\U<"PAED/\T:=EE-/<!?V6>L<Q:OU7^O+[D_L1K1&'Y-=1
M1V(Y)7(&T<7&F>2CN+F2QY,$=Y+*?+#+M5G'DE++CUDGEU*#AB2:\S+1YJM<
M@RJ]MGF.'>:]ME(N:<$_V.I:V[C-NN->R%5[+!$(;+8VD_RVU"KX:V6I([=E
M, *1X9GF9R2?YYYX__6,_?VN:LD'L;:[9$@_.F\NDE4R34GC74RQ8!6\^D=E
M3AKJ6_Q8B8I!.GT0VO(ESM^OF-:OK'=$NY\Z3FS;EOMXWV[@*0\__BJ"$?X,
M=@KNDS0P$?3D20=38<Z/A\NU]4Y<?N6QB=\Q];W.B%\P@@BA%;OB72[=$@E3
MB.4U"N >YRV'^.5))>H4015;/\YAQ&EW3>CB4//&J)QI.'?8_2;H@TZ[Q$OE
MVF7=6]<U-\S>JC<HN5W32@\9_UQ38>.V61)R'1ZDWX//0_MO"?+# ILT##ZN
M"HGNU]_(43PGWM4X/A;D<B4QBX#^9GR<H)5N8 A[9IMI:,AF1NYQ-H\?T)/3
M]E0]](X<L1K#NK*8NB#E%^_(598S&B1E95KL-V5F.:G$$)JB%IQXTV'0J\/:
M$G+X!8I^R%FU]]QRBT9]6(=@^?MT,Q&62W(TMDWI_+J=<6+&<'_QW92&G,BY
M+X-/[\88KX^+/U -+PVX4OU]>-G"HMS' Q^KURWS+,-R1U\U\<I;QY<"W!6E
MU3=44<'YP+!<=(<M47O@&GV ._WD$$_DF)B*<GO\U)-<$]]??)]+GP'D^N\,
M;K_L6=EZ[,95E',6W$#V[YU3_"@JK!Q72L4QCXT9)X1/NJWJ:.+22])O;^=T
M0-3TV#EKE>7/?[]P^+T(U5B(=8>$,><::A+1Y-"_K>??CS]1TY'#G[Z+6+ML
M6A8\##>>[Y(B;56OO2,B.<H\KT?!_;7"9 5%HZ_8:$KK/*F14]MX*9NC,74T
M/;)&M'L"W[#S9DJS^V+8K"B;J3;C_)S%\4:IF<$>.4:< NHU8FN_TFHN>BMV
M#AUMULC0ZCO\A5/.>/.[S'$3\:!4O$!8R^5OD?#'-B]//+D:-W^V$\G^+#O,
M>R4*VX;H(G8>-Q6;/Q$2;>Q@-X")&I8TUM_O'+$U2YH:IO-+R2*R#HH=%ZLD
MR=4USJ**^?>7?>9=[HLDJ].W'V^NW<H3\N:24$$JX6F^A3#;\%NW*J1\#^"X
M_?C,=%CB^//;G5(FXQ6+-=16&E8AJ9P:#XV.K#7L]M8+10S*Z?RRTB71@;"B
M "=%\W@:Q?>VHIU9R-]M?VQ.9-NF\^^8\BF.4P=?K0AU'W=SL42S%NWO%3U@
M,[\9H7_C<S%S3#7&<RO-KKLF8-G"=BI$FC X15+^YDGU5A^74&0G<]-(9J3-
M_+%HQYSO4,:[4^5BRE/2<&=40TQ"@J,-282.\;;1/>R*QL?V\(GW'2%51Z78
MM[!G"2SUC5QGH^0_E 2E!H?$*FB=SSDZ8<*IF/:(,#_1&#WMUGPM5KWO18[O
M*WW5[3.OQ:\[!1%FV#M%E/2L<HC:(3.=N>;PP.QY:$CTG:5MU8XQ_C*S;+?E
M_H3'4]LU>!ZO8BCCLO'EFB+&1>'\V+3%YZ(:H]8G1<YZ[30^:X+I+Q>O*AKC
MT$%DSOK<,26Q\<(TV<@4EI6,8>Y;DU\7*Z6]N/.M=P(]@6%G?T.,&#_LC(T4
MHU5DFXW%J?B+?'<^F?!'\/"4Y[QW9E2#GI81$AL=9/>+GR3)&55$S 1B#$>5
MUHE#/YC.J-*H&3C45M^L?+F2)[1!K.1X@=-MU>)(8T6.Y=O9;(CQ.MQ$.2:_
M[+F$(C8AIN"[K&+PO<TH<,83(VR\0&+ @6NYR&E';)]VRDY&/)L"#*:B]ZA0
M36Y^G4E.+13 <*QZ^2G7RNXX5"<80AZG ",PFZA:=N.@2?3Q\1%G#;7!]+Z5
MR+DY7;M+)T*^V!]*:N+,3O3S/(LEI-9?2;P6:[J3WV:386A,+6U+/BT<A\>R
MY8:<)MY1,5' 1?A%/W.SO1+UI'10YH.V>U9S[8Q)>8.K8CW]6SD.7#L7RY5Y
MC=YT3'SB0^_&7DD68OC[C@OVBAPF1RM9I52V*O?S5_<@"?U^!@$-V1K6HGV/
M-F=U7@9&EJKNM516#QHQ>NQ\+1=RYYY\&R1EX&9K3DKWLQ2R\V8STSXO8!-<
MI2.;0:3%<R4=C>+O2!^JR;#?+GUO;'1L)DSS^;ND9X/<NSK/,HF:.-4",GM5
M992NW_+=ZDC<;>9B,YZC*DN5[Z*-GX7[& X&>5Z!AL#K:)/UQX(\&[>7IEL#
M9;]'&H2("'/U*C-L<O2H]-OR]"_/E)"KWN$_ND?R:?C,/7OGHFF&ASZ3SK'<
M"M_HWY084YR<*TPEN*[I5P9+" JB8E7-G.J+VW:\4?:R-OE][M!)&*TS:YU4
MWG:(0Y:A=0OWJ)3QQU+;I^[93,$))>7[:LYU@CK&F!?*NMJ8E5"/;/+XS<."
M*Y]$/TUG&2?&/QHGI-1Q\>!@KS?CU2F 9D'B?:4S9J6%2G=C8Z'\;#J0P)AG
M<?/'6G86A[LV7/=TY_-\:Q\5.K\38XE])\@J[>[>@U"RC G"P++-NDX3F2(9
MG*YY/754/O<QU^)SC-ZV\MDO'IFQPOZ7OW3>$XZ9*Z'W&9Z-[],NZ,BP%D>X
M;!\M^URI=RD8\>,S3G$P[>4.A..%S3+GDZ;FOA?+]XRDL*HWT]R'DLK>%PF;
M?/5\+L$MEBHG9ZDOOSAH7>9YI=]6C#D!;$^\>1G!HX?8:%.$G9[&%3;)9EW5
M@MFA_1)Q"!(\/9_U4NYN->I:S/<<G@[^[^ZJVX85LNRJ;5IS.U@:L1$Q':7B
MY>::/H'9R.%5O?,?P-[T>AHQF :C^0J2'6RL0X92QE*+6$NQB)YA ,O50Y$7
M.H]*')X?KG3QO.%L)YW&*JZ_%B!@T:>]9&. *U1@DN<Q;WA^Z7Q"7G"$E>=-
MR],+&E8=*$*PWJ5^EG7^2C?=3VZZWB*KMZO]V2!J"1\<!DJQ XDX9+M:V[JB
MN&N%S7:4\DB;D?1(7H@8_#7[6&=*AMY05X9UB'LOGVS$<$73+&F==.(5E20W
MAS8B@ Q9\F3!Y#FRI1578_(O6:K_:$3<E%WN5_I:BWI40OKT@HY;H^=:Y/B\
M=DV0W:.:?G(#<]S<<1WK[.RB0SI^+3+3'#I'\(Q31X(K)V,%N=JT!APCE:.^
M1"YK?'MP]'IV(;_(S*F\N!AK1P,EU-+:9F%38*T9TX*J9O:X!_- S+VVO!^C
M*//>TF54K)H"\Y#[H[]\1.%?_OCT_C;-89V%P97%::IIF)^^X(B$VYN+^P+8
M-1Y(&_-NZU$5SP#/C@1ZD+P(3>:'/IVV[6@W__&4 KCL0M+Y.QM'0IV@NKCE
M$:2EUBQ!TG&K)C%K^86:@G/&YJU_TB6JV*E',+^MAY)7>N$D8'#F4@U[?\+>
M0G[LR]L?UR\BUCSXMVET*,![E362/9)T>+!CS\8,3II=_<&?'&'Q8%NQS2+Z
MY(T2%=64$,%MG7'LC+ML.L% SXILQ+<A[0=]WE2PG5<M7>?:'7:#%.J&(3L7
MKFZB*HF2ZZ/B56]7B5>Q>R!]?RFEQMW&74#^(7UB2?>[T&=W3:)TDC@R%TT\
M@HS>'2<S#-(3ZX20.#;_S71D'7>^3V@JG#IQ=^<QB7^SN0>VW$O6H"?X#2'W
MCB,))RC C8WK!'DCD_!4../2(P0NA7R:Y$!^M8,EG,).PM-?J&TM(GG14^R3
M%&#A"OQ7A1M_E%$D7MB;)U&MH7&<Z#KT+PLIH(&'%."-C3\%^!2-G. G=K5W
M$>2WNO:HL<@)::0O!.>_G+A)4T,!OKZD "=(-Y)#4,J[\N0+^1"RMQD%>(7:
M@-Z 3M(/0A?H/<#353(3L@Z2C^SFV@=YR0B1?[,S4*Y::!8,X@L81!3Y$+J=
MV [6 -00M"B[0Z8N(ZA1@&.>(*F]Y;9&I$'@4!@IWKU-] ?HOV\<+RA ^]\6
MOHK%^2Y3@,TC:- UIP/71/_VGS7_A?(ZBGRZ&DE^548!"*<HP $,KA2 1(6@
M #A."E"'UN+]+Y!H11/N;%& O4,@P9^0!HL2\E>3FO\%&GS@^K2#H&U:)'AA
M[0 /5A0%Z&:A *#C6"+_EOH_(I)S\'3#0<N"%(!,C?X)B3%HYI8!!2#2('&H
M_@?_">M_&!:WL[BQ<848;F^DC*"SE&>^1#(A6OX7UM;^C1Z0_U_&T8^SJQH3
MM9G>+$/@TOY2<3I+5T)W+NT%=O\?^2#X+=</I[U]_063G_1$A'GRT7UB-F0E
M![N[F4@F)>)0 P^NDEPH@-"4*5$TPT/8#CM! 59#6KI68M=V-T 1<8(:*11,
MEIP39&<1A$]W(6-KGHA^ ^YT\F1O+)D*Y$F0</30#@78F'U& 3QCB;SD1M"M
M1/Z0_4UP9\S55-_;(,._(?%T5\$006>_0O=-UMWVSX%0)I[[*:2X?2T)-"$.
M_=6$9<IRUP%B:= ]6B2!A@(\]811@"?6T(U)A[]9J.M#SM?-'[BGLWR$R0.,
M@)<"3+%K@/!D@) BMYMF:;9/@9F48_VY:,@*IS+9:P>Z,PL:T%FDEU<<3%SW
M)\H_@&\R@2V!GCQ$3"+7]J'_MBA('QY9(S?IP4)#JY"9]YP4(,;(5BC![P-Z
M 8QB@I\"A$&%H9.0/A!I3D?0*0,BZ,!K-TW0 <=!TNY!95;P@H$?U(N5(MD[
M$<SA+O<&*YEA3(?L-0@_<"2$H"@&>GQ]!+V_#B*5H:D&0IOR!X5V8B.XJ(TV
MN*@9]F#1@]*TT/GM%(4)O.KA"F^%X.DL06S!M;[J["9^! -Z9SU/?AR%/+ 2
M16;P,"%[.27N3(*QJ_Q>_O)_-](,K@K7!5<UFB<1#B8;!EL+LI?.'Q7 8OLF
M!N;H-I@(*OB<IRG80_ES09M\&V2B^,]:3"\!:S$6NX\[&(?Z?HY#R#_IF"'K
MKN8ANZ_L_%TCLNP/&L5_U!#Z3>-R'FCDXD\5,"EUW+^?ZBRF,?T]>&2W\J^Q
M1R-Q;\ >=*SZ;ST(.LD =AN&7[L-\YX5F,>H@[SK0S;/@# QDRWF0^KA?C%E
M 3*.*;J&BV4/#93LTZTN!41H4;5(<G?K+'2&LLOS*9X]\2962_$6S6TMOO$H
M"@"!XQ@-2W(JNC0]FNAQLUR0# F-V-CP2EL#VZCYG5@F-04'B+'F,X_J4MDO
MO^#+#21VYF++'I))920<=EK'\M,) T?ZM1$DEHXL:ML'1=M2 '=Q0O\P[Z'(
M,?G];>Q./3+HW-\EQ%X& FF_*=_[3< H^=75WY5[_OV7IX;HL+_J1:GN([;H
MB8(DS!I<8M%[@CNHQ^+YMAQ:?\_F3X2BPL!.>SE^N1&+''@E!:5[&_[\OF49
M&],+'H(.YS*J5Z7EN _0I5HS3AP4G"R*#7_EN;=EB#P!MC&)1:/@#_<8,[='
M0F"MKVX6.I(6D&OA9-&/E>1-Z$X+!6 O4KK%C/_[Y2?+^]T4 ,M#M&Y@HH*S
MPL?]R;O0Z7O7T-7TI'5D8Z[:O[(LTYVUCE]$)4>AKRE D.WJ;V@/F$*7P4;D
MK'/[%E/I$@1;2@%JSA$M1S*1GB-D @*?4_SPB&"%_\XJ>LT/!.3F;R+6JTQ4
MRG9)I'W$_B2Z,>AWD4H%0/TW]93?)/)[_C4,)&73CJ;/E1&9T8UE_#\_HG/K
M[%#%WQ,N_#?PQ)X$ JBWJ#5Y$*1$?,K?@=;F_72"\*\L7)3V=C7LJ9MG2G89
MH7_L]ZC-?YUK_GWZ!7/?=4^W7_/>R^7W2M+0".D*V9\!B_OL;\ 4*@ Z#8,[
MX#93 R/T_ 9C#M/#(^[_%N+&/=_ D8DT^2X?LW.;9K=/# %NCB$HPO%/=($_
M/TF;;RUT3IXGQ!R'_I[*V&1>9CYM/WQ;HE%J+D;GY=W6!WPKBY;Y.O6)IS=)
M+V75E0*M0H>PLEYN61%W@ZMK)987-72=>SEA#8A4@SOAPV^%7U:\TQ&N0FRL
M\C%QCKIN9K12 )0R^:[;?012J!$;W:NF:2O6(44!.O=O)MD\FT'FK:=KKU.
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MX'"-;J(  2CQ4^,9ZQDT"(V?8$P/(?5RB$TI(6\[D7,<B3L$"H 71>/*."A
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MD7TQJO:U\9I0[*03$=V,"SDS9*0\#0\H;6,J8]5Q%;@W+*K>OMP\G"VUL6@
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M#GS&(%SE_98A<(H%S,1@(3[F#(,%=,$.RJ'96Z'L/5'=U<$S+(!#'RS'E+(
M#!T>]PVM!3&":+$#I;\TF2TS9/;T4=E'UU%MD<0+;'D&8KG6D FCXATOP$41
M@\[K5G[JHQC&8A98 !<\%&8V7>$XW,JS55 [-*D!2VQ8&;I9HS[B)8CYGT*X
MV?1L)(G&2Q_"T^H41@3+6R&#AVE5C6V.,/BX!0B$N[,R'1F&5(DYU0\>2<GW
M5NP"/WOCU)$?;E',LADR&3@JQ+Y"G"V<W.1;R+O"J/D/Y< ,1MIVFXI4-\QL
M!AP*)#+,-2&HG)[# A3>PRQ() U((_./LL7XX9XGJY9C%@,'B5-UK]>8?>U8
M-#!8"H9'"\JP?SC<EI2:]<A#!L:F< @Z%PMMA>\.2"/(ZF:5Q9F/M@&Z5<=4
MF@M@_C9<80$+"X@A&Q8P&X1F_X44EBY*Z\9=-\AY?+Z _>1 5-]"+[*Z\:3D
M0180,T855"U5(T[*N!WB-?7R;;J,G W680&JA'FE.:+-J:H$S+.4"8-IXYST
M]FKT)]U,U]D?B6 6NAH/1XBR H.,KF[VMG;GM3#(B2B%.Y16X;U18*TE(U1J
M=@BWT($417<9% Y[[R8?CIWACLA??W\?<L)X7HD%3!Y'DI*AB\*M0C5D@TDK
MA?->ON-E2MI<C'SSFF@7*R[F#<C0^Y([[TVU;S(^ON,D\AEXWC48Z;6I*BQ
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ML0PI4;IYJ)*X88$VD_@2$K V7'P#3:=A&>J48 3H8E0A4U?GFSHV,I5<2]J
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M$;LEBQXXCOK#WG!D8^D@?&ZU<+!#5@NT.D6LA''8UHF*O:NY8J:U60SN67M
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M4$L! A0#%     @ VH.D5ML21U&Q,P  II4" !0              ( !T3
M '!L>"TR,#(S,#,S,5]L86(N>&UL4$L! A0#%     @ VH.D5OI#WK;B)
MXU " !0              ( !M&0  '!L>"TR,#(S,#,S,5]P<F4N>&UL4$L!
M A0#%     @ VH.D5KSO1<YE20$ VF(, !0              ( !R(D  '!L
M>"TR,#(S,#,S,7@Q,'$N:'1M4$L! A0#%     @ VH.D5J^UZ#/K@P$ H[L!
M !<              ( !7],! '!L>"TR,#(S,#,S,7@Q,'$P,#4N:G!G4$L!
M A0#%     @ VH.D5O!VK/)H>0$ >HD! !<              ( !?U<# '!L
M>"TR,#(S,#,S,7@Q,'$P,#8N:G!G4$L! A0#%     @ VH.D5FXP4C=@9
MS88  !<              ( !'-$$ '!L>"TR,#(S,#,S,7@Q,'$P,#<N:G!G
M4$L! A0#%     @ VH.D5GD8_+)?"   L28  !<              ( !L34%
M '!L>"TR,#(S,#,S,7AE>#,Q9#$N:'1M4$L! A0#%     @ VH.D5H^/CB)S
M"   &2@  !<              ( !13X% '!L>"TR,#(S,#,S,7AE>#,Q9#(N
M:'1M4$L! A0#%     @ VH.D5D9D$0"*!0  ;Q<  !<              ( !
M[48% '!L>"TR,#(S,#,S,7AE>#,R9#$N:'1M4$L! A0#%     @ VH.D5JZ*
MX@&,!0  B1<  !<              ( !K$P% '!L>"TR,#(S,#,S,7AE>#,R
<9#(N:'1M4$L%!@     -  T :P,  &U2!0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
